BOARD OF DIRECTORS

Linda J. Porrino, PhD, President
Sharon Walsh, PhD, Past-President
Anna Rose Childress, PhD, President-Elect
Stephen G. Holtzman, PhD, Treasurer
Patrick M. Beardsley, PhD
Lawrence S. Brown, MD, MPH
Steven R. Childers, PhD
Theodore J. Cicero, PhD
Sandra D. Comer, PhD
Richard De La Garza, II, PhD

David A. Fiellin, MD
Leonard L. Howell, PhD
Scott E. Lukas, PhD
Geoffrey K. Mumford, PhD
Michael A. Nader, PhD
Edward V. Nunes, MD
Richard A. Rawson, PhD
Maxine L. Stitzer, PhD
Eric C. Strain, MD
Dace S. Svikis, PhD

EXECUTIVE OFFICER

Martin W. Adler, PhD

SCIENTIFIC PROGRAM COMMITTEE

Sari Izenwasser, PhD, Chair
Martin W. Adler, PhD, ex officio
Ellen B. Geller, MA, ex officio
Alan J. Budney, PhD
Howard D. Chilcoat, ScD
Sandra D. Comer, PhD
Patrick M. Flynn, PhD
Cindy Kuhn, PhD
Michelle R. Lofwall, MD
Lance R. McMahon, PhD
Janet L. Neisewander, PhD
Jennifer W. Tidey, PhD
Ellen M. Unterwald, PhD
Elise M. Weerts, PhD
PRE-MEETING SATELLITES

NIDA: Application of Genetic Approaches to Understand Drug Abuse and Addiction
Chaired by Minda R. Lynch and David Shurtleff

Third Meeting of the International Women’s and Children’s Health and Gender Group
Chaired by Frances E. Ashe-Goins and Wendee Wechsberg

The 14th Annual NIDA International Forum on Drug Abuse Research, Policy and the Public Good
Chaired by Steven Gust

Addiction Studies Program for Journalists (ASPJ) (By Invitation Only)
Chaired by S. Barak Caine

The International Study Group Investigating Drugs as Reinforcers (ISGIDAR)
Chaired by Peter Edwards

10th Annual Meeting Center for Substance Abuse Treatment (CSAT)
Chaired by Peter Edwards

2010 AAAP Addiction Board Review Course at CPDD: A Clinical Review of Substance Use Disorders
Chaired by Minda R. Lynch and Steven Gust

CPDD REGISTRATION
Conference Center – East Foyer

Saturday, June 12
1:30 PM - 5:30 PM

Sunday, June 13
8:00 AM - 12:00 PM
1:30 PM - 5:00 PM

Monday, June 14
9:00 AM - 12:30 PM
1:30 PM - 5:00 PM

Tuesday, June 15
11:00 AM - 5:00 PM

Wednesday, June 16
9:00 AM - 11:00 PM
2:00 PM - 5:00 PM

Thursday, June 17
8:00 AM - 1:00 PM

OPENING RECEPTION (Cash Bar)
Hacienda Plaza

Saturday, June 12
7:00 PM - 9:00 PM
(Pre-registrants can pick up badges only)
Sunday, June 13, 2010

CSAT Travel Awards Breakfast
(By Invitation Only) Princesa
7:00 - 8:00 AM

Plenary Session Salons DEFG
8:45 - 11:30 AM

8:45 Welcome, CPDD President
Linda Porrino

8:55 Report from the National Institute on Drug Abuse
Nora D. Volkow, NIDA, Bethesda, MD

9:25 Drug Strategies and Potential for Research Opportunities
A. Thomas McLellan, Deputy Director for Demand Reduction, ONDCP, Bethesda, MD

9:55 Presentation of the Distinguished Service Award to Jack Henningfield
Introduction by Sharon Walsh

10:00 Presentation of the Media Award to Allan Brandt
Introduction by Marc Kaufman

10:05 Presentation of the J. Michael Morrison Award to Cora Lee Wetherington
Introduction by Marilyn Carroll

10:10 Presentation of the Joseph Cochin Young Investigator Award to David Jentsch
Introduction by Edythe London

10:15 Presentation of the Mentorship Award to Charles O’Brien
Introduction by Anna Rose Childress

10:20 Presentation of the Nathan B. Eddy Award to Theodore Cicero
Introduction by Linda Cottler

10:30 Nathan B. Eddy Award Lecture by Theodore Cicero

Early Career Investigator Awards Luncheon La Hacienda
(By Invitation Only) 12:00 - 1:30 PM

President’s Lecture Salons DEFG
1:30 - 2:30 PM

GENE X ENVIRONMENT INTERACTIONS IN PRIMATES
Stephen J. Suomi, National Institutes of Health, DHHS

Symposium I Salons HI
3:00 - 5:00 PM

TRANSLATING THE GENETICS AND NEUROCHEMISTRY OF NICOTINE DEPENDENCE TO DRUG DEVELOPMENT

Chairs: Linda Porrino and Joni L. Rutter

3:00 Genetic variation in nicotine metabolism and implications for targeted therapy for nicotine addiction
Caryn Lerman, Psychiatry, University of Pennsylvania, Philadelphia, PA

3:25 Genetics of nicotine dependence and the convergence with lung cancer and chronic obstructive pulmonary disease
Laura Bierut, Washington University at St. Louis, St. Louis, MO
3:50  *Alpha*-5-containing nicotinic acetylcholine receptors transmit a negative reward signal that controls nicotine intake  
Paul Kenny, Molecular Therapeutics, The Scripps Research Institute, Jupiter, FL

4:15  The influence of the *Alpha*-5 subunit on the regulation of brain nicotinic cholinergic receptors by nicotine  
Ken Kellar, Pharmacology, Georgetown University School of Medicine, Washington, DC

4:40  Discussant
Nora Volkow, National Institute on Drug Abuse, Bethesda, MD

**Symposium II**

**CPDD INTERNATIONAL COMMITTEE SYMPOSIUM:**
A COMPREHENSIVE APPROACH TO EXAMINE THE USE AND IMPACT OF CANNABIS: FROM BRAIN EFFECTS TO EPIDEMIOLOGICAL IMPACT ACROSS THE WORLD

Chairs: Flavio Pechansky and Alison Ritter

3:00  Cognitive effects of cannabinoids: Lessons from animal models  
Marco Bortolato, Neurological Science, University of Cagliari, Monserrato, Italy

3:25  Is cannabis smoking harmful? Epidemiological perspectives and evidence on this question  
James C. Anthony, Epidemiology, Michigan State University, East Lansing, MI

3:50  Periadolescent cannabinoid exposure effects on self-administration behavior and several neurotransmitter systems in the adulthood  
Emilio Ambrosio Flores, Psychobiology, UNED-Ciudad Universitaria Madrid, Madrid, Spain

4:15  Imaging trials of cannabis users in South Africa  
Paul Carey, Psychiatry, University of Stellenbosch, Stellenbosch, South Africa

4:40  Discussant  
Jan Copeland, National Cannabis Prevention and Information Centre, University of New South Wales, Sydney, NSW, Australia

**Oral Communications 1**

**WHAT'S NEW WITH MU? HUMAN LABORATORY RESEARCH WITH OPIOIDS**

Chairs: Mark Greenwald and Bethea A. Kleykamp

3:00  Yohimbine increases opioid-seeking behavior in buprenorphine-stabilized, heroin-dependent volunteers  
M. Greenwald, C. L. Steinmiller, Psychiatry, Wayne State University, Detroit, MI

3:15  Pharmacodynamic and pharmacokinetic profile of crushed intranasal Suboxone® and Subutex® in sporadic opioid abusers  
1Behavioral Science/Center on Drug & Alcohol Research, and 2Psychiatry, University of Kentucky, Lexington, KY, 3Center for Human Toxicology, University of Utah, Salt Lake City, UT
3:30  **Oral intact extended-release oxymorphone has fewer subjective and cognitive effects than equianalgesic controlled-release oxycodone**  
S. O. McMorn¹, K. A. Schoedel², B. Chakraborty², E. M. Sellers², ¹Endo Pharmaceuticals Inc., Chadds Ford, PA, ²Kendle Early Stage, Toronto, ON, Canada

3:45  **The effect of methadone on emotional reactivity**  
S. Savvas, A. A. Somogyi, J. M. White, Adelaide University, Adelaide, SA, Australia

4:00  **Effects of methadone alone and in combination with alcohol on cognitive performance in methadone-maintained volunteers**  
B. A. Kleykamp, R. G. Vandrey, G. E. Bigelow, E. C. Strain, M. Z. Mintzer, Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD

4:15  **The effects of the opiate neutral antagonist 6β-naltrexol in opiate-dependent subjects**  
J. Mendelson¹, K. Flower¹, M. Jang¹, C. W. Harris¹, W. Sadee², W. Snape¹, G. P. Galloway¹, ¹Addiction Pharmacology, California Pacific Medical Center Research Institute, San Francisco, CA, ²Pharmacology, Ohio State University, Columbus, OH

4:30  **Effects of cycloserine and gabapentin in methadone-maintained humans under a naloxone novel-response discrimination procedure**  
A. Oliveto¹, W. B. Gentry¹, J. B. Guise¹, C. Cargile², W. K. Bickel¹, M. J. Mancino¹, ¹Psychiatry, University of Arkansas for Medical Sciences, Little Rock, AR, ²Psychiatry, Texas A & M Health Science Center, College Station, TX

4:45  **Assessing temptations to use heroin and cocaine during drug detoxification using ecological momentary assessment**  
A. J. Waters¹, I. Franken², R. Marhe², ¹Medical and Clinical Psychology, Uniformed Services University of the Health Sciences, Bethesda, MD, ²Psychology, Erasmus University, Rotterdam, Netherlands

---

**Oral Communications 2**

**Salon FG**

**UP FRONT WITH DRUG ADDICTION: ROLE OF FRONTAL CORTEX**

Chairs: Anna R. Childress and Hedy Kober

3:00  **Blockade of 5-HT2A receptors in the medial prefrontal cortex attenuates cue-elicited reinstatement of cocaine-seeking behavior in rats**  
L. A. Pockros, N. S. Pentkowski, S. E. Swinford, L. M. Robertson, M. Ostos, J. L. Neisewander, Arizona State University, Tempe, AZ

3:15  **BDNF in the prefrontal cortex: Involvement in psychostimulant- and social defeat stress-induced behavioral sensitization**  
E. Nikulina¹², M. Lacagnina¹, J. Wang², S. Fanous¹, R. Hammer, Jr¹², ¹Basic Medical Sciences, University of Arizona, College of Medicine -Phoenix, Phoenix, AZ, ²Neuroscience, Arizona State University, Tempe, AZ

3:30  **Psychostimulant drug effects on spike train coding of sensory and decision-related signals in rodent thalamic and cortical circuits during quiet resting and sustained attention**  
B. Waterhouse, K. L. Agster, B. D. Clark, J. S. Shumsky, Neurobiology & Anatomy, Drexel University College of Medicine, Philadelphia, PA

---

**BADGES MUST BE WORN FOR ALL SESSIONS AND SOCIAL EVENTS**
3:45 Impaired fronto-amygdalar connectivity: A marker of poor behavioral control in cocaine dependence?
J. J. Suh1,2, R. Ehrman1,2, Y. Li1, Z. Wang1, D. Willard1, R. Fabianski1, R. Carson1, R. Hazan1, A. Fornash1, M. Goldman1, T. Franklin1, A. V. Hole1,2, R. Szucs1,2, C. P. O’Brien1,2, A. R. Childress1,2, 1University of Pennsylvania School of Medicine, and 2VA VISN4 MIRECC, Philadelphia, PA

4:00 Changes in brain activation pattern during cue reactivity after one month abstinence in heroin dependents
H. Ganjgahi1, P. Hasani Abharian1,2, J. Mc Clernom1, Z. Alam Mehrjerdi1, H. Tabatabaei1, M. Oghabian1, H. Ekhtiari1, 1Neurocognitive, Iranian National Center for Addiction Studies, 2Institute for Cognitive Sciences Studies, and 3Neuroimaging, Research Center for Science and Technologies, Tehran, Islamic Republic of Iran, 4Center for Nicotine and Smoking Cessation Research, Duke University Medical Center, Durham, NC

4:15 Relationship of impulsive personality traits and orbitofrontal rCBF in cocaine-addicted and healthy subjects
J. Braud1, A. Mazzarulli1, A. Minhaajuddin1, T. Harris1, M. Devous1, B. Adinoff1,2, 1UT Southwestern Medical Center, and 2VA North Texas Health Care System, Dallas, TX

4:30 Prefrontal-subcortical pathways mediating successful regulation of craving in cigarette smokers
H. Kober1,2, P. Mende-Siedlecki3, E. F. Kross4, J. Weber2, W. Mischel2, C. L. Hart2-5, K. N. Ochsner2, 1Psychiatry, Yale University, New Haven, CT, 2Psychology, Columbia University, New York, NY, 3Psychology, Princeton University, Princeton, NJ, 4Psychology, University of Michigan, Ann Arbor, MI, 5Psychiatry, Columbia University, New York, NY

4:45 Neural correlates of habit learning and reward processing in cocaine users
G. Tau1, R. Marsh1, F. Garcia1, X. Hao1, D. Xu1, S. Xu1, M. Packard2, Z. Wang1, Y. Duan1, A. Kangarlu1, D. Martinez1, B. Peterson1, 1Child and Adolescent Psychiatry, Columbia University / New York State Psychiatric Institute, NY, NY, 2Psychology, Texas A&M University, College Station, TX

Primm-Singleton Travel Awardees Meeting
Princesa
5:00 - 6:00 PM

Workshop I
Salons H1
8:00 - 10:00 PM

EPIDEMIOLOGY AND PUBLIC HEALTH RESEARCH METHODS

Chairs: James C. Anthony and Silvia S. Martins

Epidemiology and public health research: A Journal Editor’s Perspective
Deborah Hasin, Columbia University Mailman School of Public Health, New York, NY

Differential item functioning: Issues in measurement across population sub-groups
Eric Johnson, Research Triangle Institute, Research Triangle Park, NC

Methods issues in research on non-medical prescription drug use and dependence
Silvia Martins, Mental Health, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD

International and global health research challenges for scientists interested in methods issues
James C. Anthony, Epidemiology, Michigan State University, East Lansing, MI
Workshop II

EFFECTIVELY MENTORING TRAINEES FROM DIVERSE BACKGROUNDS: FUNDING OPPORTUNITIES AND PRACTICAL ADVICE

Chairs: Danielle C. Ompad and Liliane C. Windsor

Resources to increase diversity in drug abuse research
Lula A. Beatty, National Institute on Drug Abuse, Bethesda, MD

Mentoring students from diverse backgrounds: Interventions at UNC
Linda Dykstra, Psychology, University of North Carolina, Chapel Hill, NC

The truth about mentoring minorities
Carl Hart, New York State Psychiatric Institute, Columbia University, New York, NY

Practical advice for career development from a grateful former mentee
Martin Iguchi, Department of Community Health Sciences, UCLA School of Public Health, Los Angeles, CA

TBA
Danielle C. Ompad, New York Academy of Medicine, New York, NY

Workshop III

MINIMIZE LIABILITY, MANAGE RISK, ENSURE PATIENT SAFETY: EFFECTIVE STRATEGIES IN OUTPATIENT METHADONE TREATMENT

Chair: Michael T. Flaherty

Managing risk, patient safety and best practice – Panel Discussion
Todd Mandell, Vermont ADAP, Burlington, VT

Managing Risk: Basic definitions, guiding principles, and relationship between risk and practice in OPMM today
Lisa Torres, New Jersey Division of Addiction Services, Lawrenceville, NJ

Workshop IV

16TH ANNUAL CONTINGENCY MANAGEMENT WORKING GROUP

Chairs: Kelly E. Dunn and Kathryn A. Saulsgiver
Monday, June 14, 2010

Animals in Research Forum

WHAT CAN I DO AND HOW CAN WE WORK WITH OTHERS TO BUILD SUPPORT FOR ANIMAL RESEARCH?

Chairs: Nancy Ator and Shane Perrine

- Ways individual scientists and clinicians support animal research
  J. David Jentsch, Psychology, Psychiatry and Biobehavioral Sciences, University of California-LA, Los Angeles, CA

- Ways universities can support animal research and protect investigators and animals
  Marilyn E. Carroll, University of Minnesota, Minneapolis, MN

- Working with other scientific organizations to build support for animal research
  Nancy A. Ator, Johns Hopkins University, Baltimore, MD

- Working with national advocacy groups to build support for animal research
  Kristen Bocanegra, Americans for Medical Progress, Alexandria, VA

Symposium III

ADDRESSING THE INTERSECTION OF ADDICTION AND HIV IN CRIMINAL JUSTICE-INVOLVED POPULATIONS

Chairs: Timothy P. Condon and Redonna Chandler

- 10:00 Phase three clinical study of extended release naltrexone
  Evgeny Krupitsky, St. Petersburg Bekhterev Research, St. Petersburg, Russia

- 10:25 Addressing HIV and drug addiction in jail settings
  Frederick Altice, Yale School of Medicine, New Haven, CT

- 10:50 Addiction treatment in criminal justice populations
  Robert Schwartz, Friends Research Institute, Baltimore, MD

- 11:15 HIV continuum of care model in criminal justice populations
  David Wohl, Center for Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, NC

- 11:40 Discussant
  Charles O'Brien, University of Pennsylvania, Philadelphia VA Medical Center, Philadelphia, PA

Symposium IV

GENDER DIFFERENCES IN RESPONSE TO SOCIAL STRESS: PARALLELS FROM COCAINE AND ALCOHOL RESEARCH IN HUMAN AND NON-HUMAN PRIMATES

Chairs: Colleen A. Hanlon and Cora Lee Wetherington

- 10:00 Gender differences in effects of social variables on dopamine function and cocaine self-administration
  Paul W. Czoty, Wake Forest University School of Medicine, Winston-Salem, NC
The interaction of time, gender, and hormones on alcohol consumption
Kathleen A. Grant, Oregon National Primate Research Center, Oregon Health Sciences University, Portland, OR

Imaging the effects of social ostracism in cocaine users
Colleen A. Hanlon, Wake Forest University School of Medicine, Winston-Salem, NC

Female substance abusers and social drinkers show increased sensitivity to stress and stress-related drug intake
Helen Fox, Yale University School of Medicine, South New Haven, CT

Discussant
Mary Jeanne Kreek, Laboratory of the Biology of Addictive Diseases, Rockefeller University, New York, NY

Oral Communications 3

PRECLINICAL OPIOID RESEARCH

Chairs: Katharine M. Seip and Drake Morgan

Rewarding properties of heroin differ by dose and across individuals of an inbred rat strain
K. M. Seip, Y. Zhang, B. Reed, A. Ho, M. J. Kreek, Laboratory of the Biology of Addictive Diseases, The Rockefeller University, New York City, NY

Loperamide-induced taste aversions in F344 and LEW rats: Assessment of peripheral opioid activation
C. M. Davis1, J. L. Cobuzzi2, A. L. Riley2, 1Psychiatry and Behavioral Sciences, Division of Behavioral Biology, Johns Hopkins University School of Medicine, Baltimore, MD, 2Psychology, American University, Washington, DC

Brain metabolism in Lewis and Fischer 344 rats after morphine self-administration and extinction: A PET imaging study
E. Ambrosio1, G. L. Montoya1, M. L. Soto-Montenegro2,3, V. García-Vázquez2, J. Pascau3, M. Miguéns1, A. Higuera-Matas1, N. Del Olmo2, J. J. Vaquero2, C. García-Lecumberri1, M. Desco2,3, 1Psychobiology, UNED, 2Unidad de Medicina y Cirugía Experimental, and 3CIBERSAM, Hospital General Universitario Gregorio Marañón, and 4Pharmacology, Pharmaceutical Technology and Development, CEU University, Madrid, Spain

Prolonged reward after oxycodone treatment in females
V. Batra, L. M. Schrott, Pharmacology, Toxicology and Neuroscience, Louisiana State University Health Sciences Center-Shreveport, Shreveport, LA

Effects of morphine on thermal sensitivity in aged rats
D. Morgan1, L. Koerper2, J. D. Mitzelfelt1, C. S. Carter2, 1Psychiatry, University of Florida, and 2Aging and Geriatric Research, University of Florida, Gainesville, FL

Morphine in combination with metabotropic glutamate receptor antagonists in a model of inflammatory pain
D. E. Daugherty1, M. J. Picker1, L. A. Dykstra1,2, 1Psychology, and 2Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC

Why reinforcing drugs reinforce behavior?
F. Leri1, E. Nahas2, N. M. White2, 1Psychology, University of Guelph, Guelph, ON, and 2Psychology, McGill University, Montreal, QC, Canada
Morphine-induced motor stimulation and motor incoordination: Age-related differences in mice
W. Koek1,2, C. P. France2,1, 1Psychiatry, and 2Pharmacology, University of Texas Health Science
Center at San Antonio, San Antonio, TX

Oral Communications 4
Salon FG
10:00 AM - 12:00 PM

MISERY LOVES COMPANY: CO-OCCURRING DISORDERS

Chairs: Amy S. Bohnert and Roy Pickens

10:00  Psychiatric comorbidity as predictor of relapse after long-term abstinence from smoking
H. Chilcoat1, A. C. Andorn2, F. Tozzi4, D. J. Webb1, J. A. Graham3, 1Worldwide Epidemiology,
2Discovery Medicine, and 3Medicine Development Center, GlaxoSmithKline, Research
Triangle Park, NC, 4Genetics Operations, GlaxoSmithKline, Verona, Italy

10:15  The impact of psychiatric and substance use disorders on the risk of fatal accidental overdose
among veterans
A. S. Bohnert1,2, M. A. Ilgen1,2, R. Ignacio1,2, F. C. Blow1,2, 1VA National Serious Mental
Illness Treatment Research and Evaluation Center, and 2Psychiatry, University of Michigan,
Ann Arbor, MI

10:30  Adding Axis II personality disorders into the mix: Do they increase treatment-seeking behaviors
in males and females with substance use disorders?
A. Engels Dibble, D. Svikis, L. Keyser-Marcus, R. Pickens, VCU, Richmond, VA

10:45  Personal social networks of women with substance use and co-occurring mental disorders
E. M. Tracy1, L. Singer1, L. Stevenson1, S. Brown1, M. Oh Min1, A. Laudet1, C. McCarty2,
H. Kim1, M. Jun1, 1Case Western Reserve University, Mandel School of Applied Social
Sciences, Cleveland, OH, 2University of Florida, Gainesville, FL

11:00  Psychiatric comorbidity and the persistence of drug use disorders
M. Fenton1,2, K. Keyes1,2, T. Geier2, D. Hasin2,1, 1Epidemiology, Columbia University, and
2Psychiatry, New York State Psychiatric Institute, New York, NY

11:15  Adolescent cannabis use disorders and later depression: Effects of psychosocial mediators
N. R. Marmorstein1, W. G. Iacono2, 1Psychology, Rutgers University, Camden, NJ,
2Psychology, University of Minnesota, Minneapolis, MN

11:30  Comorbidity among drug use, anxiety, depression, and conduct disorder from adolescence to
young adulthood in a population-based prospective cohort study
M. Cerda1,3, M. S. Tracy2, B. N. Sanchez4, S. Galea2,3, 1New York Academy of Medicine, New
York, NY, 2Epidemiology, University of Michigan, Ann Arbor, MI, 3Epidemiology, Columbia
University, New York, NY, 4Biostatistics, University of Michigan, Ann Arbor, MI

11:45  A comparison of independent and substance-induced depression in cannabis-,
cocaine-, and opioid-dependent treatment seekers
E. Dakwar, E. V. Nunes, F. R. Levin, New York State Psychiatric Institute, New York City, NY
Poster Session I (Lunch)

Odd-numbered posters manned first hour;
Even-numbered, second hour

Set-up time begins Sunday no earlier than 2:30 PM
Must be removed by Monday no later than 2:30 PM

ADOLESCENT DRUG ABUSE I

1 Substance use disorders in siblings
   M. D. Reynolds, S. Mosovsky, L. Kirisci, S. Knopf, R. Tarter, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA

2 A latent class analysis of adolescent substance use and childhood sexual abuse
   S. H. Shin¹, H. Hong², A. Hazen³, ¹School of Social Work, Boston University, Boston, MA, ²Zicklin School of Business, Baruch College of the City University of New York, New York, NY, ³Rady Children’s Hospital, San Diego, CA

3 Early substance use and risks associated with father absence
   K. Stewart, M. Waldron, Counseling and Educational Psychology, Indiana University Bloomington, Bloomington, IN

4 Longitudinal study of levels of adolescent drug use: An SEM analysis of parental monitoring
   K. M. Bohnert, J. C. Anthony, N. Breslau, Epidemiology, Michigan State University, East Lansing, MI

5 Parental approval and adolescent smoking: Gender and race/ethnicity differences
   G. Kong, R. Desai, D. Cavallo, M. Potenza, S. Krishnan-Sarin, Psychiatry, Yale University School of Medicine, New Haven, CT

6 Neighborhood risk and protective factor influences on school conduct and performance
   R. J. Evans, A. E. Goldweber, W. W. Latimer, Mental Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD

7 How resilience and its factors contribute to drug use in adolescents
   T. D. Amato¹, T. M. Ronzani², A. R. Noto¹, ¹Psychobiology, Federal University of São Paulo, São Paulo, ²Psychology, Federal University of Juiz de Fora, Juiz de Fora, Brazil

8 Psychoactive drug use and associated risk behaviors in Brazil
   D. P. Locatelli, E. S. Opaleye, Z. V. Sanchez, A. R. Noto, Psychobiology, Federal University of Sao Paulo, Sao Paulo, Brazil

9 Substance use among urban adolescents presenting to indigent primary care clinics
   M. Walton¹, K. T. Barry¹,², S. Resko³, S. T. Chermack¹,², R. A. Zucker¹, M. A. Zimmerman¹, B. M. Booth¹, F. C. Blow¹,², ¹University of Michigan, and ²VA, Ann Arbor, ³Wayne State University, Detroit, MI, ⁴University of Arkansas for Medical Sciences and VA, Little Rock, AR

10 Psychometric evaluation of the A-SIDE assessment of relapse risk for youth
   L. Brackenbury, M. Buras, K. G. Anderson, Psychology, Reed College, Portland, OR

11 Illicit drug use and extracurricular involvement during college
   L. M. Garnier-Dykstra¹, K. E. O’Grady², K. M. Caldeira¹, K. B. Vincent¹, A. Arria¹, ¹Center on Young Adult Health and Development, and ²Psychology, University of Maryland, College Park, MD
SEDATIVE-HYPNOTICS

12 Subtypes of adolescent sedative/anxiolytic misusers: A latent profile analysis
M. T. Hall1, M. O. Howard2, S. E. McCabe3, 1Behavioral Science, University of Kentucky, Lexington, KY, 2School of Social Work, University of North Carolina at Chapel Hill, Chapel Hill, NC, 3Substance Abuse Research Center and Institute for Research on Women and Gender, University of Michigan, Ann Arbor, MI

13 Progesterone modulation of the discriminative stimulus effects of triazolam
S. Babalonis, J. A. Lile, C. A. Martin, T. H. Kelly, University of Kentucky, Lexington, KY

14 Twelve months of nightly zolpidem does not enhance the likelihood of rebound insomnia: A prospective placebo controlled study
S. Randall, T. Roehrs, E. Harris, R. Maan, T. Roth, Sleep Disorders Center, Henry Ford Health System, Detroit, MI

15 Twelve months of nightly zolpidem does not lead to dose escalation: A prospective placebo-controlled study
T. Roehrs, S. Randall, E. Harris, R. Maan, T. Roth, T. Roth, Sleep Disorders Center, Henry Ford Health System, Detroit, MI

16 Acute effects of Ambien CR™ on cognitive performance and sleep in healthy male volunteers after chronic nightly use
M. Z. Mintzer, B. A. Kleykamp, R. R. Griffiths, U. D. McCann, M. T. Smith, Johns Hopkins University, Baltimore, MD

17 Healthy volunteers feel “high” and “like” the subjective effects of zolpidem but do not choose it over money
Y. Mashhoon1, S. E. Lukas1,2, S. C. Licata1, 1Behavioral Psychopharmacology Research Laboratory, McLean Hospital/Harvard Medical School, Belmont, MA, 2Brain Imaging Center, McLean Hospital/Harvard Medical School, Belmont, MA

ALCOHOL

18 Kudzu root extract does not affect the sleep/wake cycle in moderate drinkers
B. K. Bracken1,2, D. M. Penetar1,2, R. R. Maclean3, D. Y. Lee1,2, S. E. Lukas1,2, 1McLean Hospital, and 2Harvard Medical School, Belmont, MA, 3Penn State, State College, PA

19 Electronic monitoring of cortisol daytime profiles during alcohol withdrawal in humans
M. Warnecke1, J. Cordes1, W. Gaebel1, C. G. Schuetz2, H. D. Chilcoat3, 1Psychiatry, Section Addictive Disorders, University of Duesseldorf, Duesseldorf, Germany, 2Psychiatry, University of British Columbia, Vancouver, BC, Canada, 3Glaxo Smith Kline, Chapel Hill, NC

20 Are the effects of alcohol on cue-induced craving mediated by attentional bias?
A. Ataya, M. R. Munafò, University of Bristol, Bristol, United Kingdom

21 Effects of acute alcohol consumption on response inhibition: Evidence of a task-dependent effect
S. Adams, M. R. Munafò, Experimental Psychology, University of Bristol, Bristol, United Kingdom

22 The anticonvulsant Levetiracetam can potentiate alcohol consumption in non-treatment-seeking heavy drinkers: Contribution of DRD2 polymorphisms
J. Mitchell, L. E. Grossman, A. R. Coker, R. O. Messing, Department of Neurology: Ernest Gallo Clinic and Research Center, UCSF, San Francisco, CA

23 Exercise and fitness levels among treatment-seeking substance-dependent individuals
24 Alcohol and other drugs related violence reported at special police stations for women
A. R. Noto, L. P. Augusto, Psicobiologia, UNIFESP, São Paulo, Brazil

25 Changing university students’ stigmatizing attitudes toward substance abuse using a research-based neuroscience of addiction curriculum infusion: Results from the NIDA enters college project
J. A. Hartje1, N. A. Roget1, M. S. Berry1, W. L. Woods1, P. Riggs2, 1Center for the Application of Substance Abuse Technologies, University of Nevada, Reno, NV, 2Health Sciences Center, University of Colorado, Denver, CO

26 Drunk and drugged driving on Brazilian highways
F. Pechansky1, R. DeBonì1, D. Benzano1, C. G. Leukefeld2, 1Psychiatry, Center for Drug and Alcohol Research, UFRGS, Porto Alegre, Brazil, 2University of Kentucky, Lexington, KY

27 Drinking and driving in a driver probabilistic sample from alcohol outlets of Porto Alegre, Brazil: Preliminary findings
R. De Bonì1, M. T. Vasconcellos2, F. I. Bastos3, F. Pechansky1, 1Psychiatry, CPAD- Federal University Rio Grande do Sul, Porto Alegre, 2ENCE/IBGE, and 3FIOCRÚZ, Rio de Janeiro, Brazil

28 Beyond sanctions: Is there a need to treat first-time DUI offenders?
J. C. Maxwell1, J. Freeman2, J. Davey3, 1University of Texas, Austin, TX, 2Queensland University of Technology, Brisbane, QLD, Australia

29 Abstinence and drinking patterns among women in Africa
P. Martinez, J. Røislien, T. Clausen, Norwegian Center for Addiction Research, University of Oslo, Oslo, Norway

30 A cross-national view of socially maladaptive behavior and drug use: Evidence from seven Latin American countries
O. McBride, J. C. Anthony, Epidemiology, Michigan State University, East Lansing, MI

31 Prevalence of hepatitis B in a group of French alcohol abusers
M. Marc1,2, P. Melin1,2, A. Hjì1, M. Guillaumot2, S. Samouri1, M. Schoeny1, F. Fournier2, C. Bremart2, 1CHG St dizier, and 2CSAPA52, Saint dizier, France

32 Can Fibroscan® predict esophageal varices among cirrhotic alcohol abusers?
A. Hjì1, P. Melin1,2, S. Samouri1, M. Marc1,2, M. Schoeny1, M. Guillaumot2, J. Fournier2, C. Bremard2, 1CHG St dizier, 2CSAPA 52, and 3gastro enterology, CHG, Saint dizier, France

33 Preliminary NIATx 200 results: Waiting time reduction from first request to assessment
A. Quanbeck1, A. Wheelock1, J. H. Ford1, A. Pulvermacher1, J. Robinson1, D. McCarty2, D. Gustafson1, 1University of Wisconsin - Madison, Madison, WI, 2Oregon Health Sciences University, Portland, OR

34 Staff perspectives on innovation adoption: Lessons learned from NIATx 200

34 Positive reinforcement improves attendance and achievement on self-paced typing training programs in a Therapeutic Workplace for alcohol dependence
M. N. Koffarnus, C. J. Wong, K. Diemer, M. Fingerhood, G. E. Bigelow, K. Silverman, Johns Hopkins University School of Medicine, Baltimore, MD

36 Relational and technical processes of MI, Cognitive, and Client-Centered therapies
K. S. Ingersoll1, C. C. Wagner2, 1Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, VA, 2Rehab Counseling, Virginia Commonwealth University, Richmond, VA
37 Perceptions of alcohol stigma: Consequences for treatment utilization in a general population sample
K. Keyes\textsuperscript{1}, M. Hatzenbuehler\textsuperscript{2}, K. McLaughlin\textsuperscript{3}, T. Kushnir\textsuperscript{4}, D. Hasin\textsuperscript{1}, \textsuperscript{1}New York State Psychiatric Institute, New York, NY, \textsuperscript{2}Yale University, New Haven, CT, \textsuperscript{3}Harvard University, Cambridge, MA

EPIDEMIOLOGY

38 Relationships between substance use and neuropsychological functioning among drug users in Novosibirsk, Russia
E. Dunne, J. Zur, A. Melnikov, W. Latimer, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

39 Emergence of clinical features of dependence soon after onset of extra-medical use of opioid-analgesic compounds
O. A. Adelaja, N. S. Miller, J. C. Anthony, Michigan State University, East Lansing, MI

40 Resolving diagnostic comparability of opiate addiction using two datasets collected 30 years apart
R. K. Price, G. Widner, Psychiatry, Washington University School of Medicine, St. Louis, MO

41 Persistent nonmarijuana drug use trajectories and general health status among adults followed over 18 years (the CARDIA study)
S. Kertesz\textsuperscript{1,2}, Y. Khodneva\textsuperscript{1}, M. Safford\textsuperscript{1}, J. Richman\textsuperscript{1}, M. Pletcher\textsuperscript{3}, \textsuperscript{1}University of Alabama, and \textsuperscript{2}VA Medical Center, Birmingham, AL, \textsuperscript{3}University of California, San Francisco, CA

42 Young adult substance use and workplace policies and conditions
C. L. Storr\textsuperscript{1,2}, K. B. Roth\textsuperscript{2}, \textsuperscript{1}University of Maryland Baltimore, and \textsuperscript{2}Johns Hopkins University, Baltimore, MD

43 Prevalence of substance use and dependence in the workplace. A cross-sectional study in French occupational medicine centers, Aquitaine, France, EU
F. Serre\textsuperscript{1}, S. Moulonguet-Cordier\textsuperscript{2,1}, C. Denis\textsuperscript{1}, M. Fatséas\textsuperscript{1}, C. Maysonnave\textsuperscript{3}, M. Auriacombe\textsuperscript{1}, \textsuperscript{1}Addiction Psychiatry EA4139/INSERM-IFR99, Universite Victor Segalen Bordeaux 2, \textsuperscript{2}Occupational medicine, Occupational medicine center, and \textsuperscript{3}Occupational medicine, Regional State Control Agency, Bordeaux, France

44 Cumulative occurrence of illegal drug use clinical features in 16 World Mental Health Surveys countries
M. Radovanovic\textsuperscript{1,2}, J. C. Anthony\textsuperscript{2}, H. Cheng\textsuperscript{2}, W. M. H. S. Initiative\textsuperscript{3}, \textsuperscript{1}University Psychiatric Hospital, Ljubljana, Slovenia, \textsuperscript{2}Michigan State University, East Lansing, MI, \textsuperscript{3}World Mental Health Surveys Consortium, Boston, MA

45 Traumatic event re-exposure increases treatment-seeking in syringe exchange participants
J. Peirce, V. L. King, R. K. Brooner, M. S. Kidorf, Johns Hopkins University School of Medicine, Baltimore, MD

46 Early vs. late onset crack use: A case-control study
D. C. Ompad, V. Nandi, D. Vlahov, Center for Urban Epidemiologic Studies, New York Academy of Medicine, New York, NY

47 Individual, study, and neighborhood characteristics associated with successful peer recruitment of drug users via respondent-driven sampling in New York City
A. Rudolph\textsuperscript{1}, N. D. Crawford\textsuperscript{2,3}, C. Latkin\textsuperscript{1}, D. C. Ompad\textsuperscript{1}, E. O. Benjamin\textsuperscript{3}, K. White\textsuperscript{4}, C. M. Fuller\textsuperscript{2,3}, \textsuperscript{1}Johns Hopkins School of Public Health, Baltimore, MD, \textsuperscript{2}Columbia University, and \textsuperscript{3}New York Academy of Medicine, New York, NY, \textsuperscript{4}Harvard University, Boston, MA

Monday, June 14, 2010
48 Higher acute care hospital utilization among medical inpatients discharged with a substance use disorder diagnosis
A. Y. Walley¹, M. K. Paasche-Orlow¹, E. C. Lee², S. R. Forsythe², B. W. Jack², ¹General Internal Medicine, and ²Family Medicine, Boston University School of Medicine, Boston, MA

49 Sex, drugs, and rock and roll: Visualizing behavioral mortality for the US population
C. Wright, R. K. Lanier, Rock Creek Pharmaceuticals, Inc., Gloucester, MA

50 Is cannabis an aphrodisiac or sexual suppressant? A view from the past
S. Chandra, D. Barondess, J. C. Anthony, Michigan State University, East Lansing, MI

51 Cannabis use among convicted drinking drivers
B. Brands¹,², R. Zalcman², R. Mann²³, G. Stoduto², R. Thomas², ¹Office of Drug and Alcohol Research and Surveillance, Health Canada, Ottawa, ²Centre for Addiction and Mental Health, and ³University of Toronto, Toronto, ON, Canada

52 Cross-national research on early-onset cannabis use and failure to complete educational milestones
F. A. Fiestas, J. C. Anthony, Epidemiology, Michigan State University, Lima, Peru

53 The growth of neighborhood hazards and youthful drug involvement
C. M. Furr-Holden, A. J. Milam, N. Ialongo, P. J. Leaf, Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

54 French modified Addiction Severity Index: Psychometrics properties in tobacco users and validity of the added tobacco section
C. Denis¹, M. Fatséas¹, S. Vittet¹, V. Beltrand²,¹, J. Daulouède²,¹, M. Auriacombe¹,², ¹Addiction Psychiatry EA4139/INSERM-IFR99, Université Victor Segalen Bordeaux 2, Bordeaux, France, ²Addiction Treatment Center, Bizia, Bayonne, France

55 Nicotine dependence among very recent-onset cigarette smokers in the USA
M. M. Catacora, J. C. Anthony, Epidemiology, Michigan State University, East Lansing, MI

56 Smoking cessation in a low-income urban setting: Lessons learned
P. Sheikhattari¹,², M. Bolden¹, P. Cassat³, L. Chao³, D. Wall³, F. A. Wagner¹,², ¹Center for Health Disparity Solutions, Morgan State University, ²School of Community Health and Policy, Morgan State University, and ³Peoples’ Community Health Centers, Baltimore, MD

57 A population-based investigation of the co-occurrence of non-medical prescription stimulant use and cigarette smoking among US Youth (Age 12-21)
S. P. Novak, E. Johnson, D. Fishbein, A. Kral, Behavioral Epidemiology, RTI International, Research Triangle Park, NC

58 Clustering of tobacco use: Results from the Peruvian mental health survey, 2002-2006
V. Cruz¹,², C. Cachay², J. Saavedra²,³, E. Kraenau¹, J. Galindo², G. Cruz², J. C. Anthony¹, ¹Department of Epidemiology, Michigan State University, East Lansing, MI, ²Office of Epidemiology, Peruvian National Institute of Mental Health, Lima, Peru, ³Department of Psychiatry, Cayetano Heredia Peruvian University, Lima, Peru, ⁴School of Statistics, Main National University of San Marcos, Lima, Peru

THEORETICAL/COMMENTARY

59 The status of drug use among club drug users in Taiwan
J. Hsu¹, W. I. Tsay¹, C. H. Lin¹, C. S. Chien¹, K. S. Leung², L. B. Cottler², ¹Epidemiology and Education Division, National Bureau of Controlled Drugs, DOH, Taipei, Taiwan, ²Epidemiology and Prevention Research Group, Psychiatry, Washington University School of Medicine, St. Louis, MO
60 Collegiate recovery communities: Facilitating and investigating recovery in the young adult demographic
K. S. Harris, S. A. Smock, A. K. Baker, Center for the Study of Addiction and Recovery, Texas Tech University, Lubbock, TX

61 Latin American psychiatrists develop biological protocols to control craving and prevent relapse in cocaine dependence
T. Llosa, COCA MEDICA, Lima, Peru

62 A performance-based pilot project in alcohol and other drug treatment
L. L. Ransom1,2, D. A. Crevecoeur1, A. C. Myers1, J. A. Annon1, R. A. Rawson1, 1Integrated Substance Abuse Programs, UCLA, Los Angeles, CA, 2Psychology, California Lutheran University, Thousand Oaks, CA

63 Revision of the Reynolds Horton Theory of Executive Functioning: Implications for addictions treatment
A. M. Horton, C. R. Reynolds, Neuropsychology Section, Psych Associates of Maryland, Bethesda, MD

64 The exponential model of demand: A novel, robust, and broadly applicable assay for translational behavioral pharmacology
P. Roma1,2, B. J. Kaminski2, R. Spiga1, N. A. Ator1, S. R. Hursh1,2, 1Institutes for Behavior Resources, and 2Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD

65 Where the rubber meets the road: An integrated model of technology transfer in the innovation process
A. ATTC Network Technology Transfer Workgroup, ATTC Network, Kansas City, MO

66 From concept to practice: A strategic approach in disseminating motivational interviewing in a rural and frontier state
C. Peters1,2, A. H. Skinstad1,2, K. Summers1,2, 1Prairielands Addiction Technology Transfer Center, and 2Community and Behavioral Health, University of Iowa, College of Public Health, Iowa City, IA

67 Robust optimal decision policies for adaptive, time-varying interventions using Model Predictive Control
D. E. Rivera1, N. Nandola1, L. M. Collins2,3, 1Mechanical, Aerospace, Chemical and Materials Engineering, Arizona State University, Tempe, AZ, 2The Methodology Center, and 3Human Development and Family Studies, Penn State University, State College, PA

68 Prescription opioids: Managing the risks while maintaining appropriate patient access
J. Henningfield, R. Fant, S. Schnoll, M. Sembower, Research & Health Policy and Risk Management, Pinney Associates, Bethesda, MD

69 Free vs paid services: A comparative analysis in a harm-reduction-oriented outpatient methadone maintenance center
A. O. Abagiu1,2, M. Anghelescu2, R. Ianos-Rancovici2, B. Rusu2, I. G. Stoica2, L. Stanciut2, F. Georgescu2, F. Gheorghe2, L. Velica2, E. Cojocaru2, 1Adults 6, National Institute for Infectious Diseases Prof. Dr. Matei Bals, and 2Arena - First low threshold MMT Center, Bucharest, Romania

70 The CPDD Special Conference on Risk Management and Post-Marketing Surveillance of CNS Drugs: Implications for opioid REMS
C. R. Schuster1, J. Henningfield2, R. Balster1, A. Barthwell4, C. E. Johanson1, 1CRS Associates, Chicago, IL, 2Research and Health Policy, Pinney Associates and Johns Hopkins, Bethesda, MD, 3Medical College of VA, Richmond, VA, 4EMGlobal, Arlington, VA
71 Comparison of the European and US approaches to the evaluation of abuse liability and drug scheduling for new chemical entities
   R. Fant¹, J. E. Henningfield¹, D. J. Heal², ¹Pinney Associates, Bethesda, MD, ²RenaSci Consultancy Ltd, Nottingham, United Kingdom

72 The global infrastructure for addiction science: A public health perspective
   D. Morisano¹, T. F. Babor², ¹Psychiatry/Child & Family Institute, St. Luke’s-Roosevelt Hospital Center, New York, NY, ²Community Medicine, University of Connecticut School of Medicine, Farmington, CT

73 The development of a new model for international collaborative research and education
   C. B. McCoy, M. Comerford, Comprehensive Drug Research Center, University of Miami, Miami, FL

COCAINE: HUMAN STUDIES

74 Assessing the reliability and validity of cocaine use algorithms in clinical trials
   W. Y. Cheng, E. Nunes, F. Levin, A. Bisaga, Psychiatry, Columbia University, New York, NY

75 Theories of addiction: Cocaine users’ explanation for continuing drug use and relapse
   C. N. Haile, R. De La Garza, II, J. J. Mahoney, A. D. Kalechstein, T. F. Newton, Menninger Department of Psychiatry & Behavioral Sciences, Baylor College of Medicine, Houston, TX

76 The reinforcing effects of intranasal cocaine on a progressive ratio schedule
   W. W. Stoops¹,², J. A. Lile¹, C. R. Rush¹³⁴, ¹Behavioral Science, ²Center on Drug and Alcohol Research, ³Psychiatry, and ⁴Psychology, University of Kentucky, Lexington, KY

77 Dopamine β hydroxylase inhibitor SYN117 decreases subjective effects of cocaine
   K. A. Cunningham¹, C. L. Carbone¹, N. C. Anastasio¹, T. A. Harper¹, F. G. Moeller², D. L. Ware¹, M. A. Fuller¹, G. J. Holstein¹, K. E. Smith¹, J. B. Jayroe¹, S. Bandak³, K. Reiman³, A. Neale³, L. Pickford³, ¹Center for Addiction Research, University Texas Medical Branch, Galveston, TX, ²Psychiatry Behavioral Science, University of Texas Health Science Center, Houston, TX, ³Synosia Therapeutics, Inc., San Francisco, CA

78 Effect of cocaine on buprenorphine or methadone pharmacokinetics: Clinical implications
   E. McCance-Katz¹, P. M. Rainey², D. E. Moody³, J. Arenander¹, P. Jatlow⁴, ¹Psychiatry, UCSF, Berkeley, CA, ²Laboratory Medicine, University of Washington, Seattle, WA, ³Toxicology, University of Utah, Salt Lake City, UT, ⁴Laboratory Medicine, Yale University, New Haven, CT

79 Impact of D-cycloserine on cocaine cue extinction
   K. L. Price¹, S. M. DeSantis², M. E. Saladin¹, A. L. McRae-Clark¹, C. B. McWhite¹, K. T. Brady¹, ¹Psychiatry and Behavioral Sciences, and ²Biometry, Bioinformatics and Epidemiology, Medical University of South Carolina, Charleston, SC

80 The discriminative-stimulus, subject-rated, performance and cardiovascular effects of cocaine alone and in combination with aripiprazole in humans
   J. Lile, W. Stoops, L. Hays, C. Rush, University of Kentucky College of Medicine, Lexington, KY

81 Extinction of attentional bias to cocaine-related stimuli: Difference between non-treatment-seeking and treatment-seeking cocaine-dependent subjects
   S. Liu¹, S. D. Lane¹, J. M. Schmitz¹, A. J. Waters², K. A. Cunningham³, F. G. Moeller¹, ¹Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston, Houston, TX, ²Medical and Clinical Psychology, Uniformed Services University of the Health Sciences, Bethesda, MD, ³Center for Addiction Research and Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX
82 Neuropsychological performance of cocaine addicts during treatment
G. García-Fernández1, O. García-Rodriguez2, R. Secades-Villa1, S. Fernandez-Artamendi1, J. Fernandez-Hermida1, 1Psychology, University of Oviedo, Oviedo, Spain, 2Clinical Psychology, University of Barcelona, Barcelona, Spain

83 Adding voucher-based incentives to CRA improves outcomes during treatment for cocaine dependence

84 A money management-based therapy increases valuation of future rewards
A. C. Black, M. I. Rosen, Psychiatry, Yale University, West Haven, CT

85 Inter-temporal choice of cocaine addicts: Single and cross commodity discounting of cocaine and money
W. K. Bickel, D. R. Christensen, R. D. Landes, L. Jackson, B. A. Jones, University of Arkansas for Medical Sciences, Little Rock, AR

86 The case for cash: Contingency management for cocaine dependence
D. S. Festinger1, K. L. Dugosh1, K. C. Kirby1, J. C. Croft1, D. B. Marlowe1,2, 1Treatment Research Institute, Philadelphia, PA, 2National Association of Drug Court Professionals, Alexandria, VA

87 Effects of voucher payment through contingency management in topiramate treatment for cocaine dependence
A. Umbricht1, J. P. Nanda2, E. L. Winstanley1, D. A. Tompkins1, M. Z. Mintzer1, E. C. Strain1, G. E. Bigelow1, 1Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, and 2Bloomberg School of Public Health, Baltimore, MD

88 CM treatment outcomes for cocaine-dependent homeless as a function of age
J. Milby1, J. Schumacher1, D. Wallace2, L. Hayes1, M. Cobb-Burns3, J. Reese1, S. Mennemeyer1, R. Vuchinich1, 1University of Alabama at Birmingham, Birmingham, AL, 2RTI International, Raleigh, NC, 3Northwestern University, Chicago, IL

89 Alcohol dependence does not influence drug abstinence outcomes from contingency management treatment among cocaine-dependent homeless persons
R. Vuchinich1, D. Wallace2, J. Milby1, J. Schumacher1, S. Mennemeyer1, S. Kertesz1, 1University of Alabama at Birmingham, Birmingham, AL, 2RTI International, Research Triangle Park, NC

90 The ability of initial urine drug screen results to identify good prognosis patients among individuals addicted to both cocaine and alcohol

91 Feasibility and effectiveness of computer-based therapy in a community-based program
A. C. Brooks, D. Ryder, D. Carise, K. Kirby, Treatment Research Institute, Philadelphia, PA

92 Balloon Analogue Risk Task and Affect
T. L. White1, C. W. Lejuez2, H. de Wit3, 1Alcohol & Addiction/Community Health, Brown University, Providence, RI, 2Psychology, University of Maryland, College Park, MD, 3Psychiatry, University of Chicago, Chicago, IL

93 Changes in risk-taking behavior as a function of motivational saliency and value
C. Kopetz, N. Calvin, A. Lee, C. Lejuez, Center for Addictions, Personality, and Emotion Research, University of Maryland, College Park, MD
94 Excited delirium, tasers and sudden death
D. C. Mash1, B. A. Hyma2, S. B. Karch3, H. Druid4, C. V. Wettl5, L. Duque1, N. Adi1,
J. P. Pablo1, X. Xie1, 1Neurology, Molecular and Cellular Pharmacology, Univ. of Miami Miller
School of Medicine, and 2Miami-Dade Medical Examiner, Miami, FL, 3University of
California, Berkeley, CA, 4Karolinska Institute, Stockholm, Sweden, 5Medical Legal
Investigations and Forensic Sciences, Suffolk, NY

95 Specific predictors of suicide attempts in a high risk community corrections population
C. McCullumsmith, J. Hammell, J. Fife, K. Cropsey, Psychiatry, University of Alabama at
Birmingham, Birmingham, AL

96 Variations in sexual risk behaviors associated with sexually transmitted diseases among African-
American and white female drug users
C. E. Cavanaugh1, L. J. Floyd1, T. V. Penniman1, A. Hulbert1, C. Gaydos2, W. W. Latimer1,
1Public Health, Mental Health, and 2Div Infectious Disease, Medicine, Johns Hopkins
University, Baltimore, MD

97 Strategies developed by crack users to deal with the risks resulting from the consumption
L. A. Ribeiro, Z. V. Sanchez, S. A. Nappo, Psychobiology, Federal University of Sao Paulo,
Sao Paulo, Brazil

STIMULANTS: ANIMAL I

98 Repeated administration of a longer-acting mutant cocaine esterase: Interactions with the acute
cardiovascular effects of cocaine and immune responses in freely moving rhesus monkeys
J. H. Woods, M. C. Ko, University of Michigan Medical School, Ann Arbor, MI

99 Tetrahydroisoquinolines as orexin-1 receptor antagonists: Structure-activity relationships
Y. Zhang, D. A. Perrey, B. P. Gilmour, K. Warner, T. Langston, H. A. Navarro, B. F. Thomas,
Research Triangle Institute, Research Triangle Park, NC

100 Fat content and amount of chow impact the sensitivity of rats to quinpirole-induced yawning
M. Baladi1, C. P. France1,2, 1Pharmacology, and 2Psychiatry, University of Texas Health Science
Center, San Antonio, TX

101 Knockdown of presynaptic D2 receptors in dorsal striatum inhibits the behavioral and
neurochemical effects of haloperidol
C. E. Bass, E. B. Oleson, L. C. Blume, D. C. Roberts, A. C. Howlett, E. A. Budygin,
Physiology and Pharmacology, Wake Forest University Health Sciences, Winston Salem, NC

102 Attenuation of cocaine self-administration by novel dopamine D3 receptor ligands
B. C. Nolan1, L. M. Robertson1, J. M. Pang1, M. Barajas1, S. M. Weber1, J. Durbin2,
N. A. Peartree1, R. H. Mach2, R. R. Luedtke1, J. L. Neisewander1, 1Psychology, Arizona State
University, Tempe, AZ, 2Washington University School of Medicine, St. Louis, MO,
3University of North Texas Health Science Center, Fort Worth, TX

103 Enhanced dopamine release in the dorsolateral caudate putamen during relapse as a function of
previous cocaine self-administration history
A. Gabriele, A. M. Pacchioni, R. E. See, Neurosciences, Medical University of South
Carolina, Charleston, SC

104 Anxiogenic properties of cocaine-paired cues in rats with a prior history of self-administration
D. Buffalari, C. K. Baldwin, R. E. See, Neuroscience, Medical University of South Carolina,
Charleston, SC

BADGES MUST BE WORN FOR ALL SESSIONS AND SOCIAL EVENTS
105 Effects of the monoamine releasers PAL-353 and (+)phenmetrazine on choice between cocaine and food in rhesus monkeys
M. L. Banks1, B. E. Blough2, S. S. Negus1, 1Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, 2Center for Organic and Medicinal Chemistry, Research Triangle Institute, Research Triangle Park, NC

106 Reversible and persistent decreases in cocaine self-administration after treatment with the cholinesterase inhibitors rivastigmine and donepezil
K. Grasing1, Y. Yang2, S. He1, 1Substance Abuse Research Laboratory, Kansas City VA Medical Center, Kansas City, MO, 2Institute of Combined Chinese and Western Medicine, Southern Medical University, Guangzhou, China

107 Acetylcholine esterase inhibitor tacrine reduces extinction responding for amphetamine
A. S. Giarola1, A. Auber2, V. Tedesco2, G. Fumagalli2, C. Chiamulera2, 1Safety Assessment, GlaxoSmithKline, and 2Medicine and Public Health, University of Verona, Verona, Italy

108 Effects of the nicotinic receptor partial agonist varenicline on cocaine- and food-maintained behavior in rats
M. G. LeSage1,2, F. I. Carroll3, 1Medicine, Minneapolis Medical Research Foundation, and 2Medicine, University of Minnesota, Minneapolis, MN, 3Organic and Medicinal Chemistry, Research Triangle Institute, Research Triangle Park, NC

109 Galantamine ameliorates the impairment of recognition memory in mice treated with methamphetamine repeatedly
A. Mouri1,2, Y. Noda3,4, D. Wang1, Y. Ando1, Y. Waki3, S. Yamada3, T. Nabeshima1,4, 1Chemical Pharmacology, Graduate School of Pharmaceutical Sciences Meijo University, Nagoya, 2Division of Scientific Affairs, Japanese Society of Pharmacopoeia, Tokyo, 3Division of Clinical Sciences and Neuropsychopharmacology, Graduate School of Pharmaceutical Sciences, Meijo University, Nagoya, and 4The Academic Frontier Project for Private Universities, Comparative Cognitive Science Institutes, Meijo University, Nagoya, Japan

110 Effects of dopamine D1 and NMDA receptors on acute cocaine-induced Fos protein expression and MKP-1 phosphorylation in the striatum of Fischer rats

111 A rapid method to measure limbic and striatal behavior and dopamine neurochemistry in mice
S. P. Vickers, D. J. Heal, M. R. Prow, S. G. Dykes, S. C. Cheetham, RenaSci Consultancy Ltd, Nottingham, United Kingdom

112 “Neurochemical fingerprinting” as a rapid technique to discriminate between drugs with different presynaptic dopaminergic mechanisms
D. J. Heal, M. R. Prow, S. C. Cheetham, RenaSci Consultancy Ltd, Nottingham, United Kingdom

113 Do dopaminergic drugs induce a place preference in normal rat?
Y. Zengin1, N. Authier1, P. Courty1, P. Llorca1, F. Durif2, 1CHU Gabriel Montpied - CMP B - Service de Psychiatrie du Pr. PM Llorca, and 2Service de Neurologie, Clermont Ferrand, France

114 Disruption of prepulse inhibition by apomorphine across modalities
L. Moran, R. M. Booze, C. F. Mactutus, Psychology, University of South Carolina, Columbia, SC

BADGES MUST BE WORN FOR ALL SESSIONS AND SOCIAL EVENTS
Monday, June 14, 2010

HALUCINOGENS

115 Behavioral effects of the novel hallucinogen 2C-C
M. B. Gatch, C. Taylor, C. Elsken, M. J. Forster, Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX

116 Discriminative stimulus effects of various classes of psychoactive compounds in ketamine-trained rats
K. Yoshizawa, K. Aoki, T. Mori, N. Kuzumaki, M. Narita, T. Suzuki, Toxicology, Hoshi University School of Pharmacy and Pharmaceutical Science, Tokyo, Japan

117 Discriminative stimulus effects of the synthetic hallucinogen N,N-diisopropyltryptamine
T. Carbonaro, M. B. Gatch, Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX

118 Discriminative, locomotor, and place conditioning effects of salvinorin A and its synthetic derivatives
L. E. Baker, M. M. Peet, S. L. Walker, J. J. Panos, Psychology, Western Michigan University, Kalamazoo, MI

119 MTEP drug discrimination: Psychoactive effects selectively induced by mGluR5 antagonists
M. D. Swedberg¹, P. Raboisson², C. Velasquez¹, M. Ståhlberg¹, ¹Safety Pharmacology, and ²Disease Biology, AstraZeneca R&D Södertälje, Södertälje, Sweden

120 Psilocybin dose-effects in healthy volunteers: Mystical-type experience, fear, and headache
R. R. Griffiths¹, M. W. Johnson², ¹Psychiatry and Neuroscience, and ²Psychiatry, Johns Hopkins School of Medicine, Baltimore, MD

121 Psilocybin-occasioned mystical experience predicts increases in the NEO-PI personality trait of openness
K. MacLean, M. Johnson, R. Griffiths, Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD

PROGRAM DESCRIPTION

122 Current drug scheduling reviews reported by the Drug Enforcement Administration

123 DEA monitoring of anabolic steroids and emerging drugs
T. L. Boos, L. L. Wong, C. M. Carr, C. A. Sannerud, Drug & Chemical Evaluation Section, Office of Diversion Control, Drug Enforcement Administration, Springfield, VA

124 Manufacture, characterization, and stability of standardized marijuana cigarettes
K. Davis¹, P. G. Pande¹, B. Thomas¹, S. Sabharwal¹, M. McCleary¹, L. Caddell¹, P. Leahy¹, M. ElSohly², ¹Analytical Chemistry & Pharmaceutics, RTI International, Research Triangle Park, NC, ²University of Mississippi, University, MS

125 Use of the Michigan Automated Prescription System to monitor and manage diversion in an urban methadone clinic
C. Christensen, G. L. Rhodes, M. Berman, J. Bado, S. Entenman, M. Greenwald, Wayne State University, Detroit, MI

126 Identification of Internet discussion aimed at defeating abuse deterrent formulations
E. McNaughton, T. A. Cassidy, S. F. Butler, S. H. Budman, E. Whalley, Inflexxion, Inc., Newton, MA

127 Internet survey to explore methods for collecting street price of prescription opioids
M. Weiss, T. A. Cassidy, E. McNaughton, S. F. Butler, Inflexxion, Inc., Newton, MA
128 Drug life cycle situation awareness: A novel approach to signal detection and post-marketing surveillance of prescription drugs
T. A. Cassidy, S. F. Butler, S. H. Budman, Inflexxion, Inc., Newton, MA

129 Development of a behavioral activation intervention for smokers with elevated depressive symptoms in a residential substance use program
A. N. Banducci, L. MacPherson, J. R. Leonard, W. Francis, C. W. Lejuez, University of Maryland College Park, College Park, MD

130 Online self-help for methamphetamines users: Development and evaluation of an Australian Website
L. L. Jenner1, N. K. Lee1,2,3, R. Noble1, 1Clinical Research, Turning Point Alcohol and Drug Centre, Fitzroy, VIC, 2Psychology, Psychiatry and Psychological Medicine, Monash University, Melbourne, VIC, and 3National Drug Research Institute, Curtin University, Perth, WA, Australia

131 In-home-messaging devices for veterans with substance use disorders
E. J. Santa Ana1, S. Martino2, D. L. Stallings3, B. J. Rounsaville2, 1Charleston VAMC, Charleston, SC, 2Yale SOM and VA CT Healthcare System, West Haven, CT, 3VHA Office of Tele-health Services, Lake City, FL

132 Modified therapeutic community approach in partial-day outpatient substance abuse treatment: Attendance, retention, and completion
J. Kimbro1, S. Smith1, C. Duncan2, S. Sacks3, J. Sacks4, K. McKendrick3, 1Phoenix Programs, Inc., and 2Tre, LLC, Columbia, MO, 3Center for the Integration of Research & Practice, 4National Development & Research Institutes, Inc., New York, NY

133 NIDA’s Clinical Trials Network can facilitate comparative effectiveness research on addiction treatments
U. E. Ghitza, S. Sparenborg, D. Liu, B. Tai, Center for the Clinical Trials Network, NIH/NIDA, Bethesda, MD

134 Implementing research in traditional community treatment programs: Findings from a CTN Trial

135 Small changes – big results: The effects of a reorganization of intake procedures on access to treatment
A. H. Skinstad1,2, J. Zwick3, G. Lutz4, T. Berghold1,2, M. Van der Linden5, R. Kierksick5, K. Summers1,2, 1Prairielands Addiction Technology Transfer Center, and 3Community and Behavioral Health, University of Iowa, College of Public Health, Iowa City, 3Zwick Healthcare Consultants, Urbandale, 4Center for Behavioral Research, University of Northern Iowa, Cedar Falls, and 5Iowa Gambling Treatment Program, Iowa Department of Public Health, Des Moines, IA

136 Physician mentoring to facilitate buprenorphine treatment: The PCSS-Buprenorphine Project
J. E. Egan1, L. Weiss1, A. J. Saxon2, P. P. Casadonte4, J. Martin4, E. McCance-Katz5, J. Renner6, D. A. Fiellin7, 1The New York Academy of Medicine, New York, NY, 2Addictions Care Line VA Puget Sound Health Care System, Seattle, WA, 3New York University, New York, NY, 4BAART Turk Street Clinic, and 5University of California, San Francisco, CA, 6Boston University, Boston, MA, 7Yale University, New Haven, CT
137 Back to basics: Utilizing training, performance feedback, and coaching to develop a clinical supervision infrastructure for frontier states
W. L. Woods, N. A. Roget, J. A. Hartje, K. L. Cahoon, Center for the Application of Substance Abuse Technologies, University of Nevada, Reno, NV

138 A retrospective study of protégés and mentors of the Prairielands ATTC Leadership Development program: The importance of the mentor-protégés relationship
T. Bergthold1,2, A. H. Skinstad1,2, K. Summers1,2, 1Prairielands Addiction Technology Transfer Center, and 2Community and Behavioral Health, University of Iowa, College of Public Health, Iowa City, IA

139 Treatnet II: Working towards evidence-based drug dependence treatment and care: Capacity Building Cascade
G. Gerra, A. Busse, E. Saenz, B. Gerbautz, J. Tomas-Rossello, K. Niaz, I. Palacios, S. Ibanez de Benito, G. Campello, HHDS, United Nations Office on Drugs and Crime, Vienna, Austria

140 On-site hepatitis C treatment in methadone maintenance: Description of a model of care
K. Canfield1,2, S. L. Batki2,1, 1SUNY Upstate Medical University, Syracuse, NY, 2Psychiatry, University of California, San Francisco, San Francisco, CA

141 The influence of neuro-cognitive impairment on intervention outcomes among injection drug users living with HIV/AIDS
I. Ezeabogu, M. Copenhaver, J. Potrepka, A. Meier, University of Connecticut, Storrs, CT

142 The impact of age of drug use debut on subsequent HIV risk behavior among injection drug users
J. Potrepka, M. Copenhaver, I. Ezeabogu, A. Meier, University of Connecticut, Storrs, CT

143 Adoption of HIV counseling and testing following completion of randomized clinical trial
L. Haynes1, B. Holmes3, A. Amberg3, K. Brady1, L. Metsch2, 1Psychiatry, Medical University of South Carolina, Columbia, SC, 2Epidemiology and Public Health, University of Miami, Miami, FL, 3LRADAC, Columbia, SC

144 Integrating HIV medical and behavioral health care in an urban setting
C. L. Arfken1, M. Greenwald1, L. L. Zeman1, D. Johnson1, C. Christensen3, J. Cohn2, 1Psychiatry, 2Infectious Diseases, and 3OB-GYN, Wayne State University, Detroit, MI

145 The evolution of combined economic, social network and geographic research with marginalized populations
J. K. Roddy1, P. J. Draus1, M. K. Greenwald2, 1Social Sciences, University of Michigan Dearborn, Dearborn, MI, 2Substance Abuse Research Division (Psychiatry), Wayne State University, Detroit, MI

146 A national primary care and prevention system for addictions in Mexico
O. Campollo1, A. Ramos2, F. J. Anguiano2, 1Center of Studies on Alcohol and Addictions, Antiguo Hospital Civil, University of Guadalajara, and 2State Council Against Addictions of Jalisco (CECAJ), Guadalajara, Mexico

BADGES MUST BE WORN FOR ALL SESSIONS AND SOCIAL EVENTS
THE ROLE OF THE HYPOCRETIN/OREXIN SYSTEM IN ADDICTION: CURRENT STATUS AND RATIONALE AS A DRUG DISCOVERY TARGET

Chairs: David Shurtleff and Sari Izenwasser

2:00 Optogenetic control of arousal and brain reward
Luis De Lecea, Stanford University School of Medicine, Palo Alto, CA

2:25 Role of the orexin/hypocretin system in seeking natural and drug rewards
Gary Aston-Jones, Neuroscience, Medical University of South Carolina, Charleston, NC

2:50 Hypocretin/orexin promotes motivation for highly salient rewards
Stephanie L. Borgland, The University of British Columbia, Vancouver, BC, Canada

3:15 Selective OX1 and OX2 receptor antagonists differentially modulate brain circuits relevant for sleep and reward processing
Emilio Merlo Pich, Neurosciences, CEDD, GlaxoSmithKline, Verona, Italy

3:40 Hypocretin mechanisms as a drug discovery target in nicotine dependence
William Corrigall, Division of Basic Neuroscience and Behavioral Science, National Institute on Drug Abuse, Bethesda, MD

Oral Communications 5

AGE MATTERS: ADOLESCENT ISSUES OF DRUG USE

Chairs: Brent E. Mancha and Catherine Stanger

2:00 Mental health, school problems, and substance use among urban adolescents: The mediating effect of social network quality
M. J. Mason, Education & Human Services, Villanova University, Bryn Mawr, PA

2:15 Adolescent access to substance abuse treatment in the United States
R. Ramchand, A. Kofner, A. Morral, B. Griffin, K. Harris, RAND, Arlington, VA

2:30 Contingency Management for adolescent marijuana abuse: CACE models
C. Stanger, A. Budney, G. Norton, Center for Addiction Research, University of Arkansas for Medical Sciences, Little Rock, AR

2:45 Brief intervention for drug-abusing adolescents
K. Winters1,2, T. Fahnhorst1, A. Botzet1, 1Psychiatry, University of Minnesota, Minneapolis, MN, 2Treatment Research Institute, Philadelphia, PA

3:00 A multi-site trial of OROS-MPH with CBT for adolescents with ADHD and substance use disorders
P. Riggs1, T. Winhusen2, J. Leimberger3, S. K. Mikulich-Gilbertson1, 1Psychiatry, University of Colorado, Denver, Aurora, CO, 2Psychiatry, University of Cincinnati, Cincinnati, OH, 3Duke University Research Institute, Duke University Medical Center, Durham, NC

3:15 Patterns of alcohol abuse and dependence symptoms among male youths in the United States: A latent class analysis
3:30  Prescription stimulant misuse among adolescents and young adults  
S. Lankenau1, J. Jackson Bloom2, A. Harocpos3, M. Treese2, M. Teti1, 1School of Public Health, Drexel University, Philadelphia, PA, 2Childrens Hospital Los Angeles, Los Angeles, CA, 3National Development and Research Institutes, Inc., New York, NY  
3:45  Self-reported stimulant use, ADHD symptoms and knowledge of ADHD diagnosis among a national sample of youth  
K. D. Fitterling1,2, S. E. Bradford2, A. Ben Abdallah2, L. B. Cottler2, 1St. Louis College of Pharmacy, and 2Washington University School of Medicine, St. Louis, MO

Oral Communications 6  
Salon FG  
2:00 - 4:00 PM  
TREATMENTS FOR NICOTINE ADDICTION: MORE THAN SMOKE AND MIRRORS  

Chairs: Jennifer Tidey and Laurie A. Zawertailo  

2:00  Up in smoke? Cognitive-behavioral motivational enhancement +/- nicotine replacement therapy for adolescent smokers  
A. Swanson1, S. Shoptaw1,2, K. G. Heinzerling1, E. D. London1,2, E. Cederblom1, 1Family Medicine, and 2Psychiatry and Biobehavioral Sciences, UCLA David Geffen School of Medicine, Los Angeles, CA  
2:15  Sensorimotor replacement reduces cigarette craving, withdrawal symptoms and smoking in smokers with schizophrenia  
J. Tidey1, D. Rohsenow2,1, R. Swint2,1, G. Kaplan3, 1Brown University, Providence, RI, 2Providence VA Medical Center, Providence, RI, 3VA Boston Healthcare System, Brockton, MA  
2:30  Methods to efficiently recruit and effectively retain unmotivated smokers in a nationwide randomized clinical trial  
M. J. Carpenter, A. J. Alberg, K. M. Gray, M. E. Saladin, Medical University of South Carolina, Charleston, SC  
2:45  Effect of varenicline on cue-induced cigarette craving: A randomized placebo-controlled study  
L. A. Zawertailo1,2, G. Staios2,3, S. Wang3,4, P. Selby1, U. Busto2,3,4, 1Addictions Program, Centre for Addiction and Mental Health, 2Pharmacology and Toxicology, University of Toronto, 3Clinical Neuroscience, Centre for Addiction and Mental Health, and 4Pharmaceutical Sciences, University of Toronto, Toronto, ON, Canada  
3:00  The brain substrate underlying varenicline’s actions in reducing smoking satisfaction  
3:15  Effects of D-cycloserine on extinction of nicotine cues among cocaine-dependent cigarette smokers  
J. H. Yoon1, C. Culbertson2, R. T. Fintzy1, C. N. Haile1, R. Y. Hawkins1, J. J. Mahoney1, H. R. Patel1, T. F. Newton1, R. De La Garza, II1, K. R. Labounty1, D. E. Croft1, 1Menninger Department of Psychiatry & Behavioral Sciences, Baylor College of Medicine, Houston, TX, 2Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA  
3:30  Modafinil effects on smoking cessation: A clinical trial  
C. A. Martin1,2, G. Guenthner1, K. House1, B. Beck1, R. Charnigo1, J. Lile2, T. Kelly2,1, 1Psychiatry, and 2Behavioral Science, University of Kentucky College of Medicine, 3College of Public Health, University of Kentucky, Lexington, KY
3:45  Effect of chronic treatment with aripiprazole on the waking and postprandial urges to smoke in Chinese heavy smokers
Y. Liu\textsuperscript{1}, Y. Bao\textsuperscript{2}, H. Sun\textsuperscript{2}, S. Li\textsuperscript{2}, L. Lu\textsuperscript{2}, \textsuperscript{1}School of Medicine, Ningbo University, Ningbo, \textsuperscript{2}National Institute on Drug Dependence, Peking University, Beijing, China

**Oral Communications 7**

Salons ABC

2:00 - 3:00 PM

**IT’S ALL ABOUT CHEMISTRY**

Chairs: Richard A. Houghten and Madhaven Nair

2:00  \textit{3-Aminothiazole derivatives of cyclorphan and morphinan: Affinity, selectivity and pharmacological opioid properties}
J. M. Bidlack\textsuperscript{1}, B. I. Knapp\textsuperscript{1}, T. Zhang\textsuperscript{2}, J. L. Neumeyer\textsuperscript{2}, \textsuperscript{1}Pharmacology and Physiology, University of Rochester, Rochester, NY, \textsuperscript{2}Alcohol and Drug Abuse Research Center, McLean Hospital, Belmont, MA

2:15  The direct in vivo screening of mixture-based combinatorial libraries for the identification of novel analgesics
R. A. Houghten, C. T. Dooley, J. P. McLaughlin, Torrey Pines Institute for Molecular Studies, Port St. Lucie, FL

2:30  \textit{Nanotherapy for neuroAIDS and opiate addiction}
Z. M. Saiyed, N. H. Gandhi, M. N. Nair, Institute of NeuroImmune Pharmacology, College of Medicine, Florida International University, Miami, FL

2:45  Analysis of content and in vitro dissolution of morphine in morphine implant pellets for release and stability
P. G. Pande\textsuperscript{1}, K. Davis\textsuperscript{1}, B. Thomas\textsuperscript{1}, S. Sabharwal\textsuperscript{1}, L. Caddell\textsuperscript{1}, R. Murty\textsuperscript{2}, \textsuperscript{1}Analytical Chemistry and Pharmaceutics, RTI International, Research Triangle Park, NC, \textsuperscript{2}Murty Pharmaceuticals, Inc, Lexington, KY

**Oral Communications 8**

Salons ABC

3:15 - 4:15 PM

**IMPACT OF PERINATAL DRUG EXPOSURE**

Chairs: Hann E. Marroun and Margaret S. Chisolm

3:15  \textit{Parental cannabis use during pregnancy and child behavior problems at 18 months}
H. El Marroun\textsuperscript{1,2}, H. Creemers\textsuperscript{3}, H. Tiemeier\textsuperscript{1,3}, E. Steegers\textsuperscript{4}, V. Jaddoe\textsuperscript{2,3}, A. Hofman\textsuperscript{3}, F. Verhulst\textsuperscript{1}, W. van den Brink\textsuperscript{5}, A. Huizink\textsuperscript{1,6}, \textsuperscript{1}Child and Adolescent Psychiatry, \textsuperscript{2}The Generation R Study group, \textsuperscript{3}Epidemiology, and \textsuperscript{4}Obstetrics, ErasmusMC, Rotterdam, Netherlands, \textsuperscript{5}Psychiatry, Amsterdam MC, and \textsuperscript{6}Social and Behavioral Sciences, University of Amsterdam, Amsterdam, Netherlands

3:30  \textit{Cigarette smoking and neonatal outcomes in depressed and non-depressed opioid-dependent agonist-maintained pregnant patients}
M. S. Chisolm\textsuperscript{1}, K. Kaltenbach\textsuperscript{2}, G. Fischer\textsuperscript{1}, S. Heil\textsuperscript{4}, S. Stine\textsuperscript{5}, P. Martin\textsuperscript{6}, M. Coyle\textsuperscript{7}, H. Jones\textsuperscript{1}, \textsuperscript{1}Johns Hopkins U, Baltimore, MD, \textsuperscript{2}Thomas Jefferson U, Philadelphia, PA, \textsuperscript{3}Medical U Vienna, Vienna, Austria, \textsuperscript{4}U of Vermont, Burlington, VT, \textsuperscript{5}Wayne State U, Detroit, MI, \textsuperscript{6}Vanderbilt U, Nashville, TN, \textsuperscript{7}Brown U, Providence, RI
Children of women on opioid maintenance therapy: A follow-up study 4 years later
C. Konijnenberg1,2, M. Sarfì1, A. Melinder2, 1Norwegian Centre for Addiction Research, and
2Cognitive Developmental Research Unit (EKUP), University of Oslo, Oslo, Norway

Effect of prenatal cocaine exposure on childhood growth
S. E. Messiah1, K. L. Arheart2,1, D. Ludwig1,2, V. H. Accornero1, L. Xue1, S. E. Lipshultz1,2,
T. L. Miller1,2, E. S. Bandstra1, 1Pediatrics, and 2Epidemiology and Public Health, University of
Miami Miller School of Medicine, Miami, FL

Marian W. Fischman Memorial Award Lecture
Salons DEFG
4:30 - 5:30 PM
Presentation of the Marian W. Fischman Memorial Award to Linda Cottler
Introduction by William Dewey

Pre- and Post-Doc Networking Event
McDowell
5:30 - 7:00 PM

Workshop V
Salons HI
8:00 - 10:00 PM
SCHOOL-BASED SYSTEMS OF CARE FOR SUBSTANCE ABUSE:
STUDENT ASSISTANCE PROGRAMS AND RECOVERY SCHOOLS
Chairs: Andrew J. Finch and Michael L. Dennis

Student assistance: Addressing social and emotional barriers to learning
Carl Nixon, Evaluation Design, Brentwood, TN

School-based recovery support: Continuing care services in high schools
Andrew Finch, Vanderbilt University, Nashville, TN

Study of GAIN and brief intervention in true North Program
Rob Vincent, ESD113 True North-Student Assistance & Treatment Services, Turnwater, WA

Research on recovery high schools: Empirical findings and proposed future studies
D. Paul Moberg, Population Health Institute, University of Wisconsin School of Medicine,
Madison, WI

SASATE Business Meeting
Michael Dennis, Chestnut Health System, Normal, IL

Workshop VI
Salon DE
8:00 - 10:00 PM
TEACH YOUR PARENTS WELL: TEACHING AND TRAINING
PARENTS CONCERNED ABOUT THEIR CHILD’S DRUG USE
Chair: Kimberly C. Kirby

WebSafe: The development of a parent workshop to help protect children from drug threats on
the Internet
David Festinger, Treatment Research Institute, Philadelphia, PA

Longitudinal associations between parent-child factors and risk of SUD in college
Amelia Arria, Treatment Research Institute, Philadelphia, PA
Monday, June 14, 2010

Teaching parents to be intervention agents
Ken C. Winters, University of Minnesota and Treatment Research Institute, Minneapolis, MN

Training parents as change agents for risky behavior
MaryLouise E. Kerwin, Rowan University and Treatment Research Institute, Glassboro, NJ

Workshop VII
Salon FG
8:00 - 10:00 PM

COMPARISON OF METHADONE AND BUPRENORPHINE:
RESULTS OF THE MATERNAL OPIOID TREATMENT:
HUMAN EXPERIMENTAL RESEARCH (MOTHER) TRIAL

Chairs: Ivan D. Montoya and Sarah H. Heil

Which medication is better for mother and baby, methadone or buprenorphine? Primary outcome results of the MOTHER Trial
Hendree E. Jones, Johns Hopkins School of Medicine, Center for Addiction and Pregnancy, Baltimore, MD

How representative are MOTHER Study participants of the larger pool of opioid-dependent pregnant patients?
Susan M. Stine, Substance Abuse Research Division, Wayne State University School of Medicine, Detroit, MI

Transcontinental Randomized Control Trials in opioid-dependent pregnant women: Are we investigating the same patients?
Gabriele Fischer, Psychiatry, Addiction Clinic, Medical University of Vienna, Vienna, Austria

Addressing and managing co-morbid psychiatric disorders in opioid-dependent pregnant patients: Results from the MOTHER study
Peter R. Martin, Addiction Psychiatry Training Program and Vanderbilt Addiction Center, Nashville, TN

Placing the MOTHER study results in context: A historical perspective and implications on future practice
Karol Kaltenbach, Thomas Jefferson University, Philadelphia, PA

Workshop VIII
Salons ABC
8:00 - 10:00 PM

CAREER DEVELOPMENT: A PERSPECTIVE FROM JUNIOR AND SENIOR RESEARCHERS

Chairs: Gerald McLaughlin and Jose Ruiz

Speakers: David Herin, John Grabowski, Kathleen Brady and Mary Jeanne Kreek

BADGES MUST BE WORN FOR ALL SESSIONS AND SOCIAL EVENTS
**Monday, June 14, 2010**

**NIDA International Meeting Poster Session**

**Chair: Steven W. Gust**

---

**BASIC SCIENCE**

*Effects of harman and norharman on dopamine, serotonin, and their metabolites in mouse brain regions*

S. Ali\(^1\), G.F. Marrone\(^2\), S.J. Heishman\(^2\), M. Baumann\(^2\). \(^1\)National Center for Toxicological Research, U.S. Food and Drug Administration, United States; \(^2\)Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, United States

*Genetic differences in glutamatergic NMDA receptor-binding levels after extinction of morphine self-administration behavior in Lewis and Fischer 344 rats*


*Morphine-induced changes of self-stimulation behavior in rat strains*

E.V. Borisova. Research Institute on Addictions, Russian Federation

*Are GABAergic neurons of the retrosplenial cortex targets of the neurotoxic effect of the noncompetitive NMDA antagonist MK801?*

S. de Olmos, J. de Olmos, A. Lorenzo. Instituto de Investigacion Meica Mercedes y Martina Ferreyra, Consejo Nacional de Investigacion Científica y Tecnológica, Argentina

*Producing smoking craving by using immersive virtual environments*

O. García-Rodríguez\(^1\), I. Pericot-Valverde\(^1\), J. Gutiérrez-Maldonado\(^1\), M. Ferrer-García\(^1\), R. Secades-Villa\(^2\), F. Alonso-Perez\(^3\). \(^1\)University of Barcelona, Spain; \(^2\)University of Oviedo, Spain; \(^3\)Public Health Service of Asturias, Spain

*Role of nitric oxide synthase inhibitors in the operant decrement produced by naloxone in morphine-treated rats*

R. Jain. All India Institute of Medical Sciences, India

*Circadian alteration in neurobiology during opiate protracted withdrawal in rats*

S. Li\(^1\), L. Liu\(^1\), W. Jiang\(^1\), L. Sun\(^1\), S. Zhou\(^1\), L. Lu\(^1\), B.L. Foll\(^2\). \(^1\)National Institute on Drug Dependence, Peking University, China; \(^2\)Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, Canada

*Selective attention to smoking cues in smokers and nonsmokers: An event-related potential study using the visual oddball paradigm*

M. Littel, I. Franken. Erasmus University Rotterdam, The Netherlands
Attentional control brain regions involved in attentional bias in smokers
M. Luijten\textsuperscript{1}, D.J. Veltman\textsuperscript{2,3}, I. Franken\textsuperscript{1}. \textsuperscript{1}Institute of Psychology, Erasmus University Rotterdam, The Netherlands; \textsuperscript{2}Academic Medical Center, University of Amsterdam, The Netherlands; \textsuperscript{3}Department of Psychiatry, Amsterdam Institute for Addiction Research, The Netherlands

Role of CRF and ACTH\textsubscript{4-10} in the neuronal mechanisms of stress and drug addiction
A. Meshcheryakova. I.M. Sechenov Moscow Medical Academy, Russia

Influence of cytokines (interleukin-1\textbeta, interleukin-4) on craving for drugs
A.F. Meshcheryakov. P.K. Anokhin Institute of Normal Physiology, Russian Academy of Medical Science, Russia

Attenuation and enhancement of amphetamine-induced behavioral effects by acute and chronic exposure to cannabis smoke in rats
H. Obianwu\textsuperscript{1,2}, A. Ibeh\textsuperscript{1}. \textsuperscript{1}Niger Delta University, Nigeria; \textsuperscript{2}University of Benin, Nigeria

Characteristics of contact formations between lymphocytes and fibroblasts during the healing process of surgical wounds in drug addicts
A. Sapargaliyeva, G. Kapanova. Kazakh National Medical University, Kazakhstan

Dopaminergic neurotoxicity in recreational users of amphetamine: Preliminary results
M. Schouw, J. Booij, L. Reneman. Academic Medical Center, University of Amsterdam, The Netherlands

Reinforcing effects of d-amphetamine: Influence of novel ratios on a progressive-ratio schedule
R. Sevak\textsuperscript{1}, W. Stoops\textsuperscript{2}, P.E.A. Glaser\textsuperscript{2}, C.R. Rush\textsuperscript{2}. \textsuperscript{1}David Geffen School of Medicine, University of California, Los Angeles, United States; \textsuperscript{2}College of Medicine, University of Kentucky, United States

Association of ADH\textsubscript{2} and ALDH\textsubscript{2} gene polymorphisms with alcohol dependence: First study from India
M. Vaswani. All Indian Institute of Medical Sciences, India

Role of D\textsubscript{1} and D\textsubscript{2} dopaminergic receptors in MDMA-induced conditioned place preference
A. Vidal-Infer, M. Rodriguez-Arias, M.A. Aguilar, J. Miñarro. Unit of Research on Psychobiology of Drug Dependence, Department of Psychobiology, University of Valencia, Spain

Social interaction prevents cocaine relapse in a rat model: Functional brain mapping
G. Zernig\textsuperscript{1}, M. Fritz\textsuperscript{1}, R. El Rawas\textsuperscript{1}, A. Salti\textsuperscript{1}, S. Klement\textsuperscript{1}, M.T. Bardo\textsuperscript{2}, G. Dechant\textsuperscript{1}, A. Saria\textsuperscript{1}. \textsuperscript{1}Medical University Innsbruck, Austria; \textsuperscript{2}University of Kentucky, United States
Epidemiology

Description of areca nut use in a Cordilleran community
R. Abat, J.C. Pascual. University of the Philippines-Manila, Philippine General Hospital, Philippines

Media examines the drug use and abuse problem

A study of addictive in-patients at Ibn-Rushd Psychiatric Teaching Hospital in Baghdad
R. Aqraw1,2, A. Hussain1. 1Ministry of Health, Iraq; 2Virginia Commonwealth University, United States

Association between substance use and premature sexual behavior among Thai youth
S. Assanangkornchai, N. Samangsi, U. Pattanasattayawong. Prince of Songkla University, Thailand

Ecstasy use among high school children in private schools in the city of São Paulo, Brazil
M. Battisti1,2, D. Locatelli2, A.R. Noto2. 1Virginia Commonwealth University, United States; 2Federal University of São Paulo, Brazil

Family attention and coca paste use in four northern regions of Chile, 1999 and 2005:
Secondary data analyses from national epidemiological studies
L. Caris1, D. Huepe2, J. Anthony3. 1University of Chile, Chile; 2Diego Portales University, Chile; 3Michigan State University, United States

Shebeen life in two communities: Alcohol, drugs, and risks
T. Carney1, W.M. Wechsberg2, F. Browne2, R. Fortuin3, B. Myers1. 1Medical Research Council, South Africa; 2RTI International, United States; 3EngenderHealth, South Africa

Nicotine dependence among very recent-onset cigarette smokers in the United States
M. Catacora, J.C. Anthony. Department of Epidemiology, Michigan State University, United States

Predictors of current alcohol use in a rural community in Sikkim, North East India—
secondary analysis from a pilot population survey
A. Chakrabarti, A. Goel. Sikkim Manipal Institute of Medical Sciences, India

DRD2/ANKK1 in relation to regular alcohol and cannabis use among adolescents:
Does parenting modify the impact of genetic vulnerability? The TRAILS study
H. Creemers1,2, Z. Harakeh3, D. Dick1, J. Meyers4, W. Vollebergh3, J. Ormel5, F. Verhulst1, A. Huizink2. 1Erasmus Medical Center Rotterdam, The Netherlands; 2University of Amsterdam, The Netherlands; 3Utrecht University, The Netherlands; 4Virginia Commonwealth University, United States; 5University Medical Center Groningen, The Netherlands
Inhalant misuse in Mexico: Facts and trends
S.L. Cruz1,2, J.A. Villatoro2, A. Ortiz2. 1Department of Pharmacobiology, Center for Research and Advanced Studies of National Polytechnic Institute, Mexico; 2Division of Epidemiologic and Social Research, Mexican Institute of Psychiatry, Mexico

Illicit drug use in seven Latin American countries: Critical perspectives of families and friends on causes, prevention, treatment availability, access, and barriers
J. Da Silva1, C. Ventura2, O. Vargens3, C.M. Douat Loyola1, D. Albarracin4, J. Diaz5, G. Funes6, M. Hernandez7, R. Torres8, R. Rodriguez9. 1Federal University of Rio de Janeiro, Brazil; 2World Health Organization Collaborating Centre for Nursing Research Development, Brazil; 3Rio de Janeiro State University, Brazil; 4Pontifical Xavonian University, Colombia; 5University of San Carlos of Guatemala, Guatemala; 6National Autonomous University of Honduras, Honduras; 7University of Costa Rica, Costa Rica; 8Autonomous University of Querétaro, Mexico; 9School of Nursing, University of Guayaquil, Ecuador

Drinking and driving in a driver probabilistic sample from alcohol outlets of Porto Alegre, Brazil: Preliminary findings
R. De Boni1, M. de Vasconcellos2, F.I. Bastos3, F. Pechansky1. 1Center for Drug and Alcohol Research, Federal University of Rio Grande do Sul, Hospital de Clínicas de Porto Alegre, Brazil; 2Brazilian Institute for Geography and Statistics, Brazil; 3Oswaldo Cruz Foundation, Brazil

Parental cannabis use during pregnancy and child behavior problems at 18 months
H. El Marroun1,2, H. Creemers1,2, H. Tiemeier1,2, E. Steegers1,2, V. Jaddoe1,2, A. Hofman2, F. Verhulst1,2, W. van den Brink3,4. 1Sophia Children’s Hospital, Erasmus Medical Center, The Netherlands; 2Erasmus Medical Center Rotterdam, The Netherlands; 3Department of Psychiatry, Academic Medical Center, University of Amsterdam, The Netherlands; 4Amsterdam Institute for Addiction Research, The Netherlands

Substance misuse among Moroccan inpatients with schizophrenia
F. El Omari1, A. Derveau2, M. Sabir1, M.C. Bourdel3, M.O. Krebs3, J. Toufiq1. 1Arrazi University Psychiatric Hospital, Morocco; 2Addiction Service, Sainte-Anne Hospital, France; 3Laboratory of Physiopathology of Psychiatric Diseases, Center for Neurosciences and Psychiatry, France

Assessing methamphetamine use among drug-using Filipino youth
L. Estacio, Jr. University of Washington, United States; University of the Philippines-Manila, Philippines
The P300 event-related brain potential as a neurobiological marker for substance use disorders: A meta-analytic investigation
A. Euser¹, L. Arends¹, A. Huizink², I. Franken¹. ¹Institute of Psychology, Erasmus University Rotterdam, The Netherlands; ²Department of Child and Adolescent Psychiatry, Erasmus Medical Center, Sophia Children’s Hospital, The Netherlands

The relation between HPA axis reactivity and age of onset of alcohol use
B.E. Evans¹, K. Greaves-Lord¹, A. Euser², I.H.A. Franken², A.C. Huizink³. ¹Erasmus Medical Center Rotterdam, The Netherlands; ²Erasmus University Rotterdam, The Netherlands; ³University of Amsterdam, The Netherlands

An exploratory study of substance use biomarkers and psychiatric disorders in Brazilian drivers
S. Faller¹, J.M. Webster², C.G. Leukefeld², D.B. Bumaguín¹. ¹Center for Drug and Alcohol Studies, Federal University of Rio Grande do Sul, Brazil; ²Center on Drug and Alcohol Research, University of Kentucky, United States

Cross-national research on early-onset cannabis use and failure to complete educational milestones
F. Fiestas¹, J.C. Anthony². ¹Universidad Peruana Cayetano Heredia, Peru; ²Department of Epidemiology, Michigan State University, United States

A call for expansion of comparative urban research as an international epidemiologic and policy research tool
S. Friedman¹, B. Tempalski¹, H. Cooper², C. Cleland¹, S. Chatterjee¹, E. Pouget¹. ¹National Development and Research Institutes, United States; ²Emory University, United States

Using the Gelberg-Andersen Behavioral Model for Vulnerable Populations to predict health services’ utilization among homeless adults by hepatitis B or C serostatus
L. Gelberg¹, M. Robertson², R.M. Andersen², J. Stein³, L. Aranguí¹. ¹Department of Family Medicine, University of California, Los Angeles (UCLA), United States; ²Alcohol Research Group, Public Health Institute, United States; ³School of Public Health, UCLA, United States; ⁴Department of Psychology, UCLA, United States

The role of mental health issues in HIV acquisition among female drug users
G. Gilchrist¹, A. Blazquez¹, J. Mestre¹, F. Fonseca¹, L. Díaz¹, M. Torrens¹, ², ³, ⁴, ⁵. ¹Institut Municipal d’Investigació Mèdica-Hospital del Mar, Spain; ²Institut d’Atenció Psiquiàtrica i Addiccions-Hospital del Mar, Spain; ³Unidad de Patología Dual, Centre Fòrum-Hospital del Mar, Spain; ⁴Departamento de Psiquiatría, Universidad Autónoma de Barcelona

National regulations of opioid maintenance treatment programs do not guarantee uniform treatment delivery
L. Gjersing, H. Waal, T. Clausen. Norwegian Center for Addiction Research, University of Oslo, Norway
Simultaneous polydrug consumption among undergraduate university students in six Latin American countries and in one Caribbean country: Gender, legal, and social implications

A. Herrera1, F. Bautista2, J. Harrison3, C. Mitchell3, M. Nóbrega4, R. Prieto5, G. Riquelme6, M. Veloza7, P. Whitehorne3, C.I. Zea8, F. Brands9, L. Simich9, C. Strike9, R. Mann9, N. Giesbrecht9, M. Wright10. 1Universidad Nacional de Nicaragua–León, Nicaragua; 2Universidad Evangelica, El Salvador; 3University of the West Indies, Jamaica; 4Faculdade de Medicina da Fundacao do ABC, Brazil; 5Universidad Nacional de Colombia, Colombia; 6Pontificia Universidad Católica de Chile, Chile; 7Universidad de La Sabana, Colombia; 8Universidad de San Carlos de Guatemala, Guatemala; 9The Center for Addiction and Mental Health–CAMH/University of Toronto, Canada; 10Government of Canada–DFAIT, The Inter-American Drug Abuse Control Commission–CICAD/ Organization of American States–OAS

Birth order and substance use in Latin America

P. Horner1, F. Andrade2, J. Delva2. 1Michigan State University, United States; 2University of Michigan, United States

Association between alcohol, tobacco, and other drug use and bullying among secondary school students in Nakuru District, Kenya

M. Kariuki1, P. Ndege2, J.S. Oteyo1. 1Egerton University, Kenya; 2Center for Addiction Studies in Africa, Kenya

Patterns of amphetamine-type stimulant abuse among opiate-dependent individuals in Kuala Lumpur, Malaysia

V.B. Kasinather1, M. Mazlan2, M.C. Chawarsi3, R.S. Schottenfeld3. 1Centre for Drug Research, Universiti Sains, Malaysia; 2Substance Abuse Research Centre, Malaysia; 3Yale University School of Medicine, United States

Characterization of drug-related death cases with a special emphasis on heroin-related cases in Budapest, Hungary, between 1998–2009

E. Keller1, G. Nagy2, M. Horvath1,3. 1Department of Forensic and Insurance Medicine, Semmelweis University, Hungary; 2Drug Laboratory, Institute for Forensic Sciences, Hungary; 3National Board of Forensic Medicine, Department of Forensic Medicine, Uppsala University, Sweden

Brazilian crack users who seek treatment show more antisocial personality and less drinking than other drug users

F. Kessler, M. Terra, S. Faller, A. Peuker. Center for Alcohol and Drug Research, Federal University of Rio Grande do Sul, Brazil

Correlation between HIV infection prevalence and drug use experience in correctional settings of Odessa Region, Ukraine

T. Kiriazova1,2, O. Neduzhko3. 1Rollins School of Public Health, Emory University, United States; 2Odessa Regional Coordination Council on HIV/AIDS, Drug Abuse and TB Prevention, Ukraine; 3Odessa State Medical University, Ukraine
Exploring the phenomena of home-made stimulant injection in Tbilisi, Georgia
I. Kirtadze1, D. Otashvili1, G. Piralishvili2, R. Booth3, T. Zabransky4. 1Addiction Research Center, Union Alternative Georgia, Georgia; 2Medical Centre Uranti, Georgia; 3University of Colorado-Denver, United States; 4Center for Addictology, Charles University, Czech Republic

Consumption of alcohol among high school students in a government secondary school in Southern Philippines
A.R. Lanaban1, J. Pascual2, E. Catillo2, L.C. Panganiban2. 1Davao Medical Center, Philippines; 2University of the Philippines-Manila, Philippine General Hospital, Philippines

The prevalence of anxiety and depression among adult substance abusers admitted at a government drug treatment and rehabilitation center in the Philippines
J.B. Leabres1, J. Pascual2, M.R. deGuzman2, C.G. Quingking2. 1Department of Health, Treatment and Rehabilitation Center-Bicutan, Philippines; 2Philippine General Hospital, Philippines

Factors associated with current substance use among intravenous drug users under antiretroviral treatment in Jakarta and Bali, Indonesia
Y. Li1, R. Hershov1, Irwanto2, J. Levy1, R. Tambunan2, O. Kamii2, S. Lenggogeni2, M. Setiawan3. 1University of Illinois at Chicago, United States; 2Atma Jaya Catholic University of Indonesia, Indonesia; 3Udayana University, Indonesia

Drug use and leisure time in secondary school students in the autonomous region of Valencia, 2008–2009
N. Llorens1, S. Tomas2, S. Tortajada1, J. Aguilar1. 1The Foundation for the Study, Prevention and Assistance on Drug Addiction, Spain; 2Direccion General de Drogodependencias, Conselleria de Sanitat, Spain

Tobacco, alcohol, and caffeine consumption during pregnancy: survey and biomarkers
R. Magri1, M. Suárez1, H. Míguez2, J. Jones3, R. Rios3, H. Suarez4, P. Putti5. 1Universidad de la Republica, Uruguay; 2CONICET, Argentina; 3United States Testing Laboratory, United States; 4Observatorio de Drogas, Uruguay; 5Unidad de Perinatologia Social Security Maternity Hospital Uruguay

Differential survival benefit of universal HAART access in Brazil: A nationwide comparison of injecting drug users versus men who have sex with men
M. Malta1, F. Bastos1, C. da Silva1, G. Pereira2, F. Lucena2, M. Fonseca1, S. Strathdee3. 1Oswaldo Cruz Foundation, Brazil; 2Ministry of Health, Brazil; 3University of California, San Diego, United States

Comparison of injection drug users in Shanghai, China, and Miami, Florida
C. McCoy1, M. Zhao2, M. Comerford3. 1University of Miami, United States; 2Shanghai Jiao Tong University School of Medicine, China
Codependency on drug abusers’ mothers
D. Molina, A. Villalobos. José Felix Ribas Foundation, Venezuela

Outcomes of residential treatment of substance abuse in a Philippine government substance abuse treatment and rehabilitation center
R. Mollenido1, C.G. Quingking2, I. Escartin3. 1Western Visayas Medical Center, Philippines; 2National Poison Control Center, University of the Philippines, Philippine General Hospital, Philippines; 3Department of Health, Philippines

Low rates of HIV seroconversion among injecting and noninjecting drug users in Barcelona, Spain, 1997–2006
R. Muga1, E. Martinez1, M. Torrens2, F. Bolao3, I. Rivas4, R. Rall1, A. Sanvisens1, D. Fuster1, J. Tor1. 1Hospital Universitari Germans Trias i Pujol, Spain; 2Institut Municipal d’Investigació Mèdica-Hospital del Mar, Spain; 3Hospital de Bellvitge, L’Hospitalet de Llobregat, Spain; 4Centro Delta de Toxicomanías, Badalona, Spain

Is there a new population of opioid users in Australia? A Web-based survey on nonprescription codeine use
S. Nielsen1, J. Cameron1, N. Lee1,2. 1Turning Point Alcohol and Drug Centre, Australia; 2Monash University, Australia

Drawing back the veil: Drug use and mental health problems among female adolescents in Uruguay
G. Olivera1,2, M. Kurgans3, H. Suarez4. 1Virginia Commonwealth University, United States; 2National Drug Assembly at the Presidency of Uruguay, Uruguay; 3Office of Child and Family Services, Virginia Department of Behavioral Health and Developmental Services, United States; 4Drugs Observatory of Uruguay, Uruguay

Prevalence of substance abuse among secondary school students—a comparative study of government and private secondary schools in Jos, Nigeria
M. Onoja. Pathfinder International, Nigeria

Drug abuse in Thamel, Nepal
M. Poudel, M. Poudyal Chhetri. Commission for the Investigation of Abuse of Authority, Nepal

Kathmandu slum dwellers’ health and drug abuse problems
M. Poudyal Chhetri. Commission for the Investigation of Abuse of Authority, Nepal

Sexual partnering and condom use among injecting drug users in Indonesia
I. Praptoraharjo1, R.I. Syafitri2, N. Hadi2, T. Zaenuri2, M. Suharni2, O. Kamil2. 1School of Public Health, University of Illinois at Chicago, United States; 2Family Health International, Indonesia
Perception of coercion in the process of informed consent in research on alcohol and traffic in Brazilian highways
J. Protas¹, C.F. Fernandes², M.S. Fernandes², R. De Boni¹,², F. Pechansky¹,², J.R. Goldim¹,². ¹Federal University of Rio Grande do Sul, Brazil; ²Hospital de Clinicas de Porto Alegre, Brazil

Survival of adults with alcohol-dependence syndrome in Barcelona, Spain
I. Rivas¹, F. Bolao², A. Sanvisens³, E. Martinez³, J. Tor³, D. Fuster³, R. Muga³. ¹Centro Delta de Drogodependencias de Badalona, Spain; ²Hospital de Bellvitge, L’Hospitalet de Llobregat, Spain; ³Hospital Universitari Germans Trias i Pujol, Spain

Factors related to use of rice wine (Tapoy) among families in a municipality in Cordillera Region, Philippines
J. Sagabaen, Jr., R. Abat, J. Pascual, E. Castillo. Postgraduate Institute of Medicine, University of the Philippines College of Medicine, Department of Health, Manila, Philippines

Changing trends of inhalant abuse in juveniles in India
S. Sharma, G. Sharma. Institute of Human Behaviour and Allied Sciences, India

Substance abuse and health-risk behaviors in Baglung, Nepal
S. Sharma¹, M. Poudyal Chhetri². ¹Care Nepal, Nepal; ²Commission for the Investigation of Abuse of Authority, Nepal

Toward DSM-V: A comprehensive exploration of the latent structure of problematic cannabis use in a community sample
T. Slade¹, R. Grove¹, O. McBride², M. Teesson¹, A. Baillie³, N. Carragher¹. ¹University of New South Wales, Australia; ²Ulster University, Ireland; ³Macquarie University, Australia

Female drug users and service’ accessibility in Burma (Myanmar)
Z.N. Soe. United Nations Office on Drugs and Crime, Burma (Myanmar)

Adult substance abusers with attention deficit and hyperactivity disorder show higher prevalence of marijuana and cocaine use
A. Stolf, F. Kessler, S. Faller, D.B. Bumagun. Center for Alcohol and Drug Research, Federal University of Rio Grande do Sul, Brazil

Gender, pregnancy, and treatment completion by criminal justice referral status
M. Terplan¹, M.Palisoul¹, S. Liu², C. Friedman³. ¹University of Maryland School of Medicine, United States; ²University of Huddersfield, United Kingdom; ³University of Pittsburgh Medical Center, United States
Liquor accessibility of Chiang Mai youth in Chiang Mai Municipality, Chiang Mai, Thailand
K. Thaikla. Institute for Health Sciences, Chiang Mai University, Thailand

Risk factors for substance-induced disorders among illicit drug users
M. Torrens¹, G. Gilchrist¹, A. Domingo-Salvany³,⁴, F. Fonseca¹,², The PsyCo Barcelona Group*¹,⁴,⁵,⁶. The PsyCoBarcelona Group Includes: M.C. Rodriguez-Llera³, M.J.Herrero³, M. Astals¹,¹, L. Diaz¹,², R. Martin-Santos²,⁵,⁶, M.T. Brugal⁴,⁷.
¹Substance Use Disorders Research Group, Neuropsychopharmacology Program, Institut Municipal d’Investigació Mèdica (IMIM)-Parc de Salut Mar, Parc de Recerca Biomèdica de Barcelona, Spain; ²Institut d’Atenció Psiquiàtrica i Addiccions-Parc de Salut Mar, Spain; ³Drug Abuse Epidemiology Research Group, IMIM-Hospital del Mar, Parc de Recerca Biomèdica de Barcelona, Spain; ⁴Biomedical Research Center Network of Epidemiology and Public Health, Spain; ⁵Pharmacology Research Unit, Neuropsychopharmacology Program, IMIM-Parc de Salut Mar, Parc de Recerca Biomèdica de Barcelona, Spain; ⁶Psychiatry Department, Institut de Neurociències, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Spain; ⁷Barcelona Public Health Agency, Spain

Youthful tobacco smoking for males and females in Brazil
Z. van der Meer Sanchez¹, A.R. Noto¹,². ¹Federal University of São Paulo, Brazil; ²Brazilian Center of Information on Psychotropic Drugs, Federal University of São Paulo, Brazil

Prior sexual abuse among female substance dependents admitted in a government-operated drug treatment center in metropolitan Manila
A. Villaroman¹, J. Pascual², E. Castillo², C. Quingking². ¹Department of Health, University of the Philippines-Manilla, Philippine General Hospital, Philippines; ²Department of Toxicology and Pharmacology, University of the Philippines-Manila, Philippine General Hospital, Philippines

Risk of pathological gambling and associated disorders in adolescents from Medellin, Colombia, 2009
M. Zapata, Y. Torres de Galvis, L.P. Montoya. CES University, Colombia

Use of the alcohol, smoking, and substance involvement screening test among HIV-positive patients on regular antiretroviral therapy in southern Brazil
C. Zubaran¹, I. Tres², K. Foresti³, University of Caxias do Sul-United Nations Educational, Scientific and Cultural Organization Research Group². ¹University of Western Sydney, Australia; ²University of Caxias do Sul, Brazil; ³Sydney West Area Health Service, Australia
**Variations in needles and syringes used by injecting drug users**
W. Zule\(^1\), D. Otashvili\(^2\), S. Friedman\(^3\), D.D. Jarlais\(^4\), A. Gyarmathy\(^5\), G. Bobashev\(^1\), C. Coomes\(^1\), Winona Poulton\(^1\). \(^1\)RTI International, United States; \(^2\)Union Alternative Georgia, Georgia; \(^3\)National Development and Research Institutes, United States; \(^4\)Beth Israel Medical Center, United States; \(^5\)European Monitoring Centre for Drugs and Drug Addiction, Portugal

**Pharmacoepidemiology of the use of strong opioids: Comparison between St. Petersburg, Russia, and U.S. data**
E. Zvartau, M. Pchelintsev. St. Petersburg Pavlov Medical University, Russia

**PREVENTION**

**Harm reduction knowledge and beliefs among prison armed personnel in Albania**
A. Boci\(^1\), E. Sharra\(^2\). \(^1\)STOP AIDS Association, Albania; \(^2\)Global Fund for HIV—Albania Office, Albania

**Methamphetamine use among young black and colored women in Cape Town, South Africa**
F. Browne\(^1\), W.M. Wechsberg\(^1\), H.E. Jones\(^1\), B.J. Myers\(^2\), T. Carney\(^2\), R.M. Ellerson\(^1\), T.L. Kline\(^1\). \(^1\)RTI International, United States; \(^2\)Medical Research Council, South Africa

**Beliefs significantly associated with the consumption and nonconsumption of tobacco in school students at Valencia City in Spain**
F.J. Bueno-Cañigril\(^1\), C.C. Morales-Manrique\(^2\), R. Aleixandre-Benavent\(^2\), J.C. Valderrama-Zurián\(^3\). \(^1\)Plan Municipal Drogodependencias, Ayuntamiento de Valencia, Spain; \(^2\)Unidad de Información e Investigación Social y Sanitaria, Universitat de València-CSIC, Spain; \(^3\)Generalitat Valenciana, Spain

**A national primary care and prevention system for addictions in Mexico**
O. Campollo\(^1\), A. Ramos\(^2\), F.J. Anguiano\(^2\). \(^1\)University of Guadalajara, Mexico; \(^2\)Consejo Estatal Contra las Adicciones en Jalisco, Mexico

**“Cannabis—it’s not our culture”: Engaging with indigenous Australians about cannabis and their community**
J. Copeland, P. Dillon, J. Howard. National Cannabis Prevention and Information Centre, Australia

**Republic Act 6425 as amended by Republic Act 9165—the Comprehensive Dangerous Drugs Act of 2002: Its effect on the volume of drug cases in Dipolog City**
A. Cuivillas. Jose Rizal Memorial State University, Philippines

**Crack cocaine—a accelerating use in Brazil**
A. Domanico\(^1\), M. Malta\(^2\), C. Latkin\(^1\). \(^1\)Johns Hopkins Bloomberg School of Public Health, United States; \(^2\)Sergio Arouca Public Health School, FIOCRUZ, Brazil
Hepatitis C knowledge among methadone maintenance treatment staff and social workers in China
J. Du. Shanghai Mental Health Center, Shanghai Jiao Tong University, China

High school students with a substance-abusing family member interested in school-based support groups
B. Gance-Cleveland1, M. Choi1, K. Ickes2, V. Bush1. 1Arizona State University, United States; 2LaJoya High School, United States

Drug abuse increasing HIV transmission in sub-Saharan countries
J.Y. Gatete. Collectif National pour les Droits de l'Homme, Burundi

Selective prevention: Addressing vulnerability to problem drug use in Europe
V.A. Gyarmathy1,2, A. Bo1. 1European Monitoring Centre for Drugs and Drug Addiction, Portugal; 2Johns Hopkins Bloomberg School of Public Health, United States

Strengthening community-based drug prevention and intervention for youngsters in Kosovo
R. Ismajli. Kosovo Health Foundation, Kosovo; The Center for Developing of Family Medicine, Kosovo; Drug Abuse Center, Kosovo

Family factors as predictors of drug and alcohol-related problems among Mexican American youth
A. Kopak1, A.C.C. Chen2, S.A. Haas3, M.R. Gillmore4. 1Southwest Interdisciplinary Research Center, Arizona State University, United States; 2College of Nursing and Health Care Innovation, Arizona State University, United States; 3School of Social and Family Dynamics, Arizona State University, United States; 4School of Social Work, Arizona State University, United States

Drug resistance strategies of adolescents in Guanajuato, Mexico
S. Kulis, F.F. Marsiglia, S.L. Ayers, C.O. Calderón-Tena. Southwest Interdisciplinary Research Center, Arizona State University, United States

Multisectoral collaboration model for prevention of injecting drug use and HIV/AIDS in Burma (Myanmar)
T. Khin. United Nations Office on Drugs and Crime, Burma (Myanmar); Virginia Commonwealth University, United States

Tobacco and other substance behaviors among street children
S. Lamsal1, I. Walia2, R. Kumar3, B. Kaur2. 1B.P. Koirala Institute of Health Sciences, Nepal; 2National Institute of Nursing Education, India; 3Postgraduate Institute of Medical Education and Research, India
Religion and adolescent substance use in Mexico: Exploring the interaction between internal and external religiosity
F. Marsiglia¹, S. Ayers², S. Hoffman¹. ¹Arizona State University, United States; ²Southwest Interdisciplinary Research Center, United States

Opal, the silver bullet—an Australian low-aromatic fuel replacement strategy
B. McFarland. Tangentyere Council, Australia

Motives associated with resilience of tobacco use among school students in Spain—differences by gender
C. Morales-Manrique¹, F.J. Bueno-Cañigratal², J.C. Valderrama-Zurián³, R. Aleixandre-Benavent¹. ¹Unidad de Información e Investigación Social y Sanitaria, Universitat Valencia-CSIC, Spain; ²Plan Municipal Drogodependencias, Ayuntamiento de Valencia, Spain; ³Generalitat Valenciana, Spain

Reducing injection intensity is associated with decreased risk for invasive bacterial infection among high-frequency injection drug users
A. Moriggia¹², J. Astemborski³, D. Thomas¹, S.H. Mehta³. ¹Division of Infectious Diseases, Johns Hopkins University School of Medicine, United States; ²Division of Infectious and Tropical Diseases, IRCCS San Matteo Foundation, University of Pavia, Italy; ³Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, United States

Ethnic differences in drug-related risks for HIV and intimate partner violence among vulnerable women in Cape Town, South Africa
B. Myers¹², W.M. Wechsberg³, F. Browne², T. Carney¹, R.M. Ellerson³, T. Kline³, C.D.H. Parry¹, R. Jewkes¹. ¹Medical Research Council, South Africa; ²University of Cape Town, South Africa; ³RTI International, United States

Substance use among students in a public senior secondary school in Lagos, Nigeria
C. Okonkwo¹², R. Lawal¹, M. Ojo², C. Eze², H.T. Ladapo², T. Hary², C. Nwigwe², O. Ogunwale², E. Ladeji², M. Agwu². ¹Virginia Commonwealth University, United States; ²Federal Neuro Psychiatric Hospital, Yaba, Nigeria

How effective is street drug testing?
D. Otashvili¹, I. Kirtadze¹, T. Zabransky². ¹Addiction Research Center, Union Alternative Georgia, Georgia; ²Centre for Addictology, Charles University in Prague, Czech Republic

Medical student attitudes toward substance abuse: A study of the effectiveness of an educational program involving small-group and discussion formats of patient management problems
S. Pati. SCB Medical College, India
Effectiveness of implementing the Strengthening Families Program for families of schoolchildren in Songkhla Province, Thailand
M. Pinyuchon¹, T. Maneesrikham², S. Santiwaranont³. ¹Strengthening Families Program, Thailand; ²Srinakharinwirot University, Thailand; ³Thaksin University, Thailand

A comparative study of risk and protective factors for drug abuse among adolescents in Malaysia
M.M.S.M. Razali¹,², W. Kliweer². ¹Sultan Idris Education University, Malaysia; ²Virginia Commonwealth University, United States

Research on adaptation/design and implementation of an evidence-based drug abuse, HIV, and crime prevention program for schoolchildren in Ukraine
V. Ryabukha. Virginia Commonwealth University, United States

Police involvement with HIV-infected Russian heroin users: Insights from the HERMITAGE study
J. Samet¹, A.Y. Walley¹,², D.M. Cheng¹,²,³, C. Bridden¹,², A. Raj¹,²,³, R. Booth⁴, C.E. Chaisson³, E. Blokhina⁵, E. Zvartau⁵, E. Krupitsky⁵. ¹Boston University School of Medicine, United States; ²Boston Medical Center, United States; ³Boston University School of Public Health, United States; ⁴University of Colorado School of Medicine, United States; ⁵Pavlov State Medical University, Russia

Health kiosks 2009: Preventing drug use in recreational areas
S. Tortajada, S. Tomas, N. Llorens, J. Aguilar. Fundación para el Estudio, Prevención y Asistencia a las Drogodependencias, Spain

Are adolescents gambling with cannabis use? A longitudinal study of observed and reported impulsivity measures in relation to adolescent substance use: The TRAILS study
A.P. van Leeuwen¹, H.E. Creemers²,³, F.C. Verhulst³, J. Ormel⁴,⁵, A.C. Huizink²,³. ¹University of Amsterdam, The Netherlands; ²Research Institute of Child Development and Education, University of Amsterdam, The Netherlands; ³Department of Child and Adolescent Psychiatry, Erasmus Medical Center, Sophia Children’s Hospital, The Netherlands; ⁴University Medical Center Groningen, The Netherlands; ⁵University of Groningen, The Netherlands; ⁶Graduate School for Experimental Psychopathology, The Netherlands

Impulsivity and HIV sexual risk behaviors in Bulgarian heroin users
G. Vasilev¹, I. Raynov¹, S. Bliznaski¹, E. Martin-Thormeyer², J. Vassileva². ¹Bulgarian Addictions Institute, Bulgaria; ²University of Illinois at Chicago, United States

Impulsive personality traits as a predictor of psychiatric problems of drug users
Z. Wang, J. Du, H. Sun, M. Zhao. Shanghai Mental Health Center, Shanghai Jiao Tong University, China
Gender differences in HIV risk behaviors and other issues among Chinese methadone patients
R. Zhang¹, Y. Hser², J. Li¹, B. Zhang¹, Z. Congbin¹. ¹Yunnan Institute on Drug Abuse, China; ²Center for Advancing Longitudinal Drug Abuse Research, University of California, Los Angeles, United States

A preliminary study of the reliability and validity of the Chinese version of the Alcohol, Smoking, and Substance Use Involvement Screening Test
M. Zhao, H. Sun, Q. Zheng, J. Du, H. Chen, C. Fan, J. Haifeng. Shanghai Mental Health Center, Shanghai Jiao Tong University, China

Assessment and comparison of attitudes toward methadone treatment between patients at a methadone maintenance clinic and compulsory detoxification center in China
W. Zhou¹,², Y. Liu¹. ¹Ningbo Addiction Research and Treatment Center, China; ²School of Medicine, Ningbo University, China

TREATMENT

First analysis of newborns of opiate-addicted mothers in Bucharest, Romania
A.O. Abagiu¹,², M. Anghelescu³, R. Ianos-Iancovici², B. Rusu², I.G. Stoica², F. Georgescu², F. Gheorghe², E. Cojocaru⁷, A.M. Tudor¹, V. Leoveanu¹, A.S. Craciun³, M. Ceausu³, A. Koulosousas²,³, A. Sirbu⁴. ¹National Institute for Infectious Diseases, Romania; ²Arena First Low-Threshold Methadone Maintenance Treatment Center, Romania; ³I. Cantacuzino Hospital, Romania; ⁴Bucharest University Hospital, Romania

Therapeutic communities: A three-country comparison
G. Bunt¹, D. Kressel², V. Stanick¹, M. Au¹. ¹Daytop Village, Inc., United States; ²National Development and Research Institutes, United States

Effect of naltrexone and buprenorphine on smoking in opioid-dependent subjects
B. Chatterjee, R. Jain, S. Jhanjee. All India Institute of Medical Sciences, India

A pilot study of relapse prevention intervention for heroin addicts in prison in China
H. Chen, M. Zhao, J. Du. Shanghai Mental Health Center, Shanghai Jiao Tong University, China

Assessment of medication-assisted treatment programs’ staff perceptions concerning their jobs
V. Chtenguelov, S. Dvoriak, G. Prib. Ukrainian Institute on Public Health Policy, Ukraine

System and services integration for homeless persons with substance use and other mental disorders
E. Conroy¹, L. Burns¹, P. Flatau³. ¹National Drug and Alcohol Research Centre, Australia; ²Murdoch Business School, Australia
Prenatal cocaine exposure in the south of Brazil: Neurobehavioral effects on the newborn infant

From stilettos to moccasins: First Nations’ women’s healing from drug abuse
C. Dell, University of Saskatchewan, Canada

From benzos to berries: Treatment offered at an Aboriginal youth solvent abuse treatment center relays the importance of culture
D. Dell¹, C.A. Dell², M. Seguin², C. Hopkins³, R. Tempier², L. Mehl-Madrona⁴,⁵, R. Duncan², K. Mosier⁶. ¹National Youth Solvent Addiction Committee, Canada; ²University of Saskatchewan, Canada; ³National Native Addictions Partnership Foundation, Canada; ⁴University of Hawaii School of Medicine, United States; ⁵Coyote Institute for Studies of Change and Transformation, United States; ⁶Western College of Veterinary Medicine, University of Saskatchewan, Canada

Setting up a drug treatment service for female drug users in Iran
K. Dolan¹, S. Mohsenifar², B. Nassirimanesh³, S. Salimi¹, M. Azarakshh¹. ¹University of New South Wales, Australia; ²Iranian National Centre for Addiction Studies, Iran; ³Persepolis Centre, Iran

The attendance of babies exposed to drugs of abuse program: A first experience in Brazil
F.M. Driemeier¹,², G. Cunha¹,², M.L.S. Zavaschi¹, J. Dreyer¹, S. Décimo², M. Zanatta², R. Riesgo¹, F. Pechansky¹. ¹Federal University of Rio Grande do Sul, Hospital de Clínicas de Porto Alegre, Brazil; ²Hospital Materno Infantil Presidente Vargas, Brazil

Lack of hepatic injury during chronic abuse of combination of acetaminophen and codeine: A case series
S. Djezzar¹,², E. Guillem³, F. Vorspan⁴, A. Buisene⁴, J. Guilleraut¹, E. Burin¹,², R. Sicot¹, S. Dally¹,². ¹Hôpital Fernand Widal, Assistance Publique Hôpitaux de Paris, France; ²Center of Evaluation and Information on Pharmacodpendence-Addictovigilance, Groupe Hôpitalier Lariboisiere-Fernand Widal, France; ³Department of Psychiatry, Groupe Hôpitalier Lariboisiere-Fernand Widal, France; ⁴Toxicology Laboratory, Groupe Hôpitalier Lariboisiere-Fernand Widal, France
Qualitative study on residential abstinence-based detoxification program in heroin dependence: Barriers/incentives and advantageous/disadvantageous characteristics in 3-month follow-up

H. Ekhtiari1, P. Hasani-Abharian1,3, Z. Alam-Mehrjerdi1, A. Deilamizadeh4, I.A. Jillson5, A. Mokri2. 1Neurocognitive Laboratory, Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Iran; 2Clinical Dept., Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Iran; 3Institute for Cognitive Sciences Studies, Iran; 4Rebirth Society, Non- Governmental Organization in Drug Dependence Treatment, Iran; 5Dept. of Public Health and Nursing Studies, Georgetown University, United States

Validating medical knowledge internationally: The international certification of addiction medicine

N. el-Guebaly1, C. Violato2. 1Foothills Medical Centre, Canada; 2 Medical Education and Research Unit, Faculty of Medicine, University of Calgary, Canada

Cytochrome P450 and ABCB1 genetic polymorphisms and methadone plasma concentrations in opioid dependence disorder

F. Fonseca1, A. Pastor2, K. Langohr2, R. Martín-Santos2,3, M. Farré2,4, R. de la Torre1,5, M. Torrens2,4. 1Institut d’Atenció Psiquiàtrica i Addiccions-Parc de Salut Mar, Spain; 2Institut Municipal d’Investigació Mèdica, Parc de Salut Mar, Parc de Recerca Biomèdica de Barcelona, Spain; 3Institut de Neurociències, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Spain; 4Universitat Autònoma de Barcelona, Spain; 5Pompeu Fabra University, Spain

Neuropsychological performance of cocaine addicts during treatment

G. García-Fernández1, O. García-Rodríguez2, R. Secades-Villa1, S. Fernández-Artamendi1, J.R. Fernández-Hermida1. 1University of Oviedo, Spain; 2University of Barcelona, Spain

Morbidity and mortality among drug users admitted to the complication ward of the Drug Dependence Hospital in Jakarta, Indonesia

M. Hidayat1, A. Nurhidayat1, R. Sarasvita1, D. Utami1, D. Metzger2. 1Drug Dependence Hospital RSKO, Indonesia; 2University of Pennsylvania, United States

The effectiveness of cognitive behavior therapy for depression and substance use compared to standard care among young people with co-occurring depression/anxiety and substance use

L. Hides1, D.I. Lubman2, K. Elkins2, S. Carroll2, A. Scaffidi2, S.M. Cotton2, R. Marks3. 1University of Melbourne, Australia; 2Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, Australia; 3Youth Outreach Team, Drug and Alcohol Services West, Western Health, Australia
Medication-assisted treatment, scale-up strategy for Ukraine
Z. Islam\(^1\), S. Filippovych\(^1\), A. Lebega\(^1\), R.D. Bruce\(^2\). \(^1\)International HIV/AIDS Alliance in Ukraine; \(^2\)Yale AIDS Program, Yale University School of Medicine, United States

Efficacy and safety of extended-release injectable naltrexone for the treatment of opioid dependence
E. Krupitsky\(^1\), A. Illeperuma\(^2\), D. Gastfriend\(^2\), B. Silverman\(^2\). \(^1\)St. Petersburg Bekhterev Research Psychoneurological Institute, Russia; \(^2\)Alkermes, Inc., United States

The prevalence and correlates of aberrant drug behaviors among a sample of Australian opioid substitution treatment clients
B. Larance, L. Degenhardt. National Drug and Alcohol Research Centre, University of New South Wales, Australia

Change in organizational dual-diagnosis capacity after a whole of workforce initiative in substance use treatment settings
N. Lee, J. Cameron, A. Harney, S. Roeg. Turning Point Alcohol and Drug Centre, Australia

Preliminary outcomes of methadone treatment among heroin users in northern Taiwan
T.S.H. Lee\(^1\), D.S. Metzger\(^2\), M. Charwarski\(^3\). \(^1\)National Taiwan Normal University, Taiwan; \(^2\)Center for AIDS Research, University of Pennsylvania, United States; \(^3\)School of Medicine, Yale University, United States

Methadone patients’ treatment outcomes: Longitudinal study on the associations between background and process variables and retention rate, illicit drug use, and risk behavior
S. Levit\(^1\), M. Schiff\(^2\), R. Benbenishty\(^3\). \(^1\)Association for Public Health, Israel; \(^2\)School of Social Work and Social Welfare, Hebrew University, Israel; \(^3\)School of Social Work, Bar Ilan University, Israel

Contingency management for Chinese methadone patients
J. Li\(^1\), Y. Hser\(^2\), R. Zhang\(^1\), B. Zhang\(^1\), C. Zhang\(^1\), X. Tang\(^1\). \(^1\)Yunnan Institute for Drug Abuse, China; \(^2\)Center for Advancing Longitudinal Drug Abuse Research, University of California, Los Angeles, United States

Hypnotherapy in the treatment of alcoholism
B. Lobodov. Center "Semya," Russia
Short-term safety of buprenorphine/naloxone in HIV-seronegative opioid-dependent Chinese and Thai drug injectors enrolled in HIV prevention trials network 058
G. Lucas¹, G. Beauchamp², A. Aramrattana³, Y. Shao⁴, W. Liu⁵, L. Fu⁶, B. Jackson¹, D. Celentano⁷, M. Chawarski⁸, D. Burns⁹, K. Davenny¹⁰, D. Donnell¹², S. Rose¹¹, D. Metzger for HPTN 058 Study Group¹². ¹Johns Hopkins School of Medicine, United States; ²Statistical Center for HIV/AIDS Research and Prevention-Fred Hutchinson Cancer Research Center, United States; ³Chiang Mai University, Thailand; ⁴China Center for Disease Control and Prevention, China; ⁵Guangxi China Center for Disease Control and Prevention, China; ⁶Xinjiang China Center for Disease Control and Prevention, China; ⁷Johns Hopkins Bloomberg School of Public Health, United States; ⁸Yale University, United States; ⁹National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), United States; ¹⁰National Institute on Drug Abuse, NIH, United States; ¹¹Family Health International, United States; ¹²University of Pennsylvania, United States

Creating lesbian, gay, bisexual, transgender, and queer treatment-sensitive substance abuse counselors: The importance of cultural competency

Associations between implicit and explicit drug-related cognitions and relapse: An ecological momentary assessment study
R. Marhe¹, I. Franken¹, A. Walters². ¹Institute of Psychology, Erasmus University Rotterdam, The Netherlands; ²Department of Medical and Clinical Psychology, Uniformed Services University of the Health Sciences, United States

Involving family physicians in methadone treatment maintenance programs in Kosovo
I. Miftari. Main Family Medicine Center, Kosovo

Is exposure therapy for post-traumatic stress disorder efficacious among people with substance use disorders? Results from a randomized controlled trial
K. Mills, M. Teesson, E. Barrett, S. Merz, J. Rosenfeld, P. Farrugia. University of New South Wales, Australia

Factors associated with heroin use in patients on the pilot methadone maintenance therapy program in Vietnam
N. Nguyen¹, N.T. Long², N.T. Huynh², N.Q. Mai², T.V. Hoang¹, P.H. Minh¹, S.J. Mills¹, R. Burdon¹, K.P. Mulvey¹, N.T.M. Ngoc⁴, N.T. Hong⁵, D. Jacka⁶, R. Ali⁷. ¹Family Health International, Vietnam; ²Vietnam Administration of HIV/AIDS Control, Ministry of Health, Vietnam; ³Substance Abuse and Mental Health Services Administration, United States; ⁴United States Agency for International Development, Vietnam; ⁵HHS Center for Disease Control, Vietnam; ⁶World Health Organization, Vietnam; ⁷World Health Organization Collaborating Center on Drug and Alcohol Abuse Treatment, Adelaide University, Australia
**Methadone maintenance treatment in Jakarta, Indonesia: Organizational and programmatic challenges**

A. Nurhidayat\(^1\), V. Fardhadian\(^1\), M. Chawarski\(^2\), G. Woody\(^3\), D. Metzger\(^3\).

\(^1\)Drug Dependence Hospital RSKO, Indonesia; \(^2\)Yale University, United States; \(^3\)University of Pennsylvania, United States

**Peculiarities of methcathinone (“Jeff”) consumption in patients on methadone maintenance treatment**

G. Piralishvili, N. Papuashvili, Z. Zikharulidze. Medical Centre Uranti, Georgia

**Bringing gender-based analysis to substance use treatment and policy in Canada**

N. Poole. British Columbia Centre of Excellence for Women's Health, Canada

**Advertising representation of substance abuse treatment clinics in Iran**

S. Rezaee\(^1,2\), M. Noori\(^1\), L. Jahromi\(^1\), M.R. Jamshidi\(^1\), H. Ekhtiar\(^1\). \(^1\)Neuro Cognitive Laboratory, Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Iran; \(^2\)Cultural Studies Department, Social Studies School, Allame Tabatabai University, Iran

**Long-term residential substance abuse treatment for women: Lessons learned from Israel**

M. Schori\(^1\), E. Lawental\(^2,3\), Y. Sapir\(^4\). \(^1\)School of Social Policy and Practice, University of Pennsylvania, United States; \(^2\)Haifa Drug Abuse Treatment Center, Israel; \(^3\)Tel-Hai Academic College, Israel; \(^4\)The Central School for Social Welfare Workers, Ministry of Social Affairs, Israel

**Adding voucher-based incentives to the community reinforcement approach improves outcomes during treatment for cocaine dependence**

R. Secades-Villa\(^1\), G. García-Fernández\(^1\), O. García-Rodríguez\(^2\), H. Álvarez Rodríguez\(^3\), J.A. Álvarez García\(^1\), E. Sánchez-Hervás\(^4\). \(^1\)University of Oviedo, Spain; \(^2\)University of Barcelona, Spain; \(^3\)Proyecto Hombre Asturias, Spain; \(^4\)Valencia State Health Agency, Spain

**Relationship between cognitive behavioral therapy knowledge transfer and skill implementation among South African substance abuse clinicians**

R. Sodano\(^1\), S. Rataemane\(^2\), L. Rataemane\(^3\), N. Ntlhe\(^3\), R.A. Rawson\(^1\). \(^1\)Integrated Substance Abuse Programs, University of California, Los Angeles, United States; \(^2\)Department of Psychiatry, University of Limpopo, South Africa; \(^3\)Mental Health and Addiction Centre, South Africa

**Effects of acute tyrosine, tryptophan, and phenylalanine depletion treatment on cue-induced alcohol urging in patients with alcohol dependence in China**

H. Sun\(^1\), Y. Liu\(^2\), X. Bao\(^2\), X. Di\(^1\), F. Yang\(^1\), L. Lu\(^2\). \(^1\)Beijing Hui-Long-Guan Hospital, China; \(^2\)National Institute on Drug Dependence, Peking University, China

46
Does co-occurring social phobia interfere with alcoholism treatment adherence and relapse?
M. Terra¹, H.M. Tannahauer Barros², A. Tetelbom Stein². ¹Center for Drug and Alcohol Research, Federal University of Rio Grande do Sul, Brazil; ²Federal University of Health Sciences of Porto Alegre, Brazil

Detection of alcohol-related problems in primary care health centers in the autonomous region of Valencia (Spain)
S. Tomas¹, P. Torrjo², S. Tortajada², J. Aguilar², N. Llorens². ¹Direccion General de Drogodependencias, Spain; ²Fundación para el Estudio, Prevención y Asistencia a las Drogodependencias, Spain

Injection drug use and anemia among AIDS patients in Vietnam
H. Vu¹, P. Sullivan¹, C. del Rio¹, N.T. Do², L.T. Nguyen², Q.H. Tran³. ¹Rollins School of Public Health, Emory University, United States; ²Ministry of Health, Vietnam; ³Hanoi School of Public Health, Vietnam

INFORMATIONAL

Hubert Humphrey Fellowship Program at Virginia Commonwealth University
J.R. Koch, R. Balster, C. Thomas, E. Turf, C. O’Keefe. Virginia Commonwealth University, United States

International Program in Addiction Studies
J.R. Koch, R. Balster, M. Loos, E. Turf, C. O’Keefe. Virginia Commonwealth University, United States

The Virginia Commonwealth University Hubert H. Humphrey Fellowship in Substance Abuse Prevention, Treatment, and Policy: Follow-up assessment
J.R. Koch, L. Leonchuk, R. Balster, E. Turf, C. O’Keefe. Virginia Commonwealth University, United States
Tuesday, June 15, 2010

Grant-Writing Workshop  
(Pre-Registration Only)  
Sonoran  
8:00 AM - 12:00 PM

Poster Session II (Lunch)  
Pavilion  
11:30 AM - 1:30 PM

Odd-numbered posters manned first hour;  
Even-numbered, second hour

Set-up time begins Monday no earlier than 3:00 PM  
Must be removed by Tuesday no later than 2:00 PM

CRIMINAL JUSTICE

1 Predictors of treatment completion among offenders enrolled in a community-based outpatient program  
D. M. Coviello\textsuperscript{1}, D. A. Zanis\textsuperscript{1,2}, S. A. Wesnoski\textsuperscript{1}, N. R. Palman\textsuperscript{1}, A. Erez\textsuperscript{1}, \textsuperscript{1}University of Pennsylvania, Philadelphia, PA, \textsuperscript{2}Temple University, Philadelphia, PA

2 Lifetime and past-year prevalence of drug use and drugged driving among rural Appalachian DUI offenders  
M. Webster, M. F. Dickson, N. E. Wasarhaley, M. Staton-Tindall, Center on Drug and Alcohol Research, University of Kentucky, Lexington, KY

3 Gender effects in the Step ’N Out Study of substance-use treatment mandated parolees  
J. E. Johnson\textsuperscript{1}, P. Friedmann\textsuperscript{2,1}, F. Taxman\textsuperscript{1}, \textsuperscript{1}Brown University, Providence, RI, \textsuperscript{2}Rhode Island Hospital, Providence, RI, \textsuperscript{3}George Mason University, Fairfax, VA

4 A comparison of community correction participants enrolled in methadone maintenance treatment  
A. C. Perkins, K. E. Conti, G. J. Hale, D. O. Jackson, K. L. Cropsey, Psychiatry, University of Alabama at Birmingham, Birmingham, AL

5 Heroin-dependent offenders’ experiences with buprenorphine vs. methadone maintenance  
S. Magura, E. Awgu, A. Rosenblum\textsuperscript{2}, \textsuperscript{1}Western Michigan University, Kalamazoo, MI, \textsuperscript{2}National Development and Research Institutes, New York, NY

6 A randomized control trial using buprenorphine for opiate addiction: A descriptive analysis of female offenders  
G. J. Hale, D. O. Jackson, P. S. Lane, S. Jones-Whaley, A. Perkins, K. Cropsey, Psychiatry, University of Alabama at Birmingham, Birmingham, AL

7 Characteristics of incarceration among black South African drug users  

8 Incarceration and sexually transmitted infection/HIV in Bushwick, Brooklyn, NY: A social network perspective  
M. Khan, S. Friedman, Epidemiology and Biostatistics, University of Maryland, College Park, MD

9 Polysubstance users in the criminal justice system – a comparison with heroin and amphetamine users  
A. Hakansson\textsuperscript{1}, F. Schlyter\textsuperscript{2}, M. Berglund\textsuperscript{1}, \textsuperscript{1}Clinical Alcohol Research, Lund University, Malmö, Sweden, \textsuperscript{2}Swedish Prison and Probation Service, Norrköping, Sweden

10 New factors to consider in assessing accuracy of self-reported drug use in treatment settings  
F. Taxman, A. Wooditch, George Mason University, Manassas, VA
11 *Risk of death and crime among program-quitters*
   T. Clausen¹, S. Skurtveit²,¹, ¹Norwegian Centre for Addiction Research, University of Oslo, and
   ²Pharmacoepidemiology, Norwegian Institute of Public Health, Oslo, Norway

12 *Comparing outcomes of ‘voluntary’ and ‘quasi-compulsory’ treatment of substance dependence in Europe*
   M. P. Schaub¹, A. Stevens², N. Hunt², D. Berto³, T. McSweeney⁴, B. Trinkl⁵, V. Kerschl⁶,
   W. Werdenich⁶, A. Uchtenhagen¹, ¹Research Institute for Public Health and Addiction, Zurich,
   Switzerland, ²European Institute of Social Services, University of Kent, Canterbury, United
   Kingdom, ³Servizio Tossicodipendenze, Padova, Italy, ⁴SPI Forschung, Berlin, Germany,
   ⁵Institute for Criminal Policy Research, King’s College London, London, United Kingdom,
   ⁶Lehr- und Forschungspraxis der Universität Wien, Vienna, Austria

13 *Relationship of criminal thinking to personality and criminal behavior among female offenders*
   B. B. Riley¹, C. K. Scott¹, M. L. Dennis¹, R. Funk¹, S. Kim², ¹Chestnut Health Systems,
   Bloomington, IL, ²School of Public Health, University of Illinois at Chicago, Chicago, IL

14 *Examining the relationship between social support and crack and cocaine use in an incarcerated population of mothers and non-mothers*
   K. L. Harp¹,², C. Leukefeld³,²,³, C. B. Oser¹,², ¹Sociology, ²Center on Drug and Alcohol
   Research, and ³Behavioral Science, University of Kentucky, Lexington, KY

15 *Women’s TC—preliminary psychological findings at 12-month follow-up*
   J. Y. Sacks, S. Sacks, K. McKendrick, G. Melnick, National Development & Research
   Institutes, Inc., New York, NY

16 *Re-entry programming for offenders with co-occurring disorders: Process and outcome findings from a pilot study*
   A. Pande, P. Mulvey, M. S. Shafer, V. Staples, R. Rivera, Center for Applied Behavioral Health
   Policy, Arizona State University, Phoenix, AZ

17 *Co-occurring mental health and substance use disorders among recently booked arrestees*
   D. Choate², M. S. Shafer¹, C. Katz², ¹College of Public Programs, and ²Center for Violence
   Prevention and Community Safety, Arizona State University, Phoenix, AZ

18 *Preliminary analysis of TASC offenders with co-occurring substance use and mental health disorders*
   D. O. Jackson, G. Hale, A. Perkins, K. Cropsey, University of Alabama, Birmingham, AL

19 *Collaborative behavioral management reduces crime, drug use among drug-involved parolees*
   P. D. Friedmann¹,², M. Harrington², T. C. Green², F. S. Taxman³, ¹Research Enhancement Award
   Program, Providence VA Medical Center, Providence, RI, ²Medicine, Rhode Island Hospital,
   Providence, RI, ³George Mason University, Fairfax, VA

20 *The social networks of drug-using probationers in a randomized trial in Maryland*
   A. G. Rhodes, F. S. Taxman, Adminstration of Justice, George Mason University,
   Richmond, VA

21 *The relationship between substance abuse halfway houses and crime in Baltimore City, Maryland*
   S. J. Boyd¹, L. J. Fang¹, D. R. Medoff¹, L. B. Dixon¹, D. A. Gorelick², ¹Psychiatry, University of
   Maryland School of Medicine, ²Intramural Research Program, NIH/NIDA/DHHS,
   Baltimore, MD

22 *Re-entry MTC—preliminary findings on reincarceration at 12-month follow-up*
   S. Sacks, J. Y. Sacks, K. McKendrick, National Development and Research Institutes, Inc,
   New York, NY
23 Towards evidence-based dispositions: A preliminary evaluation of the Risk and Needs Triage in a sample of drug court candidates
K. L. Dugosh1, D. S. Festinger1, D. B. Marlowe1,2, A. Caron1, M. R. Padkpacz1, 1Treatment Research Institute, Philadelphia, PA, 2National Association of Drug Court Professionals, Alexandria, VA, 3Fourth Judicial District, Minnesota Judicial Branch, Hennepin County, MN

24 Jail sanctions during drug court participation and substance abuse treatment completion
R. T. Brown1,2, P. A. Allison2, F. J. Nieto3, 1Family Medicine, University of Wisconsin School of Medicine & Public Health, Madison, WI, 2Sociology, University of Pennsylvania, Philadelphia, PA, 3Population Health Sciences, University of Wisconsin School of Medicine & Public Health, Madison, WI

POLICY

25 Coordination between Single State Authorities and Departments of Corrections in the treatment of offenders within the community
S. P. Kubiak2, C. L. Arfken1, E. Tillander2, 1Psychiatry, Wayne State University, Detroit, MI, 2Social Work, Michigan State University, E. Lansing, MI

26 California’s Substance Abuse and Crime Prevention Act, aka Proposition 36: Arrest outcomes, state crime trends, and prison population trends associated with implementation
D. Urada, M. D. Anglin, J. Fan, Integrated Substance Abuse Programs, UCLA, Los Angeles, CA

27 Cost savings under Proposition 36 - What groups save the most money?
M. D. Anglin2, A. Jaffe2,1, D. Urada2, 1Psychology, UCLA, and 2Integrated Substance Abuse Program, Los Angeles, CA

28 Mechanisms of prescription drug diversion among impaired physicians
S. M. Cummings, L. J. Merlo, L. B. Cottler, Psychiatry, Washington University School of Medicine, St. Louis, MO

29 Adoption of buprenorphine in two health plans
D. McCarty1, F. Lynch2, J. Mertens3, C. Green2, S. Parthasarathy3, M. Polen2, A. Hilde1, N. Perrin2, 1Public Health & Preventive Medicine, Oregon Health & Science University, Portland, OR, 2Center for Health Research, Kaiser Permanente Northwest, Portland, OR, 3Division of Research, Kaiser Permanente Northern California, Oakland, CA

30 Nicotine is the thing: Reducing harm from tobacco through proper labeling
R. K. Lanier, C. Wright, Rock Creek Pharmaceuticals, Gloucester, MA

31 Toxin delivery after Black & Mild little cigar smoking
W. Pickworth, V. M. Smith, R. Martin, L. Canlas, J. Malson, Battelle CPHRE, Baltimore, MD

NICOTINE: HUMAN STUDIES

32 Oral nicotine discrimination in nicotine non-users
A. N. Duke, R. R. Griffiths, Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, Baltimore, MD

33 The effects of varenicline on smoking in a brief abstinence model
E. A. McClure, R. G. Vandrey, M. Stitzer, Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD

34 A placebo-controlled trial of varenicline treatment on the acute effects of cigarette smoking followed by a one-week quit attempt
M. S. Reid, V. Thakkar, Psychiatry, New York University, New York, NY
Pretreatment with nicotine patch facilitates smoking reduction in adult smokers with Attention Deficit Hyperactivity Disorder
J. S. English, M. Hallyburton, F. J. Mcclernon, S. H. Kollins, Duke University Medical Center, Durham, NC

Findings from a clinical trial of bupropion for smokers in alcohol recovery
D. Kalman1,2, U. Sambamoorthi3, L. Herz2, G. Gonzalez1, P. Monti4, 1University of Massachusetts, Worcester, MA, 2ENRM VAMC, Bedford, MA, 3West Virginia University, Morgantown, WV, 4Brown University, Providence, RI

Individual differences in Iowa Gambling Task: Possible role of early punishment intensity
A. A. Lopez1, M. P. Bradstreet1, S. T. Higgins1,2, 1Psychology, and 2Psychiatry, University of Vermont, Burlington, VT

Pathological learning in smokers: A conditioning experiment utilizing ERP measurements
M. Littel, I. Franken, Institute for Psychology, Erasmus University, Rotterdam, Netherlands

Individual and concomitant influences of positive and negative affect on urge to smoke
A. M. Leventhal, K. J. Ameringer, S. W. Sharifian, Preventive Medicine, University of Southern California, Alhambra, CA

Smokers delay discounting indifference points are associated with changes in opportunity-cost-informed price
E. T. Mueller, R. D. Landes, R. Yi, W. K. Bickel, Psychiatry, University of Arkansas for Medical Sciences, Little Rock, AR

Body composition and metabolic changes in women smokers during a cessation attempt
K. M. Gray, M. E. Saladin, M. J. Carpenter, K. J. Hartwell, Psychiatry & Behavioral Sciences, Medical University of South Carolina, Charleston, SC

Distress tolerance and adolescent smoking cessation
A. Collado-Rodriguez, W. Francis, K. Young, J. Gottlieb, C. W. Lejuez, L. MacPherson, University of Maryland, College Park, MD

Treatment acceptability of Internet-based contingency management for cigarette smoking
B. R. Raiff1,2, M. Turturici2, C. Faix2, J. Dallery2, 1National Development and Research Institutes, and 2University of Florida, Gainesville, FL

New York state policy to address tobacco dependence in drug treatment: Preliminary client baseline-follow-up results
B. Tajima1, J. Guydish1, A. Kulaga2, L. Brown2, R. Zavala1, 1Institute for Health Policy Studies, University of California, San Francisco, CA, 2New York University, New York City, NY, 3Addiction Research & Treatment Corporation, Brooklyn, NY

Organizational change to address tobacco dependence: Pre, post and follow-up results
J. Guydish1, B. Tajima1, D. Ziedonis2, E. Passalacqua1, M. Chan1, M. Levy3, G. Brigham4, L. Zamarelli5, 1Institute for Health Policy Studies, University of California, San Francisco, CA, 2University of Massachusetts, Worcester, MA, 3CAB Recovery Services, Inc, Lynn, MA, 4Maryhaven, Inc, Columbus, OH, 5Willamette Family, Inc, Eugene, OR

Attitudes and behaviors toward smoking cessation interventions by the dental team
G. G. Homish1, Y. Gonzalez2, E. Lozier3, L. Blair3, J. Fabiano3, 1Health Behavior, and 2School of Dental Medicine, University at Buffalo, Buffalo, NY, 3Roswell Park Cancer Institute, Buffalo, NY

DSM-IV and Fagerstrom nicotine dependence: Relationship in an Israeli general population sample
D. Shmulewitz, E. Aharonovich, D. Hasin, Columbia University, New York, NY
The Brazilian smoker: A cross-sectional survey in Brazil
E. S. Opaleye1, Z. V. Sanchez1, Y. G. Moura2, D. P. Locatelli1, A. R. Noto1, 1Psychobiology, Federal University of Sao Paulo, and 2AFIP, Sao Paulo, Brazil

Youthful tobacco smoking for males and females in Brazil
Z. V. Sanchez1,2, A. R. Noto1,2, 1Psychobiology, Federal University of Sao Paulo, and 2Brazilian Center of Information on Psychotropic Drugs (CEBRID), Sao Paulo, Brazil

Beliefs associated with the consumption and non-consumption of tobacco in school students in Spain
F. J. Bueno-Cañigral2, C. C. Morales-Manrique1, R. Aleixandre-Benavent1, J. C. Valderrama-Zurián3, 1Unidad de Información e Investigación Social y Sanitaria, Universitat de València-CSIC., 2Plan Municipal Drogodependencias (PMD), Ayuntamiento de Valencia, and 3Generalitat Valenciana, Valencia, Spain

Tobacco use and spirituality among freshman students in a historically black university
C. Johnson, R. Beharie, J. Hazel, J. Carr, Z. Boone, P. Sheikhattari, F. A. Wagner, School of Community Health and Policy, Morgan State University, Baltimore, MD

Effects of voucher-based treatment for cigarette smoking cessation on maternal weight gain during pregnancy
Y. T. Washio1, S. T. Higgins1,2, S. H. Heil1,2, G. J. Badger3, J. Skelly3, I. M. Bernstein4, L. J. Solomon5, M. E. Lynch1, 1Psychiatry, 2Psychology, 3Medical Biostatistics, 4Obstetrics and Gynecology, and 5Family Practice, University of Vermont, Burlington, VT

Social discounting among pregnant cigarette smokers, quitters, and never-smokers
M. P. Bradstreet2, S. T. Higgins1,2, S. H. Heil1,2, M. C. Flynn1, 1Psychiatry, and 2Psychology, University of Vermont, Burlington, VT

One Tiny Reason to Quit: A prenatal smoking cessation campaign in Richmond, VA
A. Sepulveda, M. Kennedy, S. Garland, D. Svikis, W. Smith, Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, VA

Nicotine withdrawal in pregnant cigarette smokers
S. H. Heil, S. Higgins, S. Sigmon, Psychiatry, University of Vermont, Burlington, VT

Reduced-nicotine content cigarettes: Knowledge, attitudes and practice in drug-dependent pregnant and post-partum smokers
A. M. Andersen, F. Yunus, M. Chisolm, Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD

Preliminary evaluation of two high-reach interventions for smoking during pregnancy: Computer-delivered 5As and low-intensity Contingency Management
S. J. Ondersma1, D. S. Svikis2, P. K. Lam1, V. Connors1, K. Husar1, D. M. Ledgerwood1, 1Wayne State University, Detroit, MI, 2Virginia Commonwealth University, Richmond, VA

Smoking and depression in post-partum women: Does severity matter?
S. B. Varner, L. Keyser-Marcus, S. Masho, D. Svikis, L. Meloy, Virginia Commonwealth University, Richmond, VA

Greater prevalence of marijuana use than tobacco use among low-income pregnant women in Detroit
J. R. Beatty1, D. S. Svikis2, V. Connors1, P. Lam1, S. J. Ondersma1, 1Psychiatry and Merrill Palmer Skillman Institute, Wayne State University, Detroit, MI, 2Virginia Commonwealth University, Richmond, VA
Fetal neurobehavioral effects of maternal methadone vs. buprenorphine administration
L. M. Jansson¹, J. A. DiPietro², M. L. Velez¹, A. Elko¹, H. E. Jones¹, ¹Johns Hopkins University School of Medicine, and ²Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

Methadone during pregnancy: Sleep and neurocognitive performance in the neonate
M. J. Hayes¹,², J. Paul¹, B. Matano-Logan¹, N. Heller¹, M. Brown³, R. Krishnan², P. Tisher⁴, ¹Psychology, University of Maine, Orono, ME, ²Maine Institute for Human Genetics & Health, ³Pediatrics, Eastern Maine Medical Center, and ⁴Private Practice, Bangor, ME, ²Pediatrics, University of Tennessee Medical Center, Knoxville, TN

Methadone dose and NAS
A. Holbrook, K. Kaltenbach, Thomas Jefferson University, Philadelphia, PA

Intensity of care is the only predictor of out-patient opiate treatment retention among pregnant women
M. Terplan¹, C. Friedman², ¹OB/Gyn, University of Maryland, Baltimore, MD, ²Psychiatry, University of Pittsburgh, Pittsburgh, PA

Correlation of fetal heart rate and opioid withdrawal signs in pregnant opioid-dependent women
P. Thakur¹, C. Christensen², D. Tansil³, E. Cepeda³, G. Gorden¹, G. Arora¹, S. Stine¹, ¹Psychiatry and Behavioral Neurosciences, Wayne State University, Detroit, MI, ²Obstetrics and Gynecology, and ³Pediatrics and Neonatology, WSU School of Medicine, Detroit, MI

Children born from mothers treated with substitution (buprenorphine or methadone): Long-term outcomes?
L. Gourarier¹, C. Lejeune², C. Deslandes³, J. Jungman¹, ¹CASAT La Terrasse, Groupe Hospitalier Maison Blanche, Paris, ²Service de Néonatalogie, Hopital Louis Mourier, Colombes, ³Centre Montecristro, HEGP, Paris 15, France

Examining the impact of an FASD curriculum infusion on nursing and social work students’ attitudes related to FASDs and alcohol use among women of child-bearing age
N. A. Roget¹, J. A. Hartje¹, M. S. Berry¹, M. Saleh¹, R. Tolleson Knee², S. Williams¹, ¹Center for the Application of Substance Abuse Technologies, University of Nevada, Reno, Reno, NV, ²University of Montana, Missoula, MT, ³Colorado State University, Pueblo, CO

Methamphetamine-using pregnant women in California drug treatment: Characteristics, referral source, program completion and prenatal care
M. S. Stemmler¹, D. Huang², Y. Hser³, ¹School of Nursing, ²Integrated Substance Abuse Programs, and ³Center for Advancing Longitudinal Drug Abuse Research, University of California, Los Angeles, Los Angeles, CA

Adverse consequences for children of cocaine-dependent parents
J. R. Strickland, S. E. Afful, L. B. Cottler, L. J. Bierut, Psychiatry, Washington University School of Medicine, St. Louis, MO

Attention at 12 years in prenatally cocaine-exposed children
S. Minnes, L. Singer, M. Min, E. Short, Case Western Reserve University, Cleveland, OH

Prenatal cocaine exposure and memory and learning deficits in early adolescence: Male-female differences
E. S. Bandstra¹, V. H. Accornero¹, E. Mansoor¹, C. E. Morrow¹, A. Y. Ofir¹, J. C. Anthony², L. Xue¹, ¹Pediatrics, University of Miami Miller School of Medicine, Miami, FL, ²Epidemiology, Michigan State University, East Lansing, MI

Environmental enrichment dampens the effects of prenatal cocaine on cocaine reward and dopaminergic markers in adolescent male and female rats
D. Dow-Edwards¹, A. Jackson¹, M. Iijima¹, S. Stephenson¹, C. Mayer², B. Vignoli², S. Izenwasser², ¹SUNY Downstate Medical Center, Brooklyn, NY, ²University of Miami Miller School of Medicine, Miami, FL
72 Prenatal stress increases cocaine-seeking in C57BL/6J mice
   T. E. Kippin, J. C. Campbell, K. K. Szumlinski, Psychology, University of California at Santa
   Barbara, Santa Barbara, CA

73 IV gestational nicotine exposure increases brain-derived neurotrophic factor in adolescent rats
   R. T. Lacy1, R. Brown2, L. Ballina1, B. Hughes2, S. Harrod1, 1Psychology, University of South
   Carolina, Columbia, SC, 2Psychology, East Tennessee State University, Johnson City, TN

74 WITHDRAWN

75 Gestational and postnatal toluene exposure impairs learning and memory in juvenile rats
   A. Huerta Rivas, C. López-Rubalcava, S. Cruz, Pharmacobiology, Cinvestav, Mexico City,
   Mexico

76 Neurobehavioral and developmental effects of prenatal exposure to stress and/or toluene in mice
   P. Soberanes-Chávez, S. Cruz, C. López-Rubalcava, Pharmacobiology, Cinvestav, Mexico City,
   Mexico

IMAGING I

77 Gray matter decline with depression scores in methamphetamine users and control subjects
   H. Nakama1, L. Chang2, G. Fein3, T. Ernst2, 1Psychiatry, and 2Medicine, University of Hawaii,
   3Neurobehavioral Research, Honolulu, HI

78 Altered resting state fMRI default modes in methamphetamine users
   A. Stenger1, H. Nakama1, G. Fein2, L. Chang1, 1University of Hawaii, and 2Neurobehavioral
   Research Inc., Honolulu, HI

79 The effect of methamphetamine addiction on metabolite levels in the human brain using proton
   magnetic resonance spectroscopy
   J. C. Lin1, R. K. Jan1, R. R. Kydd2, B. R. Russell1, 1School of Pharmacy, and 2Psychological
   Medicine, The University of Auckland, Auckland, New Zealand

80 The effect of methamphetamine addiction on executive function and cognition in the human
   brain using functional magnetic resonance imaging and the Stroop task
   R. K. Jan1, J. C. Lin1, N. A. McNair1, I. J. Kirk2, R. R. Kydd3, B. R. Russell1, 1School of
   Pharmacy, 2Psychology, and 3Psychological Medicine, University of Auckland, Auckland, New
   Zealand

81 Human MDMA use is associated with increased activation in anterior cingulate gyrus during
   flanker task performance: An fMRI study
   R. Cowan, E. Toaz, E. J. Charboneau, M. S. Dietrich, A. Cao, Psychiatric Neuroimaging
   Program, Vanderbilt University, Nashville, TN

82 Effect of d-amphetamine on fMRI during cue-reactivity task in cocaine-dependent subjects
   compared to controls
   K. L. Kjome1, J. L. Steinberg1, T. Kosten3, S. D. Lane1, A. Waters4, L. Ma1, L. A. Kramer2,
   P. A. Narayana2, F. G. Moeller1, 1Psychiatry, and 2Diagnostic and Interventional Imaging,
   University of Texas-Houston, Houston, TX, 3Psychiatry, Baylor College of Medicine,
   Houston, TX, 4Medical and Clinical Psychology, Uniformed Services University,
   Bethesda, MD

83 Lower diffusion in parietal white matter of adolescent drug users
   R. Gonzales1, C. Cloak1, D. Alicata2, G. King1, T. Ernst1, L. Chang1, 1Medicine, and
   2Psychiatry, University of Hawaii, Honolulu, HI

BADGES MUST BE WORN FOR ALL SESSIONS AND SOCIAL EVENTS
84 Decreased N-acetylaspartate levels in adolescents concurrently using both methamphetamine and cannabis
  Y. H. Sung1, P. D. Carey2, P. F. Renshaw1, D. A. Yurgelun-Todd1, 1University of Utah, Salt Lake City, UT, 2University of Stellenbosch, Cape Town, South Africa

85 Less efficient psychomotor function in chronic cannabis users
  G. R. King, T. Ernst, J. Sabugo, R. Gonzales, A. Stenger, L. Chang, Medicine, University of Hawaii, Honolulu, HI

86 Resting state intra-limbic connectivity predicts affective symptoms in marijuana-dependent subjects
  R. P. Szucs1,2, M. Goldman2, Z. Wang2, Y. Li2, R. Ehrman1,2, W. Jens2, J. Hakun2, J. Suh2,1, A. Hole1,2, K. Kampman2,1, C. P. O’Brien2,1, A. R. Childress2,1, 1VA Medical Center and, and 2University of Pennsylvania, Philadelphia, PA

87 Impaired anterior cingulate cortex glutamatergic neurotransmission in adolescent marijuana users
  A. P. Prescott, A. E. Locatelli, P. F. Renshaw, D. A. Yurgelun-Todd, Brain Institute, University of Utah, Salt Lake City, UT

88 Association between cingulate volume and impulsivity in adolescent cannabis smokers
  J. C. Churchwell, E. Bueler, D. A. Yurgelun-Todd, School of Medicine, University of Utah, The Brain Institute, Salt Lake City, UT

MARIJUANA, CANNABINOIDS

89 Amygdalar volume and mood ratings in adolescent marijuana users
  E. C. McGlade, J. Terry, J. King, D. Yurgelun-Todd, University of Utah Brain Institute, Salt Lake City, UT

90 Estimated cannabis-associated risk of developing a newly incident depression spell: Focus on early-onset cannabis use
  B. Fairman, J. C. Anthony, Epidemiology, Michigan State University, East Lansing, MI

91 “Youthful epidemic” or diagnostic bias? Differential item functioning of DSM-IV cannabis use criteria in an Australian general population survey
  L. R. Mewton, M. Teesson, T. Slade, University of New South Wales, Randwick, NSW, Australia

92 Characteristics of urban adolescents who screen positive for marijuana dependence in indigent primary care clinics
  K. Barry1,2, M. A. Walton1, S. Resko3, S. T. Chermack1,2, R. A. Zucker1, M. Zimmerman4, B. M. Booth4, F. C. Blow1,2, 1Psychiatry, University of Michigan, and 2VA, Ann Arbor, MI, 3Social Work, Wayne State University, Detroit, MI, 4Public Health, University of Michigan, Ann Arbor, MI, 5Psychiatry, University of Arkansas for Medical Sciences and VA, Little Rock, AR

93 Computerized MET/CBT for the treatment of cannabis abuse and dependence
  A. J. Budney1, S. Fearer1, C. Stanger1, P. Costello1, M. Grabinski2, W. K. Bickel1, 1University of Arkansas for Medical Sciences, Little Rock, AR, 2HealthSim, Inc., New York, NY

94 Quantification of risk for substance use disorder using Computerized Adaptive Test Format: A simulation study
  L. Kirisci, M. Vanyukov, R. Tarter, T. Ridenour, M. Reynolds, A. Mezzich, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA
Marijuana use patterns, but not depressive symptoms, are associated with verbal learning and memory function in marijuana-dependent individuals in treatment
P. Roebke\textsuperscript{1,2}, N. P. Vadhan\textsuperscript{1,2}, D. J. Brooks\textsuperscript{1,2}, F. R. Levin\textsuperscript{1,2}, \textsuperscript{1}Substance Abuse, Columbia University, New York, NY, \textsuperscript{2}Substance Abuse, NY State Psychiatric Institute, New York, NY

Vividness of mental imagery (Trait Absorption) and impulsivity (Trait Constraint) predict self-reported consumption of cannabis in healthy volunteers
J. M. Kang, R. Youssef, T. L. White, Alcohol & Addiction/Community Health, Brown University, Providence, RI

Marijuana self-administration under a modified progressive-ratio procedure: Effects of marijuana use history

Influence of marijuana use on the effects of d-amphetamine
F. P. Wagner\textsuperscript{1}, S. J. Durkin\textsuperscript{2}, M. M. Poole\textsuperscript{3}, C. R. Rush\textsuperscript{1,3,4}, \textsuperscript{1}Behavioral Science, \textsuperscript{2}Biology, \textsuperscript{3}Psychology, and \textsuperscript{4}Psychiatry, University of Kentucky, Lexington, KY

Quetiapine increases marijuana craving and relapse in the human laboratory

Sleep dysfunction and the effects of extended-release zolpidem during cannabis withdrawal
R. Vandrey\textsuperscript{1}, U. McCann\textsuperscript{1}, M. Smith\textsuperscript{1}, A. Budney\textsuperscript{2}, \textsuperscript{1}Johns Hopkins University, Baltimore, MD, \textsuperscript{2}University of Arkansas for Medical Sciences, Little Rock, AR

Methadone enhances antinociceptive but not discriminative effects of THC
A. A. Wakley, R. M. Craft, Psychology, Washington State University, Pullman, WA

The fatty acid amide hydrolase inhibitor, URB597, morphine, and the CB1 agonist, CP55940 in assays of pain-elicited, pain-suppressed, and schedule-controlled behavior

Cannabinoids inhibit the Mixed Lymphocyte Reaction in vitro
R. Hartzell\textsuperscript{1,2}, J. J. Meissler\textsuperscript{1,2}, M. W. Adler\textsuperscript{1}, T. K. Eisenstein\textsuperscript{1,2}, \textsuperscript{1}Center for Substance Abuse Research, and \textsuperscript{2}Microbiology and Immunology, Temple University School of Medicine, Philadelphia, PA

HIV/HCV

Correlates of Mexico-US drug injection relationships among IDUs in Tijuana, Mexico
K. D. Wagner\textsuperscript{1}, R. Lozada\textsuperscript{2}, R. A. Pollini\textsuperscript{1}, V. D. Ojeda\textsuperscript{1}, K. C. Brouwer\textsuperscript{1}, A. Vera\textsuperscript{1}, T. A. Volkmann\textsuperscript{1}, S. A. Strathdee\textsuperscript{1}, \textsuperscript{1}Division of Global Public Health, University of California San Diego, La Jolla, CA, \textsuperscript{2}Patronado Pro-COMUSIDA A.C., Tijuana, Mexico

Development of a risk reduction intervention for injection drug users to reduce bacterial and viral infections
K. T. Phillips\textsuperscript{1}, K. F. Corsi\textsuperscript{2}, J. K. Altman\textsuperscript{1}, M. D. Stein\textsuperscript{3}, \textsuperscript{1}Psychological Sciences, University of Northern Colorado, Greeley, CO, \textsuperscript{2}University of Colorado-Denver School of Medicine, Denver, CO, \textsuperscript{3}Brown University and Butler Hospital, Providence, RI

Hepatitis C viral load: A comparative study between capillary micro sample and venous blood
P. Melin\textsuperscript{1,2}, A. Hijj\textsuperscript{2}, M. Marc\textsuperscript{1,2}, M. Guillaumot\textsuperscript{3}, M. Schoeny\textsuperscript{1}, C. Bremard\textsuperscript{2}, J. Fournier\textsuperscript{2}, S. Samouri\textsuperscript{1}, E. Ragot\textsuperscript{1}, \textsuperscript{1}CHG St dizier, and \textsuperscript{2}CSAPA 52, Saint dizier, France
107 Impact of a non-invasive method of liver stiffness measurement (Fibroscan®) in the care of patients suffering from HCV in an addiction center
E. Herran¹, P. Lavignasse¹, C. Kerloc’h¹, V. Beltran¹, A. Aguerretxe Colina¹, J. Daulouede¹,²
¹Addiction Clinic, BIZIA, and ²Resapsad Health Network, Bayonne, France

108 Withdrawal symptoms as a predictor of mortality in patients HIV-infected through drug use and receiving highly active antiretroviral therapy
L. Michel¹,², R. Giorgi³, V. Villes³, I. Poizot-Martin⁴, P. Dellamonica⁵, B. Spire⁴,
C. Protopopescu⁴, M. P. Carrière⁴, ¹Assistance Publique Hôpitaux de Paris, Limeil-Brévannes,
²Inserm U669, Paris, France, ³Lertim, Marseille, ⁴Inserm U912, Marseille, ⁵Sainte Marguerite Hospital, Marseille, and ⁶Archet Hospital, Nice, France

109 Effects of infectious diseases, HCV & HIV, and their treatments on therapeutic management in opiate-dependent patients undergoing a replacement therapy program in Spain: The PROTEUS study
C. Roncero¹,², B. Box³, G. Fuste¹, N. Martinez-Luna¹, J. Llaudó³, C. Barral¹, F. Eiroa¹,
M. Casas¹,², ¹Psychiatry, Out-patient Drug Clinic, Servicio de Psiquiatría, Hospital Universitario Vall Hebron, Barcelona, ²Psychiatry, Universidad Autónoma de Barcelona, Barcelona, and ³Medical Departament, Schering-Plough, S.A., Madrid, Spain

110 A controlled trial of on-site hepatitis C treatment in methadone maintenance
S. L. Batki¹,², K. Canfield², R. Levine², E. Smyth², K. Amadio², K. Manser², R. Ploutz-Snyder³,², ¹Psychiatry, University of California, San Francisco, San Francisco, CA, ²SUNY Upstate Medical University, Syracuse, NY, ³NASA, Houston, TX

111 An electronic health system in opioid agonist treatment clinics: Study design and baseline characteristics
M. Chu, S. A. Kritz, R. Zavala, L. S. Brown, Medical Services, Research and Information Technology, ARTC, Brooklyn, NY

112 Hepatitis C knowledge among MMT staff and social workers in China
J. Du, Z. Wang, M. Zhao, Shanghai Mental Health Center, Shanghai, China

113 Efficacy of an HIV/hepatitis educational intervention during buprenorphine detoxification in prescription opioid abusers
M. E. Patrick, K. Saulsgiver, K. Dunn, S. Sigmon, S. Higgins, University of Vermont, Burlington, VT

A. E. Jordan¹, C. L. Masson², P. Mateu-Gelabert³,⁴, C. McKnight¹, N. Pepper², R. Seewald¹,
C. Young¹, D. J. Perlman¹, A. Talal⁵, D. C. Des Jarlais¹,⁴, J. L. Sorensen², D. C. Perlman¹,⁴,
¹Chemical Dependency Institute, Beth Israel Medical Center, New York, NY, ²University of California, San Francisco, CA, ³Center for Drug Use and HIV Research, ⁴NDRI, and ⁵Weill Cornell Medical College, New York, NY

115 Using the Gelberg-Andersen Behavioral Model for vulnerable populations to predict health services utilization among homeless adults, by hepatitis B or C serostatus
L. Gelberg¹,⁴, J. Stein¹, M. Robertson², R. M. Andersen¹, L. E. Arangua¹, ¹Family Medicine,
²ARG, PHI, Emoryville, CA, ³Psychology, and ⁴Public Health, UCLA, Los Angeles, CA

116 Hepatitis B and C prevalence in opioid-dependent treatment participants: Comparisons between heroin users and prescription opioid users
C. M. Thomas²,¹, M. Hillhouse¹, A. L. Hasson¹, W. Ling¹, ¹Integrated Substance Abuse Programs, UCLA, and ²Clinical Research, Friends Research Institute, Inc., Los Angeles, CA
117 Prevalence of hepatitis C among a cohort of Hispanic injection drug users
J. Sanchez, Health Promotion and Disease Prevention, Florida International University, Doral, FL

118 Prevalence of HIV and hepatitis serology among black drug users in South Africa
L. Ropelewski, A. Hulbert, J. Zur, W. W. Latimer, Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

119 The integration of drug and HIV services at a drug treatment center in Durban, South Africa
T. Carney, C. D. Parry, P. M. Petersen, A. Pluddemann, Alcohol and Drug Abuse Research Unit, Medical Research Council, Cape Town, South Africa

120 Structural barriers: Qualitative research with social workers in Odessa, Ukraine
M. S. Royer, J. T. Brewster, S. Dvoryak, R. Booth, Psychiatry, University of Colorado School of Medicine, Denver, CO

121 Differences in drug use among white and African-American women who use methamphetamine
J. Lorvick1, A. Lutnick1, L. D. Wengen1, W. M. Wechsberg2, A. H. Kral1, 1RTI International, San Francisco, CA, 2RTI International, Raleigh-Durham, NC

122 HIV/AIDS “conspiracy beliefs” among racial/ethnic minority drug users
C. L. Masson1, K. L. Delucchi1, P. Mateu-Gelabert1, N. Pepper1, C. Ramin1, C. McKnight3, A. Jordan3, C. Young3, R. Seewald1, L. Guzman2, J. L. Sorensen1, D. Des Jarlais3,5, D. C. Perlman3,5, 1University of California, and 2Mission Neighborhood Resource Center, San Francisco, CA, 3Beth Israel Medical Center, 4National Development Research Institutes Inc., and 5Center for Drug Use and HIV Research, New York, NY

OPIOIDS: HUMAN

123 Drug use attitudes and beliefs and treatment outcome
M. P. Hillhouse, J. Fahey, W. Ling, Integrated Substance Abuse Programs, University of California, Los Angeles, Los Angeles, CA

124 Counselor attitudes toward buprenorphine in the Clinical Trials Network
H. K. Knudsen1, P. M. Roman2, 1Behavioral Science, University of Kentucky, Lexington, KY, 2University of Georgia, Athens, GA

125 Predictors of opiate use following opioid detoxification
E. C. Katz1,2, B. Brown3, R. Schwartz1, K. O’Grady4, 1Friends Research Institute, Baltimore, and 2Psychology, Towson University, Towson, MD, 3University of North Carolina, Wilmington, NC, 4University of Maryland, College Park, MD

126 Multicenter study of the switch from buprenorphine to buprenorphine/naloxone in stable patients
D. Touzeau1, C. Gerbaud2, L. Nacache3, P. Villeger4, S. Sakoman5, A. Bagaric6, D. Vitezic8, G. Plaehn9, Y. Wei7, L. Amass7, 1Clinique de la Liberte, Bagneux, 2Hópital Saint-Roch, Nice, 3Hopital Edouard Herriot, Lyon, 4CH Esquirol, Limoges, France, 5Clinical Hospital Sestre milosrdnice, and 6Psychiatric Hospital Vrapce, Zagreb, Croatia, 7Schering Corporation, a division of Merck and Company, Kenilworth, NJ, 8Clinical Hospital Center, Rijeka, Croatia, 9KABS, Rodovre, Denmark

127 Evaluating multiple buprenorphine treatment approaches
L. Madden1, A. R. Quanbeck2, S. O. Farnum3, R. Freeman3, S. Ball1, 1APT Foundation and Yale University, New Haven, CT, 2Industrial and Systems Engineering, University of Wisconsin, Madison, WI, 3APT Foundation, New Haven, CT

128 Craving intensity and withdrawal severity across phases of opioid detoxification with buprenorphine
H. Chen2, M. P. Hillhouse1, A. Hasson1, W. Ling1, 1Integrated Substance Abuse Programs, University of California, Los Angeles, CA, 2Shanghai Mental Health Center, Shanghai, China
129 Cognitive behavioral therapy session attendance, retention and opioid use in primary-care-based buprenorphine/naloxone treatment  
C. J. Cutter, D. T. Barry, B. A. Moore, L. E. Sullivan, R. S. Schottenfeld, P. G. O’Connor,  
D. A. Fiellin, Yale University, School of Medicine, New Haven, CT

130 Physician management with and without cognitive behavioral therapy in primary-care-based buprenorphine/naloxone  
D. A. Fiellin1, L. Sullivan1, D. Barry2, C. Cutter2, B. Moore2, P. O’Connor1, R. Schottenfeld2,  
1Internal Medicine, and 2Psychiatry, Yale University, New Haven, CT

131 Internet use among opioid-dependent individuals seeking primary-care-based buprenorphine/naloxone treatment  
B. A. Moore1,3, T. Fazzino3, L. E. Sullivan2, D. A. Fiellin2, 1Psychiatry, and 2Internal Medicine,  
Yale University School of Medicine, 3APT Foundation, New Haven, CT

132 Retaining participants in Starting Treatment with Agonist Replacement Therapies: Perspectives of early Suboxone dropouts  
C. Teruya, C. Thomas, A. Hasson, M. Hillhouse, Y. Hser, W. Ling, UCLA Integrated Substance Abuse Programs, Los Angeles, CA

133 Efficacy of continuing medical education for promoting physician practices aimed at decreasing buprenorphine misuse and diversion  
M. Lofwall1,2, M. Wunsch1,1, S. L. Walsh2,1, 1Psychiatry, and 2Behavioral Science, Center for Drug and Alcohol Research, UK, Lexington, KY

134 Unobserved versus office buprenorphine/naloxone induction: A pilot randomized clinical trial  
E. W. Gunderson1,2, X. Q. Wang1, D. A. Fiellin4, B. Bryan4, F. R. Levin3,3, 1University of Virginia, Charlottesville, VA, 2Columbia University, New York, NY, 3NYS Psychiatric Institute, New York, NY, 4Yale University, New Haven, CT

135 Dispensing of methadone and buprenorphine by pharmacists. Cross-sectional survey, Bayonne, France  
C. Maitre1,2, E. Herran1,2, J. Renaudin1, V. Beltran1,2, J. Daulouede2,1, M. Auriacombe3,  
1Resapsad Health Network, and 2Addiction Clinic, BIZIA, Bayonne, 3Addiction Psychiatry,  
JE2358, INSERM IFR 99, University Victor Segalen Bordeaux 2, Bordeaux, France

136 Duration to achieve “take home” privilege in methadone maintenance treatment as outcome predictor: Retention and survival  
E. Peles1,2, S. Schreiber1,2, A. Sason1, M. Adelson1, 1Adelson Clinic for Drug Abuse Treatment & Research, Tel Aviv Medical Center, and 2Tel Aviv University, Tel Aviv, Israel

137 Reducing drug use and other risk behaviors in syringe exchange participants  
M. S. Kidorf, V. L. King, J. Peirce, R. K. Brooner, Psychiatry, Johns Hopkins, Baltimore, MD

138 Does somatic morbidity increase after termination of opioid maintenance treatment?  
I. Skeie3,1,2, M. Brekke2, M. Lindbæk2, H. Waal1,3, 1Norwegian Centre for Addiction Research, and 2Institute of General Practice and Community Medicine, University of Oslo, 3Oslo University Hospital Aker, Oslo, Norway

139 Methadone-associated deaths by formulation as reported by the Researched Abuse, Diversion and Addiction-Related Surveillance System  
A. Zosel1,2, E. Bailey1, C. Buchholtz1, E. Ross1, R. Dart1,2, 1Rocky Mountain Poison & Drug Center, Denver Health, Denver, CO, 2University of Colorado Denver School of Medicine, Aurora, CO, 3Rocky Vista University College of Medicine, Parker, CO

140 Methadone maintenance treatment in China: Perspectives of clients and service providers  
F. Wu1, C. Peng1, H. Jiang2, R. Zhang3, M. Zhao2, J. Li3, Y. Hser1, 1Social Welfare, UCLA, Los Angeles, CA, 2Center of Drug Abuse, Shanghai Mental Health Center, Shanghai, China, 3Yun Nan Institute on Drug Abuse, Kunming, China
Predictors of treatment entry in a sample of methadone maintenance patients
S. M. Kelly¹, K. E. O’Grady², S. G. Mitchell¹, B. S. Brown³, R. P. Schwartz¹, ¹Friends Research Institute, Social Research Center, Baltimore, MD, ²University of Maryland, College Park, College Park, MD, ³University of North Carolina, Wilmington, NC

Methadone patients' treatment outcomes: Longitudinal study on the associations between background and process variables and retention rate, illicit drug use and risk behavior
S. Levit¹², M. Schiff², R. Benbenishty³, ¹Association for Public Health Services, Methadone Clinic in Jerusalem and Ashdod, and ²School of Social Work and Social Welfare, Hebrew University, Jerusalem, Israel, ³School of Social Work, Bar Ilan University, Ramat Gan, Israel

Acceptance and commitment therapy as an adjunct to methadone detoxification
A. L. Stotts¹, J. M. Schmitz¹, C. Green¹, J. Lindsay¹, J. Grabowski², ¹University of Texas Medical School at Houston, Houston, TX, ²University of Minnesota, Minneapolis, MN

Acceptance and commitment therapy for methadone detoxification: Identifying mechanisms of change
J. A. Lindsay¹, A. Stotts², C. Dodrill¹, J. Schmitz², C. Green², ¹Baylor College of Medicine and ²Department of Psychiatry and Behavioral Sciences, University of Texas Medical School, Houston, TX

A randomized trial of entry into methadone treatment via interim maintenance: Preliminary findings
R. P. Schwartz¹, S. M. Kelly¹, K. E. O’Grady², J. H. Jaffe³, ¹Friends Research Institute, Baltimore, ²University of Maryland, College Park, and ³University of Maryland School of Medicine, Baltimore, MD

The safety of prazosin in drug-abusing populations
L. Hu¹, A. J. Saxon²³, C. A. Malte³, M. Leff¹, B. Tai¹, S. Sparenborg¹, ¹NIDA, Rockville, MD, ²University of Washington, Seattle, WA, ³VA Puget Sound Healthcare System, Seattle, WA

Smoking prevalence in addiction treatment: A literature review
E. Passalacqua, J. Guydish, B. Tajima, S. Manser, J. Chun, M. Chan, Institute for Health Policy Studies, University of California, San Francisco, CA

Agonist replacement therapy for marijuana dependence
S. Sparenborg, L. Hu, B. Tai, Center for the Clinical Trials Network, National Institute on Drug Abuse, Bethesda, MD

Late-Breaking Research News

Chair: Sari Izenwasser

Symposium VI

HAIR OF THE DOG: AGONISTS FOR STIMULANT DEPENDENCE

Chair: John Grabowski and David Herin

Agonizing over pharmacotherapy: Stimulants for stimulant dependence
David Herin, Psychiatry, University of Minnesota, Minneapolis, MN
Tuesday, June 15, 2010

3:10 Human laboratory research: Closer to treatment but foibles exist
Craig R. Rush, College of Medicine, University of Kentucky, Lexington, KY

3:35 Effects of candidate agonists medication on abuse-related effects of stimulants: Preclinical investigations
Steve Negus, Pharmacology, Virginia Commonwealth University, Richmond, VA

4:00 Neurochemical underpinnings of agonist therapy for stimulant dependence
Michael Baumann, Intramural Research Program, NIDA/NIH/DHHS, Baltimore, MD

4:25 Threading the needle: translation from science through regulation to marketing
Jack Henningfield, Pinney Associates, Bethesda, MD

Symposium VII

THE ROLE OF GABA IN DRUG ABUSE

Chairs: Diana Dow-Edwards and Nora Siegal

2:45 GABA B alters cocaine self-administration
David Roberts, Physiology and Pharmacology, Wake Forest University Health Sciences, Winston-Salem, NC

3:10 Chronic methamphetamine alters tonic inhibition and responses to a stress steroid via increases in Alpha 4-beta-delta GABA-A receptors
Sheryl Smith, Psysio/Pharm, State University of New York-Downstate, Brooklyn, NY

3:35 GABA A modulation alters the responses to acute and chronic cocaine administration
Diana Dow-Edwards, Physiology and Pharmacology, State University of New York-Downstate, Brooklyn, NY

4:00 Clinical experience with flumazenil
J. Greg Sullivan, Parkway Medical Center, Birmingham, AL

4:25 Discussant
Thomas Kosten, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX

Oral Communications 9

GETTING UP TO SPEED ON AMPHETAMINES

Chairs: Ellen Unterwald and Michael A. Taffe

2:45 Methamphetamine modulates axonal guidance molecules in mouse hippocampus
B. K. Madras1,2, G. M. Miller3, E. Vallender4, 1NEPRC, Harvard Medical School, Southborough, MA, 2Psychiatry, Massachusetts General Hospital, Boston, MA

3:00 The clinically validated mGluR5 receptor antagonist fenobam decreases methamphetamine self-administration following escalation of intake
M. F. Olive, E. Plasters, R. M. Cleva, Psychiatry, Medical University of South Carolina, Charleston, SC

3:15 Valproic acid attenuates amphetamine-induced behavior in mice
N. Enman, E. M. Unterwald, Pharmacology & Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA
3:30  The 5-HT2C receptor inverse agonist SB 206553 decreases methamphetamine-seeking in rats
S. M. Graves1,2, T. C. Napier1,2, 1Pharmacology, and 2Center for Compulsive Behavior and
Addiction, Rush University Medical Center, Chicago, IL

3:45  L-5-hydroxytryptophan combined with D-amphetamine as potential treatment agents for
stimulant addiction: Initial evidence
R. B. Rothman, Z. Williams, M. H. Baumann, Clinical Psychopharmacology Section, IRP,
NIDA, NIH, Baltimore, MD

4:00  Dopamine receptor involvement in enrichment-induced differences in methamphetamine drug
discrimination in rats
D. J. Stairs, E. Adams, T. Hickle, B. Hovenga, B. BaDour, Psychology, Creighton University,
Omaha, NE

4:15  Dopamine receptor agonists modify the discriminative stimulus effects of rimonabant in
∆9-THC-treated rhesus monkeys
J. L. Stewart, L. R. McMahon, Pharmacology, The University of Texas Health Science Center
at San Antonio, San Antonio, TX

4:30  Sustained locomotor activity increases MDMA-induced hyperthermia and death
M. A. Taffe, M. J. Wright, Committee on the Neurobiology of Addictive Disorders,
The Scripps Research Institute, La Jolla, CA

Oral Communications 10  Salons ABC

HASHING OUT THE STORY ON CANNABINOIDS

Chairs: Leslie H. Lundahl and Jane Metrik

2:45  Would CB1 neutral antagonists be non-dysphoric?
H. H. Seltzman1, P. H. Reggio2, L. Chun3, Z. X. Xi3, E. L. Gardner3, 1Organic and Medicinal
Chemistry, Research Triangle Institute, Research Triangle Park, NC, 2Chemistry and
Biochemistry, University of North Carolina, Greensboro, NC, 3Neuropsychopharmacology
Section, National Institute on Drug Abuse, NIH, Baltimore, MD

3:00  URB597, a fatty acid amide hydrolase metabolism inhibitor, effects locomotor activity
immediately after the forced swim test
T. Culmer1, L. A. Dykstra1,2, 1Pharmacology, and 2Psychology, University of North Carolina at
Chapel Hill, Chapel Hill, NC

3:15  Effect of long-term ∆9-THC exposure on rat cognitive performance
L. H. Parsons, I. Polis, Committee on the Neurobiology of Addictive Disorders, The Scripps
Research Institute, La Jolla, CA

3:30  The effects of sleep deprivation on marijuana cue-reactivity and craving
G. H. Trksak1,2, N. A. Conn1, W. L. Tartarini1, L. D. Nickerson1,2, D. M. Penetar1,2,
S. E. Lukas1,2, 1Behavioral Psychopharmacology Research Laboratory, McLean Hospital,
Belmont, MA, 2Psychiatry, Harvard Medical School, Boston, MA

3:45  Stress and cue-elicited craving in marijuana-dependent individuals
A. McRae-Clark1, R. E. Carter2, K. L. Price1, N. Baker1, M. E. Saladin1, K. T. Brady1,
1Psychiatry, Medical University of South Carolina, Charleston, SC, 2Mayo Clinic,
Rochester, MN

4:00  Acute effects of marijuana smoking on negative and positive affect
J. Metrik1, C. W. Kahler1, J. McGearry2,1, P. M. Monti2,1, D. J. Rohsenow2,1, 1Center for Alcohol
and Addiction Studies, Brown University, Providence, RI, 2VA Medical Center, Providence, RI
Tuesday, June 15, 2010

4:15 Testing the ability of oral THC to block the discriminative stimulus effects of marijuana in cannabis-dependent individuals
L. H. Lundahl, C. L. Steinmiller, M. K. Greenwald, C. E. Johanson, Psychiatry and Behavioral Neuroscience, Wayne State University School of Medicine, Detroit, MI

4:30 Construct validity of computerized cognitive performance: Implications for measurement of acute drug effects

Symposium VIII
Salons HI
5:00 - 6:00 PM

MEDICATIONS DEVELOPMENT FOR THE TREATMENT OF SUBSTANCE DEPENDENCE: STATUS OF ADVANCED PROJECTS
Chair: David McCann

5:00 Dronabinol for the treatment of cannabis dependence
Frances Levin, New York State Psychiatric Institute, Columbia University College of Physicians and Surgeons, New York, NY

5:20 Vigabatrin for the treatment of stimulant dependence
Charles Gorodetzky, Catalyst Pharmaceutical Partners, Kansas City, MO

5:40 Bupropion for the treatment of methamphetamine dependence
David McCann, National Institute on Drug Abuse, Rockville, MD

Symposium IX
Salon DE
5:00 - 6:00 PM

NEW PATHWAYS TO FUTURE ADDICTION THERAPY
Chair: John Satterlee

5:00 From drosophila to drugs: Novel pathways in cocaine responses
Ulrike Heberlein, Anatomy, School of Medicine, University of California, San Francisco, San Francisco, CA

5:20 Histone deacetylase inhibitors improve extinction of drug cue learning in rodents
Matthew Lattal, Behavioral Neuroscience, Oregon Health Science University, Portland, OR

5:40 Identification of unanticipated nicotine response genes using zebra fish
Stephen Ekker, Mayo Clinic, Rochester, MN

Symposium X
Salon FG
5:00 - 6:00 PM

NICO-TEEN: ADOLESCENCE IS A PERIOD OF ENHANCED VULNERABILITY TO TOBACCO ABUSE
 Chairs: Laura O’Dell and Janet Neisewander

5:00 Psychobiological factors that contribute to tobacco abuse during adolescence
Laura O’Dell, Psychology, The University of Texas at El Paso, El Paso, TX

5:20 Social context is a contributing factor to adolescent vulnerability to nicotine
Janet Neisewander, Psychology, Arizona State University, Tempe, AZ
Tuesday, June 15, 2010

5:40 Tobacco abuse across the formative years: A road map to developmental vulnerabilities in adolescent smokers
Suchitra Krishnan-Sarin, Psychiatry, Yale University School of Medicine, New Haven, CT

**Oral Communications 11**

**NALTREXONE/ALCOHOL INTERACTIONS**

Chairs: Scott E. Lukas and David A. Fiellin

5:00 Ethanol/Naltrexone interactions at the opioid receptor: CLSM/FCS study in live cells
L. Terenius¹, V. Vukojevic¹, Y. Ming¹, B. Johansson¹, C. D’Addario¹, R. Rigler²,³, ¹Clinical Neuroscience, and ²Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden, ³Laboratory of Biomedical Optics, Swiss Federal Institute of Technology, Lausanne, Switzerland

5:15 Extended-release injectable naltrexone attenuates BOLD signal activation to olfactory and visual cues in detoxified alcohol-dependent volunteers
D. M. Penetar¹, S. Lowen¹, S. E. Lukas¹, N. Conn¹, W. Tartarini¹, J. Rodolico¹, G. Mallya¹, C. Palmer¹, B. L. Silverman², D. R. Gastfriend², K. Lindsey¹, ¹McLean Hospital, Belmont, MA, ²Alkermes, Inc, Cambridge, MA

5:30 Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone
J. M. Tetrault¹, K. McGinnis², L. Sullivan¹, A. Justice¹, D. Fiellin¹, ¹Yale University, New Haven, CT, ²VA Pittsburgh, Pittsburgh, PA

5:45 Cost outcomes with extended-release naltrexone in insured alcoholics
T. Mark¹, L. Montejano¹, H. R. Kranzler², M. Chalk³, D. R. Gastfriend⁴, ¹Thomson Reuters, Inc, Washington, DC, ²Psychiatry, University of Connecticut School of Medicine, Farmington, CT, ³Treatment Research Institute, Philadelphia, PA, ⁴Alkermes, Inc., Cambridge, MA

**FILM NIGHT**

**THE NARCOTIC FARM**
A documentary on the history of drugs, addiction, drug policy, research and treatment

**LOST WEEKEND**
1945 Best Picture with Ray Milland

**Workshop IX**

**NEW APPROACHES TO DIAGNOSIS IN THE DSM-V**

Chairs: Wilson M. Compton and Charles O’Brien

Neuroscience perspectives on the diagnosis of substance use disorders
Charles O’Brien, Treatment Research Center, University of Pennsylvania, Philadelphia, PA

Item response analysis approaches to changes in diagnostic criteria
Deborah Hasin, Columbia University, New York, NY

Terminology of substance use disorders for DSM-V
Wilson M. Compton, National Institute on Drug Abuse, Bethesda, MD
Tuesday, June 15, 2010

Workshop X

ESTABLISHED AND EMERGING APPROACHES TO HUMAN ABUSE LIABILITY TESTING: IS THERE ROOM FOR IMPROVEMENT?

Chair: Edward M. Sellers

- Sensitivity and selectivity analysis of subjective abuse liability measures
  Kerri A. Schoedel, Clinical Pharmacology, Kendle Early Stage-Toronto, Toronto, ON, Canada

- Utility of behavioral economic analysis for improving drug abuse liability assessment
  Mark Greenwald, Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, MI

- Comparison of drug self-administration procedures in human abuse liability testing
  Sandra D. Comer, Division on Substance Abuse, Columbia University and New York State Psychiatric Institute, New York, NY

- Regulatory challenges in evaluating clinical abuse liability studies
  Silvia N. Calderon, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD

- Industry perspective: Assessing abuse liability during drug development
  Doug Feltner, Pfizer Global Research and Development, Groton, CT

Workshop XI

ACADEMICS AND REGULATED INDUSTRIES: PERSPECTIVES ON 21ST CENTURY INTERACTIONS WITH PHARMACEUTICAL AND TOBACCO COMPANIES

Chairs: Jed Rose and George Uhl

- Ethical principals, academics and for profits
  Barbara Koenig, Program in Professionalism and Bioethics, Mayo College of Medicine, Rochester, NY

- Managing conflicts of interest in academic/tobacco company interactions: Risks and benefits of interactions with a newly regulated industry
  Jed Rose, Psychiatry and Behavioral Sciences and Center for Nicotine and Smoking Cessation Research, Duke University Medical Center, Durham, NC

- Managing conflicts of interest in government/pharma interactions: Special case of pharmaceuticals with abuse liabilities
  Charles Gorodetzky, Consultant, Kansas City, MO

- Managing conflicts of interest in academic/tobacco company interactions: Likely changes in a regulated environment
  Tony Albino, Vector Group Ltd, New York, NY

Discussant
George Uhl, NIH, National Institute on Drug Abuse, Baltimore, MD

BADGES MUST BE WORN FOR ALL SESSIONS AND SOCIAL EVENTS
Workshop XII

EMPIRICALLY SUPPORTED TREATMENTS AND DIVERSE POPULATIONS: SOME EXAMPLES OF CHALLENGES TO ADAPTATION

Chairs: Anne H. Skinstad and Lonnetta Albright

Women: Are they men with special needs?
Anne Helene Skinstad, Prairielands ATTC, University of Iowa, Iowa City, IA

Specific needs for research and data for conducting cultural competencies for sexual minorities
Joseph Amico, Brattleboro Retreat, Fitzwilliam, NH

Challenges of implementing empirically supported approaches in Native American communities
E. Somoza, Prairielands ATTC, Vermillion, SD

It is not just about language and translation
Marco Jacome, Healthcare Alternative System, Inc., Chicago, IL

Bridging the gap between empirically supported treatments and African-American communities
Ijeoma Achara¹, Lonnetta Albright², ¹Achara Consulting, LLC, Chicago, IL, ²Great Lakes ATTC, Chicago, IL

Workshop XIII

WHAT’S NEW AT NIDA AND NIH: ENHANCING PEER REVIEW IMPLEMENTATION AND MORE

Chairs: Mark R. Green and Mark Swieter

BADGES MUST BE WORN FOR ALL SESSIONS AND SOCIAL EVENTS
Public Policy Forum
Salons HI
8:00 - 9:45 AM

Chairs: Martin Iguchi and William L. Dewey

Introduction
Martin Iguchi, RAND, Santa Monica, CA

DC issues
Ed Long, Cap Hill, Washington, DC

Demand control strategies
John Strang, King’s College, London, United Kingdom

Supply control strategies
Peter Reuter, University of Maryland, College Park, MD

Cannabis policy: Moving beyond stalemate
Robin Room, Turning Point Alcohol and Drug Centre, University of Melbourne, Melbourne, NSW, Australia

Evidence-informed drug policy: What do we know? What do we need to know?
Thomas Babor, University of Connecticut, Farmington, CT

Discussion

Symposium XI
Salons HI
10:00 AM - 12:00 PM

PRECLINICAL TO CLINICAL ABUSE LIABILITY ASSESSMENT:
CURRENT CHALLENGES IN INDUSTRY PRACTICES

Chairs: Mary Jeanne Kallman and David Compton

10:00 Current Issues in Clinical Trial Design for Assessment of Novel Pharmaceuticals for Abuse and Dependence Liability
Marta Sokolowska, Center of Excellence for Abuse Liability, Grunenthal, Bedminster, NJ

10:25 Overview of current challenges facing the pharmaceutical industry in assessment of abuse potential of new drugs
Carrie G. Markgraf, Merck Research Laboratories, Lafayette, NJ

10:50 Abuse Potential Assessment for Drug Combinations
Andy Mead, Pfizer, Sandwich, Kent, UK

11:15 Regulatory review and scheduling: Roles of nonclinical and clinical studies in recent studies
Michael Klein, Controlled Substance Staff, FDA, Silver Spring, MD

Symposium XII
Salon FG
10:00 - 11:00 AM

METHAMPHETAMINE ADDICTION: FROM MOLECULAR MECHANISMS TO TREATMENT

Chairs: John Mendelson and Jean Lud Cadet

10:00 Neurobiological aspects of methamphetamine addiction and toxicity
Jean Lud Cadet, NIH/NIDA Intramural Research Program, Baltimore, MD

10:20 The effects of methamphetamine exposure: Evidence from brain imaging studies
Panayotis Thanos, State University of New York at Stony Brook, New York, NY
Wednesday, June 16, 2010

10:40 Challenges in developing pharmacotherapies for methamphetamine addiction  
John Mendelson, California Pacific Medical Center Research Institute, St. Luke’s Hospital, San Francisco, CA

Symposium XIII  
CURRENT ISSUES SURROUNDING CHRONIC PAIN AMONG INDIVIDUALS WITH A SUBSTANCE USE DISORDER

Chair: Benjamin J. Morasco

11:15 A systematic review of the prevalence, correlates, and treatment outcomes for chronic non-cancer pain in patients with comorbid substance use disorder  
Benjamin J. Morasco, Behavioral Health and Clinical Neurosciences Division, Oregon Health and Science University, Portland, OR

11:35 Developing and evaluating treatments for co-occurring opioid dependence and chronic pain among methadone-maintained patients  
Declan T. Barry, Psychiatry, Yale University School of Medicine, New Haven, CT

11:55 Cognitive-behavioral therapy for pain management during addictions treatment  
Mark Ilgen, VA Serious Mental Illness Treatment Research and Evaluation Center, Ann Arbor VA Medical Center, University of Michigan, Ann Arbor, MI

Oral Communications 12

WHAT'S UP WITH COCAINE? REINSTATEMENT RESEARCH

Chairs: Xiaohu Xie and Kathleen Kantak

10:00 The dorsal hippocampus: A neural substrate for cocaine cue extinction consolidation  
J. J. Szalay, K. M. Kantak, Psychology and Program in Neuroscience, Boston University, Boston, MA

10:15 Preclinical examination of environmental enrichment as an anti-relapse strategy  

10:30 Subregion-specific effects of mGLUR1 antagonism in the nucleus accumbens on drug context-induced reinstatement of cocaine-seeking behavior in rats  

10:45 D-cycloserine in the nucleus accumbens produces a context-independent enhancement of extinction learning to attenuate cue-induced reinstatement in rats  
M. M. Torregrossa, H. Sanchez, J. R. Taylor, Psychiatry, Yale University, New Haven, CT

11:00 Individual differences in incentive salience attribution to a food-associated cue modulate both novelty seeking and acquisition of cocaine self-administration in rats  
J. Beckmann, M. T. Bardo, Psychology, University of Kentucky, Lexington, KY

11:15 Differential recruitment of the Orx/Hcrt system by cocaine vs. palatable natural reward  
R. Martin-Fardon, F. Weiss, Molecular and Integrative Neuroscience, The Scripps Research Institute, La Jolla, CA
11:30  How do prediction errors in conditioned drug-reward influence cocaine place preference?
Y. Itzhak, K. L. Anderson, Psychiatry, University of Miami, Miami, FL

11:45  Blockade of dopamine D3 receptors by SB-277011A inhibits incubation of craving for cocaine in rats
E. Gardner, X. Li, J. Li, Z. X. Xi, Neuropsychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, Baltimore, MD

**Oral Communications 13**

**TRAJECTORIES OF DRUG USE: TAKING IT ONE DAY AT A TIME**

Chairs: Arpana Agrawal and Eric O. Johnson

10:00  Daily life hour-by-hour, with and without cocaine: An ecological momentary assessment study

10:15  First 5 years of methamphetamine use: Trajectories, characteristics of trajectory groups, and prediction of later treatment outcomes
M. Brecht, D. Herbeck, Integrated Substance Abuse Programs, UCLA, Los Angeles, CA

10:30  Alcohol consumption over 11 years in a problem drinking and dependent general population sample
K. L. Delucchi¹, L. Kaskutas², ¹Psychiatry, University of California, San Francisco, San Francisco, CA, ²Alcohol Research Group, Public Health Institute, Emeryville, CA

10:45  Examining the differences in the progression to nicotine dependence by gender and ethnicity in the US population
R. Beharie¹, F. A. Wagner¹, D. C. Browne², C. L. Storr³, ¹Morgan State University, Baltimore, MD, ²Norfolk State University, Norfolk, VA, ³University of Maryland, College Park, MD

11:00  Natural history of changes in cigarette smoking upon learning of pregnancy

11:15  Executive function clusters predict patterns of drug dependence and use
S. A. Golub¹,²,³, T. Starks³, W. Kowalczyk¹,³, J. T. Parsons²,²,³, ¹Neuropsychology, CUNY Graduate Center, New York, NY, ²Psychology, Hunter College of the City University of New York, New York, NY, ³Center for HIV Educational Studies and Training, New York, NY

11:30  Projected lifetime risk of co-occurring substance use and mental disorders among adults in the US
E. O. Johnson, S. P. Novak, Behavioral Health Epidemiology, RTI International, Research Triangle Park, NC

11:45  Cannabis involvement and the course and measurement of bipolar disorder
A. Agrawal¹, J. I. Nurnberger², M. T. Lysaker¹, ¹Psychiatry, Washington University School of Medicine, Saint Louis, MO, ²Psychiatry, Indiana University School of Medicine, Indianapolis, IN

**BADGES MUST BE WORN FOR ALL SESSIONS AND SOCIAL EVENTS**
CO-OCCURRING DISORDERS

1 Effect of varenicline on cue-induced alcohol craving: A randomized placebo-controlled study
   U. E. Busto, S. Wang, P. Selby, G. Staios, L. Zawertailo, Centre for Addiction and Mental Health, Toronto, ON, Canada

2 Drinking outcomes by order of onset in a placebo controlled trial of acamprosate in anxious or depressed alcoholics
   S. C. Sonne¹, J. S. Potter², R. Rosenthal³, D. Bandyopadhyay¹, ¹Medical University of SC, Charleston, SC, ²University of Texas Health Science Center at San Antonio, San Antonio, TX, ³Columbia University, New York, NY, ⁴St. Luke’s Roosevelt Hospital Center, New York, NY

3 Gender differences in the relationship between neighborhood environment and childhood depression: Results from a community epidemiologic study of predominantly African-American urban children
   A. J. Milam¹, D. Whitaker¹, C. Furr-Holden¹, S. C. Jones¹, M. Cooley¹,², P. J. Leaf³, ¹Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ²Semel Institute, Center for Culture and Health, University of California, Los Angeles, Los Angeles, CA

4 Association between psychiatric disorders, alcohol and other substances use in Brazilian drivers

5 Brazilian crack users who seek treatment show more antisocial personality and less drinking than other drug users

6 Risk factors for substance-induced disorders among illicit drug users
   M. Torrens¹,², G. Gilchrist³, A. Domingo-Salvany³, F. Fonseca¹,², R. Martin-Santos⁴,⁵, G. PsyCoBarcelona¹,²,³,⁶, ¹Institut d’Atenció Psiquiàtrica i Addiccions, IAPs, Hospital del Mar, Barcelona, Spain, ²Substance Use Disorders Research Group. Neuropsychopharmacology Program, IMIM-Hospital del Mar, Barcelona, Spain, ³Drug Abuse Epidemiology Research Group, IMIM-Hospital del Mar, Barcelona, Spain, ⁴Pharmacology Research Unit. Neuropsychopharmacology Program., IMIM- Hospital del Mar, Barcelona, Spain, ⁵Psychiatry Department, Hospital Clinic i Provincial, Barcelona, Spain, ⁶Public Health Agency, ASP, Barcelona, Spain

7 What’s with that kid? The relationship between familial substance use and child behavior problems in a general pediatric setting
   L. A. Keyser-Marcus, L. Meloy, R. Pickens, D. Svikis, Virginia Commonwealth University, Richmond, VA

8 Adult substance abusers with ADHD show higher prevalence of marijuana and cocaine use
9 Gender differences in the prevalence of co-occurring mental health disorders in a substance abuse treatment population
R. C. Desmond¹, B. R. Rush¹, ², S. Castel², ³, B. Brands¹, ², ⁴, ¹Centre for Addiction and Mental Health, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Sunnybrook Health Sciences Centre, Toronto, ON, Canada, ⁴Health Canada, Ottawa, ON, Canada

10 Neighborhood environment, distance, and individual factors predicting initial outpatient treatment attendance following acute inpatient care
G. Stahler, J. Mennis, D. Baron, Temple University, Philadelphia, PA

11 A randomized controlled trial of a brief care coordination intervention for individuals with a mental health and substance abuse problem
D. A. Smelson¹, D. Kalman¹, M. Losonczy², ¹, A. Kline², ¹, G. Gonzalez¹, B. Sussner², ¹, D. Ziedonis¹, ¹Psychiatry, University of Massachusetts Medical School, Worcester, MA, ²Mental Health and Behavioral Science, VA Jersey Health Care System, Lyons, NJ

12 Psychiatric distress predicts treatment enrollment in syringe exchange participants
V. L. King, R. K. Brooner, J. Peirce, M. Kidorf, Psychiatry, Johns Hopkins School of Medicine, Baltimore, MD

13 Opiate dependence, alcohol dependence and ASPD among age cohorts: A triple threat to the service system
C. L. Striley, K. S. Leung, A. Ben Abdallah, L. B. Cottler, Psychiatry, Washington University School of Medicine, St. Louis, MO

14 Medical and psychiatric severity of opioid-addicted individuals in- vs. out-of-treatment
D. Tzall¹, S. Mitchell², S. Kelly², K. O’Grady³, B. Brown⁴, R. Schwartz⁵, ¹Towson University, Towson, MD, ²Friends Research Institute, Baltimore, MD, ³University of Maryland, College Park, MD, ⁴University of North Carolina, Wilmington, NC

15 Advisor-Teller Money Manager therapy for substance abuse
M. I. Rosen¹, ², B. J. Rounsaville¹, ², K. Ablondi¹, A. C. Black¹, R. A. Rosenheck², ¹Yale University School of Medicine, New Haven, CT, ²VA Connecticut, West Haven, CT

16 Treatment outcomes of methamphetamine-dependent adults with anxiety disorders
S. Glasner-Edwards¹, L. J. Mooney¹, P. Marinelli-Casey¹, M. Hillhouse¹, A. Ang², R. A. Rawson¹, ¹Integrated Substance Abuse Programs, UCLA, Los Angeles, CA, ²Family Medicine, UCLA, Los Angeles, CA

17 Do race and sex alter the association between non-marijuana drug use trajectories and depressive symptoms in a community-based adult cohort? (the CARDIA study)
Y. Khodneva¹, M. Pletcher², M. Safford¹, J. Schumacher¹, J. Tucker¹, S. Kertesz¹, ³, ¹University of Alabama, Birmingham, AL, ²University of California San Francisco, San Francisco, CA, ³Birmingham VA Medical Center, Birmingham, AL

18 Effects of a brief behavioral activation treatment on substance abuse treatment dropout, depression, and activation among low-income substance users
J. Magidson, A. Lavelle, C. W. Lejuez, S. B. Daughters, University of Maryland, College Park, MD

ADOLESCENT DRUG ABUSE II

19 Retrospective evaluation of ASAM criteria in adolescents receiving weekly outpatient treatment for co-occurring psychiatric and substance use disorders
B. W. Holmes¹, L. Haynes¹, J. Leimberger¹, P. Riggs¹, ¹NIDA CTN, LRADAC, Columbia, SC, ²Psychiatry and Behavioral Sciences, Medical University of SC, Charleston, SC, ³Duke Clinical Research Institute, Durham, NC, ⁴University of Colorado at Denver, Aurora, CO
20 National Monitoring of Adolescent Prescription Stimulants Study: Stimulant medication use among 10 to 18 year olds
L. B. Cottler, A. Ben Abdallah, S. E. Bradford, C. L. Striley, Psychiatry, Washington University School of Medicine, St. Louis, MO

21 Nonmedical use of prescription stimulants among adolescents: Rural vs. urban
E. W. Ndichu, C. W. Striley, A. Ben Abdallah, S. E. Bradford, L. B. Cottler, Psychiatry, Washington University School of Medicine, St. Louis, MO

22 Youth perspectives on prescription drug non-medical use among their peers
S. E. Bradford, L. J. Wright, S. Cummings, L. B. Cottler, Washington University School of Medicine, St. Louis, MO

23 Trends in prescription drug use disorders secondary to non-medical use in adolescence
S. S. Martins1, L. N. LaFlair1, M. Fenton2, K. M. Keyes2, C. L. Storr3,1, 1Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 2Epidemiology, Columbia University, New York City, NY, 3Family and Community Health, University of Maryland School of Nursing, Baltimore, MD

24 Non-prescribed use of Vicodin® and OxyContin® among US youth
L. K. Lee1, D. McCarty2, J. D. Haddock3, J. Fitzgerald3, W. Wakeland4, L. Webster5, 1University of California, Los Angeles, Los Angeles, CA, 2Oregon Health and Science University, Portland, OR, 3Purdue Pharma L.P., Stamford, CT, 4Portland State University, Portland, OR, 5LifeTree Medical, Salt Lake City, UT

25 Correlates of prescription opioid diversion among middle- and high-school students
C. J. Boyd1,2, S. E. McCabe1,2, C. E. Teter2, A. M. Young1, P. Ross-Durow1, T. H. Ackerson1, M. Epstein2, J. A. Cranford2,1, 1Institute for Research on Women and Gender, University of Michigan, Ann Arbor, MI, 2Substance Abuse Research Center, University of Michigan, Ann Arbor, MI, 3Psychiatry, University of Michigan, Ann Arbor, MI

26 Prescription opioid abuse in adult and adolescent substance abuse treatment center populations: Early findings from CHAT™

27 Improvement in psychopathology among opioid-dependent youth during behavioral-pharmacological treatment
S. K. Moore1, L. A. Marsch1, R. Solhkhah2, Y. Hofstein1, 1Center for Technology and Health, National Development and Research Institutes, New York, NY, 2Psychiatry, Maimonides Medical Center, Brooklyn, NY

28 Dimensional modeling of substance use and conduct disorder and their association with neurocognition in adolescence
M. Worley, K. L. Hanson, J. Winward, S. F. Tapert, S. A. Brown, Psychiatry, University of California, San Diego, La Jolla, CA

29 Double-blind fluoxetine in comorbid MDD-CUD youth
J. R. Cornelius1, O. Bukstein1, A. Douaihy1, J. Pettegrew1, D. Clark1, D. Daley1, S. Brown2, 1Psychiatry, University of Pittsburgh, Pittsburgh, PA, 2Psychology, University of California, San Diego, CA

30 The added risk of opioid problem use among treatment-seeking youth with marijuana/alcohol problem use
G. Subramaniam1,2, M. L. Ives3, M. L. Stitzer3, M. L. Dennis2, 1DCNBR, NIDA, Bethesda, MD, 2Chestnut Health Systems, Bloomington, IL, 3Psychiatry, Johns Hopkins University, Baltimore, MD
31 Verbal memory, learning and executive functioning among young inhalant and cannabis users
M. Takagi1, M. Yücel1, S. Cotton1, Y. Baliz2, A. Tucker2, K. Elkins1, D. Lubman1, 1Psychiatry,
University of Melbourne, Parkville, VIC, Australia, 2Psychology, Victoria University,
Footscray, VIC, Australia

32 Developmental momentum and risk for substance use disorder: Natural histories of risk factors
in youth experiencing chronic stress
T. Ridenour, University of Pittsburgh, Pittsburgh, PA

33 Drugged driving: Prevalence and trends in a college student sample
A. Arria1, K. M. Caldeira1, K. B. Vincent1, K. E. O’Grady2, 1Center on Young Adult Health and
Development, University of Maryland, College Park, MD, 2Psychology, University of
Maryland, College Park, MD

34 Type of contraception method used at last intercourse and health risk behaviors among US
adolescents
P. Cavazos1, M. Krauss3, E. Spitznagel5, M. Schootman4, J. F. Peipert2, L. Cottler1, L. Bierut1,
1Psychiatry, 2Obstetrics and Gynecology, 3Biostatistics, 4Health Behavior Research, and
5Mathematics, Washington University, St. Louis, MO

35 Clinical features associated with alcohol dependence emerging soon after drinking onset
L. A. Comment, J. C. Anthony, Epidemiology, Michigan State University, East Lansing, MI

36 Motivations not to drink alcohol in adolescence
K. G. Anderson, I. Grunwald, A. Grant, Psychology, Reed College, Portland, OR

37 Motives associated with resilience of tobacco use among school students in Spain. Differences
by gender
C. C. Morales-Manrique1, F. J. Bueno-Cañigral2, J. C. Valderrama-Zurión3, R. Aleixandre-
Benavent1, 1Unidad de Información e Investigación Social y Sanitaria., Universitat de
València-CSIC, Valencia, Spain, 2Plan Municipal Drogodependencias., Ayuntamiento de
Valencia, Valencia, Spain, 3Generalitat Valenciana., Valencia, Spain

GENES

38 DRD2/ANKK1 in relation to regular alcohol and cannabis use among adolescents: Does
parenting modify the impact of genetic vulnerability? The TRAILS study
H. E. Creemers1, Z. Harakeh2, D. Dick3, J. Meyers3, W. Vollebergh2, J. Ormë1, F. Verhulst1,
A. Huizink1,5, 1Child and Adolescent Psychiatry, Erasmus MC - Sophia Children's Hospital,
Rotterdam, Netherlands, 2Utrecht University, Utrecht, Netherlands, 3Virginia Commonwealth
University, Richmond, VA, 4University of Groningen, Groningen, Netherlands, 5University of
Amsterdam, Amsterdam, Netherlands

39 Examination of the effects of the 830 bp indel OPRK1 promoter polymorphism and PDYN mRNA
levels on OPRK1 expression in the caudate from postmortem human brain
V. Yuferov1, N. Fang1, A. Ho1, S. Morgello2, M. J. Kreek1, 1Laboratory of the Biology of
Addictive Diseases, The Rockefeller University, New York, NY, 2Mount Sinai Medical Center,
New York, NY

40 Associations between heroin-dependent patient satisfaction with methadone maintenance
treatment centers and CYP3A4, CYP2B6, CYP2D6, OPRM1, and DRD2 genetic polymorphisms
J. C. Pérez de los Cobos1, N. Sinoł1, F. Calafell2, M. Baiget1, J. Trujols1, J. Salazar1,
M. Cardus1, E. Alvarez1, B. Barcelona Group for Addiction Genetics1,2, 1Addictive Behavior
Unit, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 2Unitat de Biologia Evolutiva,
Universitat Pompeu Fabra, Barcelona, Spain
41 Genetic studies of the proopiomelanocortin gene with heroin addiction in ethnically diverse population
D. Proudnikov1, D. Londono2, J. Ott3, M. J. Kreek1, 1Laboratory of the Biology of Addictive Diseases, The Rockefeller University, New York, NY, 2Genetics, Rutgers University, Piscataway, NJ, 3Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China

42 Identification of differentially expressed genes and enriched molecular pathways by topiramate for treatment of methamphetamine dependence using genome-wide expression microarrays
T. Niu1, J. Wang1, J. Z. Ma1, R. Morris2, H. Liu2, D. Weis2, M. McCann2, C. Stock2, E. Iturriaga2, S. H. Li2, N. Chiang2, E. Yu2, A. Elkashef2, B. A. Johnson1, M. D. Li1, 1Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, VA, 2NIDA, NIH, Bethesda, MD

43 Transcriptome profiling and pathway analysis of genes differentially expressed in response to topiramate for treatment of methamphetamine dependence
M. D. Li1, J. Wang1, T. Niu1, J. Saadvandi2, R. Morris2, N. Ait-Daoud1, J. Campbell2, W. Haning2, J. Mawhinney2, R. Kahn2, A. Anderson2, E. Iturriaga2, X. Lou1, A. Elkashef2, B. A. Johnson1, 1Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, VA, 2NIDA, NIH, Bethesda, MD

44 Long-term memory of cue-induced incentive learning is dependent on the nNOS gene and CREB
J. B. Kelley1, K. L. Anderson2, Y. Itzhak1,2, 1Neuroscience, University of Miami, Miami, FL, 2Psychiatry, University of Miami, Miami, FL

45 Serotonin transporter polymorphisms and attentional bias in cocaine dependence
L. Maili1, D. N. Nielsen2, S. Liu1, S. Hamon3, K. A. Cunningham4, F. G. Moeller1, 1Psychiatry and Behavioral Sciences, University of Texas Health Science Center, Houston, TX, 2Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, 3Statistical Genetics, The Rockefeller University, New York, NY, 4Pharmacology and Toxicology, Center for Addiction Research, Galveston, TX

46 Epigenetic effects of cocaine on white matter
D. A. Nielsen1,2, W. Huang1,2, S. C. Hamon3, L. Maili4, K. A. Cunningham5, F. G. Moeller4, 1Baylor College of Medicine, Houston, TX, 2Michael E. DeBakey V.A. Medical Center, Houston, TX, 3The Rockefeller University, New York, NY, 4University of Texas Health Science Center at Houston, Houston, TX, 5University of Texas Medical Branch, Galveston, TX

47 Implication of epigenetic modulation in reduced mesolimbic dopaminergic activity under a neuropathic pain-like state
M. Saeki, M. Narita, S. Imai, M. Narita, K. Niikura, N. Kuzumaki, T. Suzuki, Toxicology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan

48 Neuropathogenic mechanisms of HIV-1 clade B and C: Role of dopamine receptor-2
S. Thangavel, Z. M. Saiyed, M. Agudelo, N. Gandhi, P. V. Reddy, M. P. Nair, Immunology, Florida International University, Miami, FL

HIV/AIDS I

49 The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine/naloxone
L. E. Sullivan1, M. Botsko2, C. Cunningham3, J. A. Mitty4, D. Hersh4, P. J. Lum4, R. S. Schottenfeld1, P. G. O’Connor1, D. A. Fiellin1, 1Yale University School of Medicine, New Haven, CT, 2New York Academy of Medicine, New York, NY, 3Albert Einstein College of Medicine, New York, NY, 4University of California, San Francisco, CA, 5Harvard Medical School, Boston, MA
50 Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone
L. Weiss2, M. Botsko2, J. Egan2, R. Finkelstein2, F. Altice1, L. Bazerman3, A. Chaudhry4,
C. Cunningham5, M. Gourevitch6, P. Lun7, L. Sullivan1, R. Schottenfeld1, P. O’Connor1,
D. Fiellin1, 1Internal Medicine, Yale University, New Haven, CT, 2New York Academy of
Medicine, New York, NY, 3Brown University, Providence, RI, 4CSAT, Rockville, MD, 5Albert
Einstein College of Medicine, Bronx, NY, 6New York University, New York, NY, 7University of
California, San Francisco, CA

51 Cognitive impairment during alcohol intoxication in HIV positive drinkers
V.A. Gruber, R. Sutton, E. F. McCance-Katz, University of California, San Francisco, CA

52 Sexual discounting: HIV/AIDS risk behavior and the delay discounting of sexual rewards in
cocaine dependence
M. W. Johnson, Psychiatry and Behavioral Sciences, Johns Hopkins University School of
Medicine, Baltimore, MD

53 Neuropsychological predictors of substance use and adherence in HIV+, methamphetamine-
using men who have sex with men
W. J. Kowalczyk1,2, M. P. Pawson1, J. T. Parsons1,2,3, S. A. Golub1,2,3, 1Center for HIV/AIDS
Educational Studies and Training, 2City University of New York Graduate School and
University Center, and 3Hunter College, New York, NY

54 Integrating theory to address the association between substance use and sexual risk behavior
among MSM
B. Wells1, S. Golub1,2, J. Parsons1,2, 1The Center for HIV Educational Studies and Training, and
3Psychology, Hunter College, New York, NY

55 Gay-related stigma is predictive of problematic drinking and substance use in a sample of high-
risk HIV negative YMSM
C. Lelutiu-Weinberger1, S. A. Golub1,2,3, A. Bamonte1, J. T. Parsons1,2,3, J. Tomassilli1, 1Center
for HIV Educational Studies and Training, and 2Psychology, Hunter College, New York, NY,
3Social-Personality Psychology, CUNY Graduate Center, New York, NY

56 Sexual risk predicted by motivation to change risk behavior, temptations for and decisions
around unsafe sex in YMSM
J. T. Parsons1,2,3, C. Lelutiu-Weinberger1, S. A. Golub1,2,3, A. Bamonte3, 1Psychology, Hunter
College, CUNY, New York, NY, 2Social-Personality Psychology, CUNY Graduate Center, New
York, NY, 3Center for HIV Educational Studies and Training, Hunter College, New York, NY

57 Substance use and heterosexual anal sex at the most recent sexual encounter
L. J. Ouellet, M. E. Mackesy-Amiti, Epidemiology and Biostatistics, University of Illinois at
Chicago, Chicago, IL

58 Internalization of complimentary sexual stereotypes as a correlate of risky sexual attitudes
among African-American females
Science, University of Kentucky, Lexington, KY

59 Intimate partner characteristics and sexual behaviors as correlates of sexually transmitted
infections among African-American female drug users
C. B. Oser, K. Harp, J. Havens, M. Staton-Tindall, B. Perry, J. Mooney, J. Duvall,
C. Leukefeld, University of Kentucky, Lexington, KY

BADGES MUST BE WORN FOR ALL SESSIONS AND SOCIAL EVENTS
60 The relative role of perceived partner risks in condom use in a three-city sample of low-income women
A. J. Ober1, M. Y. Iguchi2,3, R. E. Weiss4, P. M. Gorbach5, R. Heimer6, L. J. Ouellet7, S. Shohtaw8, W. A. Zule9, 1Semel Institute of Neuroscience and Behavior, UCLA Integrated Substance Abuse Programs, Los Angeles, CA, 2Community Health Sciences, UCLA School of Public Health, Los Angeles, CA, 3RAND Corporation, Santa Monica, CA, 4Biostatistics, UCLA School of Public Health, Los Angeles, CA, 5Epidemiology, UCLA School of Public Health, Los Angeles, CA, 6Yale University School of Public Health, New Haven, CT, 7UIC School of Public Health, Chicago, IL, 8Family Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA, 9Research Triangle Institute International, Raleigh Durham, NC

61 Drug use and sexually transmitted infections in rural North Carolina
W. A. Zule, W. M. Wechsberg, C. M. Coomes, G. V. Bobashev, RTI International, Research Triangle Park, NC

62 Changes in injection- and sex-related HIV risk behaviors for in- and out-of-treatment opiate-dependent individuals
S. G. Mitchell1, K. E. O’Grady2, S. M. Kelly1, B. S. Brown3, R. P. Schwartz1, 1Friends Research Institute, Baltimore, MD, 2University of Maryland, College Park, MD, 3University of North Carolina, Wilmington, NC

63 Factors associated with backloading among injection drug users in Baltimore, Maryland: The role of executive functioning
C. Graham, D. Whitaker, W. Latimer, Johns Hopkins University, Baltimore, MD

64 Impulsivity and HIV sexual risk behaviors in Bulgarian heroin users
G. N. Vasilev1, I. T. Raynov1, S. E. Bliznashki1, E. M. Martin-Thormeyer2, J. Vassileva2, 1Bulgarian Addictions Institute, Sofia, Bulgaria, 2Psychiatry, University of Illinois - Chicago, Chicago, IL

65 Sex-related HIV risk behaviors among injection drug users
H. L. Guentzel1, M. Iguchi1,2, R. Bluthenthal2,3, A. Kral4,5, 1CHS, UCLA, Los Angeles, CA, 2RAND Corporation, Santa Monica, CA, 3Urban Community Research Center, California State University, Dominguez Hills, Carson, CA, 4RTI International, San Francisco, CA, 5UCSF, San Francisco, CA

66 HIV transmission risk behaviors and genotypic drug resistance among HIV+ patients on opioid agonist treatment
A. Dinh, J. M. Tetrautl, M. Kozal, L. E. Sullivan, D. Fiellin, Internal Medicine, Yale University School of Medicine, New Haven, CT

67 Personality disturbances and HIV risk behaviors in HIV+ individuals
H. Newville1,2, D. L. Haller2,3, 1Yeshiva University, Bronx, NY, 2St. Luke’s-Roosevelt Hospital, New York, NY, 3Columbia University, New York, NY

PHARMACOKINETICS

68 Interactive role of HIV-1 clade specific tat protein and cocaine in blood-brain barrier dysfunction: Implications for neuroAIDS
N. Gandhi, Z. Saiyed, T. Samikkannu, M. Agudelo, P. Khatavkar, J. Napuri, M. Nair, Institute of Neuroimmune Pharmacology, College of Medicine, Florida International University, Miami, FL

BADGES MUST BE WORN FOR ALL SESSIONS AND SOCIAL EVENTS
69 Estimation of a human satiety threshold for cocaine self-administration
   G. A. Angarita¹, R. Gueorguieva¹², B. Pittman¹, R. Kalayasiri³, W. L. Lynch⁴,
   A. Sughondhabirom³, P. T. Morgan¹, R. T. Malison¹, ¹Psychiatry, Yale University,
   New Haven, CT, ²Division of Biostatistics, Yale University, New Haven, CT, ³Psychiatry,
   Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand, ⁴Psychiatry and
   Neurobehavioral Sciences, University of Viriginia School of Medicine, Charlottesville, VA

70 Estimating the intake of abused methamphetamine using experimenter-administered deuterium
   labeled R-methamphetamine: Selection of the R-methamphetamine dose
   L. Li, J. Lopez, G. Galloway, M. Baggott, T. Everhart, J. Mendelson, Research Institute,
   California Pacific Medical Center, San Francisco, CA

71 Gender differences in the pharmacokinetics and effects of 3,4-methylenedioxymethamphetamine
   in humans
   M. Farre¹², R. Pardo¹², S. Yubero¹³, E. Cuyas¹², M. Torrens⁴⁵, C. Mustata¹², C. Perez¹²,
   E. Menoyo¹, M. Perez¹, S. Martin¹, B. O’Mahony¹³, R. De la Torre¹³, ¹Human Pharmacology
   and Neurosciences, IMIM-Hospital del Mar, Barcelona, Spain, ²Pharmacology, UAB,
   Barcelona, Spain, ³CEXS, UPF, Barcelona, Spain, ⁴Drug Addiction, IAPS-IMAS, Barcelona,
   Spain, ⁵Psychiatry, UAB, Barcelona, Spain

72 Pharmacokinetic properties of a bacterial cocaine esterase to be used as a treatment against
   cocaine-induced toxicities
   R. L. Brim, R. K. Sunahara, J. H. Woods, Pharmacology, University of Michigan,
   Ann Arbor, MI

73 A slow-onset, long-duration methylphenidate analog is not self-administered in cocaine-naïve
   rats
   M. Froimowitz¹, X. Peng², X. Li², J. Li², Z. Xi², C. J. Kelley³, E. L. Gardner², ¹none,
   Newton, MA, ²Neuropsychopharmacology Section, Intramural Research Program, National
   Institutes of Health, Baltimore, MD, ³Massachusetts College of Pharmacy and Health
   Sciences, Boston, MA

74 Blood levels of fluoxetine in rhesus monkeys at doses that attenuate the abuse-related effects of
   cocaine
   E. Kessler, L. L. Howell, Neuroscience, Yerkes National Primate Research Center, Emory
   University, Atlanta, GA

75 Bupropion transport by placental P-glycoprotein and Breast Cancer Resistance Protein
   and Gynecology, University of Texas Medical Branch at Galveston, Galveston, TX

76 Bupropion metabolism by human placenta
   X. Wang, D. Abdelrahman, O. Zharikova, S. Patrikeeva, G. Hankins, M. Ahmed,
   T. Nanovskaya, Obstetrics and Gynecology, University of Texas Medical Branch at Galveston,
   Galveston, TX

COMPLIANCE

77 A study of initial riboflavin levels in 2,738 treatment-seeking substance users
   M. E. Mooney¹, D. V. Herin¹, J. M. Schmitz², J. Grabowski¹, ¹Psychiatry, University of
   Minnesota, Minneapolis, MN, ²Psychiatry and Behavioral Sciences, University of Texas
   Health Science Center, Houston, TX
Hair analysis vs. conventional methods of drug testing in pre-transplant patients
D. L. Haller1,2, M. Acosta3,2, D. Lewis3, D. Miles5, T. Schiano6, P. Shapiro2, J. Gomez1, S. Sabag-Cohen1, H. Newville2,1, 1St. Luke’s-Roosevelt Hospital, New York, NY, 2Columbia University, New York, NY, 3NDRI, Inc., New York, NY, 4US Drug Testing Laboratories, Chicago, IL, 5North Carolina State Center for Health Statistics, Chapel Hill, NC, 6Mt. Sinai School of Medicine, New York, NY, 7Yeshiva University, New York, NY

Concordance between self-report and urine drug screen data in adolescent opioid-dependent clinical trial participants
M. Nakazawa1, M. P. Bogenschutz1, C. Wilcox1, G. Woody2, 1CASAA, University of New Mexico, Albuquerque, NM, 2University of Pennsylvania, Philadelphia, PA

Effects of reimbursement on rates of missing, positive, and negative urine drug among opioid-dependent clinical trial participants
C. Wilcox1, M. P. Bogenschutz1, M. Nakazawa1, G. Woody2, 1CASAA, University of New Mexico, Albuquerque, NM, 2University of Pennsylvania, Philadelphia, PA

Factors associated with high vs. low use of evidence-based practices in addiction treatment
A. Breland2, A. Fitzgerald1, J. May1, F. Taxman3, D. Farrell-Moore1, J. R. Koch2, D. Svikis2, 1Richmond Behavioral Health Authority, Richmond, VA, 2Virginia Commonwealth University, Richmond, VA, 3George Mason University, Fairfax, VA

A randomized controlled trial evaluating the efficacy of a performance improvement system in outpatient substance abuse treatment programs
B. McClure1, A. Kulaga1, S. Ring-Kurtz2, C. Temes2, R. Gallop3, R. Forman3, P. Crits-Christoph2, J. Rotrosen1, 1Psychiatry, NYU School of Medicine, New York, NY, 2University of Pennsylvania, Philadelphia, PA, 3Alkermes, Inc., Boston, MA

Is the association of therapeutic alliance with days of use always negative?
A. A. Forcehimes1, A. S. Kosinski2, O. Silva1, K. Burlew3, L. Montgomery3, 1CASAA, University of New Mexico, Albuquerque, NM, 2Duke, Druham, NC, 3University of Cincinnati, Cincinnati, OH

Six-month outcomes for the Targeted Assessment Welfare to Work Program
C. G. Leukefeld1, E. Carlton1, M. Staton-Tindall2, M. Delaney1, 1Behavioral Science, and 2Social Work, University of Kentucky, Lexington, KY

The efficacy of Motivational Enhancement Therapy for African-American substance users
L. Montgomery1, K. Burlew1, A. Kosinski2, A. Forcehimes3, 1Psychology, University of Cincinnati, Cincinnati, OH, 2Duke University, Durham, NC, 3University of New Mexico, Albuquerque, NM

Four-year outcomes from the Early Re-Intervention Experiment with Recovery Management Checkups
M. L. Dennis1, C. K. Scott2, 1Chestnut Health Systems, Normal, IL, 2Chestnut Health Systems, Chicago, IL

A 2-year follow-up study to assess experimental Therapeutic Communities in France. An ongoing study
M. Auriacombe1, C. Denis1, E. Langlois2, M. Fatséas1, A. Vérétout2, C. Diaz-Gomez3, 1Addiction Psychiatry EA4139/INSERM-IFR99, Universite Victor Segalen Bordeaux 2, Bordeaux, France, 2Sociology LAPSAC, Universite Victor Segalen Bordeaux 2, Bordeaux, France, 3OFDT, OFDT, Paris, France
88 Normative data on clients seeking treatment assessed with the French modified Addiction Severity Index. Multidimensional comparison of substance and non-substance dependent patients
M. Fatséas, C. Denis, V. Beltrand, J. Daulouède, M. Auriacombe, Addiction Psychiatry EA4139/INSERM-IFR99, Universite Victor Segalen Bordeaux 2, Bordeaux, France, Bizia, Bayonne, France

89 Predictors and outcomes of treatment readmission: The case for Concurrent Recovery Monitoring
A. B. Laudet, V. Stanick, National Development and Research Institute, NYC, NY, Daytop Village, New York, NY

90 Predictors of study retention in drug abuse treatment trials
J. E. Korte, K. Magruder, S. Sonne, R. Sampson, K. Brady, Medical University of South Carolina, Charleston, SC, Ralph H. Johnson VA Medical Center, Charleston, SC

91 Treatment processes within seven brief therapies for addiction
C. C. Wagner, K. S. Ingersoll, Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, VA, Rehabilitation Counseling, Virginia Commonwealth University, Richmond, VA

92 Trying times: Real-time reports of cocaine-use occasions when efforts at abstinence were low or high

93 Drinking and drug use from a prospective perspective

94 Mixed emotions: Evidence supporting the simultaneous occurrence of conflicting mood states via EMA
D. E. Whitaker, D. H. Epstein, K. E. Preston, CPTR Branch, NIH/NIDA Intramural Research Program, Baltimore, MD

95 The P300 event-related brain potential as a neurobiological marker for substance use disorders: A meta-analytic investigation
A. S. Euser, L. Arends, A. Huizink, I. Franken, Erasmus University Rotterdam, Institute of Psychology, Rotterdam, Netherlands, Erasmus Medical Center/Sophia Children’s Hospital, Child and Adolescent Psychiatry, Rotterdam, Netherlands

96 Treatment with flumazenil: Comparisons of treatment outcomes among patients according to primary drug of abuse
M. Torrington, M. P. Hillhouse, W. Ling, Integrated Substance Abuse Programs, University of California, Los Angeles, Los Angeles, CA

97 A novel opioid receptor antagonist, ALKS 33, demonstrates full and durable blockade of remifentanyl

98 Relative performance of subjective measures used in human abuse potential studies
99 Validation of a rat self-administration design for preclinical abuse liability assessment of new compounds
M. Ellgren, M. D. Swedberg, Safety Pharmacology, Safety Assessment, AstraZeneca R&D, Södertälje, Sweden

100 Acute administration of drugs of abuse modulates risky decision making
M. R. Mitchell, C. M. Vokes, A. L. Blankenship, N. W. Simon, B. Setlow, Psychology, Texas A&M University, College Station, TX

STIMULANTS: HUMAN I
101 Brief intervention to reduce caffeine consumption in caffeine-dependent treatment seekers
D. P. Evatt1, L. M. Juliano2, J. Cohen1, R. R. Griffiths1, 1Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, 2Psychology, American University, Washington, DC

102 Effects of intranasal d-amphetamine and methamphetamine administration in humans
M. G. Kirkpatrick1,2, E. W. Gunderson2, C. E. Johanson1, F. R. Levin2, R. W. Foltin2, C. L. Hart1,2, 1Psychology, Columbia University, New York, NY, 2Division on Substance Abuse, New York State Psychiatric Institute and Psychiatry, Columbia University, New York, NY, 3Psychiatry and Behavioral Neurosciences, Wayne State University, Detroit, MI

103 Neurobehavioral effects of intranasal d-amphetamine

104 Reinforcing effects of d-amphetamine in light and moderate drinkers
M. D. Stanley1, M. M. Poole2, W. W. Stoops1, C. R. Rush1,2,3, 1Behavioral Science, 2Psychology, and 3Psychiatry, University of Kentucky, Lexington, KY

105 Reinforcing effects of d-amphetamine: Influence of novel ratios on a progressive-ratio schedule
R. Sevak1, W. W. Stoops1, P. E. Glaser2,4,5, C. R. Rush1,2,3, 1Behavioral Science, 2Psychiatry, 3Psychology, 4Anatomy and Neurobiology, and 5Pediatrics, University of Kentucky, Lexington, KY

106 Impact of rivastigmine treatment on methamphetamine-induced subjective and reinforcing effects
R. De La Garza, II, T. F. Newton, M. Lokireddy, C. N. Haile, R. Y. Hawkins, S. Mehtani, G. Brown, Y. Omar, J. J. Mahoney, Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX

107 Double-blind placebo-controlled pilot trial of modafinil for methamphetamine withdrawal: Results of an Australian pilot study
N. K. Lee1,2,3, A. Pennay1,3, R. Hester4, S. Nielsen1,2, J. Ferris1, 1Clinical Research, Turning Point Alcohol and Drug Centre, Fitzroy, VIC, Australia, 2Psychology, Psychiatry & Psychological Medicine, Monash University, Melbourne, VIC, Australia, 3National Drug Research Institute, Curtin University, Perth, WA, Australia, 4Psychology, Melbourne University, Melbourne, VIC, Australia

108 Identification of clinical responders to topiramate in a randomized clinical trial for treatment of methamphetamine dependence
J. Z. Ma1, B. A. Johnson1, E. Yu2, R. Rawson2, D. Weiss2, F. McSherry2, J. Saadvandi2, A. Romano2, R. Kahn2, A. Anderson2, E. Iturriaga2, S. H. Li3, N. Chiang2, M. D. Li1, A. Elkashef2, 1Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, VA, 2NIDA, NIH, Bethesda, MD
109 Disulfiram for methamphetamine dependence: An open-label pilot study
M. J. Mancino1, J. McGaugh1, C. Cargile2, A. Oliveto1, 1Psychiatry, University of Arkansas for Medical Sciences, Little Rock, AR, 2Psychiatry, Texas A&M Health Science Center, College Station, TX

110 GABAA receptor modulators as medications for methamphetamine abuse
C. R. Rush1,2,3, J. A. Little1, W. W. Stoops1, P. E. Glaser2, L. R. Hays2, 1Behavioral Science, 2Psychiatry, and 3Psychology, University of Kentucky, Lexington, KY

111 Vigabatrin as a treatment for methamphetamine dependence
G. P. Galloway1, K. Flower1, D. Winship2, C. Gorodetzky2, J. Mendelson1, 1Addiction Pharmacology, California Pacific Medical Center Research Institute, San Francisco, CA, 2Catalyst Pharmaceutical Partners, Inc, Coral Gables, FL

112 Patterns of use situations among active club drug users
T. J. Starks1, S. A. Golub1,3, B. C. Kelly1,2, J. T. Parsons1,3, 1Center for HIV/AIDS Educational Studies and Training, New York, NY, 2Sociology, Purdue University, West Lafayette, IN, 3Psychology, Hunter College CUNY, New York City, NY

113 Gender differences in MDMA-induced CYP2D6 autoinhibition in humans
S. Yubero1,2, R. Pardo1,3, M. Farre1,3, B. O’Mahony1,2, M. Torrens4,3, C. Mustata1,3, C. Perez1,3, R. De la Torre1,2, 1IMIM, 2Universitat Pompeu Fabra, 3Universitat Autonoma de Barcelona, and 4IAPS-Hospital del Mar, Barcelona, Spain

114 Pharmacodynamic effects of 3,4-methylenedioxymethamphetamine
M. J. Baggott, J. Siegrist, J. R. Coyle, E. K. Flower, G. P. Galloway, J. Mendelson, Addiction Pharmacology, California Pacific Medical Center Research Institute, San Francisco, CA

115 Evaluation of the reinforcing effects of 1,4-butandiol in baboons
E. M. Weerts, A. K. Goodwin, B. J. Kaminski, Psychiatry, Johns Hopkins University, Baltimore, MD

116 Drug-seeking in response to a priming injection of MDMA in rats: Relationship to initial sensitivity to self-administered MDMA and dorsal striatal dopamine
J. Colussi-Mas, R. J. Wise, S. Schenk, School of Psychology, Victoria University of Wellington, Wellington, New Zealand

117 The effects of metyrapone and oxazepam on cocaine self-administration following adrenalectomy in rats
G. F. Guerin, N. E. Goeders, Pharmacology, Toxicology and Neuroscience, Louisiana State University Health Sciences Center, Shreveport, LA

118 The effects of ketamine, pentobarbital and isoflurane on cocaine sensitization in female rats
N. Siegal, N. Zhao, D. Dow-Edwards, Physiology/Pharmacology, SUNY Downstate College of Medicine, Brooklyn, NY

119 Cue- and cocaine-induced reinstatement of extinguished cocaine-seeking in methylphenidate pretreated rats
M. S. Herbert1, L. A. Horn1, A. Mohd-Yusof3, A. J. Palmer1, C. M. Farley1, A. R. Zavala2, C. A. Crawford1, 1California State University, San Bernardino, San Bernardino, CA, 2Long Beach State, Long Beach, CA

120 Extended access to intravenous methylphenidate leads to escalation of self-administration in rats
J. A. Marusich, M. Bardo, University of Kentucky, Lexington, KY
121 Chronic methylphenidate treatment does not affect the course of dopaminergic development in juvenile rhesus monkeys

122 Long access to self-administered cocaine causes lasting increases in impulsive choice in a delay discounting task
C. M. Vokes1, M. R. Mitchell1, I. A. Mendez1, R. A. Fuchs2, P. J. Wellman1, B. Setlow1, 1Psychology, Texas A&M University, College Station, TX, 2Psychology, University of North Carolina, Chapel Hill, NC

123 Identifying impulsive action in rats using the one-choice serial reaction time task
N. C. Anastasio1,2, F. G. Moeller3, R. G. Fox1,2, S. Liu3, K. A. Cunningham1,2, 1Center for Addiction Research, Univ Texas Med Branch, Galveston, TX, 2Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX, 3Psychology and Behavioral Science, University of Texas Health Science Center Houston, Galveston, TX

124 Cue-induced response-potentiation in a runway model of IV heroin and cocaine self-administration
Z. Su, A. Ettenberg, University of California, Santa Barbara, CA

125 Social interaction prevents cocaine relapse in a rat model: Functional brain mapping
M. Fritz1, R. El Rawas1, A. Salti1, S. Klement1, M. Bardo3, G. Dechant1, A. Saria1, G. Zernig1, 1Institute for Experimental Psychiatry, Medical University Innsbruck, Innsbruck, Austria, 2Institute for Neuroscience, Medical University Innsbruck, Innsbruck, Austria, 3Center for Drug Abuse Research, University of Kentucky, Lexington, KY

126 Effects of basolateral amygdala - dorsal hippocampus disconnection following cocaine memory reactivation on subsequent cocaine-seeking behavior in rats
A. M. Wells, K. E. Cowhey, X. Xie, D. R. Ramirez, H. C. Lasseter, P. A. West, R. A. Fuchs, Psychology, University of North Carolina at Chapel Hill, Chapel Hill, NC

127 Sub-region specific contribution of the ventral hippocampus to drug context-induced reinstatement of cocaine-seeking behavior
H. C. Lasseter, X. Xie, A. M. Wells, R. A. Fuchs, Behavioral Neuroscience, University of North Carolina - Chapel Hill, Chapel Hill, NC

128 Behavioral and functional evidence of mGlu2/3 and mGlu5 metabotropic glutamate receptor dysregulation in cocaine-escalated rats: Factor in the transition to dependence
Y. Hao, R. Martin-Fardon, F. Weiss, The Scripps Research Institute, La Jolla, CA

129 Escalated cocaine self-administration is paralleled by significant reduction in basal extracellular glutamate levels within the medial prefrontal cortex
O. M. Ben-Shahar, K. K. Szumlinski, K. D. Lominac, E. Gordon, K. L. Ploense, K. Pagano, A. N. Nabhan, N. M. Rudy, A. Sacramento, Psychology, University California Santa Barbara, Santa Barbara, CA

130 Manipulation of GLT1 alters cue-induced cocaine reinstatement
K. D. Smith, M. Hatzigeorgiou, J. Teplinsky, G. V. Rebec, Psychological and Brain Sciences, Indiana University, Bloomington, IN

131 Proton magnetic resonance spectroscopy detects putamen glutamate changes during chronic cocaine exposure in squirrel monkeys
X. Liu, C. S. Zuo, E. Jensen, A. Prescott, N. Bolo, T. Gillis, M. Brimson, K. Cayetano, B. Adams, P. F. Renshaw, M. J. Kaufman, Brain Imaging Center, Mclean Hospital, Belmont, MA
132 Inhibiting glycine transporter-1: Effects on extinction and reacquisition of cocaine self-administration
B. Á. Nic Dhonnchadha¹, C. Achat-Mendes², D. M. Platt³, E. Pinard³, D. Alberati³, J. G. Wettstein¹, R. D. Spealman², K. M. Kantak¹, Psychology, Boston University, Boston, MA, ²New England Primate Research Center, Harvard Medical School, Southborough, MA, ³CNS Research, F. Hoffmann-La Roche Ltd., Basel, Switzerland

133 Abrupt discontinuation after chronic treatment with SSRI and SNRI induces withdrawal syndrome-like signs in mice and rats
T. Suzuki, M. Rahmadi, S. Imai, N. Kuzumaki, M. Narita, Toxicology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan

134 Effects of serotonin transporter inhibitors on cocaine-primed reinstatement in rhesus monkeys
J. C. McClung¹, L. L. Howell¹,², ¹Yerkes National Primate Research Center, Emory University, Atlanta, GA, ²Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA

135 Mice that solely express non-edited 5-HT₂c receptor isoform exhibit an anxiety-like phenotype
S. J. Stutz¹,², N. C. Anastasio¹,², M. V. Morabito⁴,⁵, C. M. Hernandez³, K. T. Dineley¹,³, R. B. Emeson⁴,⁵, K. A. Cunningham¹,², ¹Center for Addiction Research, ²Pharmacology and Toxicology, and ³Neurology, University of Texas Medical Branch, Galveston, TX, ⁴Center for Molecular Neuroscience, and ⁵Pharmacology, Vanderbilt University, Nashville, TN

136 Selective activation of the 5-HT₂c receptor reduces cocaine self-administration and cue-induced reinstatement
R. G. Fox, S. J. Stutz, K. A. Cunningham, Center for Addiction Research, Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX

137 DAT blocker/SERT substrates: Compounds with hybrid transporter activity
B. Blough¹, A. Landavazo¹, J. S. Partilla², F. I. Carroll¹, R. B. Rothman², ¹RTI International, Research Triangle Park, NC, ²Clinical Psychopharmacology, IRP, NIDA, Baltimore, MD

OPIOIDS: ANIMAL STUDIES

138 Relative expression of the five somatostatin receptors mRNA in the caudate putamen of C57BL/6J and 129P3/J mice: Strain and heroin effects
J. Cassin, S. D. Schlussman, Y. Zhang, O. Levrán, A. Ho, M. J. Kreek, The Laboratory of the Biology of Addictive Diseases, The Rockefeller University, New York, NY

139 Role of ventral medial prefrontal cortex in context-induced reinstatement of heroin seeking
A. Stern, J. M. Bossert, Y. Shaham, Behavioral Neuroscience, National Institute on Drug Abuse, Baltimore, MD

140 Effects of preweanling, preadolescent, and adolescent methylphenidate treatment on morphine-induced conditioned place preference
T. S. Der-Ghazarian, C. E. Britt, F. A. Varela, A. J. Roper, C. A. Crawford, Psychology, California State University, San Bernardino, San Bernardino, CA

141 Is dopaminergic neuron projecting from the ventral tegmental area to the cingulate cortex critical for the morphine-induced rewarding effect?
K. Nakahara, M. Narita, Y. Matsushima, M. Narita, S. Takagi, K. Niikura, S. Imai, N. Kuzumaki, T. Suzuki, Toxicology, Hoshi University School of Pharmacy and Pharmaceutical Science, Tokyo, Japan

142 Anabolic-androgenic steroid effects on acute and chronic nociception and morphine antinociception
K. Tsutsui, R. M. Craft, Psychology, Washington State University, Pullman, WA
**Symposium XIV**

**NOVEL KAPPA OPIOIDS: FROM DESIGN TO FUNCTION**

Chairs: Ellen Unterwald and Eduardo Butelman

1. **Peptide kappa opioid receptor ligands - potential for drug development**  
   Jane Aldrich, University of Kansas, Kansas City, KS

2. **Kappa-opioid mediation of stress-induced behaviors**  
   Jay McLaughlin, Torrey Pines Institute for Molecular Studies, Port St. Lucie, FL

3. **Regulation of trafficking of the kappa opioid receptor along the export pathway**  
   Lee-Yuan Liu Chen, Pharmacology, Temple University School of Medicine, Philadelphia, PA

4. **Beyond morphine: Salvia divinorum and the quest for novel kappa opioids**  
   Thomas E. Prisinzano, Medicinal Chemistry, University of Kansas, Kansas City, KS

5. **Salvinorin A and its analogs: Effects in translational animal models**  
   Eduardo Butelman, The Rockefeller University, New York, NY

**Oral Communications 14**

**HATE TO WAIT: DRUGS AND IMPULSIVITY**

Chairs: Justin J. Anker and Lawrence P. Carter

1. **Impulsivity + craving = drug use?**  
   D. Tziortzis, J. J. Mahoney, A. D. Kalechstein, T. F. Newton, R. De La Garza, II, Menninger  
   Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX

2. **Substance use disorder risk and inhibitory control on an anti-saccade task**  
   E. Long, D. L. Thatcher, B. Luna, C. F. Geier, D. B. Clark, Psychiatry, University of Pittsburgh,  
   Pittsburgh, PA

---

**Wednesday, June 16, 2010**

143 *Effects of voluntary exercise on morphine antinociception and withdrawal*  
   R. E. Balter¹, K. T. Schmidt², L. A. Dykstra¹,² ¹Neurobiology, and ²Psychology, University of  
   North Carolina, Chapel Hill, NC

144 *CXCR4 involvement in the gp120 antagonism of the antinociception induced by opioids in the  
   cold water tail-flick test*  
   Research, Temple University School of Medicine, Philadelphia, PA

145 *Functional interaction between SDF-1alpha in the brain and opioid medications*  
   K. Benamar, A. Cowan, E. B. Geller, M. W. Adler, Center for Substance Abuse Research,  
   Temple University School of Medicine, Philadelphia, PA

146 *Evaluation of morphine and chlordiazepoxide withdrawal with telemetry*  
   T. Wolinsky, P. Moser, O. Poussel, S. Rompion, V. Castagne, C. Froger-Colleaux, Porsolt and  
   Partners Pharmacology, Boulogne-Billancourt, France

147 *Socially-induced morphine pseudo-sensitization in adolescent mice*  
   S. Eitan¹, R. S. Hofford¹, K. W. Roberts², P. J. Wellman¹, ¹Psychology, Texas A&M University,  
   College Station, TX, ²Psychiatry and Biobehavioral Sciences, UCLA, Los Angeles, CA
2:30 Validity of a behavioral task of negative reinforcement underlying risky alcohol use
N. T. Calvin, C. W. Lejuez, L. MacPherson, Psychology, University of Maryland, College Park, MD

2:45 Interactions between delay discounting and DRD4 genotype on smoking following a treatment intervention
L. P. Carter¹, R. D. Landes², C. E. Sheffer³, L. C. Jackson¹, D. Christensen¹, M. L. Stitzer⁶,¹, J. MacKillop⁴, J. E. McGeary⁵, B. A. Jones¹, R. Yi¹, W. K. Bickel¹,³,¹, Psychiatry, Biostatistics, and Health Behavior and Health Education, University of Arkansas for Medical Sciences, Little Rock, AR, Psychology, University of Georgia Athens, Athens, GA, Psychiatry, Brown University, Providence, RI, Psychiatry, Johns Hopkins University, Baltimore, MD

3:00 Drug abuse, posttraumatic stress, and impulsivity in women
A. E. Waldrop¹,², J. Coetzee¹, S. L. Batki¹,², University of California, San Francisco, San Francisco, CA, San Francisco VAMC, San Francisco, CA

3:15 Are adolescents gambling with cannabis use? A longitudinal study of observed and reported impulsivity measures in relation to adolescent substance use. The TRAILS Study
A. Prince van Leeuwen¹,², H. E. Creemers², F. C. Verhulst², J. Ormel³,⁴, A. C. Huizink¹,², University of Amsterdam, Amsterdam, Netherlands, Erasmus University Medical Center Sophia Children’s Hospital, Rotterdam, Netherlands, University Medical Center Groningen and University of Groningen, Groningen, Netherlands, Graduate School for Experimental Psychology, Groningen, Netherlands

3:30 An animal model of negative urgency and the effect of d-amphetamine on behavioral outcomes of unexpected nonreward
C. Gipson, M. T. Bardo, Psychology, University of Kentucky, Lexington, KY

3:45 Stimulant-seeking behavior in adolescent vs. adult rats
J. J. Anker, M. E. Carroll, University of Minnesota, Minneapolis, MN

Oral Communications 15
Salon FG
2:00 - 4:00 PM

GENDER DIFFERENCES IN DRUG USE

Chairs: Leila Z. Islam and Karen Cropsey

2:00 He said, she said: Gender differences in lifetime NMUPD dependence rates in two epidemiological samples
L. Islam, D. Svikis, L. Keyser-Marcus, R. Pickens, Virginia Commonwealth University, Richmond, VA

2:15 Gender differences in presenting characteristics and severity of substance use among individuals with prescription opioid dependence
E. Hartwell, K. Lawson, L. Singleton, S. Back, Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, NC

2:30 Male-female differences in the estimated influence of caregiver, sibling, and peer smoking on the first chance to try tobacco during the pre-adolescent years
V. H. Accornero¹, J. C. Anthony², L. Xue¹, C. B. McCoy³, E. S. Bandstra¹, Pediatrics, University of Miami Miller School of Medicine, Miami, FL, Epidemiology, Michigan State University School of Human Medicine, East Lansing, MI, Epidemiology and Public Health, University of Miami Miller School of Medicine, Miami, FL
**Male-female and age-of-onset variations in risk of clinical features associated with cocaine dependence**
E. M. Meyer\(^1\), B. K. Ahmedani\(^2,1\), O. A. Adelaja\(^1\), J. C. Anthony\(^1\), \(^1\)Epidemiology, and \(^2\)School of Social Work, Michigan State University, East Lansing, MI

**A qualitative analysis of women’s experiences in empirically supported single-gender vs. mixed-gender substance abuse group therapy**
S. F. Greenfield\(^1,2\), A. M. Cummings\(^1\), L. A. Kuper\(^1\), M. Koro-Ljungberg\(^3\), \(^1\)McLean Hospital, Belmont, MA, \(^2\)Harvard Medical School, Boston, MA, \(^3\)University of Florida, Gainesville, FL

**Progesterone in cocaine abuse: Gender differences**
S. Specker\(^1\), J. Whelan\(^1\), R. Crosby\(^2\), S. Collum\(^1\), \(^1\)University of Minnesota, Minneapolis, MN, \(^2\)Neuropsychological Research Institute, Grand Forks, ND

**Methadone maintenance treatment for probationers: Predictors and outcomes**
J. Gryczynski, S. M. Kelly, T. W. Kinlock, M. Gordon, K. E. O’Grady, R. P. Schwartz, Social Research Center, Friends Research Institute, Baltimore, MD

**Results of a pilot RCT of buprenorphine for women in the criminal justice system: Preliminary analyses**
K. Cropsey, G. Hale, D. Jackson, S. Jones-Whaley, A. Perkins, P. Lane, Psychiatry, University of Alabama at Birmingham, Birmingham, AL

**Oral Communications 16**

**TRANSMITTING INFORMATION ON SEROTONIN**

Chairs: Gregory Miller and Ronald Cowan

**Altered serotonin1A receptor system is related to the increased cocaine intake with extended access in rats**
S. Wee, G. F. Koob, Committee on the Neurobiology of Addictive Disorders, The Scripps Research Institute, La Jolla, CA

**Elevated expression of 5-HT1B receptors in the mesolimbic pathway enhances the reinforcing effects of cocaine using the self-administration model in rats**
N. S. Pentkowski\(^1\), T. H. Cheung\(^1\), W. A. Toy\(^1\), S. Liu\(^1\), J. F. Neumaier\(^2\), J. L. Neisewander\(^1\), \(^1\)Psychology, Arizona State University, Tempe, AZ, \(^2\)Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA

**Non-human primate genetic models of serotonergic dysfunction in addiction**
E. J. Vallender, G. L. Chen, G. M. Miller, Harvard Medical School, New England Primate Research Center, Southborough, MA

**Effects of alcohol on serotonin receptors and histone deacetylase 2**
M. Agudelo, Z. Saiyed, N. Gandhi, T. Samikkannu, P. Khatavkar, M. Nair, Florida International University, Miami, FL

**MDMA and related analogs increase plasma serotonin in rats**
M. H. Baumann\(^1\), R. B. Rothman\(^1\), R. de la Torre\(^2\), S. Yubero\(^2\), \(^1\)Clinical Psychopharmacology Section, NIH/NIDA Intramural Research Program, Baltimore, MD, \(^2\)Pharmacology Research Program, Hospital del Mar, IMIM, Barcelona, Spain

**MDMA–induced feelings of sociability in humans may have a serotonergic mechanism**
K. J. Garrison, M. J. Baggott, J. R. Coyle, E. K. Flower, G. P. Galloway, J. Mendelson, Addiction Pharmacology, California Pacific Medical Center Research Institute, San Francisco, CA
3:30  *Human MDMA use is associated with chronic alterations in cerebellar activation during a motor task: An fMRI study*
      J. Karageorgiou, M. S. Dietrich, R. Cowan, Psychiatric Neuroimaging Program, Vanderbilt University, Nashville, TN

3:45  *Antidepressant-like effects of ecstasy*
      I. Majumder, R. J. Irvine, J. M. White, Pharmacology, The University of Adelaide, Adelaide, SA, Australia

---

**CPDD BUSINESS MEETING**  
(Members Only)  
**Salons HI**  
**4:15 - 5:15 PM**

**DINNER AND DANCING**  
**Ballroom Foyer**  
**7:30 - 9:30 PM**

---

*BADGES MUST BE WORN FOR ALL SESSIONS AND SOCIAL EVENTS*
SEX/GENDER DIFFERENCES

1 Characterization of users in a population of drug addicts
   H. Geniaux1,2, F. Haramburu1, A. Umbricht2, A. Cadet-Taïrou3, 1Département de
   Pharmacologie, Université Victor Segalen, CHU, Bordeaux, France, 2The Johns Hopkins
   University School of Medicine, Behavioral Pharmacology Research Unit, Baltimore, MD,
   3Observatoire Français des Drogues et Toxicomanies (OFDT), Paris, France

2 Distress tolerance and adolescent substance use problem severity
   S. B. Daughters1, S. M. Gorka1,2, C. W. Lejuez2, R. M. Travers2, J. Leonard1, K. Smith2, 1Public
   and Community Health, and 2Psychology, University of Maryland, College Park, MD

3 Sex differences in the relations between youth psychopathology and substance use
   A. Goldweber, R. Evans, W. Latimer, Johns Hopkins Bloomberg School of Public Health,
   Baltimore, MD

4 Hispanic parenting women in women-only vs. mixed-gender drug treatment
   Y. I. Hser, Y. J. Chang, E. Evans, N. Messina, Integrated Substance Abuse Programs,
   University of California, Los Angeles, CA

5 Gender differences among urban American Indians in substance abuse treatment
   S. E. Spear, D. Crevecoeur-MacPhail, L. Ransom, Semel Institute for Neuroscience and
   Human Behavior, UCLA, Los Angeles, CA

6 Effectiveness of a mass mail-out distribution of nicotine replacement therapy to smokers in
   Ontario, Canada: Gender differences in cessation and relapse rates
   P. Selby1,2,4, S. Voci1, S. Hussain1, L. Zawertailo1, 1Addictions Program, Centre for Addiction
   and Mental Health, Toronto, ON, Canada, 2Family and Community Medicine, 3Psychiatry,
   Federal University of Minas Gerais, Belo Horizonte, Brazil, 4Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada

7 Comparative findings on sugar dependence between obese and substance dependence male and
   female subjects
   M. C. Rosa1,2, C. Gomes3, S. Slavutzyk4, F. Kessler2, E. Ferreira1, F. Pechansky2, 1Social and
   Preventive Dentistry, Federal University of Minas Gerais, Belo Horizonte, Brazil, 2Psychiatry,
   Federal University of Rio Grande do Sul, Porto Alegre, Brazil, 3Psychology, Federal University
   of Minas Gerais, Belo Horizonte, Brazil, 4Dentistry, Federal University of Rio Grande do Sul,
   Porto Alegre, Brazil

8 Gender differences in treatment-seeking prescription opioid abusers
   of Vermont, Burlington, VT

9 Gender differences in acceptability of a therapeutic telephone system in primary-care
   buprenorphine maintenance
   T. L. Fazzino2, B. A. Moore1,2, 1Psychiatry, Yale University School of Medicine, New
   Haven, CT, 2APT Foundation, New Haven, CT
10 Examining gender differences in substance use and age of first use among rural Appalachian drug users in Kentucky
   L. M. Shannon, J. R. Havens, C. Oser, R. Crosby, C. Leukefeld, University of Kentucky, Lexington, KY

11 The relationship between gender and psychotic symptoms in cocaine- and methamphetamine-dependent volunteers
   R. Y. Hawkins, J. J. Mahoney, A. D. Kalechstein, R. De La Garza, II, T. F. Newton, Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX

12 Sex differences in the influence of neglect on total intracranial white matter in high-risk adolescents
   R. Blanton, L. Mayes, M. Potenza, R. Sinha, Yale University, New Haven, CT

13 Cocaine induces sex differences in PKA phosphorylation substrates, but not ERK phosphorylation

14 Estradiol and progesterone differentially alter cocaine-induced responses in dopamine-PKA mediated intracellular pathway in the nucleus accumbens

15 Effect of cocaine dose and sex in selecting between food and cocaine
   K. A. Kerstetter1, M. Ballis1, S. M. Duffin-Lutgen1, T. E. Kippin12, 1Psychology, University of California Santa Barbara, Goleta, CA, 2Neuroscience Research Institute, University of California Santa Barbara, Santa Barbara, CA

16 Effect of dopamine D1 receptor blockade in the nucleus accumbens on motivation for cocaine: Role of sex and stage of addiction
   S. E. Doyle, C. King, C. Ramoa, W. J. Lynch, Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, VA

17 Sexually dimorphic pattern of striatal PKA signaling responses may mediate cocaine-induced sensitization and tolerance

STRESS

18 Kappa opioid mediation of stress-induced behaviors
   J. P. McLaughlin, Torrey Pines Institute for Molecular Studies, Port St. Lucie, FL

19 Sex influences on alterations in immune function and levels of the stress-protective hormone DHEAS in cocaine-dependent individuals
   C. D’Sa1, H. C. Fox1, A. Kong1, R. Stowe2, R. Sinha1, 1Psychiatry, Yale University School of Medicine, New Haven, CT, 2Microgen Laboratories, Houston, TX

20 Stress-induced changes in mood and cortisol release predict stimulant effects of amphetamine
   A. Hamidovic1, E. Childs2, M. Conrad2, A. King2, H. de Wit2, 1Preventive Medicine, Northwestern University, Chicago, IL, 2Psychiatry, The University of Chicago, Chicago, IL

21 A zero-inflated hidden Markov model of cocaine using behavior
   S. DeSantis1, D. Bandyopadhyay1, S. E. Back2, K. T. Brady2, 1Biostatistics, MUSC, Charleston, SC, 2Psychiatry, Medical University of South Carolina, Charleston, SC

22 Physiological stress profile by different types of stress exposures in young, low-income women
   H. Wu1, L. Divine1, J. Grady1, R. Sinha2, 1University of Texas Medical Branch, Galveston, TX, 2Yale University, New Haven, CT
Gender disparity in the association between stress and addictive behaviors
G. P. Lee1, C. L. Storr2,1, S. S. Martins1, 1Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 2Family and Community Health, University of Maryland School of Nursing, Blatimore, MD

Emotional and physiological response to stress and substance use in adolescents
T. Chaplin1, R. Sinha1, L. C. Mayes2, 1Psychiatry, and 2Yale Child Study Center, Yale University School of Medicine, New Haven, CT

Marijuana and cocaine users differ in responses to a social stressor
G. Bedi1,2, S. C. Reed1,2, S. M. Evans1,2, M. Haney1,2, 1Psychiatry, Columbia University, New York, NY, 2Substance Abuse, New York State Psychiatric Institute, New York, NY

Mindfulness training and stress reactivity in substance abuse: Results from a randomized, controlled stage I pilot study
J. Brewer, R. Sinha, J. Chen, R. Michalsen, T. Babuscio, C. Nick, A. Greer, K. Bergquist, D. Reis, M. Potenza, K. Carroll, B. Rounsaville, Psychiatry, Yale University School of Medicine, West Haven, CT

Is exposure therapy for posttraumatic stress disorder efficacious among people with substance use disorders? Results from a randomised controlled trial
K. L. Mills1, M. Teesson1, E. Barrett1, S. Merz1, J. Rosenfeld1, P. Farrugia1, C. Sannibale1, S. Hopwood2, A. Baker3, S. Back4, K. Brady4, 1National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia, 2Centre for Traumatic Stress, Westmead Hospital, Sydney, NSW, Australia, 3Centre for Brain and Mental Health Research, University of Newcastle, Newcastle, NSW, Australia, 4Psychiatry, Medical University of South Carolina, Charleston, SC

Predictors of family reunification and child maltreatment recurrence among substance abusing families
M. S. Shafer1,2, L. Williams2,1, B. Carlson2,1, R. Rivera1, 1Center for Applied Behavioral Health Policy, and 2School of Social Work, Arizona State University, Phoenix, AZ

Maltreatment and early substance use
C. Larkby1, S. L. Leech2, M. D. Cornelius1, 1Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, 2University of Pittsburgh Medical Center, Pittsburgh, PA

Offspring early substance use and risks from parental drug problems and parental separation
M. Waldron1,2, A. C. Heath2, 1Counseling and Educational Psychology, Indiana University, Bloomington, IN, 2Psychiatry, Washington University School of Medicine, St Louis, MO

Predicting and explaining multiple and simultaneous intimate relationships among African Americans in distressed households in New York City
V. Murugan1, L. C. Windsor1, E. Benoit2, E. Dunlap2, 1School of Social Work, Rutgers: The State University of New Jersey, New Brunswick, NJ, 2National Development and Research Institute, New York, NY

Drug use and help-seeking behaviors among male and female victims of intimate partner violence
S. M. Resko1, K. Lacey2, 1Social Work and Merrill Palmer Skillman Institute, Wayne State University, Detroit, MI, 2Research Center for Group Dynamics, University of Michigan, Ann Arbor, MI
Differences in risky behaviors and male partner characteristics as an explanation for race disparities in STIs
L. Floyd, T. Penniman, A. Lawson, W. Latimer, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

Is recent monogamy or being in a committed relationship a marker for low sexual risk in men in substance abuse treatment?
D. A. Calsyn¹, S. Tross²,³, M. A. Hatch-Maillette¹, A. N. Campbell², ¹Alcohol and Drug Abuse Institute/Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, ²Substance Abuse Division, New York State Psychiatric Institute, New York, NY, ³Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY

WITHDRAWN

Receipt of continuing care by parenting women
E. Evans, D. Huang, Y. Chang, Y. Hser, Integrated Substance Abuse Programs, UCLA, Los Angeles, CA

Propensity to work among chronically unemployed adult drug users
S. O. Sigurdsson¹,², A. DeFulio², K. Silverman³, ¹Psychology, University of Maryland, Baltimore County, Baltimore, MD, ²School of Medicine, Johns Hopkins University, Baltimore, MD

Patient and staff perspectives on managing addiction as a chronic disease
R. G. Carlson¹, G. S. Brigham², L. Hammar¹, R. Falck¹, ¹Wright State University Boonshoft School of Medicine, Dayton, OH, ²Maryhaven, Columbus, OH

Perceptions of impaired health professionals regarding participation in a state monitoring program
L. J. Merlo¹,², S. M. Cummings², L. B. Cottler², ¹Psychiatry, University of Florida, Gainesville, FL, ²Psychiatry, Washington University, St. Louis, MO

Psychosocial and substance use severity in unemployed patients enrolled in methadone maintenance and psychosocial abstinence-based programs
R. Pickens, L. A. Keyser-Marcus, A. Sepulveda, N. Snead, D. Svikis, Psychiatry, Virginia Commonwealth University, Richmond, VA

French survey about students’ health in 5 university Health and Prevention Centers
P. Courty¹,², G. Illes³, C. Auclair³, A. Perreve², M. Argillet⁴, B. Poizat⁵, M. Zorman⁶, S. Blondel⁷, L. Gerbaud²,³, ¹CMP B, CSST SATIS, Clermont Ferrand cedex 1, France, ²University Health and Prevention Center, CLERMONT FERRAND, France, ³Epidemiology and Public Health, University Hospital Clermont Ferrand, CLERMONT FERRAND, France, ⁴University Health and Prevention Center, SAVOIE, France, ⁵University Health and Prevention Center, Saint Etienne, France, ⁶University Health and Prevention Center, Grenoble, France, ⁷University Health and Prevention Center, Lyon, France

Computer-based identification of substance use in primary care patients
L. Hull¹, P. Dillon¹, L. Thacker¹, D. Svikis¹, S. Ondersma², ¹Virginia Commonwealth University, Richmond, VA, ²Psychology and Behavior Neuroscience/OBYGN, Wayne State University School of Medicine, Detroit, MI

Acceptability of a guided computerized health screening in primary care
T. B. Moore, D. Svikis, Virginia Commonwealth University, Richmond, VA

BADGES MUST BE WORN FOR ALL SESSIONS AND SOCIAL EVENTS
44 A comparison of two methods of technology transfer for substance abuse clinicians
C. Barrick¹, G. G. Homish²,³, ¹Research Institute on Addictions, University at Buffalo, Buffalo, NY, ²Health Behavior, School of Public Health and Health Professions, University at Buffalo, Buffalo, NY

DRUG INTERACTIONS
45 Effects of repeated disulfiram administration on the behavioral-stimulant effects of cocaine in squirrel monkeys
H. L. Kimmel¹,², D. F. Manvich², M. Zhou², J. H. Rose², L. L. Howell¹,²,³, ¹Pharmacology, Emory University School of Medicine, Atlanta, GA, ²Division of Neuroscience, Yerkes National Primate Research Center, Emory University, Atlanta, GA, ³Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA

46 Reinforcing effects of nicotine and cocaine combinations in rhesus monkeys
J. Newman, N. K. Mello, Alcohol and Drug Abuse Research Center, McLean Hospital, Harvard Medical School, Belmont, MA

47 Concurrent nicotine and methamphetamine dependence – Why use both?
S. Raju, R. De La Garza, II, Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX

48 Discriminative-stimulus effects of methamphetamine in humans: Effects of acute d-amphetamine and bupropion pretreatment
A. R. Vansickle¹,²,³, W. W. Stoops³, M. M. Poole³,⁴, C. R. Rush²,³,⁴, ¹Virginia Commonwealth University, Richmond, VA, ²Psychiatry, ³Behavioral Science, and ⁴Psychology, University of Kentucky, Lexington, KY

49 Nicotine-dependent vs. non-dependent methadone-maintained smokers
G. Bart¹,², C. Nolan¹, G. Carlson¹, ¹Medicine, Hennepin County Medical Center, Minneapolis, MN, ²Medicine, University of Minnesota, Minneapolis, MN

50 Interaction between alcohol and opioids in opioid-dependent human subjects
R. Lees¹, T. Williams¹, S. Barford-Turner¹, A. Pickering¹, A. Kendrick², C. Waygood², G. Henderson¹, M. Hickman¹, A. Lingford-Hughes¹, ¹Psychopharmacology Unit, University of Bristol, Bristol, UK, ²Respiratory Medicine, Bristol Royal Infirmary, Bristol, UK

51 Efficacy of gabapentin in subjects with concurrent alcohol and cannabis dependence
A. E. Higley, V. Goodell, B. J. Mason, Committee on the Neurobiology of Addictive Disorders, The Scripps Research Institute, San Diego, CA

52 Comparison of cognitive performance in methadone maintenance patients with and without current cocaine dependence

53 The safety and efficacy of varenicline in cocaine-using smokers maintained on methadone: A pilot study
J. Poling¹,², B. Rounsaville¹,², K. Gonsalz²,¹, K. Severino²,¹, M. Sofuoglu¹,², ¹Psychiatry, Yale University, West Haven, CT, ²VA Connecticut Healthcare System, West Haven, CT

54 Levetiracetam treatment for cocaine-dependent methadone-maintained patients
G. Gonzalez¹, M. Romero-Gonzalez², G. DiGirolamo³, R. Desai³, I. Petrakis³, D. Smelson¹, M. Randall⁵, ¹Psychiatry, University of Massachusetts Medical School, Worcester, MA, ²MAYU of New England, New Haven, CT, ³Psychology, College of Holy Cross, Worcester, MA, ⁴Psychiatry, Yale University, New Haven, CT, ⁵Brien Center, Pittsfield, MA
Comparison of baseline and in-treatment measures of motivation and distress in predicting treatment retention
E. Girling1, B. Brown2, R. Schwartz3, K. O’Grady4, E. C. Katz3,1, 1Psychology, Towson University, Towson, MD, 2University of North Carolina, Wilmington, NC, 3Friends Research Institute, Baltimore, MD, 4University of Maryland, College Park, MD

Clinical efficacy of residential abstinence-based detoxification program in heroin dependence
H. Ekhtiari1, P. Hasani Abharian1, Z. Alam Mehrjerdi1, A. Deilamizadeh4, A. Mokri2, 1Neurocognitive, Iranian National Center for Addiction Studies, 2Clinical, Iranian National Center for Addiction Studies, 3Institute for Cognitive Sciences Studies, and 4Rebirth Addiction Treatment NGO, Tehran, Islamic Republic of Iran

Racial/ethnic differences in recent drug detoxification enrollment and the association between discrimination and neighborhood factors in New York City drug-users
N. D. Crawford1,2, K. Jones1, C. Fuller1,2, 1New York Academy of Medicine, New York, NY, 2Columbia University Mailman School of Public Health, New York, NY

Delay discounting predicts voucher redemption among participants in a contingency management program
B. A. Jones1, R. D. Landes2, D. R. Christensen1, M. Mancino1, W. K. Bickel1, 1Psychiatry, and 2Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR

Promoting the use of depot naltrexone with an employment-based contingency management intervention
A. DeFulio, J. J. Everly, A. Umbricht, M. Fingerhood, G. E. Bigelow, K. Silverman, Johns Hopkins University School of Medicine, Baltimore, MD

Employment-based reinforcement of oral naltrexone compliance within unemployed injection drug users
K. E. Dunn, A. DeFulio, J. Everly, W. Donlin, A. Umbricht, M. Fingerhood, G. Bigelow, K. Silverman, Johns Hopkins University School of Medicine, Baltimore, MD

Opioids, chronic pain, and addiction in primary care
D. Barry1, K. S. Irwin2, W. C. Becker1, J. M. Tetault1, L. E. Sullivan1, H. Hansen3, P. G. O’Connor1, R. S. Schottenfeld1, D. A. Fiellin1, 1Yale University School of Medicine, New Haven, CT, 2Tufts University, Medford, MA, 3NYU School of Medicine, New York, NY

Probing acute opioid effects in bipolar disorder
B. Sproule1,2, J. Mascarenhas1, S. Manuel1, B. Brands3,1,2, U. Busto1,2, A. Ravindran1,2, 1Centre for Addiction and Mental Health, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3Health Canada, Ottawa, ON, Canada

Route of administration patterns across extended release prescription opioid products
S. F. Butler, T. A. Cassidy, S. H. Budman, Inflexion, Inc., Newton, MA

Associations between implicit and explicit drug-related cognitions and relapse: An ecological momentary assessment study
R. Marhe1, I. Franken1, A. J. Waters2, 1Psychology, Erasmus University, Rotterdam, Netherlands, 2Medical and Clinical Psychology, Uniformed Services University of the Health Sciences, Bethesda, MD

Chewing then swallowing in self-reported non-medical opioid use by college students as reported by the Researched Abuse, Diversion and Addiction-Related Surveillance System
C. Buchholtz1, L. Reifler1, J. E. Bailey1, R. Dart1,2, 1Rocky Mountain Poison and Drug Center, Denver, CO, 2University of Colorado Denver School of Medicine, Denver, CO
66 Non-fatal overdose among people who abuse prescription opioids
T. C. Green¹, T. A. Cassidy², S. H. Budman², S. F. Butler², ¹Brown Medical School, Providence, RI, ²Inflexxion, Inc., Newton, MA

67 Internet-based post-marketing surveillance of newly marketed opioid analgesics
J. S. Brownstein, E. McNaughton, T. A. Cassidy, S. H. Budman, S. F. Butler, Inflexxion, Inc., Newton, MA

68 Prescription drug misuse in an urban primary care clinic
M. F. Weaver, L. Thacker, P. Dillon, D. Svikis, Virginia Commonwealth University, Richmond, VA

69 How accurate are estimates of community abuse made by local key informants?
S. H. Budman, T. A. Cassidy, K. Lioy, S. F. Butler, Inflexxion, Inc., Newton, MA

70 Differences between treatment-seeking prescription opioid and heroin users in Australia
S. Nielsen¹, R. Bruno², M. Stoove³, N. Lintzeris¹,², ¹Turning Point Alcohol and Drug Centre, Fitzroy, VIC, Australia, ²University of Tasmania, Hobart, TAS, Australia, ³Burnett Institute, Melbourne, VIC, Australia

71 Prescription opioid use and harms in Australia: A review of national data collections
A. Roxburgh¹, B. Larance¹, R. Bruno², L. Burns¹, ¹National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia

72 Non-medical use of prescription ADHD stimulants is typically part of a pre-existing pattern of drug abuse
M. Ertischek¹, C. T. Sweeney¹, M. A. Sembower², S. Shiffman², S. H. Schnoll¹, ¹Pinney Associates, Bethesda, MD, ²Pinney Associates, Pittsburgh, PA

73 Non-medical use of extended release prescription stimulants: An examination of amphetamine and methylphenidate
S. H. Schnoll¹, M. A. Sembower², S. Shiffman², S. Varughese³, M. Ertischek¹, E. St. Jean¹, S. Rosen¹, ¹Pinney Associates, Inc., Bethesda, MD, ²Pinney Associates, Inc., Pittsburgh, PA, ³Shire Development, Inc., Wayne, PA

74 Predictors of non-medical prescription stimulant use among college students
S. J. Lookatch, E. C. Katz, Psychology, Towson University, Towson, MD

75 Strategies that work in obtaining active consent for school-based adolescent drug studies
P. L. Ross-Durow¹, S. E. McCabe¹,², A. M. Young¹, T. Ackerson¹, M. Epstein², J. A. Cranford², C. J. Boyd¹,², ¹Institute for Research on Women and Gender, University of Michigan, Ann Arbor, MI

76 Predictors of prescription opioid non-medical use, abuse and dependence: Findings from the National Survey on Drug Use and Health
S. E. Back, R. A. Payne, A. N. Simpson, K. T. Brady, Psychiatry, Medical University of South Carolina, Charleston, SC

77 Data gaps regarding diversion and abuse of prescription opioid analgesics
W. Wakeland¹, L. Lee², D. McCarty³, J. D. Haddox², J. Fitzgerald², A. Gilson³, J. Homer⁴, L. Macovsky¹, L. Webster², ¹Systems Science, Portland State University, Portland, OR, ²Purdue Pharma, L.P., Stamford, CT, ³Carbone Comprehensive Cancer Center, University of Wisconsin, Madison, WI, ⁴Homer Consulting, Voorhees, NJ, ⁵University of California, Los Angeles, CA, ⁶Public Health and Preventative Medicine, Oregon Health and Science University, Portland, OR, ⁷Lifetree Clinical Research and Pain Clinic, Salt Lake City, UT
78 Gender differences in motives to use and sources of prescription opioids
K. Lawson, L. M. Singleton, E. Hartwell, K. T. Brady, S. E. Back, Clinical Neuroscience Division, Medical University of South Carolina, Charleston, SC

79 Pattern of OxyContin® use in opioid abusers experienced in tampering with the formulation: A retrospective assessment of drug administration methods from the first use to the current preferred method
M. Sokolowska1, S. D. Comer2, M. A. Sullivan2, J. B. Ashworth1, 1Grünenthal USA, Bedminster, NJ, 2New York State Psychiatric Institute, Columbia University, New York, NY, 3Grünenthal GmbH, Aachen, Germany

80 Comparing heroin users and prescription opioid users seeking Suboxone® treatment for opioid dependence
J. Fahey, M. Hillhouse, J. Jenkins, R. Rawson, W. Ling, Integrated Substance Abuse Programs, University of California, Los Angeles, Los Angeles, CA

81 Prescription opioid abuse predicts first admission into methadone maintenance treatment
C. Cleland1, A. Rosenblum1, C. Fong1, M. Parrino2, S. Magura3, 1National Development and Research Institute, New York, NY, 2American Association for the Treatment of Opioid Dependence, New York, NY, 3Western Michigan University, Kalamazoo, MI

82 Parametric evaluation of buprenorphine taper duration for prescription opioid abuse
S. C. Sigmon1, K. Saulsizer1, M. Patrick2, K. Dunn2, S. Heil1, S. Higgins1, 1Psychiatry, and 2Psychology, University of Vermont, Burlington, VT

83 Abuse Deterrent Adjusted Measurement Model: Adjusting for local prescription opioid availability and local use of heroin

HIV/AIDS II

84 Is sex trade for drugs different from sex trade for money? An examination of correlates among recent heroin- or cocaine-using women in Baltimore
T. V. Penniman, C. E. Cavanaugh, L. J. Floyd, W. W. Latimer, Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

85 The impact of homelessness on HIV risk behavior in drug-dependent pregnant women
Q. L. Brown, C. E. Cavanaugh, T. V. Penniman, W. W. Latimer, Mental Health, Johns Hopkins School of Public Health, Baltimore, MD

86 (Wo)man vs. machine: A comparison of a computer- vs. interviewer-directed assessment of perinatal drug use and HIV/STD risk behaviors
C. Smith1, D. L. Terrell1, S. J. Ondersma2, G. Villalobos1, N. Karjane1, D. S. Svikis1, 1Psychology, Virginia Commonwealth University, Richmond, VA, 2Psychiatry, Wayne State University, Detroit, MI

87 Effect of audio computer-assisted self-interview on self-reported drug use and risky health behaviors
D. H. Caldwell, Friends Research Institute, Baltimore, MD

88 The use of the ASSIST among HIV-positive patients on regular antiretroviral therapy in southern Brazil
C. Zubaran1, I. Tres2, K. Foresti2, .. UCS-UNESCO Group2, 1University of Western Sydney, Sydney, NSW, Australia, 2University of Caxias do Sul, Caxias do Sul, Brazil

89 Technologically-enhanced intervention to reduce NIDU in HIV primary care patients
E. Aharonovich1, B. Johnston2, D. Hasin1, 1Columbia University, New York, NY, 2Saint Vincent’s Catholic Medical Center, New York, NY
90 Behavioral drug and HIV risk reduction counseling in MMT programs in Wuhan China  
M. C. Chawarski1, W. Zhou2, P. Liu3, X. Wang2, L. Luo2, R. S. Schottenfeld1, 1Psychiatry, Yale  
University School of Medicine, New Haven, CT, 2Division of HIV/AIDS Prevention, Center  
for Disease Control and Prevention, Wuhan, China

91 Training HIV+ drug-abstinent peers in a care linkage intervention (PEERLINK) for HIV+  
substance users  
H. Wolfe1, D. Haller1, E. Benoit1, K. Bolger1, V. Sharp1, K. Ingersoll2, 1HIV Center for  
Comprehensive Care, St. Luke’s-Roosevelt, New York, NY, 2University of VA,  
Charlottesville, VA

92 The association between individual social factors and neighborhood social context on frequent  
HIV testing among New York City drug users  
C. Fuller1,2, N. D. Crawford1,2, D. Ompad1,2, 1Columbia University, New York, NY, 2New York  
Academy of Medicine, New York, NY

93 Characteristics of treatment responders to a contingency management intervention for homeless,  
out-of-treatment, substance-abusing men who have sex with men  
R. Dierst-Davies1, C. J. Reback1,2, J. A. Peck1,2, M. Nuno3, S. Shoptaw4, 1Friends Research  
Institute Inc., Los Angeles, CA, 2Integrated Substance Abuse Programs, UCLA Psychiatry and  
Bio-Behavioral Sciences, Los Angeles, CA, 3Cedars-Sinai Medical Center, Los Angeles, CA,  
4Family Medicine, UCLA School of Medicine, Los Angeles, CA

94 Contingency management facilitates HIV post-exposure prophylaxis in methamphetamine-using  
MSM  
R. J. Landovitz1, G. Inzhakova2, P. Ebrahimzadeh2, S. Shoptaw3, C. J. Reback2, 1Center for  
Clinical AIDS Research and Education, UCLA, Los Angeles, CA, 2Friends Research Institute,  
Los Angeles, CA, 3Family Medicine, UCLA, Los Angeles, CA

95 Altered default mode resting brain network in HIV-infected individuals  
L. Chang1, R. Yakupov1, A. Stenger1, U. Feger1, H. Nakama2, T. Ernst1, 1Medicine, and  
2Psychiatry, John A. Burns School of Medicine, Honolulu, HI

96 Prolonged cocaine self-administration does not result in altered concentrations of dopamine D1  
receptors in nonhuman primates: An autoradiographic analysis  
H. R. Smith, T. J. Beveridge, K. E. Gill, B. H. Legg, M. A. Nader, L. J. Porrino, Physiology and  
Pharmacology, Wake Forest University School of Medicine, Winston-Salem, NC

97 Cocaine rewards activate neural processing used for performance of cognitive tasks in  
nonhuman primates  
S. Deadwyler, R. Hampson, J. Long, J. Noto, M. Todd, M. Miller, L. Porrino,  
Physiology/Pharmacology, Wake Forest University Health Sciences, Winston-Salem, NC

98 Probabilistic fiber tracking of working memory pathways in cocaine-dependent subjects  
L. Ma1, J. L. Steinberg1, K. M. Hasan2, P. A. Narayana2, L. A. Kramer2, F. G. Moeller1,  
1Psychiatry and Behavioral Sciences, and 2Diagnostic and Interventional Imaging, University  
of Texas Health Science Center, Houston, TX

99 Addiction-associated spontaneous brain activation alterations in the resting state  
Z. Wang, A. R. Childress, Y. Li, A. V. Hole, J. J. Suh, A. Fornash, D. Willard, R. N. Ehrman,  
T. Franklin, C. P. O’Brien, Psychiatry, University of Pennsylvania, Philadelphia, PA

100 The effects of ostracism on behavior and brain activity in chronic cocaine users  
School of Medicine, Winston-Salem, NC
A whole-brain classifier approach for real-time fMRI feedback training in cocaine addiction
A. R. Childress¹,², J. Magland¹, Z. Wang¹, A. V. Hole¹,², J. J. Suh¹,², A. Fornash¹,², D. Willard¹,
R. Fabianski¹, R. Carson¹, R. Hazan¹, R. N. Ehrman¹,², T. R. Franklin¹, M. Goldman¹,
R. Szucs Reed¹, C. P. O’Brien¹,², ¹Psychiatry, University of Pennsylvania School of Medicine,
Philadelphia, PA, ²VA VISN 4 MIRECC, Philadelphia, PA

FMRI of the selective adenosine A2A antagonist SYN115 in cocaine-dependent subjects
F. Moeller¹, J. L. Steinberg¹, K. L. Kjome¹, S. I. Bandak², L. Ma¹, S. Liu¹, N. Rathnayaka¹,
L. A. Kramer³, P. A. Narayana³, ¹Psychiatry, University of Texas Health Science Center at
Houston, Houston, TX, ²Synosia Therapeutics, San Francisco, CA, ³Diagnostic and
Interventional Imaging, University of Texas Health Science Center at Houston, Houston, TX

Determining the effects of benzylpiperazine on reward pathways in comparison to
dexamphetamine and placebo using a gambling task and functional magnetic resonance imaging
B. R. Russell¹, N. A. McNair¹, M. Kwok¹, S. Gempton¹, R. R. Kydd², I. J. Kirk¹, L. E. Curley¹,
¹School of Pharmacy, ²Psychological Medicine, and ³Psychology, The University of Auckland,
Auckland, New Zealand

Determining the acute effects of benzylpiperazine combined with trifluromethylphenylpiperazine
on cognition and executive functioning using functional magnetic resonance imaging
R. R. Kydd¹, N. A. Mcnair², I. J. Kirk³, L. E. Curley², B. R. Russell¹, ¹Psychological Medicine,
²School of Pharmacy, and ³Psychology, The University of Auckland, Auckland, New Zealand

Acute effects of benzylpiperazine on cognition and executive functioning using functional
magnetic resonance imaging using the Stroop paradigm
L. E. Curley¹, N. A. Mcnair¹, R. R. Kydd², I. J. Kirk³, B. R. Russell¹, ¹School of Pharmacy,
²Psychological Medicine, and ³Psychology, The University of Auckland, Auckland, New Zealand

Novelty detection and recognition memory among individuals varying in reward seeking and
impulsivity
C. Klumpp, C. Black, C. Corbly, C. Benca, H. Collins, Y. Jiang, J. Joseph, T. Kelly,
Behavioral Science, University of Kentucky, Lexington, KY

Increased striatal activation in compulsive indoor tanners upon exposure to ultraviolet light
compared to sham light
B. Adinoff³, C. R. Harrington², T. C. Beswick², M. Graves², H. T. Jacobe², M. D. Devous, Sr.³,
T. S. Harris³, ¹Psychiatry, University of Texas Southwestern Medical Center and VA North
Texas Health Care System, Dallas, TX, ²Dermatology, UT Southwestern Med Ctr, Dallas, TX,
³Radiology, University of Texas Southwestern Medical Center, Dallas, TX

Comparison of psychosocial characteristics of subjects who volunteer for research involving
PET scans vs. those who decline participation
V. Selby, R. Bausell, C. Storr, L. Oswald, University of Maryland School of Nursing,
Baltimore, MD

Intrasynaptic dopamine release measured by PET in alcohol-dependent subjects
D. Wong¹, E. Weerts², M. McCaul³, A. Kumar¹, Y. Zhou¹, M. Guevara¹, V. Raymont¹,
H. Kuwabara¹, J. Brasic¹, W. Ye¹, A. Nandi¹, D. Jasinski², G. Wand³, ¹Radiology, ²Psychiatry
and Behavioral Science, ³Psychiatry, and ⁴Medicine, Johns Hopkins University School of
Medicine., Baltimore, MD

Attentional control brain regions involved in attentional bias in smokers
M. Luijten¹, D. J. Veltman², I. H. Franken¹, ¹Institute for Psychology, Erasmus University
Rotterdam, Rotterdam, Netherlands, ²Psychiatry, Academic Medical Centre, Amsterdam,
Netherlands
Varenicline’s impact on BOLD fMRI activation during cue-induced craving and craving resistance in nicotine-dependent adults: Preliminary findings
K. Hartwell1, K. Johnson2, T. LeMatty1, H. Myrick1, M. S. George1, K. Brady1, 1Medical University of South Carolina, Charleston, SC, 2Stanford, Palo Alto, CA

Brain reactivity to smoking cues is greater in smokers with an attentional bias for smoking words
A. C. Janes1, D. A. Pizzagalli2, S. Richardt1, B. Frederick1, A. J. Holmes2, M. Fava3, A. E. Evins3, M. J. Kaufman1, 1McLean Hospital, Belmont, MA, 2Harvard University, Cambridge, MA, 3Massachusetts General Hospital, Boston, MA

Differential antagonism of the behavioral effects of nicotine, varenicline, and cytisine in mice
C. S. Cunningham, L. R. McMahon, Pharmacology, University of Texas Health Science Center, San Antonio, TX

Cardiovascular effects of the nicotine receptor partial agonists cytisine and varenicline
E. M. Jutkiewicz, E. A. Brooks, J. H. Woods, Pharmacology, University of Michigan, Ann Arbor, MI

Varenicline demonstrates partial agonist characteristics by enhancing responding for non-pharmacological reinforcers and attenuating the reinforcement-enhancing effects of nicotine
M. Levin1, M. Weaver1, M. Palmatier3, A. Caggiula1, A. Sved2, E. Donny1, 1Psychology, and 2Neuroscience, University of Pittsburgh, Pittsburgh, PA, 3Psychology, Kansas State University, Manhattan, KS

The roles of nicotinic and muscarinic cholinergic receptors in cost-benefit decision making
I. A. Mendez, J. L. Bizon, B. Setlow, Psychology, Texas A&M University, College Station, TX

Cholinergic transmission in the nucleus accumbens is lower in adolescent vs adult rats experiencing nicotine withdrawal
J. E. Orfíla, I. Torres, L. A. Natividad, E. Castaneda, L. E. O’Dell, Psychology, University of Texas at El Paso, El Paso, TX

Effect of novel nicotinic receptor antagonist r-b3,5L/3PiddB on nicotine- and food-maintained self-administration
A. C. Meyer1,2, T. E. Wooters2, Z. Zhang3, G. Zheng3, P. A. Crooks3, L. P. Dwoskin1,3, M. T. Bardo1,2, 1Center for Drug Abuse Research Translation, 2Psychology, and 3Pharmaceutical Sciences, University of Kentucky, Lexington, KY

The novel mixed opioid RDC-5768 reduces the behavioral effects of nicotine and D-amphetamine in rats

Insula inactivation as a novel therapeutic strategy for nicotine addiction
B. Le Foll1,2, A. Pushparaj1, B. Forget1, 1Centre for Addiction and Mental Health, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada

Development of animal models of tobacco dependence using cigarette smoke exposure
A. C. Harris1,2, C. Mattson1, M. G. LeSege1,2, D. E. Keyler1,2,3, P. R. Pentel1,2,4, 1Medicine, Minneapolis Medical Research Foundation, Minneapolis, MN, 2Medicine, 3Experimental and Clinical Pharmacology, College of Pharmacy, and 4Pharmacology, University of Minnesota, Minneapolis, MN

BADGES MUST BE WORN FOR ALL SESSIONS AND SOCIAL EVENTS
122 *Reinforcement-enhancing effects of nicotine on responding for an unconditioned visual reinforcer in adolescent rats*
M. T. Weaver¹, K. Healey¹, M. Levin¹, A. Caggiula¹, A. Sved², E. Donny¹, ¹Psychology, and ²Neuroscience, University of Pittsburgh, Pittsburgh, PA

123 *Exposure to nicotine during periadolescence impacts the reinforcing effects of alcohol in adulthood*
J. A. Rinker, A. L. Riley, Psychology, American University, Washington, DC

124 *Is nicotine susceptible to the blocking effect?*
A. Jaffe¹, A. Pham¹, S. Gitisetan¹, I. Tarash¹, J. D. Jentsch¹,², ¹Psychology, UCLA, Los Angeles, CA, ²Center for Addictive Behaviors, Semel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles, CA

125 *Comparison of acquisition of nicotine vs. cocaine self-administration without food restriction or prior training*

**STIMULANTS: HUMAN II**

126 *Influence of methylphenidate on the reinforcing effects of cigarette smoking*
M. M. Poole¹, A. R. Vansickle⁴, W. W. Stoops², C. R. Rush²,¹,³, ¹Psychology, ²Behavioral Science, and ³Psychiatry, University of Kentucky, Lexington, KY, ⁴Psychology, Virginia Commonwealth University, Richmond, VA

127 *Pronounced attentional bias in methamphetamine-dependent subjects upon methamphetamine cue exposure: Relationship to craving*
B. K. Tolliver, S. D. LaRowe, E. Chapman, M. Garrett, K. L. Price, M. Saladin, A. L. McRae-Clark, K. T. Brady, Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC

128 *Brain potential indices of reward vary with behavioral control*
F. Gabbay, C. C. Duncan, S. Williams, Uniformed Services University of the Health Sciences, Bethesda, MD

129 *Effect of acute amphetamine on emotional memory*
M. E. Ballard, G. Bedi, D. A. Gallo, H. de Wit, Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, IL

130 *The effects of oral d-amphetamine on impulsivity, mood and performance in smoked cocaine users*
S. C. Reed, S. M. Evans, Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY

131 *Effects of naltrexone on amphetamine-induced changes in the brain dopamine system*
N. Jayaram-Lindström¹, J. Häggkvist¹, T. Malmlöf², T. Saijo¹, C. Halldin¹, S. Lindholm¹, B. Schilström², A. Nordström¹, J. Franck¹, ¹Clinical Neuroscience, and ²Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden, ³Clinical Development Study Delivery, AstraZeneca R&D, Stockholm, Sweden

132 *Neurocognitive dysfunction is associated with treatment drop-out in methamphetamine dependence*
K. G. Heinzerling¹, A. N. Swanson¹, W. Ling², S. Shoptaw¹,², ¹Family Medicine, and ²Psychiatry, UCLA, Los Angeles, CA
Thursday, June 17, 2010

133 Dissemination and implementation of cognitive behavioral therapy for stimulant dependence in South Africa
R. Sodano¹, R. Rawson¹, S. Rataemane², L. Rataemane³, ¹Integrated Substance Abuse Programs, UCLA, Los Angeles, CA, ²University of Limpopo, Sovenga, South Africa, ³MEHADIC, Pretoria, South Africa

134 Performance measures as predictors of client outcome among a methamphetamine-dependent sample at 24- and 36-month follow-up
R. Gonzales, L. Greenwell, R. Rawson, Integrated Substance Abuse Programs, UCLA, Los Angeles, CA

135 Treatment outcomes for methamphetamine dependence: Findings from the Methamphetamine Treatment Evaluation Study
R. McKetin¹, J. Ross¹, J. M. Najman², A. Baker³, D. Lubman⁴, S. Dawe⁵, R. Ali⁶, N. Lee⁷, R. Mattick¹, A. A. Mamun², ¹University of New South Wales, Sydney, NSW, Australia, ²University of Queensland, Brisbane, QLD, Australia, ³University of Newcastle, Newcastle, NSW, Australia, ⁴University of Melbourne, Melbourne, VIC, Australia, ⁵Griffith University, Brisbane, QLD, Australia, ⁶University of Adelaide, Adelaide, SA, Australia, ⁷Turning Point Alcohol and Drug Centre, Melbourne, VIC, Australia

136 Beliefs and treatment outcome
W. Ling, M. P. Hillhouse, Integrated Substance Abuse Programs, UCLA, Los Angeles, CA

137 Physical, sexual, and emotional abuse in a methamphetamine-dependent treatment follow-up sample
S. M. Schroeder, M. Hillhouse, W. Ling, Integrated Substance Abuse Programs, UCLA, Los Angeles, CA

138 Life trajectories of women methamphetamine users with child sexual abuse histories
A. Hamilton¹, N. E. Goeders², ¹Psychiatry, UCLA, Los Angeles, CA, ²Pharmacology, Toxicology and Neuroscience, Louisiana State University Health Sciences Center, Shreveport, LA

139 False power: Qualitative research with women who use methamphetamine
D. J. Rinehart¹, K. F. Corsi¹, K. Mead¹, W. Wechsberg², R. E. Booth¹, ¹Psychiatry, University of Colorado Denver, Denver, CO, ²RTI International, Research Triangle Park, NC

140 Racial/ethnic differences in morbidity and health status among adult methamphetamine users
D. Herbeck, M. Brecht, A. Pham, Integrated Substance Abuse Programs, UCLA, Los Angeles, CA

141 Methamphetamine and other drug use in Native American communities
J. M. Houck¹, R. Daw², M. P. Davis¹, A. A. Forcehimes¹, M. P. Bogenschutz¹, H. I. Perl³, ¹CASAA, University of New Mexico, Albuquerque, NM, ²Totah Behavioral Health Authority, Farmington, NM, ³NIDA, Rockville, MD

142 Perceptions of methamphetamine/drug use among agency personnel in southwest Native American communities
M. P. Bogenschutz¹, A. A. Forcehimes¹, J. M. Houck¹, A. Mondragon¹, M. P. Davis¹, A. Reid¹, K. Foley², ¹CASAA, University of New Mexico, Albuquerque, NM, ²Na’nízhoozhi Center Incorporated, Gallup, NM

BADGES MUST BE WORN FOR ALL SESSIONS AND SOCIAL EVENTS
Symposium XV

SCREENING AND BRIEF INTERVENTION FOR DRUG USE:
DOES IT WORK? WILL IT WORK IN THE REAL WORLD?

Chairs: Richard Saitz and Richard Denisco

10:00 Two approaches to screening and brief intervention for drug use in primary care: Do they work?
Richard Saitz, Boston Medical Center, Boston, MA

10:25 SBIRT and substance use disorders: Can computers bridge the research to practice gap?
Dace Svikis, Virginia Commonwealth University, Richmond, VA

10:50 Multidisciplinary approach to reduce injury and substance abuse in trauma settings
Mary M. Velasquez, School of Social Work, The University of Texas at Austin, Austin, TX

11:15 Translating SBIRT for opioid dependence in the Emergency Department
Gail D’Onofrio, Emergency Medicine, Yale School of Medicine, New Haven, CT

11:40 Discussant: The case for mainstreaming SBIRT into healthcare systems
Bertha K. Madras, Harvard Medical School, Southborough, MD

Oral Communications 17

THE PAIN OF ADDICTION

Chairs: Ziva D. Cooper and Sandra Comer

10:00 Pain during heroin self-administration enhances relapse of heroin-seeking in rats
M. W. Feltenstein1, T. S. Shippenberg2, A. Zapata2, R. E. See1, A. C. Riegel1, 1Neurosciences, Medical University of South Carolina, Charleston, SC, 2NIDA Intramural Research Program, NIH, Baltimore, MD

10:15 Delta9-tetrahydrocannabinol attenuates i.v. heroin self-administration in rhesus monkeys
J. Li1, C. P. France1,2, 1Pharmacology, and 2Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, TX

10:30 Analgesic effects of smoked marijuana and oral THC in healthy marijuana smokers
Z. D. Cooper, S. D. Comer, M. Haney, New York State Psychiatric Institute, College of Physicians and Surgeons of Columbia University, New York, NY

10:45 Characterizing the subjective, reinforcing and analgesic effects of oxycodone in buprenorphine/naloxone-maintained chronic pain patients
J. D. Jones, M. A. Sullivan, J. Manubay, S. K. Vosburg, S. D. Comer, Division on Substance Abuse, New York State Psychiatric Institute and College of Physicians and Surgeons, New York, NY

11:00 Early results of a protocol to use buprenorphine for chronic pain in patients with aberrant drug-related behavior
A. Rosenblum1, R. Cruciani2, E. Dvorkin2, A. Sundaram2, R. K. Portenoy2, 1National Development and Research Institutes, Inc., New York, NY, 2Beth Israel Medical Center, New York, NY
Oral Communications 18  

Salon FG  
10:00 - 11:00 AM  

COCAINE/OPIATE INTERACTIONS: SOME THINGS GO BETTER WITH COKE  

Chairs: Patrick M. Beardsley and Khampaseuth Rasakham  

10:00 Novel JDTic analogues block kappa opioid receptor agonist-induced diuresis and attenuate stress-induced cocaine reinstatement  
P. M. Beardsley¹, G. T. Pollard², J. L. Howard², F. I. Carroll³, ¹Virginia Commonwealth University, Richmond, VA, ²Howard Associates, LLC, and ³Research Triangle Institute, Research Triangle Park, NC  

10:15 Serotonin depletion blocks the effects of a kappa-opioid agonist on cocaine self-administration  
S. Izenwasser, E. Zakharova, M. Lenoir, B. Vignoli, C. Booth, University of Miami Miller School of Medicine, Miami, FL  

10:30 Sex difference in kappa opioid receptor modulation of acute cocaine-induced hyperactivity in the guinea pig  
K. Rasakham¹,², Y. Wang¹,², J. Li¹,², E. M. Unterwald¹,², L. Y. Liu-Chen¹,², ¹Pharmacology, and ²Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA  

10:45 The choice between cocaine-remifentanil mixtures and either drug alone: Increasing mixture dose  
K. Freeman, W. L. Woolverton, Psychiatry and Human Behavior, The University of Mississippi Medical Center, Jackson, MS  

BADGES MUST BE WORN FOR ALL SESSIONS AND SOCIAL EVENTS
Thursday, June 17, 2010

Oral Communications 19
Salons ABC
10:00 - 11:00 AM

IMPACT OF AGE OF ONSET OF DRUG ABUSE

Chairs: Cynthia Kuhn and Brittany E. Evans

10:00  The relation between HPA axis reactivity and age of onset of alcohol use
B. E. Evans, K. Greaves-Lord, A. Euser, I. H. Franken, A. C. Huizink,
Child and Adolescent Psychiatry, Erasmus Medical Center, Rotterdam, Netherlands,
Psychology, Erasmus University Rotterdam, Rotterdam, Netherlands,
Education, University of Amsterdam, Amsterdam, Netherlands

10:15  Conditioned aversion to ethanol in adolescent vs. adult rats: Implications for future drinking
N. L. Schramm-Sapyta, A. DiFeliceantonio, E. P. Foscue, S. Glowacz, N. Haseeb,
N. Wang, C. Zhou, C. M. Kuhn, Psychiatry, and Pharmacology, Duke University Medical Center, Durham, NC

10:30  Marijuana: Age of onset and frontal inhibitory tasks Using fMRI
S. A. Gruber, M. K. Dahlgren, S. E. Lukas, NeuroImaging Center, McLean Hospital, Belmont, MA,
Psychiatry, Harvard Medical School, Boston, MA

10:45  Cortico-cerebellar abnormalities in adolescents with marijuana dependence
M. Lopez-Larson, D. A. Yurgelun-Todd, J. Rogowska, Brain Institute, University of Utah, Salt Lake City, UT,
VISN 19 MIRECC, Salt Lake City, UT, Brain Imaging Center, McLean Hospital/ Harvard Medical School, Belmont, MA

Symposium XVI
Salon FG
11:15 AM - 12:15 PM

THE ROLE OF DOPAMINE D3 RECEPTORS IN COCAINE ABUSE

Chair: Jane B. Acri

11:15  The role of dopamine D3 receptors in drug abuse: Clinical implications
Jane B. Acri, DPMC, NIDA/NIH, Bethesda, MD

11:35  Development of potential pharmacotherapies for cocaine abuse: In vitro assessment of dopamine D3 compounds
Robert R. Luedtke, Pharmacology, University of North Texas Health Science Center, Fort Worth, TX

11:55  The behavioral pharmacology of novel dopamine D3 receptor compounds in rat and monkey models
James H. Woods, Pharmacology, University of Michigan, Ann Arbor, MI
Oral Communications 20

TRYING ON NEW GENES

Chairs: Joseph Sakai and Caren L. Steinmiller

11:15 Cannabinoid receptor gene polymorphism and marijuana’s pharmacologic effects on negative and positive affect
J. McGeary1, J. Metrik2, V. Knopik3, C. Kahler4, P. Monti1, D. Rohsenow1, 1Providence VAMC/Brown University, 2Brown University Center for Alcohol and Addiction Studies, and 3Rhode Island Hospital, Division of Behavior Genetics, Providence, RI

11:30 Association study between the OPRM1 polymorphism 17C>T and heroin or cocaine addiction in African Americans
O. Awolesi1, S. Hamon1, E. Ducat1, M. Randesi1, J. Rotrosen2, P. Casadonte2, S. Linzy3, M. Adelson3,1, M. J. Kreek1, O. Levran1, 1The Laboratory of the Biology of Addictive Diseases, Rockefeller University, New York, NY, 2VA New York Harbor Healthcare System and NYU School of Medicine, New York, NY, 3Dr. Miriam and Sheldon G. Adelson Clinic for Drug Abuse, Treatment, and Research, Las Vegas, NV

11:45 Catechol-O-methyl transferase and corticotropin-releasing hormone receptor gene variants may impact opioid abstinence initiation and withdrawal symptoms in heroin-dependent volunteers
C. L. Steinmiller1, E. Sliwerska2, M. Burmeister2, M. K. Greenwald1, 1Wayne State University, Detroit, MI, 2University of Michigan, Ann Arbor, MI

12:00 Test of association between 10 SNPs in the Oxytocin receptor gene and conduct disorder utilizing a sample of clinic referred youth with serious substance and conduct problems, controls and available first degree relatives
J. Sakai1, T. J. Crowley1, M. C. Stallings2, M. McQueen2,3, M. A. Ehringer2,3, 1School of Medicine, University of Colorado Denver, Aurora, CO, 2Institute for Behavioral Genetics, and 3Integrative Physiology, University of Colorado Boulder, Boulder, CO

BRUNCH WITH CHAMPIONS (Pre-Registrants Only)

Symposium XVII

THE MULTI-SITE NIDA CLINICAL TRIALS NETWORK PRESCRIPTION OPIOID ADDICTION TREATMENT STUDY: OUTCOMES AND IMPLICATIONS

Chairs: Roger Weiss and Petra Jacobs

1:30 The prescription opioid addiction treatment study: Description of study and main outcome results
Roger D. Weiss, McLean Hospital, Belmont, MA

1:50 Key secondary outcomes in the prescription opioid addiction treatment study: A focus on chronic pain
Jennifer S. Potter, University of Texas Health Science Center at San Antonio, San Antonio, TX

2:10 Clinical and scientific implications of results of the prescription opioid addiction treatment study
Walter Ling, University of California, Los Angeles, Los Angeles, CA
**Oral Communications 21**

**COCAIN SENSITIZATION–WHEN LESS IS MORE**

Chairs: Karen Szuminski and Quentin D. Walker

1:30  *Changes in PFC glutamate/Homer-related signaling following long-access cocaine self-administration*

K. K. Szumlinski1,2, O. Ben-Shahar1,2, B. W. Miller1, A. D. Sacramento1, N. M. Rudy1, M. G. Wroten1, N. Woodward1, 1Psychology, and 2Neuroscience Research Institute, University of California at Santa Barbara, Santa Barbara, CA

1:45  *Evidence for tolerance to the behavioral effects of cocaine after long-term self-administration by rhesus monkeys*

N. M. Shinday, D. M. Platt, J. K. Rowlett, W. D. Yao, Neuroscience, New England Primate Center - Harvard Medical School/University of Massachusetts, Southborough, MA

2:00  *Effects of cocaine place conditioning, chronic escalating-dose “binge” pattern cocaine administration and chronic withdrawal on POMC gene expression in rat hypothalamus*

Y. Zhou, A. Kruyer, A. Ho, M. J. Kreek, The Rockefeller University, New York, NY

2:15  *Adolescent rats are more sensitive to behavioral activation by guarana and repeated administration during adolescence results in cocaine cross-sensitization*

Q. D. Walker, J. C. Foster, C. M. Kuhn, Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC

**Oral Communications 22**

**JAIL TIME: CRIMINAL JUSTICE AND DRUG ABUSE**

Chairs: Christine Grella and Michael Prendergast

1:30  *Characteristics of participants with co-occurring disorders in California’s Prop 36 and their criminal justice and treatment outcomes*

C. Grella1, B. T. Conner2, M. L. Brecht1, D. I. Urada1, J. Fan1, 1Integrated Substance Abuse Programs, UCLA, Los Angeles, CA, 2Psychology, Temple University, Philadelphia, PA

1:45  *Preliminary evaluation of extended-release naltrexone in Michigan and Missouri drug courts*


2:00  *Increasing access to services for rural re-entering offenders using telemedicine*

M. Staton-Tindall1, C. Leukefeld2, J. M. Webster2, R. Freeman1, 1College of Social Work, and 2Behavioral Science, University of Kentucky, Lexington, KY

2:15  *Which parolees benefit from case management services? An application of classification and regression tree analysis*

M. Prendergast1, L. Frisman2, H. Lin2, 1UCLA, Los Angeles, CA, 2Mental Health and Addiction Services, Hartford, CT

**BADGES MUST BE WORN FOR ALL SESSIONS AND SOCIAL EVENTS**
Oral Communications 23

HIV/AIDS INFECTION AND DRUG ABUSE INTERSECTION

Chairs: Stacey B. Daughters and Steven A. Kritz

1:30 Implementation of routine HIV rapid testing in a methadone program
   R. M. Seewald, P. Friedmann, R. Tio, R. Elam, V. Bonilla, Jr., G. Sanders, D. C. Perlman,
   Beth Israel Medical Center, New York, NY

1:45 Never HIV tested: Results of screening data from 12 drug treatment programs in the CTN 0032 HIV Rapid Testing and Counseling Study
   L. R. Metsch, R. Mandler, D. Feaster, L. Gooden, S. Tross, L. Haynes, A. Douaihy,
   M. Das-Douglas, T. Kyle, T. Korthuis, R. Schwartz, S. Erickson, N. Snead, J. Sorensen,
   G. Colfax, Epidemiology, University of Miami Miller School of Medicine, Miami, FL

2:00 HIV/AIDS-related health services in substance abuse treatment programs
   L. S. Brown¹, S. A. Kritz¹, E. J. Bini², J. Robinson³, J. Rotrosen⁴, ¹Medical Services, Research
   and Information Technology, ARTC, Brooklyn, NY, ²Gastroenterology, VA NY Harbor
   Healthcare System, New York, NY, ³Nathan Kline Institute, Orangeburg, NY, ⁴Psychiatry, NY
   University College of Medicine, New York, NY

2:15 ACT HEALTHY: Effectiveness of a behavioral activation and HIV medication adherence treatment for African-American HIV positive substance users
   S. L. Howard¹, A. Lavelle¹, J. Magidson¹, J. Hemberg¹, F. Wang¹, S. M. Gorka¹, A. Ogunabi¹,
   J. Leonard¹, S. Safren², S. B. Daughters¹, ¹Public and Community Health, University of
   Maryland, College Park, MD, ²Harvard Medical School, Boston, MA

Symposium XVIII

COMMUNITY-BASED RESPONSES TO INCREASING OPIOID OVERDOSE DEATHS: STATE OF RESEARCH AND PRACTICE

Chairs: Alexander Y. Walley and Alex Kral

2:45 Implementation of a statewide intranasal naloxone overdose prevention program
   Alexander Y. Walley, Clinical Addiction Research and Education Unit, Boston University
   School of Medicine, Boston Medical Center, Boston, MA

3:05 Evaluation of two overdose prevention programs in Los Angeles: Preliminary findings
   Steven Lankenau, School of Public Health, Department of Community Health and Prevention,
   Drexel University, Philadelphia, PA

3:25 Operation OpioidSAFE: A pilot naloxone program in an active duty military setting
   Fred Brason, Project Lazarus, Wilkes County, NC

BADGES MUST BE WORN FOR ALL SESSIONS AND SOCIAL EVENTS
Oral Communications 24

PUMP IT UP! IMPACT OF EXERCISE ON DRUG USE

Chairs: Wendy J. Lynch and Mark A. Smith

2:45  The relationship between increased exercise and smoking cessation
      M. J. Dennis¹, M. L. Dennis², R. R. Funk², ¹Heartland Community College, Normal, IL,
      ²Chestnut Health Systems, Normal, IL

3:00  Psychological benefits of exercise in the treatment of chemical dependency
      P. M. Monchusie, L. K. Tennant, University of Kansas, Lawrence, KS

3:15  Aerobic exercise blocks incubation of cocaine-craving and its associated neuroadaptations
      W. J. Lynch¹, K. Piehl¹, G. Acosta², A. Peterson¹, S. E. Hemby², ¹Psychiatry, University of
      Virginia, Charlottesville, VA, ²Physiology and Pharmacology, Wake Forest University,
      Winston-Salem, NC

3:30  Effects of aerobic exercise on reinstatement of cocaine-seeking behavior
      M. A. Smith, M. M. Pennock, K. L. Walker, Psychology, Davidson College, Davidson, NC

Oral Communications 25

TECH SUPPORT: USE OF TECHNOLOGY IN RESEARCH AND TREATMENT

Chairs: Gnatt Galloway and Michelle C. Acosta

2:45  Using technology to assess substance use behaviors in a low income primary care clinic
      P. H. Smith¹, G. H. Homish¹,², C. Barrick², N. Grier¹, ¹Health Behavior, State University of
      New York at Buffalo, School of Public Health and Health Professions, Buffalo, NY, ²Research
      Institute on Addictions, State University of New York at Buffalo, Buffalo, NY

3:00  Development of a web-based psychosocial intervention for adolescents with substance use
      disorders
      M. C. Acosta¹, L. A. Marsch¹, S. H. Godley², Y. Kaminer¹, Y. Hofstein¹, ¹Center for Technology
      and Health, National Development and Research Institutes, Inc., New York, NY, ²Lighthouse
      Institute, Chestnut Health Systems, Normal, IL, ³Alcohol Research Center, University of
      Connecticut Health Center, Farmington, CT

3:15  Using pill photos taken with a cell phone to assess adherence in a clinical trial
      K. Flower, J. Guillén, J. Coyle, J. Mendelson, G. P. Galloway, Addiction Pharmacology,
      California Pacific Medical Center Research Institute, San Francisco, CA

3:30  Producing smoking craving by using immersive virtual environments
      O. Garcia-Rodríguez¹, I. Pericot-Valverde¹, J. Gutierrez-Maldonado¹, M. Ferrer-García¹,
      R. Secades-Villa², F. Alonso-Perez³, ¹Clinical Psychology, University of Barcelona, Barcelona,
      Spain, ²Psychology, University of Oviedo, Oviedo, Spain, ³Public Health Service, Asturias,
      Spain
Oral Communications 26  Salons ABC  2:45 - 3:30 PM

HEPATITIS

Chairs: Jennifer Havens and William W. Latimer

2:45  Characteristics of HIV and HBV mono and co-infections among black South African drug users
      J. B. Zur, A. Hulbert, L. Ropelewski, W. Latimer, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

3:00  Predictors of hepatitis C seroconversion among rural Appalachian prescription drug users
      J. R. Havens¹, C. B. Oser¹, R. Crosby², C. G. Leukefeld¹, ¹Center on Drug and Alcohol Research, and ²Health Behavior, University of Kentucky, Lexington, KY

3:15  Does the way of drinking (binge drinking) affect the evolution of hepatitis C among alcohol abusers?
      M. Guillaumot², P. Melin¹,², M. Marc¹,², A. Hij¹, S. Samouri¹, M. Schoeny¹, J. Fournier², C. Bremard², ¹CHG St Dizier, Saint Dizier, France, ²CSAPA 52, Saint Dizier, France

SWEEPSTAKES DRAWING  Salon HI  3:45 PM

YOU MUST BE SEATED IN ONE OF THE SESSIONS STARTING AT 2:45 PM IN ORDER TO HAVE YOUR BADGE COLLECTED

HAVE A SAFE TRIP HOME!

SEE YOU IN HOLLYWOOD, FLORIDA, JUNE 18-23, 2011

BADGES MUST BE WORN FOR ALL SESSIONS AND SOCIAL EVENTS
AUTHOR INDEX

Abagiu, A.O. 14
Abdelrahman, D. 77
Ablondi, K. 71
Accornero, V.H. 25, 53, 85
Achara, I. 66
Achat-Mendes, C. 83
Ackerson, T.H. 72, 94
Accosta, G. 107
Acosta, M.C. 78, 107
Acri, J.B. 103
Adams, B. 82
Adams, E. 62
Adams, S. 10
Adelaja, O.A. 12, 86
Adelson, M. 59, 104
Afful, S.E. 53
Agrawal, A. 69
Agster, K.L. 3
Agudelo, M. 74, 76, 86
Aguerreto Colina, A. 57
Aharonovich, E. 51, 95
Ahmed, M.S. 77
Ahmedani, B.K. 86
Ait-Daoud, N. 74
Alam Mehrjerdi, Z. 4, 93
Alberati, D. 83
Alberg, A.J. 23
Albino, T. 65
Albright, L. 66
Aldrich, J. 84
Aleixandre-Benavent, R. 52, 73
Ali, R. 100
Alicata, D. 54
Allison, P.A. 50
Alonso-Perez, F. 107
Altice, F. 6, 75
Altman, J.K. 56
Alvarez, E. 73
Álvarez-García, J.A. 16
Álvarez-Rodriguez, H. 16
Amass, L. 58
Amato, T.D. 9
Amberg, A. 21
Ambrosio Flores, E. 2, 7
Ameringer, K.J. 51
Amico, J. 66
Amojo, K. 57
Anastasio, N.C. 15, 82, 83
Andersen, A.M. 52
Andersen, R.M. 57
Anderson, A. 74, 80
Anderson, B.J. 102
Anderson, K.G. 9, 73
Anderson, K.L. 69, 74
Ando, Y. 18
Andorn, A.C. 8
Ang, A. 71
Angarita, G.A. 77
Anghelescu, M. 14
Anglin, M.D. 50
Anguiano, F.J. 21
Anker, J.J. 84, 85
Aronn, J.A. 14
Anthony, J.C. 2, 4, 9, 11, 12,
13, 53, 55, 73, 85, 86
Aoki, K. 19
Arangua, L.E. 57
Arenander, J. 15
Arends, L. 79
Arfken, C.L. 21, 50
Argillet, M. 91
Arheart, K.L. 25
Arnelle, D. 98
Arora, G. 53
Arria, A. 9, 25, 73
Ashworth, J.B. 95
Aston-Jones, G. 22
Ataya, A. 10
Ator, N.A. 6, 14
ATTTC Network Technology Transfer Workgroup
Auber, A. 18
Auclair, C. 91
Augusto, L.P. 11
Arriacome, M. 12, 13, 59, 78,
79
Authier, N. 18
Awgu, E. 48
Awolesi, O. 104
Babalonis, S. 10, 80
Babor, T.F. 15, 67
Babuscio, T. 90
Back, S.E. 85, 89, 90, 94, 95
Badger, G.J. 52
Bado, J. 19
BaDour, B. 62
Bagaric, A. 58
Beggott, M.J. 77, 81, 86
Baiget, M. 73
Bailey, J.E. 59, 93
Baker, A. 90, 100
Baker, A.K. 14
Baker, L.E. 19
Baker, N. 62
Baladi, M. 17
Baldwin, C.K. 17
Baliz, Y. 73
Ball, S. 58
Ballard, M.E. 99
Ballina, L. 54
Ballis, M. 89
Balster, R. 14
Balter, R.E. 84
Bamonte, A. 75
Bandak, S.I. 15, 97
Bandstra, E.S. 25, 53, 85
Banducci, A.N. 20
Bandyopadhyay, D. 70, 89
Banks, M.L. 18
Bao, Y. 24
Barajas, M. 17
Barcelona Group for Addiction Genetics 73
Bardo, M.T. 68, 81, 82, 85, 98
Barford-Turner, S. 92
Baron, D. 71
Barondess, D. 13
Barral, C. 57
Barrett, E. 90
Barrick, C. 92, 107
Barros, H.T. 70
Barr, D.T. 59, 68, 93
Barry, K.T. 9, 55
Bart, G. 92
Barthwell, A. 14
Bass, C.E. 17
Bastos, F.I. 11
AUTHOR INDEX

Batki, S.L. 21, 57, 85
Batra, V. 7
Baumann, M.H. 61, 62, 86
Bausell, R. 97
Bazerman, L. 75
Beardsley, P.M. 102
Beatty, J.R. 52
Beatty, L.A. 5
Beck, B. 23
Becker, W.C. 93
Beckmann, J. 68
Bedi, G. 90, 99
Beharie, R. 52, 69
Beltrand, V. 13, 57, 59, 79
Ben Abdallah, A. 23, 71, 72
Benamar, K. 84
Benbenishty, R. 60
Benca, C. 97
Benjamin, E.O. 12
Bennett, A.J. 82
Benoit, E. 90, 96
Ben-Shahar, O.M. 82, 105
Benzano, D. 11, 70
Berglund, M. 48
Bergquist, K. 90
Bergthold, T. 20, 21
Berlin, A.A. 17
Berman, M. 19
Bernstein, I.M. 52, 69
Berry, M.S. 11, 53
Berto, D. 49
Beswick, T.C. 97
Beveridge, T.J. 96
Bickel, W.K. 3, 16, 51, 55, 85, 93
Bidlack, J.M. 24
Bierut, L. 73
Bierut, L.J. 53
Bigelow, G.E. 3, 11, 16, 92, 93, 102
Billing, Jr., C.B. 79
Bini, E.J. 106
Bisaga, A. 15
Bizon, J.L. 98
Black, A.C. 16, 71
Black, C. 97
Black, R.A. 95
Blair, L. 51
Blakenship, A.L. 80
Blanton, R. 89
Bliznashki, S.E. 76
Blondel, S. 91
Blough, B.E. 18, 83
Blow, F.C. 8, 9, 55
Blume, L.C. 17
Bluthenthal, R. 76
Bobashev, G.V. 76
Bogenschutz, M.P. 78, 100
Bohner, A.S. 8
Bohnert, K.M. 9
Boden, M. 13
Bolger, K. 96
Bolo, N. 82
Bonilla, Jr., V. 106
Boone, Z. 52
Boos, T.L. 19
Booth, B.M. 9, 55
Booth, C. 102
Booth, R.E. 58, 100, 108
Booze, R.M. 18
Borgland, S.L. 22
Bortolato, M. 2
Bossert, J.M. 83
Botsko, M. 74, 75
Botzet, A. 22
Bouhion, C. 20
Box, B. 57
Boyd, C.J. 72, 94
Boyd, S.J. 49
Bracken, B.K. 10
Brackenbury, L. 9
Bradford, S.E. 23, 72
Bradstreet, M.P. 51, 52
Brady, K.T. 15, 21, 62, 79, 89, 90, 94, 95, 98, 99
Brands, B. 13, 71, 93
Brasic, J. 97
Braud, J. 4
Brecht, M.L. 69, 100, 105
Brekke, M. 59
Brelan, A. 78
Bremard, C. 11, 56, 108
Breslau, N. 9
Brewer, J. 90
Brewster, J.T. 58
Bigham, G.S. 51, 91
Brim, R.L. 77
Brimson, M. 82
Britt, C.E. 83
Brooks, A.C. 16
Brooks, D.J. 56
Brooks, E.A. 98
Brooner, R.K. 12, 59, 71
Brouwer, K.C. 56
Brown, B.S. 58, 60, 71, 76, 93
Brown, G. 80
Brown, L.S. 51, 57, 106
Brown, M. 53
Brown, Q.L. 95
Brown, R. 54
Brown, R.T. 50
Brown, S. 8, 72
Brown, S.A. 72
Browne, D.C. 69
Brownstein, J.S. 94
Bruno, R. 94
Bryan, B. 59
Buchholtz, C. 59, 93
Budman, S.H. 19, 20, 72, 93, 94, 95
Budney, A.J. 22, 55, 56
Budygin, E.A. 17
Bueller, E. 55
Bueno-Cañigral, F.J. 52, 73
Buffalari, D. 17
Bukstein, O. 72
Bumaguin, D. 70
Buras, M. 9
Burlow, K. 78
Burmeister, M. 104
Burns, L. 94
Busse, A. 21
Busto, U.E. 23, 70, 93
Butelman, E. 84
Butler, S.F. 19, 20, 72, 93, 94, 95
Cachay, C. 13
Caddell, L. 19, 24
Cadet, J. 67
Cadet-Taïrou, A. 88
AUTHOR INDEX

Caggiula, A. 98, 99
Cahoon, K.L. 21
Calafell, F. 73
Caldeira, K.M. 9, 73
Calderon, S.N. 65
Caldwell, D.H. 95
Calnan, J. 6
Calsyn, D.A. 91
Calvin, N.T. 16, 85
Cambraia Windsor, L. 5
Campbell, A.N. 91
Campbell, J. 74
Campbell, J.C. 54
Campello, G. 21
Campollo, O. 21
Canfield, K. 21, 57
Canlas, L. 50
Cao, A. 54
Carbonaro, T. 19
Carbone, C.L. 15
Cardus, M. 73
Carey, K.A. 17
Carey, P.D. 2, 55
Cargile, C. 3, 81
Carise, D. 16
Carlson, B. 90
Carlson, G. 92
Carlson, R.G. 91
Carlton, E. 78
Carney, T. 58
Caron, A. 50
Carpenter, M.J. 23, 51
Carr, C.M. 19
Carr, J. 52
Carr, S.M. 19
Carriero, M.P. 57
Carroll, F.I. 18, 83, 102
Carroll, K. 90
Carroll, M.E. 6, 85
Carson, R. 4, 97
Carter, C.S. 7
Carter, L.P. 84, 85
Carter, R.E. 62
Casadonte, P.P. 20, 104
Casas, M. 57
Cassat, P. 13
Cassidy, T.A. 19, 20, 72, 93, 94, 95
Cassin, J. 83
Castagne, V. 84
Castaneda, E. 98
Castel, S. 71
Catacora, M.M. 13
Cavallo, D. 9
Cavanagh, C.E. 17, 95
Cavazos, P. 73
Cayetano, K. 82
Cederblom, E. 23
Cepeda, E. 53
Cerda, M. 8
Chakraborty, B. 3
Chalk, M. 64
Chan, M. 51, 60
Chandler, R. 6
Chandra, S. 13
Chang, L. 54, 55, 96
Chang, Y.J. 88, 91
Chao, L. 13
Chaplin, T. 90
Chapman, E. 99
Charboneau, E.J. 54
Charnigo, R. 23
Chaudhry, A. 75
Chawarski, M.C. 96
Cheetham, S.C. 18
Chen, G.L. 86
Chen, H. 58
Chen, J. 90
Chen, N. 79
Chen, X. 84
Cheng, H. 12
Cheng, W.Y. 15, 102
Chermack, S.T. 9, 55
Cheung, T.H. 86
Chiamulera, C. 18
Chiang, N. 74, 80
Chien, C.S. 13
Chilcoat, H.D. 8, 10
Childress, A.R. 3, 4, 23, 55, 96, 97
Childs, E. 89
Chisolm, M.S. 24, 52
Choate, D. 49
Christensen, C. 19, 21, 53
Christensen, D.R. 16, 85, 93
Chu, M. 57
Chun, J. 60
Chun, L. 62
Churchwell, J.C. 55
Clark, B.D. 3
Clark, D.B. 72, 84
Clausen, T. 11, 49
Cleland, C. 95
Cleva, R.M. 61
Cloak, E. 54
Cobb-Burns, M. 16
Cobuzzi, J.L. 7
Coetzee, J. 85
Cohen, A.J. 20
Cohen, J. 80
Cohn, J. 21
Cojocaru, E. 14
Coker, A.R. 10
Colfax, G. 106
Collado-Rodriguez, A. 51
Collins, G.T. 17
Collins, H. 97
Collins, L.M. 14
Collum, S. 86
Colussi-Mas, J. 81
Comer, S.D. 56, 65, 95, 101
Comerford, M. 15
Comment, L.A. 73
Compton, D. 67
Compton, W.M. 64
Condon, T.P. 6
Conn, N.A. 62, 64
Conner, B.T. 105
Connors, V. 52
Conrad, M. 89
Conti, K.E. 48
Cooley, M. 70
Coomes, C.M. 76
Cooper, Z.D. 56, 101
Copeland, J. 2
Copenhaver, M. 21
Corbly, C.R. 80
Corbly, C. 97
Cordes, J. 10
Cornelius, J.R. 72
AUTHOR INDEX

Cornelius, M.D. 90
Corrigall, W. 22
Cori, K.F. 56, 100, 108
Cori, M. 22
Costello, P. 55
Cottler, L.B. 13, 23, 50, 53, 71, 72, 73, 91
Cotton, S. 73
Courty, P. 18, 91
Coviello, D.M. 48
Cowan, A. 84
Cowan, R. 54, 86, 87
Cowhey, K.E. 82
Coye, J.R. 81, 86, 107
Coyle, M. 24
Craft, R.M. 56, 83
Cranford, J.A. 72, 94
Crawford, C.A. 81, 83
Crawford, N.D. 12, 93, 96
Creemers, H.E. 24, 73, 85
Crevecoeur-MacPhail, D.A. 14, 88
Crits-Christoph, P. 78
Croft, D.E. 23
Croft, J.C. 16
Crooks, P.A. 98
Cropsey, K.L. 17, 48, 49, 85, 86
Crosby, R. 86, 89, 108
Crowley, T.J. 64, 104
Cruciani, R. 101
Cruz, G. 13
Cruz, J. 23
Cruz, S. 54
Cruz, V. 13
Culbertson, C. 23
Culmer, T. 62
Cummings, A.M. 86
Cummings, S.M. 50, 72, 91
Cunningham, C. 74, 75
Cunningham, C.S. 98
Cunningham, K.A. 15, 74, 82, 83
Curley, L.E. 97
Cutter, C.J. 59
Cuyas, E. 77
Czoty, P.W. 6
D’Addario, C. 64
D’Onofrio, G. 101
D’Sa, C. 89
Dackis, C. 16
Dahlgren, M.K. 103
Dailey, T. 72
Dakwar, E. 8
Daley, D. 72
Dallery, J. 51
Dart, R. 59, 93
Das-Douglass, M. 106
Daughtery, D.E. 7
Daughters, S.B. 71, 88, 106
Daoulouede, J. 13, 57, 59, 79
Daunais, J.B. 82
Davey, J. 11
Davis, C.M. 7
Davis, K. 19, 24
Davis, M.P. 100
Daw, R. 100
Daw, S. 100
De Boni, R. 11
De La Garza, II, R. 15, 23, 80, 84, 89, 92
de la Torre, R. 77, 81, 86
de Wit, H. 16, 89, 99
Deadwyler, S. 96
Dean, R.L. 98
Deaver, D.R. 98
DeBoni, R. 11, 70
Dechant, G. 82
DeFeliceantonio, A. 103
DeGirolamo, G. 92
DiGirolamo, A. 70
Dillon, P. 91, 94
Dineley, K.T. 83
Dinh, A. 76
Diniz, B. 70
DiPietro, J.A. 53
Divine, L. 89
Dixon, L.B. 49
Dodrill, C. 60
Domingo-Salvany, A. 70
Donlin, W. 93
Donny, E. 98, 99
Donovick, R. 20
Dooley, C.T. 24
Douaihy, A. 72, 106
Dow-Edwards, D. 53, 61, 81
Doye, S.E. 89
Draus, P.J. 21
Druid, H. 17
Du, J. 57
Duan, Y. 4
Ducat, E. 104
Duffin-Lutgen, S.M. 89
Dugosh, K.L. 16, 50
Duke, A.N. 50
Duncan, C. 20
Duncan, C.C. 99
Dunlap, E. 90
Dunn, K.E. 5, 57, 88, 93, 95
Dunne, E. 12
Duque, L. 17
Durbin, J. 17
Durif, F. 18

3.CPDD10.AuthIndex.v6-3 5/14/10 1:53 PM Page 112
AUTHOR INDEX

Durkin, S.J. 56
Duvall, J.L. 75
Dvorkin, E. 101
Dvoryak, S. 58
Dwoskin, L.P. 98
Dykhes, S.G. 18
Dykstra, L.A. 5, 7, 56, 62, 84
Ebrahimzadeh, P. 96
Egan, J. 75
Egan, J.E. 20
Ehrich, E. 79
Ehringer, M.A. 104
Ehrman, R.N. 4, 55, 96, 97
Eiroa, F. 57
Eisenstein, T.K. 56, 84
Eitan, S. 84
Ekhtiari, H. 4, 93
El Marroun, H. 24
El Rawas, R. 82
Elam, R. 106
Elkashef, A. 74, 80
Elkins, K. 73
Elko, A. 53
Ellgren, M. 80
Elkens, C. 19
ElSohly, M. 19
Emeson, R.B. 83
Emurian, C.E. 80
Engelhardt, B. 68
Engels Dibble, A. 8
English, J.S. 51
Enman, N. 61
Entenman, S. 19
Epstein, D.H. 69, 79
Epstein, M. 72, 94
Erez, A. 48
Erickson, S. 106
Ernst, T. 54, 55, 96
Ertischek, M. 94
Ettenberg, A. 82
Euser, A.S. 79, 103
Evans, B.E. 103
Evans, E. 88, 91
Evans, R.J. 9, 88
Evans, S.M. 90, 99
Evatt, D.P. 80
Everhart, T. 77
Everly, J.J. 93
Evins, A.E. 98
Eyerman, D.J. 98
Ezeabogu, I. 21
Fabiano, J. 51
Fabianski, R. 4, 97
Fahey, J. 58, 95
Fahnhorst, T. 22
Fairman, B. 55
Faix, C. 51
Falck, R. 91
Faller, S. 70
Fan, J. 50, 105
Fang, L.J. 49
Fang, N. 73
Fanous, S. 3
Fant, R. 14, 15
Farley, C.M. 81
Farnum, S.O. 58
Farre, M. 77, 81
Farrell-Moore, D. 78
Farrugia, P. 90
Fatsēas, M. 12, 13, 78, 79
Fava, M. 98
Fazzino, T.L. 59, 88
Fearr, S. 55
Feaster, D. 106
Feger, U. 96
Fein, G. 54
Feltenstein, M.W. 101
Feltner, D. 65, 79
Fenton, M. 8, 72
Ferigolo, M. 70
Fernandez-Artamendi, S. 16
Fernandez-Hermida, J. 16
Ferreira, E. 88
Ferrer-Garcia, M. 107
Ferisi, J. 80
Festinger, D.S. 16, 25, 50
Fiellin, D.A. 20, 59, 64, 74, 75, 76, 93
Fiestas, F.A. 13
Fife, J. 17
Finch, A.J. 25
Fingerhood, M. 11, 93
Finigan, M. 105
Finkelstein, R. 75
Fintzy, R.T. 23
Fischer, G. 24, 26
Fishbein, D. 13
Fitterling, K.D. 23
Fitzgerald, A. 78
Fitzgerald, J. 72, 94
Flaherty, M.T. 5
Flower, E.K. 3, 81, 86, 107
Floyd, L.J. 17, 91, 95
Flynn, M.C. 52
Foley, K. 100
Foltin, R.W. 56, 63, 67, 80
Fong, C. 95
Fonseca, F. 70
Forcehimes, A.A. 78, 100
Ford, J.H. 11
Foresti, K. 95
Forget, B. 98
Forman, R. 78, 79
Fornash, A. 4, 96, 97
Forster, M.J. 19
Forsythe, S.R. 13
Foscue, E.P. 103
Foster, J.C. 105
Fournier, F. 11
Fournier, J. 11, 56, 108
Fox, H. 7
Fox, H.C. 89
Fox, R.G. 82, 83
France, C.P. 8, 17, 101
Francis, W. 20, 51
Franck, J. 99
Franken, I.H. 3, 51, 79, 93, 97, 103
Franklin, T.R. 4, 23, 96, 97
Frederick, B. 98
Freeman, J. 11
Freeman, K. 102
Freeman, R. 58, 105
Friedman, C. 53
Friedman, S. 48
Friedmann, P.D. 48, 49, 106
Frisman, L. 105
Fritz, M. 82
<table>
<thead>
<tr>
<th>Author</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Froger-Colleaux, C.</td>
<td>84</td>
</tr>
<tr>
<td>Froimowitz, M.</td>
<td>77</td>
</tr>
<tr>
<td>Fruth, N.M.</td>
<td>99</td>
</tr>
<tr>
<td>Fuchs, R.A.</td>
<td>68, 82</td>
</tr>
<tr>
<td>Fuller, C.M.</td>
<td>12, 93, 96</td>
</tr>
<tr>
<td>Fuller, M.A.</td>
<td>15</td>
</tr>
<tr>
<td>Fumagalli, G.</td>
<td>18</td>
</tr>
<tr>
<td>Funk, R.R.</td>
<td>49, 107</td>
</tr>
<tr>
<td>Furr-Holden, C.M.</td>
<td>13, 70</td>
</tr>
<tr>
<td>Fuste, G.</td>
<td>57</td>
</tr>
<tr>
<td>Gabbay, F.</td>
<td>99</td>
</tr>
<tr>
<td>Gabriele, A.</td>
<td>17</td>
</tr>
<tr>
<td>Gaebel, W.</td>
<td>10</td>
</tr>
<tr>
<td>Galea, S.</td>
<td>8</td>
</tr>
<tr>
<td>Galindo, J.</td>
<td>13</td>
</tr>
<tr>
<td>Gallo, D.A.</td>
<td>99</td>
</tr>
<tr>
<td>Gallop, R.</td>
<td>78</td>
</tr>
<tr>
<td>Galloway, G.P.</td>
<td>3, 77, 81, 86, 107</td>
</tr>
<tr>
<td>Gandhi, N.H.</td>
<td>24, 74, 76, 86</td>
</tr>
<tr>
<td>Ganjgahi, H.</td>
<td>4</td>
</tr>
<tr>
<td>Garcia, F.</td>
<td>4</td>
</tr>
<tr>
<td>Garcia-Fernandez, G.</td>
<td>16</td>
</tr>
<tr>
<td>Garcia-Lecumberri, C.</td>
<td>7</td>
</tr>
<tr>
<td>Garcia-Rodriguez, O.</td>
<td>16, 107</td>
</tr>
<tr>
<td>Garcia-Vázquez, V.</td>
<td>7</td>
</tr>
<tr>
<td>Gardner, E.</td>
<td>69</td>
</tr>
<tr>
<td>Gardner, E.L.</td>
<td>62, 77</td>
</tr>
<tr>
<td>Garland, S.</td>
<td>52</td>
</tr>
<tr>
<td>Garnier-Dykstra, L.M.</td>
<td>9</td>
</tr>
<tr>
<td>Garrett, M.</td>
<td>99</td>
</tr>
<tr>
<td>Garrison, K.J.</td>
<td>86</td>
</tr>
<tr>
<td>Gastfriend, D.R.</td>
<td>6, 64</td>
</tr>
<tr>
<td>Gatch, M.B.</td>
<td>19</td>
</tr>
<tr>
<td>Gaydos, C.</td>
<td>17</td>
</tr>
<tr>
<td>Geier, C.F.</td>
<td>84</td>
</tr>
<tr>
<td>Geier, T.</td>
<td>8</td>
</tr>
<tr>
<td>Gelberg, L.</td>
<td>57</td>
</tr>
<tr>
<td>Geller, E.B.</td>
<td>84</td>
</tr>
<tr>
<td>Gempton, S.</td>
<td>97</td>
</tr>
<tr>
<td>Geniaux, H.</td>
<td>88</td>
</tr>
<tr>
<td>Gentry, W.B.</td>
<td>3</td>
</tr>
<tr>
<td>George, D.</td>
<td>20</td>
</tr>
<tr>
<td>George, M.S.</td>
<td>98</td>
</tr>
<tr>
<td>Georgescu, F.</td>
<td>14</td>
</tr>
<tr>
<td>Gerbaud, C.</td>
<td>58</td>
</tr>
<tr>
<td>Gerbaud, L.</td>
<td>91</td>
</tr>
<tr>
<td>Gerbautz, B.</td>
<td>21</td>
</tr>
<tr>
<td>Gerra, G.</td>
<td>21</td>
</tr>
<tr>
<td>Gheorghe, F.</td>
<td>14</td>
</tr>
<tr>
<td>Ghitza, U.E.</td>
<td>20</td>
</tr>
<tr>
<td>Ghozland, S.G.</td>
<td>19</td>
</tr>
<tr>
<td>Giarola, A.S.</td>
<td>18</td>
</tr>
<tr>
<td>Gilchrist, G.</td>
<td>70</td>
</tr>
<tr>
<td>Gill, K.E.</td>
<td>82, 96</td>
</tr>
<tr>
<td>Gillis, T.</td>
<td>82</td>
</tr>
<tr>
<td>Gilmour, B.P.</td>
<td>17</td>
</tr>
<tr>
<td>Gilson, A.</td>
<td>94</td>
</tr>
<tr>
<td>Giorgi, R.</td>
<td>57</td>
</tr>
<tr>
<td>Gipsone, C.</td>
<td>85</td>
</tr>
<tr>
<td>Girling, E.</td>
<td>93</td>
</tr>
<tr>
<td>Gitisetan, S.</td>
<td>99</td>
</tr>
<tr>
<td>Glaser, P.E.</td>
<td>80, 81</td>
</tr>
<tr>
<td>Glasner-Ewards, S.</td>
<td>71</td>
</tr>
<tr>
<td>Glowacz, S.</td>
<td>103</td>
</tr>
<tr>
<td>Godley, S.H.</td>
<td>107</td>
</tr>
<tr>
<td>Goeders, N.E.</td>
<td>81, 100</td>
</tr>
<tr>
<td>Goldman, M.</td>
<td>4, 23, 55, 97</td>
</tr>
<tr>
<td>Goldweber, A.E.</td>
<td>9, 88</td>
</tr>
<tr>
<td>Golub, S.A.</td>
<td>69, 75, 81</td>
</tr>
<tr>
<td>Gomes, C.</td>
<td>88</td>
</tr>
<tr>
<td>Gomez, J.</td>
<td>78</td>
</tr>
<tr>
<td>Gonsai, K.</td>
<td>92</td>
</tr>
<tr>
<td>Gonzalez, R.</td>
<td>54, 55, 100</td>
</tr>
<tr>
<td>Gonzalez, G.</td>
<td>51, 71, 92</td>
</tr>
<tr>
<td>Gonzalez, Y.</td>
<td>51</td>
</tr>
<tr>
<td>Goodell, V.</td>
<td>92</td>
</tr>
<tr>
<td>Gooden, L.</td>
<td>106</td>
</tr>
<tr>
<td>Goodwin, A.K.</td>
<td>81</td>
</tr>
<tr>
<td>Gorbach, P.M.</td>
<td>76</td>
</tr>
<tr>
<td>Gorden, G.</td>
<td>53</td>
</tr>
<tr>
<td>Gordon, E.</td>
<td>82</td>
</tr>
<tr>
<td>Gordon, M.</td>
<td>86</td>
</tr>
<tr>
<td>Gorelick, D.A.</td>
<td>49</td>
</tr>
<tr>
<td>Gorka, S.M.</td>
<td>88, 106</td>
</tr>
<tr>
<td>Gorodetzky, C.</td>
<td>63, 65, 81</td>
</tr>
<tr>
<td>Gottlieb, J.</td>
<td>51</td>
</tr>
<tr>
<td>Gourarier, L.</td>
<td>53</td>
</tr>
<tr>
<td>Gourevitch, M.</td>
<td>75</td>
</tr>
<tr>
<td>Grabinski, M.</td>
<td>55</td>
</tr>
<tr>
<td>Grabowski, J.</td>
<td>60, 77</td>
</tr>
<tr>
<td>Grady, J.</td>
<td>89</td>
</tr>
<tr>
<td>Graham, C.</td>
<td>76</td>
</tr>
<tr>
<td>Graham, J.A.</td>
<td>8</td>
</tr>
<tr>
<td>Grant, A.</td>
<td>73</td>
</tr>
<tr>
<td>Grant, K.A.</td>
<td>7</td>
</tr>
<tr>
<td>Grasing, K.</td>
<td>18</td>
</tr>
<tr>
<td>Graves, M.</td>
<td>97</td>
</tr>
<tr>
<td>Graves, S.M.</td>
<td>62</td>
</tr>
<tr>
<td>Gray, K.M.</td>
<td>51</td>
</tr>
<tr>
<td>Gray, K.M.</td>
<td>23</td>
</tr>
<tr>
<td>Greaves-Lord, K.</td>
<td>103</td>
</tr>
<tr>
<td>Green, C.</td>
<td>50, 60</td>
</tr>
<tr>
<td>Green, M.R.</td>
<td>66</td>
</tr>
<tr>
<td>Green, T.C.</td>
<td>49, 94</td>
</tr>
<tr>
<td>Greenfield, S.F.</td>
<td>86</td>
</tr>
<tr>
<td>Greenwald, M.</td>
<td>2, 19, 21, 65</td>
</tr>
<tr>
<td>Greenwald, M.K.</td>
<td>21, 63, 104</td>
</tr>
<tr>
<td>Greenwell, L.</td>
<td>100</td>
</tr>
<tr>
<td>Greer, A.</td>
<td>90</td>
</tr>
<tr>
<td>Grela, C.</td>
<td>105</td>
</tr>
<tr>
<td>Grier, N.</td>
<td>107</td>
</tr>
<tr>
<td>Griffin, B.</td>
<td>22</td>
</tr>
<tr>
<td>Griffith, R.R.</td>
<td>10, 19, 50, 80</td>
</tr>
<tr>
<td>Grossman, L.E.</td>
<td>10</td>
</tr>
<tr>
<td>Gruber, S.A.</td>
<td>103</td>
</tr>
<tr>
<td>Gruber, V.A.</td>
<td>75</td>
</tr>
<tr>
<td>Grunwald, I.</td>
<td>73</td>
</tr>
<tr>
<td>Gryczynski, J.</td>
<td>86</td>
</tr>
<tr>
<td>Guenthner, G.</td>
<td>23</td>
</tr>
<tr>
<td>Guentzel, H.L.</td>
<td>76</td>
</tr>
<tr>
<td>Gueorguieva, R.</td>
<td>77</td>
</tr>
<tr>
<td>Guerin, G.F.</td>
<td>81</td>
</tr>
<tr>
<td>Guevara, M.</td>
<td>97</td>
</tr>
<tr>
<td>Guillaumot, M.</td>
<td>11, 56, 108</td>
</tr>
<tr>
<td>Guillin, J.</td>
<td>107</td>
</tr>
<tr>
<td>Guise, J.B.</td>
<td>3</td>
</tr>
<tr>
<td>Gunderson, E.W.</td>
<td>59, 80</td>
</tr>
<tr>
<td>Gustafson, D.</td>
<td>11</td>
</tr>
<tr>
<td>Gutierrez-Maldonado, J.</td>
<td>107</td>
</tr>
<tr>
<td>Guydish, J.</td>
<td>51, 60</td>
</tr>
<tr>
<td>Guzman, L.</td>
<td>58</td>
</tr>
<tr>
<td>Haddox, J.D.</td>
<td>72, 94</td>
</tr>
<tr>
<td>Häggkvist, J.</td>
<td>99</td>
</tr>
<tr>
<td>Haile, C.N.</td>
<td>15, 23, 80</td>
</tr>
<tr>
<td>Hakansson, A.</td>
<td>48</td>
</tr>
<tr>
<td>Hakun, J.</td>
<td>55</td>
</tr>
<tr>
<td>Hale, G.J.</td>
<td>48, 49, 86</td>
</tr>
<tr>
<td>Hall, M.T.</td>
<td>10</td>
</tr>
</tbody>
</table>
AUTHOR INDEX

Halldin, C. 99
Haller, D.L. 76, 78, 96
Hallyburton, M. 51
Hamidovic, A. 89
Hamilton, A. 100
Hammar, L. 91
Hammell, J. 17
Hammer, Jr, R. 3
Hamon, S.C. 74, 104
Hampson, R. 96
Haney, M. 56, 63, 90, 101
Haning, W . 74
Hankins, G.D. 77
Hanlon, C.A. 6, 7, 96
Hansen, H. 93
Hanson, K.L. 72
Hao, X. 4
Hao, Y . 82
Harakeh, Z. 73
Haramburu, F . 88
Harocopos, A. 23
Harp, K.L. 49, 75
Harper, T.A. 15
Harrington, C.R. 97
Harrington, M. 49
Harris, A.C. 98
Harris, C.W . 3
Harris, E. 10
Harris, K. 22
Harris, K.S. 14
Harris, T.S. 4, 97
Harrod, S. 54
Hart, C.L. 4, 5, 56, 80
Hartje, J.A. 11, 21, 53
Hartwell, E. 85, 95
Hartwell, K. 98
Hartwell, K.J. 51
Hartzell, R. 56
Hasan, K.M. 96
Hasani Abharian, P. 4, 93
Haseeb, N. 103
Hasin, D. 8, 12, 51, 64, 95
Hasson, A.L. 20, 57, 58, 59
Hatch-Maillette, M.A. 91
Hatzenbuehler, M. 12
Hatzigeorgiou, M. 82
Havens, J.R. 75, 89, 108
Hawkins, R.Y . 23, 80, 89
Hayes, L. 16
Hayes, M.J. 53
Haynes, L. 21, 71, 106
Hays, L.R. 15, 81
Hazar, R. 4, 23, 97
Hazel, J. 52
Hazen, A. 9
Hazen, R. 18
He, S. 18
Heal, D.J. 15, 18
Healey, K. 99
Heath, A.C. 90
Heberlein, U. 63
Hedden, S.L. 22, 48
Heil, S.H. 24, 26, 52, 69, 95
Heimer, R. 76
Heinzerling, K.G. 23, 99
Heller, N. 53
Hemauer, S.J. 77
Hemberg, J. 106
Hemby, S.E. 107
Henderson, G. 92
Hendrickson, M. 10
Henningfield, J.E. 14, 15, 61
Henry, P.K. 92
Herbeck, D. 69, 100
Herbert, M.S. 81
Herin, D.V. 60, 77
Herman, D.M. 102
Hernandez, C.M. 83
Herran, E. 57, 59
Herrmann, E. 69
Hersh, D. 74
Herz, L. 51
Hester, R. 80
Hickle, T. 62
Hickman, M. 92
Higgins, S.T. 51, 52, 57, 69, 88, 95
Higley, A.E. 92
Higuera-Matas, A. 7
Hij, A. 11, 56, 108
Hilde, A. 50
Hillhouse, M.P. 20, 57, 58, 59, 71, 79, 95, 100
Hills, D. 99
Ho, A. 7, 73, 83, 105
Hofford, R.S. 84
Hofman, A. 24
Hofstein, Y. 72, 107
Holbrook, A. 53
Hole, A.V. 4, 55, 96, 97
Holmes, A.J. 98
Holmes, B.W. 21, 71
Holstein, G.J. 15
Homer, J. 94
Homish, G.G. 51, 92
Homish, G.H. 107
Hong, H. 9
Hood, L.E. 68, 99
Hopwood, S. 90
Horn, L.A. 81
Horton, A.M. 14
Houck, J.M. 100
Houghten, R.A. 24
House, K. 23
Hovenga, B. 62
Howard, J.L. 102
Howard, M.O. 10
Howard, S.L. 106
Howell, L.L. 77, 83, 92
Howlett, A.C. 17
Hser, Y.I. 53, 59, 88, 91
Hsu, J. 13
Hu, L. 60
Huang, D. 53, 91
Huang, W. 74
Huerta Rivas, A. 54
Hughes, B. 54
Huizink, A.C. 24, 73, 79, 85, 103
Hulbert, A. 17, 48, 58, 108
Hull, L. 91
Hunt, N. 49
Hursch, S.R. 14
Husar, K. 52
Hussain, S. 88
Hyma, B.A. 17
Iacono, W.G. 8
Ialongo, N. 13
Ianos-Rancovici, R. 14
Ibanez de Benito, S. 21
Ignacio, R. 8
### AUTHOR INDEX

<table>
<thead>
<tr>
<th>Author</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Iguchi, M.Y.</td>
<td>5, 67, 76</td>
</tr>
<tr>
<td>Iijima, M.</td>
<td>53</td>
</tr>
<tr>
<td>Ilgen, M.A.</td>
<td>8, 68</td>
</tr>
<tr>
<td>Illeperuma, A.</td>
<td>79</td>
</tr>
<tr>
<td>Illes, G.</td>
<td>91</td>
</tr>
<tr>
<td>Imai, S.</td>
<td>74, 83</td>
</tr>
<tr>
<td>Ingersoll, K.S.</td>
<td>11, 79, 96</td>
</tr>
<tr>
<td>Inzhakova, G.</td>
<td>96</td>
</tr>
<tr>
<td>Irvine, R.J.</td>
<td>87</td>
</tr>
<tr>
<td>Irwin, K.S.</td>
<td>93</td>
</tr>
<tr>
<td>Islam, L.Z.</td>
<td>85</td>
</tr>
<tr>
<td>Iturriaga, E.</td>
<td>74, 80</td>
</tr>
<tr>
<td>Itzhak, Y.</td>
<td>69, 74</td>
</tr>
<tr>
<td>Ives, M.L.</td>
<td>72</td>
</tr>
<tr>
<td>Izenwasser, S.</td>
<td>22, 53, 60, 102</td>
</tr>
<tr>
<td>Jack, B.W.</td>
<td>13</td>
</tr>
<tr>
<td>Jackson Bloom, J.</td>
<td>23</td>
</tr>
<tr>
<td>Jackson, A.</td>
<td>53</td>
</tr>
<tr>
<td>Jackson, D.O.</td>
<td>48, 49, 86</td>
</tr>
<tr>
<td>Jackson, L.C.</td>
<td>16, 85</td>
</tr>
<tr>
<td>Jacobe, H.T.</td>
<td>97</td>
</tr>
<tr>
<td>Jacobs, P.</td>
<td>104</td>
</tr>
<tr>
<td>Jacome, M.</td>
<td>66</td>
</tr>
<tr>
<td>Jaddoe, V.</td>
<td>24</td>
</tr>
<tr>
<td>Jaffè, A.</td>
<td>50, 99</td>
</tr>
<tr>
<td>Jaffè, J.H.</td>
<td>60</td>
</tr>
<tr>
<td>Jan, R.K.</td>
<td>54</td>
</tr>
<tr>
<td>Janes, A.C.</td>
<td>98</td>
</tr>
<tr>
<td>Jang, M.</td>
<td>3</td>
</tr>
<tr>
<td>Jansson, L.M.</td>
<td>53</td>
</tr>
<tr>
<td>Jasinski, D.</td>
<td>97</td>
</tr>
<tr>
<td>Jatlow, P.</td>
<td>15</td>
</tr>
<tr>
<td>Jayaram-Lindtröm, N.</td>
<td>99</td>
</tr>
<tr>
<td>Jayroe, J.B.</td>
<td>15</td>
</tr>
<tr>
<td>Jenab, S.</td>
<td>18, 89</td>
</tr>
<tr>
<td>Jenkins, J.</td>
<td>95</td>
</tr>
<tr>
<td>Jenner, L.L.</td>
<td>20</td>
</tr>
<tr>
<td>Jens, W.</td>
<td>55</td>
</tr>
<tr>
<td>Jensen, E.</td>
<td>82</td>
</tr>
<tr>
<td>Jentsch, J.D.</td>
<td>6, 99</td>
</tr>
<tr>
<td>Jiang, H.</td>
<td>59</td>
</tr>
<tr>
<td>Jiang, Y.</td>
<td>97</td>
</tr>
<tr>
<td>Jobes, M.L.</td>
<td>79</td>
</tr>
<tr>
<td>Johanson, C.E.</td>
<td>14, 63, 80</td>
</tr>
<tr>
<td>Johansson, B.</td>
<td>64</td>
</tr>
<tr>
<td>Johnson, B.A.</td>
<td>74, 80</td>
</tr>
<tr>
<td>Johnson, C.</td>
<td>52</td>
</tr>
<tr>
<td>Johnson, D.</td>
<td>21</td>
</tr>
<tr>
<td>Johnson, E.O.</td>
<td>4, 13, 69</td>
</tr>
<tr>
<td>Johnson, J.E.</td>
<td>48</td>
</tr>
<tr>
<td>Johnson, K.</td>
<td>98</td>
</tr>
<tr>
<td>Johnson, M.W.</td>
<td>19, 75</td>
</tr>
<tr>
<td>Johnston, B.</td>
<td>95</td>
</tr>
<tr>
<td>Jones, B.A.</td>
<td>16, 85, 93</td>
</tr>
<tr>
<td>Jones, H.E.</td>
<td>24, 26, 53</td>
</tr>
<tr>
<td>Jones, J.D.</td>
<td>101</td>
</tr>
<tr>
<td>Jones, K.</td>
<td>93</td>
</tr>
<tr>
<td>Jones, S.C.</td>
<td>70</td>
</tr>
<tr>
<td>Jones-Whaley, S.</td>
<td>48, 86</td>
</tr>
<tr>
<td>Jordan, A.E.</td>
<td>57, 58</td>
</tr>
<tr>
<td>Joseph, J.E.</td>
<td>80, 97</td>
</tr>
<tr>
<td>Juliano, L.M.</td>
<td>80</td>
</tr>
<tr>
<td>Jun, M.</td>
<td>8</td>
</tr>
<tr>
<td>Jungman, J.</td>
<td>53</td>
</tr>
<tr>
<td>Justice, A.</td>
<td>64</td>
</tr>
<tr>
<td>Jutkiewicz, E.M.</td>
<td>98</td>
</tr>
<tr>
<td>Kahler, C.W.</td>
<td>62, 104</td>
</tr>
<tr>
<td>Kahn, R.</td>
<td>74, 80</td>
</tr>
<tr>
<td>Kalayasiri, R.</td>
<td>77</td>
</tr>
<tr>
<td>Kallman, M.</td>
<td>67</td>
</tr>
<tr>
<td>Kallman, D.</td>
<td>51, 71</td>
</tr>
<tr>
<td>Kaltenbach, K.</td>
<td>24, 26, 53</td>
</tr>
<tr>
<td>Kammer, Y.</td>
<td>107</td>
</tr>
<tr>
<td>Kaminski, B.J.</td>
<td>14, 81</td>
</tr>
<tr>
<td>Kampman, K.M.</td>
<td>10, 16, 55</td>
</tr>
<tr>
<td>Kang, J.M.</td>
<td>56</td>
</tr>
<tr>
<td>Kangarlu, A.</td>
<td>4</td>
</tr>
<tr>
<td>Kantak, K.M.</td>
<td>68, 83</td>
</tr>
<tr>
<td>Kaplan, G.</td>
<td>23</td>
</tr>
<tr>
<td>Karageorgiou, J.</td>
<td>87</td>
</tr>
<tr>
<td>Karch, S.B.</td>
<td>17</td>
</tr>
<tr>
<td>Karjane, N.</td>
<td>95</td>
</tr>
<tr>
<td>Kaskutas, L.</td>
<td>69</td>
</tr>
<tr>
<td>Kaszycki, S.J.</td>
<td>68</td>
</tr>
<tr>
<td>Katz, C.</td>
<td>49</td>
</tr>
<tr>
<td>Katz, E.C.</td>
<td>58, 93, 94</td>
</tr>
<tr>
<td>Kaufman, M.J.</td>
<td>82, 98</td>
</tr>
<tr>
<td>Keilp, J.G.</td>
<td>63</td>
</tr>
<tr>
<td>Kellar, K.</td>
<td>2</td>
</tr>
<tr>
<td>Kelley, C.J.</td>
<td>77</td>
</tr>
<tr>
<td>Kelley, J.B.</td>
<td>74</td>
</tr>
<tr>
<td>Kelly, B.C.</td>
<td>81</td>
</tr>
<tr>
<td>Kelly, S.M.</td>
<td>60, 71, 76, 86</td>
</tr>
<tr>
<td>Kelly, T.H.</td>
<td>10, 23, 56, 80, 97</td>
</tr>
<tr>
<td>Kendrick, A.</td>
<td>92</td>
</tr>
<tr>
<td>Kennedy, M.</td>
<td>52</td>
</tr>
<tr>
<td>Kenny, P.</td>
<td>2</td>
</tr>
<tr>
<td>Kerloc’h, C.</td>
<td>57</td>
</tr>
<tr>
<td>Kershul, V.</td>
<td>49</td>
</tr>
<tr>
<td>Kerstetter, K.A.</td>
<td>89</td>
</tr>
<tr>
<td>Kertesz, S.</td>
<td>12, 16, 71</td>
</tr>
<tr>
<td>Kerwin, M.E.</td>
<td>26</td>
</tr>
<tr>
<td>Kessler, E.</td>
<td>77</td>
</tr>
<tr>
<td>Kessler, F.H.</td>
<td>70, 88</td>
</tr>
<tr>
<td>Kettavong, M.</td>
<td>102</td>
</tr>
<tr>
<td>Keyes, K.</td>
<td>8, 12</td>
</tr>
<tr>
<td>Keyes, K.M.</td>
<td>72</td>
</tr>
<tr>
<td>Keyler, D.E.</td>
<td>98</td>
</tr>
<tr>
<td>Keyser-Marcus, L.A.</td>
<td>8, 52, 70, 85, 91</td>
</tr>
<tr>
<td>Khan, M.</td>
<td>48</td>
</tr>
<tr>
<td>Khodtavkar, P.</td>
<td>76, 86</td>
</tr>
<tr>
<td>Khodneva, Y.</td>
<td>12, 71</td>
</tr>
<tr>
<td>Kidod, M.</td>
<td>71</td>
</tr>
<tr>
<td>Kiddorf, M.S.</td>
<td>12, 59</td>
</tr>
<tr>
<td>Kierksick, R.</td>
<td>20</td>
</tr>
<tr>
<td>Kim, H.</td>
<td>8</td>
</tr>
<tr>
<td>Kim, S.</td>
<td>49</td>
</tr>
<tr>
<td>Kimbro, J.</td>
<td>20</td>
</tr>
<tr>
<td>Kimmel, H.L.</td>
<td>92</td>
</tr>
<tr>
<td>King, A.</td>
<td>89</td>
</tr>
<tr>
<td>King, C.</td>
<td>89</td>
</tr>
<tr>
<td>King, G.R.</td>
<td>54, 55</td>
</tr>
<tr>
<td>King, J.</td>
<td>55</td>
</tr>
<tr>
<td>King, V.L.</td>
<td>12, 59, 71</td>
</tr>
<tr>
<td>Kinlock, T.W.</td>
<td>86</td>
</tr>
<tr>
<td>Kippin, T.E.</td>
<td>54, 89</td>
</tr>
<tr>
<td>Kirby, K.C.</td>
<td>16, 25</td>
</tr>
<tr>
<td>Kirisci, L.</td>
<td>9, 55</td>
</tr>
<tr>
<td>Kirk, I.J.</td>
<td>54, 97</td>
</tr>
<tr>
<td>Kirkpatrick, M.G.</td>
<td>80</td>
</tr>
<tr>
<td>Kjome, K.L.</td>
<td>54, 97</td>
</tr>
<tr>
<td>Klement, S.</td>
<td>82</td>
</tr>
<tr>
<td>Kleykamp, B.A.</td>
<td>2, 3, 10, 92</td>
</tr>
<tr>
<td>Kline, A.</td>
<td>71</td>
</tr>
<tr>
<td>Kluemper, C.</td>
<td>97</td>
</tr>
<tr>
<td>Knapp, B.I.</td>
<td>24</td>
</tr>
<tr>
<td>Knopf, S.</td>
<td>9</td>
</tr>
</tbody>
</table>
# AUTHOR INDEX

Knopik, V. 104
Knudsen, H.K. 58
Ko, M.C. 17
Kober, H. 3, 4
Koch, J.R. 78
Koek, W. 8
Koenig, B. 65
Koerper, L. 7
Koffarnus, M.N. 11
Kofner, A. 22
Kollins, S.H. 51
Kong, A. 89
Kong, G. 9
Konijnenberg, C. 25
Koob, G.F. 86
Kopetz, C. 16
Koro-Ljungberg, M. 86
Korte, J.E. 79
Korthuis, T. 106
Kosinski, A.S. 78
Kosten, T. 54, 61
Koutroulakis, A. 10
Kowalczyk, W.J. 69, 75
Kraenau, E. 13
Kral, A.H. 13, 58, 76, 106
Kramer, L.A. 54, 96, 97
Kranzler, H.R. 64
Krauss, M. 73
Kreek, M.J. 7, 73, 74, 83, 104, 105
Krishnan, R. 53
Krishnan-Sarin, S. 9, 63
Kritz, S.A. 57, 106
Kross, E.F. 4
Kruyer, A. 105
Kubiak, S.P. 50
Kuhn, C.M. 103, 105
Kulaga, A. 51, 78
Kumar, A. 97
Kuper, L.A. 86
Kushmir, T. 12
Kuwabara, H. 97
Kuzumaki, N. 19, 74, 83
Kwok, M. 97
Kydd, R.R. 54, 97
Kyle, T. 106
Labounty, K.R. 23
Lacagnina, M. 3
Lacey, K. 90
Lack, A.K. 96
Lacy, R.T. 54
LaFlair, L.N. 72
Lam, P.K. 52
Landavazo, A. 83
Landes, R.D. 16, 51, 85, 93
Landovitz, R.J. 96
Lane, P.S. 48, 86
Lane, S.D. 15, 54
Langlois, C. 20
Langlois, E. 78
Langston, T. 17
Lanier, R.K. 13, 50
Lankenau, S. 23, 106
Larance, B. 94
Larkby, C. 90
LaRowe, S.D. 99
Lasseter, H.C. 68, 82
Latimer, W.W. 9, 12, 17, 22, 48, 58, 76, 88, 91, 95, 108
Lattin, C. 12
Lattal, M. 63
Laudet, A.B. 8, 79
Laura, B. 1
Lavelle, A. 71, 106
Lavignasse, P. 57
Lawson, A. 91
Lawson, K. 85, 95
Le Foll, B. 98
Leaf, P.J. 13, 70
Leahy, P. 19
Leece, L. 22
Ledgerwood, D.M. 52
Lee, A. 16
Lee, D.C. 56
Lee, D.Y. 10
Lee, E.C. 13
Lee, G.P. 90
Lee, L.K. 72, 94
Lee, N.K. 20, 80, 100
Leech, S.L. 90
Lees, R. 92
Leff, M. 60
Legg, B.H. 96
Leimberger, J. 22, 71
Lejeune, C. 53
Lejuez, C.W. 16, 20, 51, 71, 85, 88
Lelutiu-Weinberger, C. 75
LeMatty, T. 98
Lenoir, M. 102
Leonard, J.R. 20, 88, 106
Leri, F. 7
Lerman, C. 1
LeSage, M.G. 18, 98
Leukefeld, C.G. 11, 49, 75, 78, 89, 105, 108
Leung, K.S. 13, 71
Leventhal, A.M. 51
Levin, F.R. 8, 15, 56, 59, 63, 80
Levin, M. 98, 99
Levine, R. 57
Levit, S. 60
Levran, O. 83, 104
Levy, M. 51
Levy-Cooperman, N. 79
Lewis, D. 78
Li, J. 59, 69, 77, 101, 102
Li, L. 77
Li, M.D. 74, 80
Li, S. 24
Li, S.H. 74, 80
Li, X. 69, 77
Li, Y. 4, 23, 55, 96
Licata, S.C. 10
Lile, J.A. 10, 15, 23, 56, 80, 81
Lin, C.H. 13
Lin, H. 105
Lin, J.C. 54
Lindbæk, M. 59
Lindholm, S. 99
Lindsay, J.A. 60
Lindsey, K. 64
Ling, W. 20, 57, 58, 59, 79, 95, 99, 100, 104
Lingford-Hughes, A. 92
Lintzeris, N. 94
Linzy, S. 104
Lioy, K. 94
Lipshtutz, S.E. 25
Littel, M. 51
<table>
<thead>
<tr>
<th>Author Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liu Chen, L. 84</td>
</tr>
<tr>
<td>Liu, D. 20</td>
</tr>
<tr>
<td>Liu, H. 74</td>
</tr>
<tr>
<td>Liu, P. 96</td>
</tr>
<tr>
<td>Liu, S. 15, 74, 82, 86, 97</td>
</tr>
<tr>
<td>Liu, X. 82</td>
</tr>
<tr>
<td>Liu, Y. 24</td>
</tr>
<tr>
<td>Liu-Chen, L.Y. 102</td>
</tr>
<tr>
<td>Llaudó, J. 57</td>
</tr>
<tr>
<td>Llorca, P. 18</td>
</tr>
<tr>
<td>Llosa, T. 14</td>
</tr>
<tr>
<td>Locatelli, A.E. 55</td>
</tr>
<tr>
<td>Locatelli, D.P. 9, 52</td>
</tr>
<tr>
<td>Lofwall, M.R. 2, 59</td>
</tr>
<tr>
<td>Lokireddy, M. 80</td>
</tr>
<tr>
<td>London, E.D. 23</td>
</tr>
<tr>
<td>Londono, D. 74</td>
</tr>
<tr>
<td>Long, E. 67, 84</td>
</tr>
<tr>
<td>Long, J. 96</td>
</tr>
<tr>
<td>Lookatch, S.J. 94</td>
</tr>
<tr>
<td>Lopez, A.A. 51</td>
</tr>
<tr>
<td>Lopez, J. 77</td>
</tr>
<tr>
<td>Lopez-Larson, M. 103</td>
</tr>
<tr>
<td>Lópeez-Rubalcava, C. 54</td>
</tr>
<tr>
<td>Lorvick, J. 58</td>
</tr>
<tr>
<td>Losonczy, M. 71</td>
</tr>
<tr>
<td>Lou, X. 74</td>
</tr>
<tr>
<td>Lowen, S. 64</td>
</tr>
<tr>
<td>Lozada, R. 56</td>
</tr>
<tr>
<td>Lozier, E. 51</td>
</tr>
<tr>
<td>Lu, L. 24</td>
</tr>
<tr>
<td>Lubman, D. 73, 100</td>
</tr>
<tr>
<td>Ludwig, D. 25</td>
</tr>
<tr>
<td>Luedtke, R.R. 17, 103</td>
</tr>
<tr>
<td>Luijten, M. 97</td>
</tr>
<tr>
<td>Lukacs, N.W. 17</td>
</tr>
<tr>
<td>Lukas, S.E. 10, 62, 64, 103</td>
</tr>
<tr>
<td>Lum, P.J. 74, 75</td>
</tr>
<tr>
<td>Luna, B. 84</td>
</tr>
<tr>
<td>Lundahl, L.H. 62, 63</td>
</tr>
<tr>
<td>Luo, L. 96</td>
</tr>
<tr>
<td>Lutnick, A. 58</td>
</tr>
<tr>
<td>Lutz, G. 20</td>
</tr>
<tr>
<td>Lynch, F. 50</td>
</tr>
<tr>
<td>Lynch, K. 16</td>
</tr>
<tr>
<td>Lynch, M.E. 52</td>
</tr>
<tr>
<td>Lynch, W.J. 89, 107</td>
</tr>
<tr>
<td>Lynch, W.L. 77</td>
</tr>
<tr>
<td>Lynskoy, M.T. 69</td>
</tr>
<tr>
<td>Ma, J.Z. 74, 80</td>
</tr>
<tr>
<td>Ma, L. 54, 96, 97</td>
</tr>
<tr>
<td>Maan, R. 10</td>
</tr>
<tr>
<td>Mach, R.H. 17</td>
</tr>
<tr>
<td>Mackesy-Amiti, M.E. 75</td>
</tr>
<tr>
<td>MacKillop, J. 85</td>
</tr>
<tr>
<td>MacLean, K. 19</td>
</tr>
<tr>
<td>Maclean, R.R. 10</td>
</tr>
<tr>
<td>Macovsky, L. 94</td>
</tr>
<tr>
<td>MacPherson, L. 20, 51, 85</td>
</tr>
<tr>
<td>MacTutus, C.F. 18</td>
</tr>
<tr>
<td>Madden, L. 58</td>
</tr>
<tr>
<td>Madras, B.K. 61, 101</td>
</tr>
<tr>
<td>Magidson, J. 71, 106</td>
</tr>
<tr>
<td>Magland, J. 97</td>
</tr>
<tr>
<td>Magruder, K. 79</td>
</tr>
<tr>
<td>Magura, S. 48, 95</td>
</tr>
<tr>
<td>Mahoney, J.J. 15, 23, 80, 84, 89</td>
</tr>
<tr>
<td>Maili, L. 74</td>
</tr>
<tr>
<td>Maitre, C. 59</td>
</tr>
<tr>
<td>Majumder, I. 87</td>
</tr>
<tr>
<td>Malison, R.T. 77</td>
</tr>
<tr>
<td>Mallya, G. 64</td>
</tr>
<tr>
<td>Malmlöf, T. 99</td>
</tr>
<tr>
<td>Malson, J. 50</td>
</tr>
<tr>
<td>Malte, C.A. 60</td>
</tr>
<tr>
<td>Mamun, A.A. 100</td>
</tr>
<tr>
<td>Mancha, B.E. 22, 48</td>
</tr>
<tr>
<td>Mancino, M.J. 3, 81, 93</td>
</tr>
<tr>
<td>Mandell, T. 5</td>
</tr>
<tr>
<td>Mander, R. 106</td>
</tr>
<tr>
<td>Mann, R. 13</td>
</tr>
<tr>
<td>Manser, K. 57</td>
</tr>
<tr>
<td>Manser, S. 60</td>
</tr>
<tr>
<td>Mansoor, E. 53</td>
</tr>
<tr>
<td>Manubay, J. 101</td>
</tr>
<tr>
<td>Manuel, S. 93</td>
</tr>
<tr>
<td>Manvich, D.F. 92</td>
</tr>
<tr>
<td>Marc, M. 11, 56, 108</td>
</tr>
<tr>
<td>Marhe, R. 3, 93</td>
</tr>
<tr>
<td>Marinelli-Casey, P. 71</td>
</tr>
<tr>
<td>Mark, T. 64</td>
</tr>
<tr>
<td>Markgraf, C.G. 67</td>
</tr>
<tr>
<td>Marlowe, D.B. 16, 50</td>
</tr>
<tr>
<td>Marmorstein, N.R. 8</td>
</tr>
<tr>
<td>Marroun, H.E. 24</td>
</tr>
<tr>
<td>Marsch, L.A. 72, 107</td>
</tr>
<tr>
<td>Marsh, R. 4</td>
</tr>
<tr>
<td>Martin, C.A. 10, 23, 56, 80</td>
</tr>
<tr>
<td>Martin, J. 20</td>
</tr>
<tr>
<td>Martin, P.R. 24, 26</td>
</tr>
<tr>
<td>Martin, R. 50</td>
</tr>
<tr>
<td>Martin, S. 77</td>
</tr>
<tr>
<td>Martinez, D. 4</td>
</tr>
<tr>
<td>Martinez, P. 11</td>
</tr>
<tr>
<td>Martinez-Luna, N. 57</td>
</tr>
<tr>
<td>Martin-Fardon, R. 68, 82</td>
</tr>
<tr>
<td>Martino, S. 20</td>
</tr>
<tr>
<td>Martins, S.S. 4, 22, 72, 90</td>
</tr>
<tr>
<td>Martin-Santos, R. 70</td>
</tr>
<tr>
<td>Martin-Thormeyer, E.M. 76</td>
</tr>
<tr>
<td>Marusich, J.A. 81</td>
</tr>
<tr>
<td>Mascarenhas, J. 93</td>
</tr>
<tr>
<td>Mash, D.C. 17</td>
</tr>
<tr>
<td>Mashhoon, Y. 10</td>
</tr>
<tr>
<td>Maslo, S. 52</td>
</tr>
<tr>
<td>Mason, B.J. 92</td>
</tr>
<tr>
<td>Mason, M.J. 22</td>
</tr>
<tr>
<td>Masson, C.L. 57, 58</td>
</tr>
<tr>
<td>Matano-Logan, B. 53</td>
</tr>
<tr>
<td>Mateu-Gelabert, P. 57, 58</td>
</tr>
<tr>
<td>Matsushima, Y. 83</td>
</tr>
<tr>
<td>Mattick, R. 100</td>
</tr>
<tr>
<td>Mattson, C. 98</td>
</tr>
<tr>
<td>Mawhinney, J. 74</td>
</tr>
<tr>
<td>Maxwell, J.C. 11</td>
</tr>
<tr>
<td>May, J. 78</td>
</tr>
<tr>
<td>Mayer, C. 53</td>
</tr>
<tr>
<td>Mayes, L.C. 89, 90</td>
</tr>
<tr>
<td>Mayssonave, C. 12</td>
</tr>
<tr>
<td>Mazzarulli, A. 4</td>
</tr>
<tr>
<td>Mc Clernon, J. 4</td>
</tr>
<tr>
<td>McBride, O. 11</td>
</tr>
<tr>
<td>McCabe, S.E. 10, 72, 94</td>
</tr>
<tr>
<td>McCance-Katz, E.F. 15, 20, 75</td>
</tr>
<tr>
<td>McCann, D. 63</td>
</tr>
<tr>
<td>McCann, M. 74</td>
</tr>
<tr>
<td>McCann, U.D. 10, 56</td>
</tr>
<tr>
<td>McCarty, C. 8</td>
</tr>
<tr>
<td>McCarty, D. 11, 50, 72, 94</td>
</tr>
</tbody>
</table>
AUTHOR INDEX

McCaul, M. 97
McCleary, M. 19
McCleron, F.J. 51
McClung, J.C. 83
McClore, B. 78
McClore, E.A. 50
McCoy, C.B. 15, 85
McCullumsmith, C. 17
McGaugh, J. 81
McGeary, J.E. 62, 85, 104
McGinnis, K. 64
McGlade, E.C. 55
McGlinchy, A. 10
McKendrick, K. 20, 49
McKetin, R. 100
McKnight, C. 57, 58
McLaughlin, G. 26
McLaughlin, J.P. 24, 84, 89
McLaughlin, K. 12
McLellan, A. 1
McMahon, L.R. 62, 98
McMorn, S.O. 3
McNaughton, E. 19, 94
McQueen, M. 104
McRae-Clark, A.L. 15, 62, 99
McSherry, F. 80
McSweeney, T. 49
McWhite, C.B. 15
Mead, K. 100
Medoff, D.R. 49
Meier, A. 21
Meissler, J.J. 56
Melin, P. 11, 56, 108
Melinder, A. 25
Mello, N.K. 92
Melnick, G. 49
Melnikov, A. 12
Melo, L. 52, 70
Mendelson, J. 3, 67, 68, 77, 81, 86, 107
Mende-Siedlecki, P. 4
Mendez, I.A. 82, 98
Mennemeyer, S. 16
Mennis, J. 71
Menoyo, E. 77
Merlo, L.J. 50, 91
Mertens, J. 50
Merz, S. 90
Messiah, S.E. 25
Messina, N. 88
Messing, R.O. 10
Metrik, J. 62, 104
Metsch, L.R. 21, 106
Newton, L.R. 55
Meyer, A.C. 98
Meyer, E.M. 86
Meyers, J. 73
Menzich, A. 55
Michalsen, R. 90
Michel, L. 57
Middleton, L.S. 2
Miguéns, M. 7
Mikulich-Gilbertson, S.K. 22
Milam, A.J. 13, 70
Milby, J. 16
Miles, D. 78
Miller, B.W. 105
Miller, G.M. 61, 86
Miller, L.L. 56
Miller, M.D. 96
Miller, N.S. 12
Miller, T.L. 25
Mills, K.L. 90
Min, M. 53
Min, S. 108
Minerly, A.C. 89
Ming, Y. 64
Minhaujuddin, A. 4
Minnes, S. 53
Mintzer, M.Z. 3, 10, 16, 92
Mischel, W. 4
Mitchell, J. 10
Mitchell, M.R. 80, 82
Mitchell, S.G. 60, 71, 76
Mitty, J.A. 74
Mitzelfelt, J.D. 7
Möberg, D. 25
Moeller, F.G. 15, 54, 74, 82, 96, 97
Mohd-Yusof, A. 81
Mokri, A. 93
Monchusie, P.M. 107
Mondragon, A. 100
Montejano, L. 64
Montgomery, L. 78
Monti, P.M. 51, 62, 104
Montoya, G.L. 7
Montoya, I.D. 26
Moody, D.E. 2, 15
Mooney, J. 75
Mooney, L.J. 71
Mooney, M.E. 77
Moore, B.A. 59, 88
Moore, S.K. 72
Moore, T.B. 91
Morabito, M.V. 83
Morales-Manrique, C.C. 52, 73
Moran, L. 18
Morasco, B.J. 68
Moreira, T. 70
Moreno, A. 20
Morgan, D. 7
Morgan, P.T. 77
Morgello, S. 73
Mori, T. 19
Morisano, D. 15
Morral, A. 22
Morris, R. 74
Morrow, C.E. 53
Moser, P. 84
Mosovsky, S. 9
Moulongouet-Cordier, S. 12
Moura, H. 70
Moura, Y.G. 52
Mouri, A. 18
Mueller, E.T. 51
Mulvey, P. 49
Munafo, M.R. 10
Murty, R. 24
Murugan, V. 90
Mustata, C. 77, 81
Myers, A.C. 14
Myrick, H. 98
Nabeshima, T. 18
Nabhan, A.N. 82
Nacache, L. 58
Nader, M.A. 82, 96
Nahas, E. 7
AUTHOR INDEX

Nair, M.N.  24, 76, 86
Nair, M.P.  74
Najman, J.M.  100
Nakahara, K.  83
Nakama, H.  54, 96
Nakazawa, M.  78
Nanda, J.P.  16
Nandi, A.  97
Nandi, V.  12
Nandola, N.  14
Nanovskaya, T.  77
Napier, T.C.  62
Nappo, S.A.  17
Napuri, J.  76
Narasimhan, D.  17
Narayana, P.A.  97
Narita, M.  19, 74, 83
Natividad, L.A.  98
Navarro, H.A.  17
Ndichu, E.W.  72
Neale, A.  15
Negus, S.S.  18, 61
Neisewander, J.L.  3, 17, 63, 68, 86, 99
Neumaier, J.F.  86
Neumeyer, J.L.  24
Newman, J.  92
Newton, T.F.  15, 23, 80, 84, 89
Newville, H.  76, 78
Niazi, K.  21
Nic Dhonnchadha, B.Á.  83
Nich, C.  90
Nickerson, L.D.  62
Nielsen, D.A.  74
Nielsen, D.N.  74
Nielsen, S.  80, 94
Nieto, F.J.  50
Niikura, K.  74, 83
Nikulina, E.  3
Niu, T.  74
Nixon, C.  25
Noble, R.  20
Noda, Y.  18
Nolan, B.C.  17
Nolan, C.  92
Nordström, A.  99
Norton, G.  22
Noto, A.R.  9, 11, 52
Noto, J.  96
Novak, S.P.  13, 69
Nunes, E.V.  8, 15
Nuno, M.  96
Nurnberger, J.I.  69
Nuzzo, P.A.  2
O’Brien, C.P.  4, 6, 23, 55, 64, 96, 97
O’Connor, P.G.  59, 74, 75, 93
O’Dell, L.E.  63, 98
O’Grady, K.E.  9, 58, 60, 71, 73, 76, 86, 93
O’Mahony, B.  77, 81
O’Neill, K.S.  98
O’Shea, A.J.  76
Ochsner, K.N.  4
Ofir, A.Y.  53
Oghabian, M.  4
Ogunabi, A.  106
Oh Min, M.  8
Ojeda, V.D.  56
Oleson, E.B.  17
Olive, M.F.  61
Oliveto, A.  3, 81
Omar, Y.  80
Ompad, D.  96
Ompad, D.C.  5, 12
Ondersma, S.J.  52, 91, 95
Opaley, E.S.  9, 52
Orf, J.  98
Ormel, J.  73, 85
Oser, C.B.  49, 75, 89, 108
Ostos, M.  3
Oswald, L.  97
Ott, J.  74
Ouellet, L.J.  75, 76
Paasche-Orlow, M.K.  13
Pablo, J.P.  17
Pacchioni, A.M.  17
Packard, M.  4
Padkoperacz, M.R.  50
Pagano, K.  82
Painter, M.R.  68, 99
Palacios, I.  21
Palma, J.  84
Palman, N.R.  48
Palmatier, M.  98
Palmer, A.J.  81
Palmer, C.  64
Pande, A.  49
Pande, P.G.  19, 24
Pang, J.M.  17
Panos, J.J.  19
Pardo, R.  77, 81
Parrino, M.  95
Parry, C.D.  58
Parsons, J.  75
Parsons, J.T.  69, 75, 81
Parsons, L.H.  62
Parthasarathy, S.  50
Partilla, J.S.  83
Pascau, J.  7
Passalacqua, E.  51, 60
Patel, H.R.  23
Patrick, M.E.  57, 88, 95
Patrikeeva, S.L.  77
Paul, J.  53
Pawson, M.P.  75
Payne, R.A.  94
Peartree, N.A.  17, 68, 99
Pechansky, F.  2, 11, 70, 88
Peck, J.A.  96
Peet, M.M.  19
Peipert, J.F.  73
Peirce, J.  12, 59, 71
Peles, E.  59
Penetar, D.M.  10, 62, 64
Peng, C.  59
Peng, X.  77
Pennay, A.  80
Penniman, T.V.  17, 91, 95
Pennock, M.M.  107
Pentel, P.R.  98
Pentkowski, N.S.  3, 68, 86
Pepper, N.  57, 58
Perez de los Cobos, J.C.  73
Perez, C.  77, 81
Perez, M.  77
Pericot-Valverde, I.  107
<table>
<thead>
<tr>
<th>Author</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Perkins, A.C.</td>
<td>48, 49, 86</td>
</tr>
<tr>
<td>Perkins, T.</td>
<td>105</td>
</tr>
<tr>
<td>Perl, H.I.</td>
<td>100</td>
</tr>
<tr>
<td>Perlman, D.C.</td>
<td>57, 58, 106</td>
</tr>
<tr>
<td>Perlman, D.J.</td>
<td>57</td>
</tr>
<tr>
<td>Perreve, A.</td>
<td>91</td>
</tr>
<tr>
<td>Perrey, D.A.</td>
<td>17</td>
</tr>
<tr>
<td>Perrin, N.</td>
<td>50</td>
</tr>
<tr>
<td>Perrine, S.</td>
<td>6</td>
</tr>
<tr>
<td>Perry, B.</td>
<td>75</td>
</tr>
<tr>
<td>Peters, C.</td>
<td>14</td>
</tr>
<tr>
<td>Petersen, P.M.</td>
<td>58</td>
</tr>
<tr>
<td>Peterson, A.</td>
<td>107</td>
</tr>
<tr>
<td>Peterson, B.</td>
<td>4</td>
</tr>
<tr>
<td>Petrakis, I.</td>
<td>92</td>
</tr>
<tr>
<td>Petry, N.M.</td>
<td>64</td>
</tr>
<tr>
<td>Pettegrew, J.</td>
<td>72</td>
</tr>
<tr>
<td>Pettinati, H.</td>
<td>16</td>
</tr>
<tr>
<td>Peuker, A.</td>
<td>70</td>
</tr>
<tr>
<td>Pham, A.</td>
<td>99, 100</td>
</tr>
<tr>
<td>Phillips, K.A.</td>
<td>69</td>
</tr>
<tr>
<td>Phillips, K.T.</td>
<td>56</td>
</tr>
<tr>
<td>Pich, E.M.</td>
<td>22</td>
</tr>
<tr>
<td>Pickens, R.</td>
<td>8, 70, 85, 91</td>
</tr>
<tr>
<td>Picker, M.J.</td>
<td>7, 56</td>
</tr>
<tr>
<td>Pickering, A.</td>
<td>92</td>
</tr>
<tr>
<td>Pickford, L.</td>
<td>15</td>
</tr>
<tr>
<td>Pickworth, W.</td>
<td>50</td>
</tr>
<tr>
<td>Piehl, K.</td>
<td>107</td>
</tr>
<tr>
<td>Pierre, P.J.</td>
<td>82</td>
</tr>
<tr>
<td>Pinard, E.</td>
<td>83</td>
</tr>
<tr>
<td>Pittman, B.</td>
<td>77</td>
</tr>
<tr>
<td>Pizzagalli, D.A.</td>
<td>98</td>
</tr>
<tr>
<td>Plaehn, G.</td>
<td>58</td>
</tr>
<tr>
<td>Plasters, E.</td>
<td>61</td>
</tr>
<tr>
<td>Platt, D.M.</td>
<td>83, 105</td>
</tr>
<tr>
<td>Plebani, J.G.</td>
<td>10</td>
</tr>
<tr>
<td>Pletcher, M.</td>
<td>12, 71</td>
</tr>
<tr>
<td>Ploense, K.L.</td>
<td>82</td>
</tr>
<tr>
<td>Plautz-Snyder, R.</td>
<td>57</td>
</tr>
<tr>
<td>Pluddemann, A.</td>
<td>58</td>
</tr>
<tr>
<td>Pockros, L.A.</td>
<td>3</td>
</tr>
<tr>
<td>Poizat, B.</td>
<td>91</td>
</tr>
<tr>
<td>Poizot-Martin, I.</td>
<td>57</td>
</tr>
<tr>
<td>Polen, M.</td>
<td>50</td>
</tr>
<tr>
<td>Poling, J.</td>
<td>92</td>
</tr>
<tr>
<td>Polis, I.</td>
<td>62</td>
</tr>
<tr>
<td>Pollard, G.T.</td>
<td>102</td>
</tr>
<tr>
<td>Pollini, R.A.</td>
<td>56</td>
</tr>
<tr>
<td>Ponds, K.L.</td>
<td>68</td>
</tr>
<tr>
<td>Poole, M.M.</td>
<td>56, 80, 92, 99</td>
</tr>
<tr>
<td>Porrino, L.J.</td>
<td>1, 82, 96</td>
</tr>
<tr>
<td>Portenoy, R.K.</td>
<td>101</td>
</tr>
<tr>
<td>Potenza, M.</td>
<td>9, 89, 90</td>
</tr>
<tr>
<td>Potrepka, J.</td>
<td>21</td>
</tr>
<tr>
<td>Potter, J.S.</td>
<td>70, 104</td>
</tr>
<tr>
<td>Pouesset, O.</td>
<td>84</td>
</tr>
<tr>
<td>Prendergast, M.</td>
<td>105</td>
</tr>
<tr>
<td>Prescott, A.</td>
<td>82</td>
</tr>
<tr>
<td>Prescott, A.P.</td>
<td>55</td>
</tr>
<tr>
<td>Preston, K.E.</td>
<td>79</td>
</tr>
<tr>
<td>Preston, K.L.</td>
<td>69, 79</td>
</tr>
<tr>
<td>Price, K.L.</td>
<td>15, 62, 99</td>
</tr>
<tr>
<td>Price, R.K.</td>
<td>12</td>
</tr>
<tr>
<td>Prince van Leeuwen, A.</td>
<td>85</td>
</tr>
<tr>
<td>Prioleau, C.</td>
<td>19</td>
</tr>
<tr>
<td>Prisinzano, T.E.</td>
<td>84</td>
</tr>
<tr>
<td>Protopopescu, C.</td>
<td>57</td>
</tr>
<tr>
<td>Proudnikov, D.</td>
<td>74</td>
</tr>
<tr>
<td>Prow, M.R.</td>
<td>18</td>
</tr>
<tr>
<td>PsyCoBarcelona, G.</td>
<td>70</td>
</tr>
<tr>
<td>Pulaski, A.R.</td>
<td>79</td>
</tr>
<tr>
<td>Pulvermacher, A.</td>
<td>11</td>
</tr>
<tr>
<td>Pushparaj, A.</td>
<td>98</td>
</tr>
<tr>
<td>Quanbeck, A.R.</td>
<td>11, 58</td>
</tr>
<tr>
<td>Quinones-Jenab, V.</td>
<td>18, 89</td>
</tr>
<tr>
<td>Raboisson, P.</td>
<td>19</td>
</tr>
<tr>
<td>Radovanovic, M.</td>
<td>12</td>
</tr>
<tr>
<td>Ragot, E.</td>
<td>56</td>
</tr>
<tr>
<td>Rahmadi, M.</td>
<td>83</td>
</tr>
<tr>
<td>Raiff, B.R.</td>
<td>51</td>
</tr>
<tr>
<td>Rainey, P.M.</td>
<td>15</td>
</tr>
<tr>
<td>Raju, S.</td>
<td>92</td>
</tr>
<tr>
<td>Ramchand, R.</td>
<td>22</td>
</tr>
<tr>
<td>Ramin, C.</td>
<td>58</td>
</tr>
<tr>
<td>Ramirez, D.R.</td>
<td>68, 82</td>
</tr>
<tr>
<td>Ramirez, E.</td>
<td>89</td>
</tr>
<tr>
<td>Ramoa, C.</td>
<td>89</td>
</tr>
<tr>
<td>Ramos, A.</td>
<td>21</td>
</tr>
<tr>
<td>Randall, M.</td>
<td>92</td>
</tr>
<tr>
<td>Randall, S.</td>
<td>10</td>
</tr>
<tr>
<td>Randesi, M.</td>
<td>104</td>
</tr>
<tr>
<td>Ransom, L.L.</td>
<td>14, 88</td>
</tr>
<tr>
<td>Rasakham, K.</td>
<td>102</td>
</tr>
<tr>
<td>Rataemane, L.</td>
<td>100</td>
</tr>
<tr>
<td>Rataemane, S.</td>
<td>100</td>
</tr>
<tr>
<td>Rathnayaka, N.</td>
<td>97</td>
</tr>
<tr>
<td>Ravindran, A.</td>
<td>93</td>
</tr>
<tr>
<td>Rawson, R.</td>
<td>80, 95, 100</td>
</tr>
<tr>
<td>Rawson, R.A.</td>
<td>14, 71</td>
</tr>
<tr>
<td>Raymont, V.</td>
<td>97</td>
</tr>
<tr>
<td>Raynov, I.T.</td>
<td>76</td>
</tr>
<tr>
<td>Reback, C.J.</td>
<td>96</td>
</tr>
<tr>
<td>Rebec, G.V.</td>
<td>82</td>
</tr>
<tr>
<td>Reddy, P.</td>
<td>93</td>
</tr>
<tr>
<td>Reed, B.</td>
<td>7</td>
</tr>
<tr>
<td>Reed, S.C.</td>
<td>63, 90, 99</td>
</tr>
<tr>
<td>Reese, J.</td>
<td>16</td>
</tr>
<tr>
<td>Reggio, P.H.</td>
<td>62</td>
</tr>
<tr>
<td>Reid, A.</td>
<td>100</td>
</tr>
<tr>
<td>Reid, M.S.</td>
<td>50</td>
</tr>
<tr>
<td>Reifler, L.</td>
<td>93</td>
</tr>
<tr>
<td>Reiman, K.</td>
<td>15</td>
</tr>
<tr>
<td>Reis, D.</td>
<td>90</td>
</tr>
<tr>
<td>Renaudin, J.</td>
<td>59</td>
</tr>
<tr>
<td>Renner, J.</td>
<td>20</td>
</tr>
<tr>
<td>Renshaw, P.F.</td>
<td>55, 82</td>
</tr>
<tr>
<td>Resko, S.M.</td>
<td>9, 55, 90</td>
</tr>
<tr>
<td>Reuter, P.</td>
<td>67</td>
</tr>
<tr>
<td>Reynolds, C.R.</td>
<td>14</td>
</tr>
<tr>
<td>Reynolds, M.D.</td>
<td>9, 55</td>
</tr>
<tr>
<td>Rhodes, A.G.</td>
<td>49</td>
</tr>
<tr>
<td>Rhodes, G.L.</td>
<td>19</td>
</tr>
<tr>
<td>Ribeiro, L.A.</td>
<td>17</td>
</tr>
<tr>
<td>Richardt, S.</td>
<td>98</td>
</tr>
<tr>
<td>Richman, J.</td>
<td>12</td>
</tr>
<tr>
<td>Ridenour, T.</td>
<td>55, 73</td>
</tr>
<tr>
<td>Riegel, A.C.</td>
<td>101</td>
</tr>
<tr>
<td>Riggs, P.</td>
<td>11, 22, 71</td>
</tr>
<tr>
<td>Rigler, R.</td>
<td>64</td>
</tr>
<tr>
<td>Riley, A.L.</td>
<td>7, 99</td>
</tr>
<tr>
<td>Riley, B.B.</td>
<td>49</td>
</tr>
<tr>
<td>Rinehart, D.J.</td>
<td>100</td>
</tr>
<tr>
<td>Ring–Kurtz, S.</td>
<td>78</td>
</tr>
<tr>
<td>Rinker, J.A.</td>
<td>99</td>
</tr>
<tr>
<td>Ritter, A.</td>
<td>2</td>
</tr>
<tr>
<td>Rivera, D.E.</td>
<td>14</td>
</tr>
<tr>
<td>Rivera, R.</td>
<td>49, 90</td>
</tr>
<tr>
<td>Robbins, G.</td>
<td>56</td>
</tr>
<tr>
<td>Author</td>
<td>Pages</td>
</tr>
<tr>
<td>------------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Roberts, D.C.</td>
<td>17, 61</td>
</tr>
<tr>
<td>Roberts, K.W.</td>
<td>84</td>
</tr>
<tr>
<td>Robertson, L.M.</td>
<td>3, 17</td>
</tr>
<tr>
<td>Robertson, M.</td>
<td>57</td>
</tr>
<tr>
<td>Robinson, J.</td>
<td>11, 106</td>
</tr>
<tr>
<td>Roddy, J.K.</td>
<td>21</td>
</tr>
<tr>
<td>Rodolico, J.</td>
<td>64</td>
</tr>
<tr>
<td>Roebke, P.</td>
<td>56</td>
</tr>
<tr>
<td>Roehrs, T.</td>
<td>10</td>
</tr>
<tr>
<td>Roget, N.A.</td>
<td>11, 21, 53</td>
</tr>
<tr>
<td>Rogowska, J.</td>
<td>103</td>
</tr>
<tr>
<td>Rohsenow, D.J.</td>
<td>23, 62, 104</td>
</tr>
<tr>
<td>Roislien, J.</td>
<td>11</td>
</tr>
<tr>
<td>Roma, P.</td>
<td>14</td>
</tr>
<tr>
<td>Roman, P.M.</td>
<td>58</td>
</tr>
<tr>
<td>Romano, A.</td>
<td>80</td>
</tr>
<tr>
<td>Romero-Gonzalez, M.</td>
<td>92</td>
</tr>
<tr>
<td>Rompion, S.</td>
<td>84</td>
</tr>
<tr>
<td>Roncero, C.</td>
<td>57</td>
</tr>
<tr>
<td>Ronzani, T.M.</td>
<td>9</td>
</tr>
<tr>
<td>Room, R.</td>
<td>67</td>
</tr>
<tr>
<td>Ropelewski, L.</td>
<td>48, 58, 108</td>
</tr>
<tr>
<td>Roper, A.J.</td>
<td>83</td>
</tr>
<tr>
<td>Rosa, M.C.</td>
<td>88</td>
</tr>
<tr>
<td>Rose, J.</td>
<td>65</td>
</tr>
<tr>
<td>Rose, J.H.</td>
<td>92</td>
</tr>
<tr>
<td>Rosen, M.I.</td>
<td>16, 71</td>
</tr>
<tr>
<td>Rosen, S.</td>
<td>94</td>
</tr>
<tr>
<td>Rosenblum, A.</td>
<td>48, 95, 101</td>
</tr>
<tr>
<td>Rosenfeld, J.</td>
<td>90</td>
</tr>
<tr>
<td>Rosenheck, R.A.</td>
<td>71</td>
</tr>
<tr>
<td>Rosenthal, R.</td>
<td>70</td>
</tr>
<tr>
<td>Ross, E.</td>
<td>59</td>
</tr>
<tr>
<td>Ross, J.</td>
<td>100</td>
</tr>
<tr>
<td>Ross-Durow, P.L.</td>
<td>72, 94</td>
</tr>
<tr>
<td>Roth, K.B.</td>
<td>12</td>
</tr>
<tr>
<td>Roth, T.</td>
<td>10</td>
</tr>
<tr>
<td>Rothman, R.B.</td>
<td>62, 83, 86</td>
</tr>
<tr>
<td>Rotrosen, J.</td>
<td>78, 104, 106</td>
</tr>
<tr>
<td>Rounsaville, B.J.</td>
<td>20, 71, 90, 92</td>
</tr>
<tr>
<td>Rowlett, J.K.</td>
<td>105</td>
</tr>
<tr>
<td>Roxburgh, A.</td>
<td>94</td>
</tr>
<tr>
<td>Royer, M.S.</td>
<td>58, 108</td>
</tr>
<tr>
<td>Rudolph, A.</td>
<td>12</td>
</tr>
<tr>
<td>Rudy, N.M.</td>
<td>82, 105</td>
</tr>
<tr>
<td>Ruiz, J.</td>
<td>26</td>
</tr>
<tr>
<td>Rush, B.R.</td>
<td>71</td>
</tr>
<tr>
<td>Rush, C.R.</td>
<td>15, 56, 61, 80, 81, 92, 99</td>
</tr>
<tr>
<td>Russell, B.R.</td>
<td>54, 97</td>
</tr>
<tr>
<td>Rusu, B.</td>
<td>14</td>
</tr>
<tr>
<td>Rutter, J.L.</td>
<td>1</td>
</tr>
<tr>
<td>Ryder, D.</td>
<td>16</td>
</tr>
<tr>
<td>Saadvandi, J.</td>
<td>74, 80</td>
</tr>
<tr>
<td>Saavedra, J.</td>
<td>13</td>
</tr>
<tr>
<td>Sabar-Cohen, S.</td>
<td>78</td>
</tr>
<tr>
<td>Sabharwal, S.</td>
<td>19, 24</td>
</tr>
<tr>
<td>Sabugo, J.</td>
<td>55</td>
</tr>
<tr>
<td>Sacerio, L.</td>
<td>16</td>
</tr>
<tr>
<td>Sacks, J.Y.</td>
<td>20, 49</td>
</tr>
<tr>
<td>Sacks, S.</td>
<td>20, 49</td>
</tr>
<tr>
<td>Sacramento, A.D.</td>
<td>82, 105</td>
</tr>
<tr>
<td>Sadee, W.</td>
<td>3</td>
</tr>
<tr>
<td>Saeki, M.</td>
<td>74</td>
</tr>
<tr>
<td>Saenz, E.</td>
<td>21</td>
</tr>
<tr>
<td>Safford, M.</td>
<td>12, 71</td>
</tr>
<tr>
<td>Safren, S.</td>
<td>106</td>
</tr>
<tr>
<td>Saijo, T.</td>
<td>99</td>
</tr>
<tr>
<td>Saitz, R.</td>
<td>101</td>
</tr>
<tr>
<td>Saiyed, Z.</td>
<td>76, 86</td>
</tr>
<tr>
<td>Saiyed, Z.M.</td>
<td>24, 74</td>
</tr>
<tr>
<td>Sakai, J.</td>
<td>104</td>
</tr>
<tr>
<td>Sakoman, S.</td>
<td>58</td>
</tr>
<tr>
<td>Saladin, M.E.</td>
<td>15, 23, 51, 62, 99</td>
</tr>
<tr>
<td>Salazar, J.</td>
<td>73</td>
</tr>
<tr>
<td>Saleh, M.</td>
<td>53</td>
</tr>
<tr>
<td>Salti, A.</td>
<td>82</td>
</tr>
<tr>
<td>Samboamoorthi, U.</td>
<td>51</td>
</tr>
<tr>
<td>Samikkannu, T.</td>
<td>76, 86</td>
</tr>
<tr>
<td>Samour, S.</td>
<td>11, 56, 108</td>
</tr>
<tr>
<td>Sampson, R.</td>
<td>79</td>
</tr>
<tr>
<td>Sanabria, E.</td>
<td>99</td>
</tr>
<tr>
<td>Sanchez, B.N.</td>
<td>8</td>
</tr>
<tr>
<td>Sanchez, H.</td>
<td>68</td>
</tr>
<tr>
<td>Sanchez, J.</td>
<td>58</td>
</tr>
<tr>
<td>Sanchez, Z.V.</td>
<td>9, 17, 52</td>
</tr>
<tr>
<td>Sánchez-Hervás, E.</td>
<td>16</td>
</tr>
<tr>
<td>Sanders, G.</td>
<td>106</td>
</tr>
<tr>
<td>Sannerud, C.A.</td>
<td>19, 67</td>
</tr>
<tr>
<td>Sannibale, C.</td>
<td>90</td>
</tr>
<tr>
<td>Santa Ana, E.J.</td>
<td>20</td>
</tr>
<tr>
<td>Sarfì, M.</td>
<td>25</td>
</tr>
<tr>
<td>Saria, A.</td>
<td>82</td>
</tr>
<tr>
<td>Saroyan, J.M.</td>
<td>102</td>
</tr>
<tr>
<td>Sason, A.</td>
<td>59</td>
</tr>
<tr>
<td>Satterlee, J.</td>
<td>63</td>
</tr>
<tr>
<td>Saulsgiver, K.A.</td>
<td>5, 57, 88, 95</td>
</tr>
<tr>
<td>Savvas, S.</td>
<td>3</td>
</tr>
<tr>
<td>Saxon, A.J.</td>
<td>20, 60</td>
</tr>
<tr>
<td>Schaub, M.P.</td>
<td>49</td>
</tr>
<tr>
<td>Schenk, S.</td>
<td>81</td>
</tr>
<tr>
<td>Schiano, T.</td>
<td>78</td>
</tr>
<tr>
<td>Schiff, M.</td>
<td>60</td>
</tr>
<tr>
<td>Schilström, B.</td>
<td>99</td>
</tr>
<tr>
<td>Schlussman, S.D.</td>
<td>83</td>
</tr>
<tr>
<td>Schlyter, F.</td>
<td>48</td>
</tr>
<tr>
<td>Schmidt, K.T.</td>
<td>56, 84</td>
</tr>
<tr>
<td>Schmitz, J.M.</td>
<td>15, 60, 77</td>
</tr>
<tr>
<td>Schnoll, S.H.</td>
<td>14, 94</td>
</tr>
<tr>
<td>Schoedel, K.A.</td>
<td>3, 65, 79</td>
</tr>
<tr>
<td>Schoeny, M.</td>
<td>11, 56, 108</td>
</tr>
<tr>
<td>Schootman, M.</td>
<td>73</td>
</tr>
<tr>
<td>Schottenfeld, R.S.</td>
<td>59, 74, 75, 93, 96</td>
</tr>
<tr>
<td>Schramm-Sapyta, N.L.</td>
<td>103</td>
</tr>
<tr>
<td>Schreiber, S.</td>
<td>59</td>
</tr>
<tr>
<td>Schroeder, S.M.</td>
<td>100</td>
</tr>
<tr>
<td>Schrott, L.M.</td>
<td>7</td>
</tr>
<tr>
<td>Schuetz, C.G.</td>
<td>10</td>
</tr>
<tr>
<td>Schumacher, J.</td>
<td>16, 71</td>
</tr>
<tr>
<td>Schuster, C.R.</td>
<td>14</td>
</tr>
<tr>
<td>Schwartz, R.P.</td>
<td>6, 58, 60, 71, 76, 86, 93, 106</td>
</tr>
<tr>
<td>Scott, C.K.</td>
<td>49, 78</td>
</tr>
<tr>
<td>Secades-Villa, R.</td>
<td>16, 107</td>
</tr>
<tr>
<td>See, R.E.</td>
<td>17, 101</td>
</tr>
<tr>
<td>Seewald, R.M.</td>
<td>57, 58, 106</td>
</tr>
<tr>
<td>Seip, K.M.</td>
<td>7</td>
</tr>
<tr>
<td>Selby, P.</td>
<td>23, 70, 88</td>
</tr>
<tr>
<td>Selby, V.</td>
<td>97</td>
</tr>
<tr>
<td>Sellers, E.M.</td>
<td>3, 65, 79</td>
</tr>
<tr>
<td>Seltzman, H.H.</td>
<td>62</td>
</tr>
<tr>
<td>Sembower, M.A.</td>
<td>14, 94</td>
</tr>
<tr>
<td>Sepulveda, A.</td>
<td>52, 91</td>
</tr>
<tr>
<td>Serre, F.</td>
<td>12</td>
</tr>
<tr>
<td>Setlow, B.</td>
<td>80, 82, 98</td>
</tr>
<tr>
<td>Sevak, R.</td>
<td>80</td>
</tr>
<tr>
<td>Severino, K.</td>
<td>92</td>
</tr>
<tr>
<td>Shafer, M.S.</td>
<td>49, 90</td>
</tr>
<tr>
<td>Shaham, Y.</td>
<td>83</td>
</tr>
</tbody>
</table>

122
AUTHOR INDEX

Shannon, L.M. 89
Shapiro, P. 78
Sharifian, S.W. 51
Sharp, V. 96
Sheffer, C.E. 85
Sheikhattari, P. 13, 52
Shiffman, S. 94
Shin, S.H. 9
Shinday, N.M. 105
Shippenberg, T.S. 101
Shmulewitz, D. 51
Shoptaw, S. 23, 76, 96, 99
Short, E. 53
Shram, M. 79
Shumsky, J.S. 3
Shurtleff, D. 22
Siegal, N. 61, 81
Siegrist, J. 81
Sigmon, S.C. 52, 57, 88, 95
Sigurdsson, S.O. 91
Silva, O. 78
Silverman, B.L. 64, 79
Silverman, K. 11, 91, 93
Simon, N.W. 80
Simpson, A.N. 94
Singer, L. 8, 53
Singleton, L. 85
Singleton, L.M. 95
Sinha, R. 89, 90
Siñol, N. 73
Skeie, I. 59
Skelly, J. 52
Skinstad, A.H. 14, 20, 21, 66
Skurtveit, S. 49
Slade, T. 55
Slavutsky, S. 88
Sliwerska, E. 104
Smelson, D.A. 71, 92
Smith, C. 95
Smith, H.R. 96
Smith, K. 88
Smith, K.D. 82
Smith, K.E. 15
Smith, M. 56
Smith, M.A. 107
Smith, M.T. 10
Smith, P.H. 107
Smith, S. 20, 61
Smith, V.M. 50
Smith, W. 52
Smock, S.A. 14
Myth, E. 57
Snepe, W. 3
Snead, N. 91, 106
Soberanes-Chávez, P. 54
Sodano, R. 100
Sofuoglu, M. 92
Sokolowska, M. 95
Solikhah, R. 72
Solomon, L.J. 52, 69
Somogyi, A.A. 3
Somoza, E. 66
Sonne, S.C. 70, 79
Sorensen, J. 106
Sorensen, J.L. 57, 58
Soto-Montenegro, M.L. 7
Sparenborg, S. 20, 60
Spealman, R.D. 83
Spear, S.E. 88
Speckler, S. 86
Spiga, R. 14
Spire, B. 57
Spitznagel, E. 73
Sproule, B. 93
St. Jean, E. 94
Stählerberg, M. 19
Stahler, G. 71
Staios, G. 23, 70
Stairs, D.J. 62
Stallings, D.L. 20
Stallings, M.C. 104
Stanciu, L. 14
Stanger, C. 22, 55
Stanick, V. 79
Stanley, M.D. 80
Staples, V. 49
Starks, T.J. 69, 81
Staton-Tindall, M. 48, 75, 78, 105
Steegers, E. 24
Stein, J. 57
Stein, M.D. 56, 102
Steinberg, J.L. 54, 96, 97
Steinmiller, C.L. 2, 63, 104
Stemmler, M.S. 53
Stenger, A. 54, 55, 96
Stephenson, S. 53
Stern, A. 83
Stevens, A. 49
Stevenson, L. 8
Stewart, J.L. 62
Stewart, K. 9
Stine, S.M. 24, 26, 53
Stitzer, M.L. 50, 72, 85
Stock, C. 74
Stoduto, G. 13
Stoica, I.G. 14
Stolf, A.R. 70
Stooops, W.W. 15, 80, 81, 92, 99
Stoove, M. 94
Storr, C.L. 12, 69, 72, 90, 97
Stotts, A.L. 60
Stowe, R. 89
Strain, E.C. 3, 16, 92
Strang, J. 67
Strathdee, S.A. 56
Strickland, J.R. 53
Striely, C.L. 71, 72
Striley, C.W. 72
Stutz, S.J. 83
Su, Z. 82
Subramaniam, G. 72
Sughondhabirom, A. 77
Suh, J.J. 4, 23, 55, 96, 97
Sullivan, B.M. 98
Sullivan, J. 61
Sullivan, L.E. 59, 64, 74, 75, 76, 93
Sullivan, M.A. 95, 101, 102
Summers, K. 14, 20, 21
Sun, H. 24
Sun, W.L. 18, 89
Sunahara, R.K. 17, 77
Sundaram, A. 101
Sung, Y.H. 55
Sussner, B. 71
Sutton, R. 75
Suzuki, T. 19, 74, 83
Sved, A. 98, 99
Svikis, D.S. 8, 52, 70, 78, 85, 91, 94, 95, 101
AUTHOR INDEX

Swanson, A.N. 23, 99
Swedberg, M.D. 19, 80
Sweeney, C.T. 94
Swieter, M. 66
Swift, R. 23
Swinford, S.E. 3
Szalay, J.J. 68
Szobot, C. 70
Szucs Reed, R.P 4, 55, 97
Szumlinski, K.K. 54, 82, 105
Tabatabaei, H. 4
Taffe, M.A. 61, 62
Tai, B. 20, 60
Tajima, B. 51, 60
Takagi, M. 73
Takagi, S. 83
Talal, A. 57
Tansil, D. 53
Tapert, S.F . 72
Tarash, I. 99
Tartarini, W.L. 62, 64
Tarter, R. 9, 55
Tau, G. 4
Taxman, F.S. 48, 49, 78
Taylor, C. 19
Taylor, J.R. 68
Tedesco, V. 18
Teesson, M. 55, 90
Tella, S.R. 19
Temes, C. 78
Tennant, L.K. 107
Teplinsky, J. 82
Terenius, L. 64
Terplan, M. 53
Terra, M. 70
Terrell, D.L. 95
Terry, J. 55
Teruya, C. 59
Teter, C.E. 72
Teti, M. 23
Tetrault, J.M. 64, 76, 93
Thacker, L. 91, 94
Thakkar, V. 50
Thakur, P. 53
Thangavel, S. 74
Thanos, P. 67
Thatcher, D.L. 84
Thiel, K.J. 68, 99
Thomas, B.F. 17, 19, 24
Thomas, C.M. 20, 57, 59
Thomas, R. 13
Tidey, J. 23
Tieemeier, H. 24
Tillander, E. 50
Tio, R. 106
Tisher, P. 53
Toaz, E. 54
Todd, M. 96
Todtenkopf, M.S. 98
Tolleson Knee, R. 53
Tolliver, B.K. 99
Tomas-Rossello, J. 21
Tomassili, J. 75
Tomkins, D.A. 16, 102
Torregrossa, M.M. 68
Torrence, M.C. 96
Torrens, M. 70, 77, 81
Torres, I. 98
Torres, L. 5
Torrington, M. 79
Touzeau, D. 58
Toy, W.A. 86
Tozzi, F. 8
Tracy, E.M. 8
Tracy, M.S. 8
Travers, R.M. 88
Treese, M. 23
Tres, I. 95
Trinkl, B. 49
Trksak, G.H. 62
Tross, S. 91, 106
Trujols, J. 73
Tsay, W.I. 13
Tsui, J.J. 102
Tsutsui, K. 83
Tucker, A. 73
Tucker, J. 71
Turncliff, R. 79
Turturici, M. 51
Tzall, D. 71
Tziortzis, D. 84
Uchtenhagen, A. 49
UCS-UNESCO Group 95
Uhl, G. 65
Umberger, M.D. 56
Umbricht, A. 16, 88, 92, 93, 102
Unterwald, E.M. 61, 84, 102
Urada, D.I. 50, 105
Vadhan, N.P. 56, 63
Valderrama-Zurián, J.C. 52, 73
Vallender, E.J. 86, 61
van den Brink, W. 24
Van der Linden, M. 20
Vandrey, R.G. 3, 50, 56
Vansickel, A.R. 92, 99
Vanyukov, M. 55
Vaquero, J.J. 7
Varela, F.A. 83
Varillo, K. 16
Varner, S.B. 52
Varughese, S. 94
Vasconcellos, M.T. 11
Vasilev, G.N. 76
Vassileva, J. 76
Velasquez, C. 19
Velasquez, M.M. 101
Velez, M.L. 53
Velica, L. 14
Veltman, D.J. 97
Vera, A. 56
Vérétout, A. 78
Verhulst, F.C. 24, 73, 85
Vickers, S.P. 18
Vignoli, B. 53, 102
Villalobos, G. 95
Villeger, P. 58
Villes, V. 57
Vimieiro, C. 20
Vincent, K.B. 9, 73
Vincent, R. 25
Vitezic, D. 58
Vittet, S. 13
Vlahov, D. 12
Voci, S. 88
Vokes, C.M. 80, 82
Volkmann, T.A. 56
Volkow, N.D. 1, 2
AUTHOR INDEX

Vollebergh, W. 73
von Diemen, L. 70
Vosburg, S.K. 56, 101
Vuchinich, R. 16
Vukojevic, V. 64

W.M.H.S. Initiative 12
Waal, H. 59
Wagner, C.C. 11, 79
Wagner, F.A. 13, 52, 69
Wagner, F.P. 56
Wagner, K.D. 56
Wakeland, W. 72, 94
Waki, Y. 18
Wakley, A.A. 56
Waldron, M. 9, 90
Waldrop, A.E. 85
Walker, K.L. 107
Walker, Q.D. 105
Walker, S.L. 19
Wall, D. 13
Wallace, D. 16
Valley, A.Y. 13, 106
Walsh, S.L. 2, 59
Walton, M.A. 9, 55
Wand, G. 97
Wang, D. 18
Wang, F. 106
Wang, J. 3, 74
Wang, N. 103
Wang, S. 23, 70
Wang, X. 77, 96
Wang, X.Q. 59
Wang, Y. 102
Wang, Z. 4, 23, 55, 57, 96, 97
Ware, D.L. 15
Warnecke, M. 10
Warner, K. 17
Wasarhaley, N.E. 48
Washio, Y.T. 52
Waterhouse, B. 3
Waters, A.J. 3, 15, 54, 93
Waygood, C. 92
Weaver, M. 98
Weaver, M.F. 94
Weaver, M.T. 99
Webb, D.J. 8
Weber, J. 4
Weber, S.M. 17, 99
Webster, J.M. 105
Webster, L. 72, 94
Webster, M. 48
Wechsberg, W.M. 58, 76, 100
Wee, S. 86
Weerts, E.M. 81, 97
Wei, Y. 58
Weierstall, K. 89
Weiner, J. 89
Weis, D. 74
Weiss, D. 80
Weiss, F. 68, 82
Weiss, L. 20, 75
Weiss, M. 19
Weiss, R.D. 104
Weiss, R.E. 76
Wellman, P.J. 82, 84
Wells, A.M. 82
Wells, B. 75
Wenger, L.D. 58
Werdenich, W. 49
Wermeling, D.P. 80
Wesnoski, S.A. 48
West, P.A. 82
Wetherington, C. 6
Wetli, C.V. 17
Wettstein, J.G. 83
Whalley, E. 19
Wheelock, A. 11
Whelan, J. 86
Whitaker, D.E. 70, 76, 79
White, J.M. 3, 87
White, K. 12
White, N.M. 7
White, T.L. 16, 56
Widner, G. 12
Wilcox, C. 78
Willard, D. 4, 96, 97
Williams, L. 90
Williams, S. 53, 99
Williams, T. 92
Williams, Z. 62
Windsor, L.C. 5, 90
Winhusen, T. 22
Winship, D. 81

Winstanley, E.L. 16, 92, 102
Winters, K.C. 22, 26
Winward, J. 72
Wise, R.J. 81
Wohl, D. 6
Wolfe, H. 96
Wolinsky, T. 84
Wolven, T. 16
Wong, C.J. 11
Wong, D. 97
Wong, L.L. 19
Wooditch, A. 48
Woods, J.H. 17, 77, 98, 103
Woods, W.L. 11, 21
Woodward, N. 105
Woody, G. 78
Woolverton, W.L. 102
Wooters, T.E. 98
Worley, M. 72
Wright, C. 13, 50
Wright, L.J. 72
Wright, M.J. 62
Wroten, M.G. 105
Wu, F. 59
Wu, H. 89
Wunsch, M.J. 2, 59

Xi, Z. 77
Xi, Z.X. 62, 69
Xie, X. 17, 68, 82
Xu, D. 4
Xu, S. 4
Xue, L. 25, 53, 85

Yakupov, R. 96
Yamada, S. 18
Yang, Y. 18
Yao, W.D. 105
Ye, W. 97
Yi, R. 51, 85
Yomjinda, D. 20
Yoon, J.H. 23
Yoshizawa, K. 19
Young, A.M. 72, 94
Young, C. 57, 58
Young, K. 51
Youssef, R. 56
AUTHOR INDEX

Yu, E. 74, 80
Yubero, S. 77, 81, 86
Yu, E. 74, 80
Yücel, M. 73
Yuferov, V. 73
Yunus, F. 52
Yurgelun-Todd, D.A. 55, 103
Zakharova, E. 102
Zalcman, R. 13
Zamarelli, L. 51
Zanis, D.A. 48
Zapata, A. 101
Zavala, A.R. 81
Zavala, R. 51, 57
Zawertailo, L.A. 23, 70, 88
Zeman, L.L. 21
Zengin, Y. 18
Zernig, G. 82
Zhang, R. 59
Zhang, T. 24
Zhang, Y. 7, 17, 83
Zhang, Z. 98
Zhao, M. 57, 59
Zhao, N. 81
Zharpikova, O. 77
Zheng, G. 98
Zhou, C. 103
Zhou, L. 18, 89
Zhou, M. 92
Zhou, W. 96
Zhou, Y. 97, 105
Ziedonis, D. 51, 71
Zimmerman, M.A. 9, 55
Zold-Kilbourn, P. 105
Zorman, M. 91
Zosel, A. 59
Zubaran, C. 95
Zucker, R.A. 9, 55
Zule, W.A. 76
Zuo, C.S. 82
Zur, J.B. 12, 48, 58, 108
Zwick, J. 20
SYMPOSIA

Sunday, June 13

I. Translating the genetics and neurochemistry of nicotine dependence to drug development
   Chairs: Linda Porrino and Joni L. Rutter

Tobacco addiction is a complex disorder involving genetic, environmental and developmental factors. There has been a recent explosion of research findings, using genome-wide association studies that link genetic variations to complex diseases, including addiction. Finding a single polymorphism within a gene that contributes to disease, however, is only the first step towards improved treatment and prevention interventions. The next goal is to understand how to take highly reproducible genetic findings and pursue their biological implications for developing diagnostic tests and targets for potential therapeutics. This symposium describes recent research into the genetics of tobacco addiction. Our speakers will present their findings about the genes encoding nicotinic acetylcholine subunit receptors, some of which have been associated with nicotine dependence, others of which have been associated with smoking cessation. These genetic findings represent examples of the power of genetics to set the stage for further translational research, such as understanding gene variant x environment interactions, or understanding the effects of genetic variation on gene function and gene pathways. The session will conclude with a discussion of drug development and future ligand development for the nicotinic acetylcholine subunit receptors, which are relatively rare, but which are expressed in areas of the brain involved in addiction and reward. These receptor subunits provide potential targets for drug development that may provide specificity and efficacy for drug dependence treatment.

II. CPDD International Committee Symposium
   A comprehensive approach to examine the use and impact of cannabis: From brain effects to epidemiological impact across the world
   Chairs: Flavio Pechansky and Alison Ritter

Despite the tremendous effort to curtail the experimentation, use and abuse of cannabis, the WHO reports that more than 147 million people are cannabis consumers, with a trend towards lower ages of initiation. Some of cannabis’ mechanisms of action have already been understood, and novel approaches are being tested – ranging from agents that affect the endocannabinoid system in animal models, the understanding and functional imaging of the effects of drug combinations in adolescents models of animals and humans, up to the epidemiological impact of its regular or chronic use and potential novel interventions to inhibit the development of a full cannabis use disorder. The international panel of speakers from the U.S., Spain, Italy, South Africa and Australia will provide a comprehensive approach. The speakers will make a deliberate attempt to forge bridgework between the fields and will be aided in this task by the discussant, who is an experienced cannabis researcher and who brings a broad global health perspective to the task.
SYMPOSIA

Monday, June 14

III. Addressing the intersection of addiction and HIV in criminal justice-involved populations
Chairs: Timothy P. Condon and Redonna Chandler

Researchers and public health officials have recognized that the criminal justice system provides a unique opportunity for addiction treatment and HIV intervention. For a variety of reasons, access to testing and HIV treatment varies across the criminal justice system. The same is true for the treatment of substance use disorders. Despite the presumption that drug-addicted prisoners undergo a period of forced abstinence during incarceration, without effective treatment, they remain at very high risk for relapse and overdose when released back into the community. Compounding this problem is the well established link between opioid drug use and the spread of HIV. This symposium will discuss emerging research findings showing that medications such as buprenorphine, methadone and long-acting naltrexone, can reduce the risk for relapse and overdose upon community re-entry as well as discuss new approaches for developing a continuum of care for HIV-infected individuals involved in the criminal justice system.

IV. Gender differences in response to social stress: Parallels from cocaine and alcohol research in human and non-human primates
Chairs: Colleen A. Hanlon and Cora Lee Wetherington

Although men are nearly twice as likely to be classified as substance-dependent, women experience a more rapid progression to dependence when introduced to drugs. Women appear to be particularly vulnerable to social stress, which may contribute to drug abuse, dependence and relapse. The primary aim of this symposium is to highlight recent translational data from clinical and nonhuman primate laboratories that suggest that this association between gender, stress, and drug use is present for several drugs of abuse. Specifically, compared to male cocaine users or non-drug using females, female cocaine users have a significantly larger neural response to social exclusion in brain regions involved in drug seeking. These data are supported by nonhuman primate investigations which demonstrate an association between social rank and cocaine self-administration in female monkeys opposite to that observed in males. In addition to substance abusers, there are gender differences among social drinkers, with females having greater hormonal responses to stress and drug craving than males, particularly with more chronic patterns of substance use. Furthermore, in nonhuman primates, as alcohol consumption progresses from acute to chronic consumption, circulating levels of ACTH/cortisol rise faster in females than males. The common themes emerging from both clinical and preclinical laboratories studying gender differences in cocaine and alcohol abuse suggest that understanding how women react to social information and environmental influences will aid the development of effective, gender-specific strategies for prevention and treatment of drug abuse.
Drug addiction is a chronic relapsing disorder consisting of a persistent desire or compulsion to use a drug, loss of control of drug intake, reduction in other important activities because of drug use, continued use despite knowledge of harm, marked tolerance, characteristic withdrawal symptoms, or intense craving and compulsive, uncontrollable drug taking and relapse following periods of abstinence. A challenge for drug abuse research is to identify targets associated with drug addiction in order to develop mechanism-based medications for treating it. One intriguing newly discovered potential target is the hypothalamic hypocretin (Hcrt)/orexin neuropeptide system. Initially implicated in feeding and energy balance, Hcrts have more recently been linked to arousal mechanisms such as sleep and narcolepsy, stress, and reward processing. Much of the emphasis with respect to the latter has focused on the mesocorticolimbic pathway, potentially involving many of these brain regions implicated in drug addiction including the ventral tegmental area and nucleus accumbens, and beyond. The wide projection field of the Hcrt-containing neurons, and the ability of drugs of abuse to influence them, suggests that Hcrt mechanisms may evoke numerous additional neurobiological and behavioral mechanisms in response to these drugs. Speakers for this symposium will discuss in detail recent research that suggest the Hcrts do play a role in pathological reward processing for addictive drugs, and in neurobiological mechanism of relapse. In addition, advances in the development of putative medications specifically targeting and involving the Hcrt system for drug addiction will be addressed and discussed.

Tuesday, June 15

VI. Hair of the dog: Agonists for stimulant dependence
Chairs: John Grabowski and David Herin

Stimulant abuse and dependence have contributed to prominent public health problems worldwide for many decades. In the treatment domain, behavioral interventions have shown promise; however, no pharmacotherapy has been approved despite evaluation of a wide spectrum of agents. Early work examining an ‘agonist approach,’ akin to methadone for the treatment of opioid dependence or nicotine for tobacco/nicotine dependence, provided titillating results. Now, a maturing literature is available that includes clinical trials and human laboratory research as well as preclinical nonhuman primate and rodent studies conducted with diverse methods from behavioral pharmacology and neuroscience. The combined data and literature point to potential efficacy of agonist pharmacotherapies, distinct refinements of the agonist strategy conceptualization, a broader array of potential medications, as well as possible limitations. In addition, these data support the view that stimulant abuse and dependence exist on a continuum of severity, and that different pharmacotherapies might be appropriate for treatment at different points along this continuum. The cumulative and latest results of clinical trials and community interventions will be described and elucidated by consideration of human
laboratory studies, preclinical studies and the neuroscience perspective of the available data, Bedside to Bench. An integrative discussion will include consideration of science, medication development, policy as well as regulatory and marketing realities.

VII. The role of GABA in drug abuse
Chair: Diana Dow-Edwards and Nora Siegal

Evidence for overlapping reward circuits for multiple drugs of abuse including alcohol supports a role for many neurotransmitters in the induction, maintenance and relapse of drug dependence including, of course, dopamine but also glutamate and GABA. Recently, several lines of evidence have suggested that GABA modulation can alter the reinforcing effects of stimulants (particularly GABA B agonists) and may be useful to eliminate craving. This symposium will present the emerging preclinical evidence related to the usefulness of GABA modulation in the responses to psychostimulants. In addition, clinical evidence that drugs like flumazenil are effective will be presented. Since the role of GABA modulation in substance abuse has received relatively little attention and new clinical and preclinical data are available, this is an important topic. The major aims of the symposium will be to present the preclinical data showing that both GABA A and GABA B receptor subtypes are involved in the responses to psychostimulants and to present new data from clinical trials using GABA modulating drugs as treatments for substance abuse.

VIII. Medications development for the treatment of substance dependence: Status of advanced projects
Chairs: David McCann

Medications can play an important role in the treatment of substance dependence disorders; however, there are many areas of unmet clinical need. Most notably, FDA-approved medications for the treatment of cocaine, methamphetamine, or cannabis dependence are lacking. These clinical needs have driven extensive medications discovery and development efforts in both the private and public sector. The purpose of this symposium is to provide an update on the status of some of the most promising medications in clinical testing. Presenters will describe evaluations of dronabinol for the treatment of cannabis dependence, evaluations of bupropion for the treatment of methamphetamine dependence, and evaluations of vigabatrin for the treatment of cocaine and methamphetamine dependence.

IX. New pathways to future addiction therapy
Chair: John Satterlee

Genetic studies in both humans and model organisms are leading to the identification of new and previously unsuspected genes and pathways involved in addictive processes. This symposium will highlight the use of three different model organisms (fruit flies,
zebra fish, and mice) to identify novel pathways involved in these processes. Potential translation of these discoveries to new diagnostic or therapeutic strategies will be explored.

X. **NICO-TEEN: Adolescence is a period of enhanced vulnerability to tobacco abuse**
   Chairs: Laura O’Dell and Janet Neisewander

Adolescence is a period of development characterized by insidious susceptibility to tobacco abuse. The underlying mechanisms that enhance adolescent tobacco abuse are largely unknown. The aim of this symposium is to highlight the multiple social and biological factors that contribute to increased tobacco abuse during adolescence. Recent work suggests that adolescents are more sensitive to the rewarding effects of nicotine but, in contrast, are less sensitive to aversive effects during nicotine withdrawal. These data provide a framework for this symposium to explore the various factors that influence enhanced vulnerability to tobacco abuse during adolescence. Recent pre-clinical studies demonstrate that nicotine preferentially facilitates the social- and cognitive-enhancing effects of this drug during adolescence. Across various animal models, the rewarding effects of nicotine are also enhanced whereas the negative affective properties of withdrawal (such as stress) are reduced during adolescence. Dopamine and opiate systems play an important role in modulating these developmental differences in nicotine reward and withdrawal. Clinical data that show adolescent smokers also display reduced nicotine withdrawal and, furthermore, they show concurrent enhanced risk-taking, impulsivity, and poor decision-making—all of which contribute to increased tobacco use during adolescence. This symposium will provide important information regarding psychosocial and biological factors that make adolescence a unique period of vulnerability to tobacco abuse.

Wednesday, June 16

XI. **Preclinical to clinical abuse liability assessment:**
   **Current challenges in industry practices**
   Chairs: Mary Jeanne Kallman and David Compton

New governmental regulations, such as the recent ICH M3(R2) guidance, have focused attention on the assessment of drugs with central nervous system activity for abuse liability potential. Both nonclinical and clinical studies contribute to the classification scheduling of a drug by regulatory agencies and to information in the product label. It is, thus, critical to understand the current issues facing pharmaceutical development in the evaluation of new drugs for abuse and dependence potential. Animal models for the study of known drugs of abuse are well characterized, and clinical trial protocols in drug-experienced users have been widely used. However, unique challenges are encountered in both nonclinical and clinical settings when evaluating drugs with novel mechanisms. In this symposium, speakers from industry, academia and regulatory communities will discuss the critical issues. Topics will include an overview and update on recent and emerging events, a review of some recent scheduling decisions and how the nonclinical and clinical data supported the decision; how the conditioned place preference (CPP)
animal model can be used in nonclinical abuse liability evaluation; special challenges posed in evaluating novel drug combinations for abuse potential as well as drugs that \textit{per se} have no reinforcing effects but which could potentiate the self-administration of known drugs of abuse, and the status and future of trial design for the clinical abuse liability study. The symposium will focus on bridging nonclinical, clinical and regulatory areas of interest.

XII. \textit{Methamphetamine addiction: From molecular mechanisms to treatment}
Chairs: John Mendelson and Jean Lud Cadet

There are an estimated 11.7 million methamphetamine (MA) abusers in the United States and epidemics of MA addiction are occurring worldwide. In this symposium we will proceed from molecular mechanisms of methamphetamine action to developing treatments for methamphetamine addiction. Neurobiological and translational principles that drive methamphetamine addiction, imaging studies, and the state of the art in developing pharmacotherapies for methamphetamine addiction will be discussed. Finding an effective treatment for methamphetamine addiction has been difficult. This series of presentations will help define a path forward for understanding this addictive disorder.

XIII. \textit{Current issues surrounding chronic pain among individuals with a substance use disorder}
Chair: Benjamin J. Morasco

There is a high rate of comorbid chronic pain conditions among patients with substance use disorders (SUDs), and the presence of this comorbidity complicates treatment. While empirical information describing this patient population has improved in recent years, there continues to be a need to expand our evidence base to guide assessment and treatment approaches for chronic pain in patients with a SUD. The aims of this symposium are to highlight contemporary clinical issues of chronic pain management among patients with comorbid SUD and to provide direction for future empirical investigations. Results of a systematic review summarizing the prevalence, demographic and clinical correlates, and treatment outcomes of chronic pain interventions in patients with comorbid SUD will be reviewed. Issues related to measuring chronic pain among SUD patients will be discussed and recommendations presented, with a focus on pain assessment in individuals misusing prescription opioids. An overview of co-occurring opioid dependence and pain in methadone maintenance treatment (MMT) will be provided, with emphasis on treatment needs, clinicians’ experiences, and initial treatment findings. A cognitive-behavioral treatment approach to addressing pain management for patients enrolled in a substance abuse treatment program will be described, and outcome data from a pilot trial will be reported. The symposium will close with a broader discussion of overarching issues for the treatment of pain in patients with SUDs, including treatment issues in primary care and key research priorities.
XIV. Novel kappa opioids: From design to function
Ellen Unterwald and Eduardo Butelman

This symposium will cover new innovations in kappa opioid receptor pharmacology. Topics will include synthesis of novel peptide and non-peptide agonists and antagonists that are selective for kappa opioid receptors, the molecular basis of kappa opioid receptor regulation in response to agonist drugs, kappa opioids in a non-human primate model, and the in vivo pharmacology of traditional and novel kappa opioid receptor ligands. The presentations will also cover the novel kappa drug of abuse, salvinorin A and its pharmacology.

Thursday, June 17

XV. Screening and brief intervention for drug use: Does it work?
Will it work in the real world?
Chairs: Richard Saitz and Richard Denisco

Alcohol screening and brief intervention (SBI) is effective, but there is insufficient evidence to recommend drug SBI widely. This symposium will describe the design and implementation (including preliminary data) of a diverse mix of real-world drug SBI randomized controlled trials (RCTs) supported by NIDA/SAMHSA to fill the evidence gap. Trial 1 compares effectiveness and efficacy of approaches in urban primary care patients with drug use screening and (1) standard BI by health advocates and (2) motivational intervention (MI) by psychologists, versus control (written resources). Trial 2 compares effectiveness of 3 levels of intervention: (1) brief advice, (2) brief MI with feedback, and (3) brief MI with feedback and booster in injured patients with drug problems at a trauma center. Trial 3, a pragmatic effectiveness and cost study, evaluates BI and referral to treatment (when indicated) for problem drug use at a safety net hospital primary care setting. Trial 4 in medical outpatients tests novel solutions, comparing: (1) screening only, (2) assessment only, (3) assessment plus computer-delivered BI, or (4) assessment plus therapist-delivered BI. Trial 5 takes an innovative step to deliver treatment to opioid-dependent emergency department (ED) patients: (1) SBI with a facilitated referral to treatment and (2) SBI with ED-initiated buprenorphine, versus standard care (written information). These studies, each unique, are all based in general medical settings, incorporate pragmatic design features, have faced implementation challenges, propose innovative ways to translate brief interventions into more universal practice, and will thus have significant implications for policy and clinical care.
XVI. The role of dopamine D3 receptors in cocaine abuse  
Chair: Jane B. Acri

The dopamine D3 receptor is a subtype of the D2-like superfamily of receptors and because the relative expression of D3 receptors in the striatum is significantly less than that for D2 receptors, it has been hypothesized that preferential blockade of D3 receptors may lead to selective antagonism of the reinforcing and discriminative stimulus effects of cocaine without producing motor side-effects. This symposium will describe the latest research involving this novel target and a general overview of the dopamine receptor system, the preclinical strategies to be employed and some exciting clinical work. Next, describes the latest compounds in development, with an emphasis on early identification of potential treatment agents based on in vitro screens. The last two talks will describe the use of these novel compounds in several well-established animal models including the use of unconditioned behaviors, cocaine reinstatement models, drug discrimination and drug self-administration. This symposium is of importance to attendees of CPDD because it describes translational studies involving very novel treatment agents, as well as preclinical strategies for future clinical work.

XVII. The multi-site NIDA Clinical Trials Network prescription opioid addiction treatment study: Outcomes and implications  
Chairs: Roger D. Weiss and Petra Jacobs

Prescription opioid dependence has become a national public health priority; prescription opioids are now the most common form of drug initiation. Most treatment studies of opioid-dependent populations have focused exclusively or predominantly on heroin users, and thus do not adequately address those with prescription opioid dependence. This symposium will provide an opportunity to review findings from the Prescription Opioid Addiction Treatment Study – the first multi-site randomized controlled trial to specifically examine treatments for individuals with prescription opioid dependence including those with chronic pain. This study, part of the NIDA Clinical Trials Network, compared the efficacy of different lengths of buprenorphine/naloxone in combination with different intensities of medical and psychosocial counseling. The study contained two treatment phases: 1) 4 weeks of buprenorphine/naloxone, including a 2-week dose taper; and, for those who relapsed during this phase, 2) a 3-month buprenorphine/naloxone treatment, followed by a one-month taper. In both phases, participants were randomized to standard medical management (SMM) alone or SMM plus individual drug counseling. A total of 653 participants at 10 sites were randomized to Phase 1; 360 entered Phase 2. This mini-symposium will review 1) the primary study outcomes involving treatment response in Phase 1 and Phase 2; 2) key secondary outcomes, including treatment response among the 42% of study participants with chronic pain; and 3) the clinical and scientific implications of study results for the treatment of prescription opioids-dependence.
From 1999 to 2006, the number of unintentional poisoning deaths involving opioids in the United States has increased 3.4 fold, from 4,041 to 13,755. This increase has been driven by growth in opioid analgesic prescriptions, increasing nonmedical use of prescription opioids, and the availability of low cost, high purity heroin. By 2006, overdose led motor vehicle accidents as the leading cause of accidental death in 16 states. Public health and community organizations in North America, Europe, and Australia have responded to increased overdoses by creating programs that educate opioid users and other laypeople how to prevent fatal overdoses. Often these programs include the distribution of naloxone, an opioid antagonist. By the end of 2007, over 20,000 lay people have been trained, reporting over 2500 overdose reversals with bystander-administered naloxone. Until 2009, there has been no federally funded research of community overdose prevention programs. This symposium will present findings from the first CDC and NIDA-funded research studies of community overdose prevention programs, the former implemented throughout Massachusetts in HIV prevention programs and the latter among two homeless outreach programs in Los Angeles and will contextualize the presentations within the epidemiology of overdose and the history of community responses to overdose with attention to future directions for this emerging field of research.
WORKSHOPS

Sunday, June 13

I. Epidemiology and public health research methods workshop
   Chairs: James C. Anthony and Silvia Martins

This year, the workshop presentations are on methodological topics that are prominent in NIDA global health research projects, including issues raised during recent journal review processes on within-country and between-country research. Presenters will cover methodological issues faced in global and international research on problems of drug dependence, measurement challenges in race-ethnic and cross-national research on nicotine dependence, methods issues faced in epidemiological research on problems of dependence upon opioid analgesics, and zero inflated statistical models that can help us understand how it happens that some people try a drug once or twice but never progress beyond first occasions of drug self-administration. We will start with introductions, an overview, and a 30 minute panel discussion of these issues. Then, we will repeat a ‘mini-lecture and demonstration carousel’ approach we used in the 2008 CPDD quantitative methodology workshop, which was well-received. In this format, after the panel discussion, we allow the attendees to organize themselves into three separate subgroups for the first short mini-lecture and demonstration of software. Then, after the first 30” mini-lecture, attendees select and move to a different spot for a different mini-lecture/demonstration. Then, attendees move to the third and final mini-lecture/demonstration. In this way, there is a small group mini-lecture/demonstration coverage of three different topics during the workshop session, in addition to the overview and panel discussion at the start.

II. Effectively mentoring trainees from diverse backgrounds:
    Funding opportunities and practical advice
   Chairs: Danielle C. Ompad and Liliane Cambraia Windsor

The purpose of this workshop is to encourage CPDD members to mentor minority researchers, and provide support to investigators that mentor students from diverse backgrounds. Specifically we will focus on mentoring students who identify as being from one or more racial/ethnic minority groups and those who come from economically disadvantaged backgrounds, consistent with CPDD’s commitment to increase minority participation and representation in CPDD activities. Topics to be addressed in this workshop will include funding opportunities within NIDA for increasing diversity, cultural competency for senior investigators, effective strategies for mentorship and challenges faced by students.
WORKSHOPS

III. Minimize liability, manage risk, ensure patient safety: Effective strategies in outpatient methadone treatment
Chair: Michael T. Flaherty

Learn how to employ best practices and reduce the risks associated with delivering methadone to treat opioid addiction. Conducted by experts in insurance, law, policy, and daily clinical practices, the training will provide the framework for applying best practices and developing comprehensive risk management strategies that improve patient safety and enable opiate treatment programs and methadone maintenance programs to eliminate, transfer, reduce, and manage the risks. The 2009 Government Accountability Office Report examined factors contributing to the significant increase in methadone-associated overdose deaths more often found in pain management situations. These concerns and adverse incidents have led to an increased number of lawsuits and legislation that seeks to legislate clinical practice, patient safety, and community values. Physicians, psychiatrists, clinical staff, nurses, and opiate treatment program directors need to understand how to minimize incidents, such as patients driving under the influence, unsafe diversion of take-home meds, and dosing practices without consideration of clinically assessed severity of dependence and metabolism rates.

IV. 16th Annual Contingency Management Working Group
Chairs: Kelly Dunn and Kathryn Saulsgiver

The Contingency Management (CM) Working Group, held annually during the CPDD convention, is an opportunity for the dissemination and discussion of current research regarding the use of CM interventions to promote behavior change and reduce drug use. CM is a behavioral treatment strategy that has demonstrated consistent success in promoting abstinence from a wide-range of drugs and across many different treatment populations. It is also being used to promote change in behaviors impacting the course of other chronic diseases (e.g., obesity, diabetes). At the 16th Annual Meeting of the CM Working Group, researchers will present preliminary data from ongoing studies involving CM. The goal for this working group is to provide an informal outlet for discussion of ongoing CM research, with an emphasis on developing or improving research strategies by seeking audience input, and providing opportunities for junior and senior researchers to interact.

Monday, June 14

V. School-based systems of care for substance abuse:
Student assistance programs and recovery schools / SASATE business meeting
Chairs: Andrew J. Finch and Michael Dennis

One of the key barriers for treating substance abuse and co-occurring disorders is access to services. While many schools in the U.S. collaborate with community agencies and even locate health centers on school grounds, few have fully integrated systems of care for substance abuse and mental health within their schools. This presentation will examine recent research supporting the institutionalization of school-based systems of care. Student assistance and recovery school programs will be discussed as providing a
continuum of services for prevention, screening, assessment, intervention, and recovery support. Student assistance helps students achieve academic and social success and avoid substance abuse by promoting healthy development, while recovery high schools provide drug-free holding environments to support recovery from substance use disorders. Over 35 recovery high schools operate nationally, and most are public alternative or charter schools. The presentation will describe components of successful programs, including prevention activities, screening and assessment instruments, brief intervention, and recovery school programs. Following the panel discussion will be a brief business meeting for the Society for Adolescent Substance Abuse Treatment Effectiveness (SASATE).

VI. Teach your parents well: Teaching and training parents concerned about their child’s drug use
Chair: Kimberly C. Kirby

Parents are often concerned about their children's involvement with drugs, and with good reason. Close to half of 12th graders have used illicit drugs at some point and almost a quarter have used in the past month. While multiple influences shape substance use parents could play a critical role at every stage of drug use involvement if they were provided with evidence-based knowledge, instruction, skills and practical tools. The specific aims of this workshop are 1) to introduce treatment providers to methods for assisting parents to manage drug use risks for their children at all levels of drug involvement, and 2) to inform researchers of new developments in translational research. The workshop will describe and discuss 1) development and research regarding a tool to help parents protect children from drugs on the internet, 2) examining how parent-child communication and relationship quality is associated with risk for drug use among college students, and how this information can be helpful to parents, 3) developing and implementing a training program to assist parents in dealing with adolescents in early stages of drug involvement, and 4) methods for training parents to act as change agents for children at risk for drug use and for adolescents who are more heavily engaged in drug use.

VII. Comparison of methadone and buprenorphine: Results of the Maternal Opioid Treatment: Human Experimental Research (MOTHER) trial
Chairs: Ivan D. Montoya and Sarah H. Heil

The specific aim of this workshop is to provide the much-anticipated neonatal and maternal outcomes of the Maternal Opioid Treatment: Human Experimental Research (MOTHER) project. MOTHER is an international, eight-site, double-blind, double-dummy, flexible-dosing, parallel-group randomized clinical trial. The MOTHER study examined the comparative safety and efficacy of methadone and buprenorphine for the treatment of opioid-dependence among pregnant women and their neonates. Topics will include the primary neonatal outcomes [e.g., incidence and severity of neonatal abstinence syndrome (NAS) and physical birth parameters] and key maternal outcomes (e.g., maternal treatment retention, average doses received, obstetrical and delivery outcomes), predictors of maternal treatment outcome, how the MOTHER sample is
representative of the larger pool of opioid-dependent pregnant women, comparisons and contrasts between the treatment and patient characteristics of U.S. and European women screened for the study, prevalence and management of co-occurring psychiatric disorders and medication interactions, and the implications of these data for affirming and changing clinical practice.

VIII. Career development: A perspective from junior and senior researchers
Chairs: Gerald McLaughlin and Jose Ruiz

Developing a career involves a series of decisions, often made with limited information or assistance. The purpose of this workshop is to provide a forum for thinking more creatively and systematically about one’s career decisions by inviting both junior and more senior scientists to reflect on their own career choices and experiences, as well as those of their colleagues, and encouraging substantial audience participation. Topics such as how to choose a mentor and what mentors look for; how to network effectively at a professional meeting; how to move to academia, industry or government positions; what not to do at job interviews, as well as what to be sure to do, will be some of the topics considered. Approximately half the time will be allotted for presentations and half the time for audience interactions and questions.

Tuesday, June 15

IX. New approaches to diagnosis in the DSM-V
Chairs: Wilson M. Compton and Charles P. O’Brien

The multidisciplinary working group for Substance Related Disorders in DSM-V was charged with making improvements that were data-based, that moved the classification towards clinical neuroscience and, above all, improved the utility of the system for clinicians. The changes being considered are in keeping with these goals and are on schedule for a 2012 publication. Each speaker in this workshop will address in detail major concepts that are under consideration. In addition to an accumulating body of research suggesting that the categories of disorder, "abuse" and "dependence", are not distinct enough to warrant separation, research is accumulating on other topics and many other questions are being considered, including: Can we clarify the nomenclature between two states of neuro-plasticity induced by drugs of abuse: "physical dependence", which is a normal adaptation to repeated dose of several categories of CNS active medications, and "dependence", meaning addiction or compulsive drug-seeking as used in DSM-IV? Do we have the data to incorporate non-substance compulsive behaviors such as gambling which have clinical and neuro-imaging similarities to drug use disorders into our classification? Can we create a severity dimension that can inform clinicians about progress in treatment? Should we continue to use the same symptoms created in DSM-IIIIR and continued in DSM-IV or should some be added or deleted?
WORKSHOPS

What is the threshold for a diagnosis? How can we best incorporate co-morbidity, a significant issue for a severity rating of substance use disorder as well as for the co-existing disorder such as depression or anxiety? The speakers will address these issues and provide an overview of DSM workgroup ongoing activities for CPDD participants to discuss.

X. Established and emerging approaches to human abuse liability testing:
   Is there room for improvement?
   Chair: Edward Sellers

Premarket abuse liability evaluation of prescription drugs is critical to identifying and controlling public health risks of drug abuse. The ‘gold standard’ subjective effects study is scientifically robust and subjective measures have strong face validity; however, questions remain. Are some designs/measures better than others? What distinguishes a drug with significant abuse liability? With older opioids and stimulants, unequivocally strong effects make evaluation of data relatively easy. However, for novel drugs, interpretation may require considerable expertise since despite a large historical record, an accepted standard for ‘clinically relevant’ effects has not yet been established. In addition, while there is generally good agreement between subjective effects and actual abuse patterns, these studies alone cannot necessarily predict whether experimental/recreational use will translate into repeated/escalating use, dependence or ‘addiction’, or whether there may be adverse consequences to the user and public health as a result. Although emerging methods such as self-administration or behavioral economics approaches are not yet widely used, they may have the potential to answer some of these additional questions. Thus, this workshop will review current human abuse liability testing within the drug development process and the potential role for novel testing methods. The aim of the workshop is to promote a dialogue between academic, regulatory, and industry representatives on improving clinical abuse liability evaluation. Refining existing approaches and exploring new methods may increase the predictive and convergent validity of premarket abuse liability assessments, in order to help address the public health need for safer drugs.

XI. Academics and regulated industries: Perspectives on 21st century interactions with pharmaceutical and tobacco companies
   Chairs: Jed Rose and George Uhl

Regulatory frameworks now increase the need to focus our best scientific expertise to optimize the efforts of progressive elements in pharmaceutical and tobacco companies to minimize harm, including the results from products whose use can lead to dependence in many individuals. However, academic researchers who interact with even enlightened members of the for-profit pharmaceutical and tobacco industries can be stigmatized by other members of the scientific community, even those whose research is funded indirectly through taxes, settlement funds etc from these industries. This workshop seeks to explore ethical issues and to provide examples of the ways in which interactions between academic and such for-profit industries can be managed appropriately, and
potential pitfalls avoided. We present several models that appear to work in specific cases. We seek to engender thought and discussion about tough yet flexible frameworks in which the best elements of academic/for profit interactions can be maintained while the risks inherent in such interactions can be reduced.

XII. Empirically supported treatments and diverse populations: Some examples of challenges to adaptation
Chairs: Anne Helene Skinstad and Lonetta Albright

The goals for this workshop include sharing experiences in translating efficacious methods to make them more culturally sensitive and discussing barriers to implementation of empirically supported treatments with diverse populations. Many treatment approaches for clients with substance use disorders have been developed over the last 50 years, prominently including motivational interviewing, cognitive behavioral treatment, and motivational incentives to mention a few. These interventions have been shown to be efficacious in randomized clinical trials. While these treatments have been shown to be efficacious in clinical trials, the translation and subsequent adoption of these methods for use with diverse populations may not meet the evidence-base standard and also not be effective with diverse populations unless reworked.

XIII. What’s new at NIDA and NIH: Enhancing peer review implementation and more
Chairs: Mark R. Green and Mark Swieter

This workshop is intended to provide an opportunity for participants to learn about new policies and procedures at NIH and NIDA that are relevant to them. Topics will include changes in the peer review process at NIDA and the Center for Scientific Review (CSR) following implementation of Enhancing Peer Review modifications such as the new 1-9 scoring system, individual criterion scoring, the new format of summary statements; as well as new grant application forms and page limits, tips on how to write a good grant application, and ways to get help on application preparation. Other topics and questions of interest to the audience will be addressed. This is very much an interactive, audience-directed activity.
The following organizations have generously supported the work of the College on Problems of Drug Dependence during the past year:

Catalyst Pharmaceutical Partners, Inc

Grunenthal USA, Inc

NIDA (National Institute on Drug Abuse)

Sanofi Aventis

Funding for this conference was made possible (in part) by Grant Agreement # R13 DA 0019790 from NIDA.

The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government